<SEC-DOCUMENT>0001493152-21-020170.txt : 20210816
<SEC-HEADER>0001493152-21-020170.hdr.sgml : 20210816
<ACCEPTANCE-DATETIME>20210816161636
ACCESSION NUMBER:		0001493152-21-020170
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		72
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210816
DATE AS OF CHANGE:		20210816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Qualigen Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001460702
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				263474527
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37428
		FILM NUMBER:		211178429

	BUSINESS ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011
		BUSINESS PHONE:		(760) 918-9165

	MAIL ADDRESS:	
		STREET 1:		2042 CORTE DEL NOGAL
		STREET 2:		CARLSBAD
		CITY:			CALIFORNIA
		STATE:			CA
		ZIP:			92011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RITTER PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20090402
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:QLGN="http://qualigeninc.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_034_QLGN_qualigeninc.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210101_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DEntityCentralIndexKey_0001460702 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DDocumentFiscalYearFocus_2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCentralIndexKey">0001460702</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0091" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2021-06-30" id="xdx2ixbrl0106" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_LicenseRevenueMember" id="xdx2ixbrl0181" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30_custom_LicenseRevenueMember" id="xdx2ixbrl0182" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30_custom_LicenseRevenueMember" id="xdx2ixbrl0184" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember" id="xdx2ixbrl0186" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember" id="xdx2ixbrl0187" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember" id="xdx2ixbrl0188" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0281" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0282" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0284" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0285" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0296" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0297" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0301" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0304" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0307" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0311" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0312" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0314" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0319" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31" id="xdx2ixbrl0320" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0322" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0326" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0327" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0328" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0329" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0337" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0497" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0498" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0499" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0500" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0501" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0503" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0506" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0507" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0508" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0509" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0510" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0511" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0513" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0517" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0518" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0519" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0520" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0521" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0535" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0536" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0537" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0543" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0547" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0550" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0551" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0558" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0559" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0560" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0561" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0563" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0569" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0570" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0572" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0605" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0609" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0610" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0611" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0612" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0613" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0614" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0615" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0617" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0620" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0621" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0622" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0623" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0624" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0625" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0627" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0636" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0652" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0664" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0665" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0681" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0682" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0683" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0684" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0685" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0686" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0689" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0694" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0695" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0696" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0697" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0698" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0701" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0702" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0707" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0709" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0710" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0711" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0712" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0713" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0714" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0717" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0722" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0723" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0724" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0725" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0726" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0727" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0730" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0735" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0737" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0738" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0739" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0740" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0741" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0742" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0745" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0750" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0751" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0752" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0753" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0754" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0755" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0756" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0758" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0761" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0762" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0763" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0764" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0765" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0766" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0767" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0769" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0772" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0773" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0774" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0775" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0776" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0777" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0780" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0785" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0786" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0787" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0788" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0789" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0790" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0791" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0793" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0796" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0797" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0798" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0799" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0800" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" id="xdx2ixbrl0801" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0802" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0803" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0807" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0808" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0809" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0810" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0811" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_custom_SeriesAConvertiblePreferredStockMember" id="xdx2ixbrl0818" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_custom_SeriesBConvertiblePreferredStockMember" id="xdx2ixbrl0820" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_custom_SeriesCConvertiblePreferredStockMember" id="xdx2ixbrl0822" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_custom_SeriesDConvertiblePreferredStockMember" id="xdx2ixbrl0824" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" id="xdx2ixbrl0826" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0901" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0908" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0943" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfAccruedInterest" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0946" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0949" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:IssuanceOfPreferredStockForConversionOfDebt" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0952" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0955" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0958" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:EffectOfReverseRecapitalization" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0961" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:InitialMeasurementOfOperatingLeaseRightofuseAssets" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0964" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NetTransfersToInventoryFromEquipmentHeldForLease" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0968" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_LicenseRevenueMember" id="xdx2ixbrl1027" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30_custom_LicenseRevenueMember" id="xdx2ixbrl1028" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30_custom_LicenseRevenueMember" id="xdx2ixbrl1032" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember" id="xdx2ixbrl1034" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember" id="xdx2ixbrl1035" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember" id="xdx2ixbrl1037" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:AccruedPatentAndLicenseFeesCurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl1247" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1276" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1278" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1288" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1290" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1292" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1294" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1312" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1314" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1320" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1322" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1324" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1326" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1328" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" id="xdx2ixbrl1330" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1346" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1348" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl1354" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl1356" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1734" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1736" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsExpired" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" id="xdx2ixbrl1738" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1838" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1840" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NumberOfSharesWarrantsLegacyRitterWarrant" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1842" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1844" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1846" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1848" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1854" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1856" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2019-12-31_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1888" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:NumberOfSharesWarrantsLegacyRitterWarrant" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1896" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1898" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1904" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1906" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1908" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" id="xdx2ixbrl1910" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1980" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1982" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1984" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1986" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1988" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl1990" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2004" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2006" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" id="xdx2ixbrl2008" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="qlgn-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-12">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-12</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_NetProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_NetProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_NetProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_NetProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SeriesAConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SeriesBConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SeriesCConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SeriesDConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_ToolsDiesAndMoldsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_PatentsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_LicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-012020-07-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-01</xbrli:startDate>
        <xbrli:endDate>2020-07-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-012020-08-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-01</xbrli:startDate>
        <xbrli:endDate>2020-08-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MachineryAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ConstructionInProgressEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:ConstructionInProgressEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_ConstructionInProgressEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:ConstructionInProgressEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_ToolsDiesAndMoldsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_ToolsDiesAndMoldsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LongtermOperatingLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-06-01</xbrli:startDate>
        <xbrli:endDate>2018-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-09-01</xbrli:startDate>
        <xbrli:endDate>2020-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-03-01</xbrli:startDate>
        <xbrli:endDate>2019-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_LicensedProductSalesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-06-01</xbrli:startDate>
        <xbrli:endDate>2019-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-11-012020-11-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-11-01</xbrli:startDate>
        <xbrli:endDate>2020-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-272020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:RoyaltiesAndNonRoyaltySublicenseeIncomeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-27</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-06-262020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:RoyaltiesAndNonRoyaltySublicenseeIncomeMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-06-26</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember_custom_CEMarkMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:CEMarkMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_SekisuiDiagnosticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_SekisuiDiagnosticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-03-30_custom_SekisuiDiagnosticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-03-30_custom_SekisuiDiagnosticsLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-03-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_YiXinZhenDuanJishuLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_LicenseRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_TechnologyTransferAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:TechnologyTransferAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_STAPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ExerciseOfOutstandingStockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:ExerciseOfOutstandingStockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_ExerciseOfOutstandingStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:ExerciseOfOutstandingStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_SerieAlphaPreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SerieAlphaPreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SingleInstitutionalInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-09</xbrli:startDate>
        <xbrli:endDate>2020-07-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-09</xbrli:startDate>
        <xbrli:endDate>2020-07-10</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:TwoYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-10</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-07-212020-07-22_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-07-21</xbrli:startDate>
        <xbrli:endDate>2020-07-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SingleInstitutionalInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-03</xbrli:startDate>
        <xbrli:endDate>2020-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-08-03</xbrli:startDate>
        <xbrli:endDate>2020-08-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:TwoYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SingleInstitutionalInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-16</xbrli:startDate>
        <xbrli:endDate>2020-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-16</xbrli:startDate>
        <xbrli:endDate>2020-12-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:TwoYearWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-02-032021-02-04_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-02-03</xbrli:startDate>
        <xbrli:endDate>2021-02-04</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_StockOptionsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_StockOptionsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockOptionsAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CompensatoryWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-12-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-07-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-05-012020-05-31_custom_SeriesDAndSeriesDOnePreferredStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDAndSeriesDOnePreferredStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-05-01</xbrli:startDate>
        <xbrli:endDate>2020-05-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-09_us-gaap_SubsequentEventMember_custom_TwpThousandTwentyPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001460702</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwpThousandTwentyPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-09</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_905_edei--DocumentType_c20210101__20210630_zoXMqY2IDxv5"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--DocumentQuarterlyReport_c20210101__20210630_zEVRsNW1Pa88"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the quarterly period ended <span id="xdx_90E_edei--DocumentPeriodEndDate_c20210101__20210630_zABDSmq4vHD8"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_903_edei--DocumentFiscalYearFocus_c20210101__20210630_z7ZARR0ukXZb"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></span></ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Or</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--DocumentTransitionReport_c20210101__20210630_z0EsCM1mdRmb"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span> TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the transition period from _____________ to _____________</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityRegistrantName_c20210101__20210630_zhC1DqPvF22d"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityRegistrantName">Qualigen Therapeutics, Inc.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20210101__20210630_zcypPAlacBo7"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityFileNumber_c20210101__20210630_zWdkzxDLtsk4"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityFileNumber">001-37428</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90C_edei--EntityTaxIdentificationNumber_c20210101__20210630_z24hdETqmh2g"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityTaxIdentificationNumber">26-3474527</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">File
    Number)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S.
    Employer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_901_edei--EntityAddressAddressLine1_c20210101__20210630_zzUcaGhNqGr4"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine1">2042 Corte Del Nogal</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressCityOrTown_c20210101__20210630_zWSED8OOFqN"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressCityOrTown">Carlsbad</ix:nonNumeric></span>, <span id="xdx_90D_edei--EntityAddressStateOrProvince_c20210101__20210630_zaV5qF5Ut7h1"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90A_edei--EntityAddressPostalZipCode_c20210101__20210630_zGwEKZ2Cy269"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressPostalZipCode">92011</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices) (Zip Code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">(<span id="xdx_90D_edei--CityAreaCode_c20210101__20210630_zAtXGvCA7rKi"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CityAreaCode">760</ix:nonNumeric></span>)
<span id="xdx_90C_edei--LocalPhoneNumber_c20210101__20210630_zyJli54MDDd8"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:LocalPhoneNumber">918-9165</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant&#8217;s
telephone number, including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>n/a</b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Former
name or former address, if changed since last report)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 39%"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 16%"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 41%"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_edei--Security12bTitle_c20210101__20210630_zf5iuIISyKH"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:Security12bTitle">Common
Stock, par value $.001 per share</ix:nonNumeric></span></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--TradingSymbol_c20210101__20210630_zvLiwEr6Gvpl"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:TradingSymbol">QLGN</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_907_edei--SecurityExchangeName_c20210101__20210630_zovoEgWGSi2l"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Capital Market of The Nasdaq Stock Market LLC </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. &#9746;&#160;<span id="xdx_905_edei--EntityCurrentReportingStatus_c20210101__20210630_zL6WpgQc0L9k"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>&#160;&#9744;&#160;No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). &#9746;&#160;<span id="xdx_908_edei--EntityInteractiveDataCurrent_c20210101__20210630_zPnpAKgYK3U6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span>&#160;&#9744;&#160;No</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%">&#9744;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 25%">&#9744;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_edei--EntityFilerCategory_c20210101__20210630_zE8sjEAudEcc"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
    reporting company </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--EntitySmallBusiness_c20210101__20210630_z20pIGaESiV"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
    growth company </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--EntityEmergingGrowthCompany_c20210101__20210630_z9483epWOsD6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#9744;&#160;Yes&#160;&#9746;&#160;<span id="xdx_90E_edei--EntityShellCompany_c20210101__20210630_z0cbT2x8Rgae"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of August 12, 2021, there were <span id="xdx_90F_edei--EntityCommonStockSharesOutstanding_c20210812_pdd" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-08-12" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,998,831</ix:nonFraction></span> shares of the registrant&#8217;s common stock, par value $0.001 per share,
outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="width: 0.1in">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 0.5in; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Page
    </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">PART
    I.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_001"><span style="font: 10pt Times New Roman, Times, Serif">Financial Information</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_001"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Financial Statements (Unaudited)</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_002"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Balance Sheets as of June 30, 2021 and December 31, 2020</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_003"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_004"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Changes in Stockholders&#8217; Equity for the Three and Six Months Ended June 30, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_005"><span style="font: 10pt Times New Roman, Times, Serif">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">4</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_006"><span style="font: 10pt Times New Roman, Times, Serif">Notes to Condensed Consolidated Financial Statements</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_007"><span style="font: 10pt Times New Roman, Times, Serif">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">24</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_008"><span style="font: 10pt Times New Roman, Times, Serif">Quantitative and Qualitative Disclosures About Market Risk</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_009"><span style="font: 10pt Times New Roman, Times, Serif">Controls and Procedures</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">33</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">PART
    II.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_010"><span style="font: 10pt Times New Roman, Times, Serif">Other Information</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_011"><span style="font: 10pt Times New Roman, Times, Serif">Legal Proceedings</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_012"><span style="font: 10pt Times New Roman, Times, Serif">Risk Factors</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_013"><span style="font: 10pt Times New Roman, Times, Serif">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">34</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_014"><span style="font: 10pt Times New Roman, Times, Serif">Defaults Upon Senior Securities</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_015"><span style="font: 10pt Times New Roman, Times, Serif">Mine Safety Disclosures</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_016"><span style="font: 10pt Times New Roman, Times, Serif">Other Information</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><a href="#a_017"><span style="font: 10pt Times New Roman, Times, Serif">Exhibits</span></a></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">35</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_001"></span>ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_002"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONDENSED
CONSOLIDATED BALANCE SHEETS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_302_111_zndnMoLWkxX3" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20210630_zUjXN29FC9C1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zuMjYSj2UOdg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_z6Tcim9lvbxi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">ASSETS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B_zSfc69IM2C7e" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_maCzAPp_zRMbBK17t3x5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,232,402</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,976,570</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccountsReceivableNetCurrent_i02I_maCzAPp_znF6f61mqgd1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts receivable, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">766,911</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">615,757</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--InventoryNet_i02I_maCzAPp_zVQwtr7E5lC3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Inventory, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,073,335</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">953,458</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_maCzAPp_z6MQvrjXeAZa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid expenses and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,033,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,678,894</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AssetsCurrent_i02TI_mtCzAPp_maCzrct_zBiWzutJv19a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,106,505</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,224,679</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maCzrct_z0rL3Pdq6k57" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">321,076</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">430,795</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentNet_i01I_maCzrct_zCnjbje9obC4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Property and equipment, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">253,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">247,323</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--EquipmentHeldForLeaseNet_i01I_maCzrct_zDxSxaWPX71g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Equipment held for lease, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EquipmentHeldForLeaseNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,821</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:EquipmentHeldForLeaseNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">17,947</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IntangibleAssetsNetExcludingGoodwill_i01I_maCzrct_z1Dp2ySVw5Ci" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Intangible assets, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">183,933</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,694</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--OtherAssetsNoncurrent_i01I_maCzrct_zq0hse6lOzJg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,334</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--Assets_i01TI_mtCzrct_znmjMys2fI3g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Assets</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,888,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,126,772</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB_z5qpFflSFZ2g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--LiabilitiesCurrentAbstract_i01B_zMpvq7rTbUf3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--AccountsPayableCurrent_i02I_maCzbMv_z6HVNXhPZiz5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">784,474</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">500,768</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AccruedLiabilitiesCurrent_i02I_maCzbMv_zaguoRvJ5qJa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,923,708</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">746,738</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--NotesPayableCurrent_i02I_maCzbMv_zwDHjppzR7X3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Notes payable, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0091">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:NotesPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">131,766</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--DeferredIncomeCurrent_i02I_maCzbMv_zVLTz2V8QOGe" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Deferred revenue, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">325,988</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DeferredIncomeCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">486,031</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maCzbMv_zjp5iSVZAlnh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Operating lease liability, current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">270,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">254,739</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--HedgingLiabilitiesCurrent_i02I_maCzbMv_zgkL9PbkShvb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Warrant liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:HedgingLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,112,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:HedgingLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,310,100</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesCurrent_i02TI_mtCzbMv_maCz94o_zQSGD1y9mcFh" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,416,910</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,430,142</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LongTermNotesPayable_i01I_maCz94o_z6jfYIdhWVRl" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Notes payable, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0106">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermNotesPayable" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,973</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OperatingLeaseLiabilityNoncurrent_i01I_maCz94o_ztOyHjNMZvgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liability, net of current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">98,145</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">236,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--DeferredRevenueNoncurrent_i01I_maCz94o_zFEXqG5mmig7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Deferred revenue, net of current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">112,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">158,271</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Liabilities_i01TI_mtCz94o_maCzaM7_zGg90ecqmqjc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,627,112</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">10,832,212</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--StockholdersEquityAbstract_i01B_zgCk7FOcrOi8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Stockholders&#8217; equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--PreferredStockValue_i02I_maCzyz2_znRCdJyJQTi1" style="vertical-align: bottom; background-color: White">
    <td>Series Alpha convertible preferred stock, $<span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210630_pdd" title="Series Alpha convertible preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pdd" title="Series Alpha convertible preferred stock, par value"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20210630_pdd" title="Series Alpha convertible preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd" title="Series Alpha convertible preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_90A_eus-gaap--PreferredStockSharesIssued_c20210630_pdd" title="Series Alpha convertible preferred stock, shares issued"><span id="xdx_909_eus-gaap--PreferredStockSharesIssued_c20201231_pdd" title="Series Alpha convertible preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesOutstanding_c20210630_pdd" title="Series Alpha convertible preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_c20201231_pdd" title="Series Alpha convertible preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> shares issued and outstanding as of June 30, 2021 and December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--CommonStockValue_i02I_maCzyz2_zick9n4yWxD9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Common stock, $<span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20210630_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></ix:nonFraction></span></span> par value; <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20210630_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">225,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20210630_pdd" title="Common stock, shares issued"><span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,902,188</ix:nonFraction></ix:nonFraction></span></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares issued"><span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,296,061</ix:nonFraction></ix:nonFraction></span></span> shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,902</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,296</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AdditionalPaidInCapital_i02I_maCzyz2_zuNslZTkxLxa" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,058,267</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,114,755</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_maCzyz2_ztLSZRESzJgb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,825,352</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,847,492</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--StockholdersEquity_i02TI_mtCzyz2_maCzaM7_zEqfLZx93qF6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,261,818</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,294,560</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_mtCzaM7_zqYdfSf9Phge" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">Total Liabilities and Stockholders&#8217; Equity</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,888,930</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">29,126,772</ix:nonFraction></td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_003"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30E_113_zWkdl0wTdQZ8" summary="xdx: Statement - Condensed Consolidated Statements of Operations (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_495_20210401__20210630_zjRCb5Kj8s75" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_499_20200401__20200630_z8RkdGKqdaq9" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49F_20210101__20210630_z1yFikh77Yi2" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49D_20200101__20200630_z9TcKF41RuC4" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Three Months<br />
 Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Six Months<br />
 Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenuesAbstract_iB_zN5Ji1FDXBy3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--NetProductSalesMember_zeGOz5VWQgz3" style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-left: 10pt">Net product sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_NetProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,117,935</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30_custom_NetProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">904,067</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_NetProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,538,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30_custom_NetProductSalesMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,315,823</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--LicenseRevenueMember_zYCnuckwzvw6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">License revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0181">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0182">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_LicenseRevenueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">478,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0184">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zLNwdnUDedvg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Collaborative research revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0186">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0187">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0188">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_i01_maCziKN_zv20SoH4hVlg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,117,935</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">904,067</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,017,430</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,360,823</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--OperatingCostsAndExpensesAbstract_iB_zWTW82tARW0g" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--CostOfProductSales_i01_maCzR7X_z8ciaHYu4gpd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:CostOfProductSales" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">916,624</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:CostOfProductSales" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">807,922</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:CostOfProductSales" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,119,103</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:CostOfProductSales" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,799,574</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--GeneralAndAdministrativeExpense_i01_maCzR7X_z1axiErYcSZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,952,100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,979,614</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,826,038</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,897,993</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ResearchAndDevelopmentExpense_i01_maCzR7X_zjn5aKwbWCWd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,508,466</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">597,345</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,007,840</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">835,403</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--MarketingAndAdvertisingExpense_i01_maCzR7X_zIOKsMVgYrX" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Sales and marketing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">135,543</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,844</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">272,129</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181,106</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OperatingExpenses_i01T_mtCzR7X_msCziKN_zEWgOxLCkC35" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,512,733</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,473,725</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,225,110</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,714,076</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--OperatingIncomeLoss_iT_mtCziKN_maCzAHh_zJA1oOzFjLo3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">7,394,798</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,569,658</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,207,680</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,353,253</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpenseAbstract_iB_zh2Yd7PMV9Oh" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER (INCOME) EXPENSE, NET</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--FairValueAdjustmentOfWarrants_i01_msCzg2K_z6IGydwiOrBf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss (gain) on change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,075,100</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,201,400</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,198,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,201,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestIncomeExpenseNet_i01N_di_maCzg2K_zc9nuwXfamHg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,718</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,364</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">30,061</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">148,121</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherNonoperatingIncomeExpense_i01N_di_maCzg2K_zH7HljU3Mtze" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,352</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">250,114</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,894</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">251,272</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_401_eus-gaap--NonoperatingIncomeExpense_i01NT_di_mtCzg2K_maCzAHh_zzWX3N4FKoo3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other (income) expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,090,170</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,008,650</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,230,955</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">16,098,249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_iT_mtCzAHh_maCzBjM_zduFZf1ILMX9" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,304,628</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,578,308</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,976,725</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,451,502</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncomeTaxExpenseBenefit_msCzBjM_zP5T7NcEk12b" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">PROVISION (BENEFIT) FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">605</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">597</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,135</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetIncomeLoss_iT_mtCzBjM_zWcpKtxhF5wa" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,305,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,578,905</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,977,860</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,451,480</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--EarningsPerShareBasicAndDiluted_zYap0lUCYao3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt">Net loss per common share, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.18</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.31</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasicAndDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">2.71</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--WeightedAverageNumberOfShareOutstandingBasicAndDiluted_z2tLL0vMutZ" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Weighted&#8212;average number of shares outstanding, basic and diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,850,451</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">8,746,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,510,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,174,233</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_004"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30B_114_zQVQZV2Pl8Hj" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" id="xdx_4B5_us-gaap--StatementClassOfStockAxis_custom--SeriesAConvertiblePreferredStockMember_zSWeojMFVfs1" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" id="xdx_4B7_us-gaap--StatementClassOfStockAxis_custom--SeriesBConvertiblePreferredStockMember_zO1K2G9aYqRe" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementClassOfStockAxis_custom--SeriesCConvertiblePreferredStockMember_zzVZNJqwrTo2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" id="xdx_4B2_us-gaap--StatementClassOfStockAxis_custom--SeriesDConvertiblePreferredStockMember_zsmz3TiRzMwi" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" id="xdx_4B4_us-gaap--StatementClassOfStockAxis_custom--SeriesDOneConvertiblePreferredStockMember_zSnx1TYmq36b" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_us-gaap--StatementClassOfStockAxis_custom--SeriesAlphaConvertiblePreferredStockMember_zoBLR8qIrQh2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BF_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zSi3EKJlbWj8" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Amount
    $</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zkTJRpullQY5" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B3_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_zDMt2kSenAjb" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BD_zqg50lFY5569" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Series
    A Convertible</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Series
    B Convertible</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Series
    C Convertible</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Series
    D Convertible</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Series
    D-1 Convertible</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Series
    Alpha Convertible</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Additional</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Preferred
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Preferred
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Preferred
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Preferred
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Preferred
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Preferred
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Paid-In</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Accumulated</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; display: none; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Amount&#160;$</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Shares</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Amount
    $</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 7pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20210101__20210331_eus-gaap--StockholdersEquity_iS_zmyMQp7M0iQe" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 15%"><span style="font: 7pt Times New Roman, Times, Serif">Balance
    at December 31, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0281">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0282">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0283">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0284">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0285">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zcxnuAB9p8i6" title="Beginning balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zTo3aqh7D0v8" title="Beginning balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">27,296,061</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">27,296</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">85,114,755</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66,847,492</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 2%; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,294,560</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif"></span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Stock
    issued upon cash-exercise of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0296">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0297">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zj27tJLjK61" title="Stock issued upon cash-exercise of warrants, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0307">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0301">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zFC0Tfy7hFGd" title="Stock issued upon cash-exercise of warrants, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,319,625</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,320</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">243,261</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0304">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">244,581</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">Stock
    issued upon net-exercise of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0311">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0312">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0314">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_z4qycwwYcyMk" title="Stock issued upon net-exercise of warrants, shares" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_989_ecustom--StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJTtUUPoFoja" title="Stock issued upon net-exercise of warrants, shares" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">192,373</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">192</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">192</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0319">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0320">&#8212;</span></span><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">Stock
    issued for professional services</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0326">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0327">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0328">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0329">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_980_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_z55ykKkaDvte" title="Stock issued for professional services, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0337">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20210101__20210331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zwikzQL6WSfa" title="Stock issued for professional services, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">25</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,725</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">101,750</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif"></span></td></tr>
  <tr id="xdx_407_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of common stock for conversion of preferred stock</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_i_pdd" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of common stock for conversion of preferred stock, shares</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ConversionOfStockAmountConverted1_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of common stock for conversion of notes payable and accrued interest</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ConversionOfStockSharesConverted1_i_pdd" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of common stock for conversion of notes payable and accrued interest, shares</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of Series Alpha preferred shares upon closing of private placement</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_i_pdd" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of Series Alpha preferred shares upon closing of private placement, shares</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueEffectOfReverseRecapitalization_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Effect
    of reverse recapitalization</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_i_pdd" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Effect
    of reverse recapitalization, shares</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of Series Alpha preferred stock for conversion of notes payable</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_i_pdd" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Issuance
    of Series Alpha preferred stock for conversion of notes payable, shares</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_408_ecustom--SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Shares
    and warrants issued to advisor upon closing of private placement</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_i_pdd" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Shares
    and warrants issued to advisor upon closing of private placement, shares</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_iN_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Fair
    value of shares issued to advisor upon closing of private placement</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_iN_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">Fair
    value of warrants issued to advisor upon closing of private placement</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; display: none">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0497">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0498">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0499">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none"></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0500">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0501">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,262,123</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0503">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,262,123</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">Net
    Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0506">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0507">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0508">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0509">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0510">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0511">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0512">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0513">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,672,627</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">3,672,627</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_438_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zX3tdjZZ16zj" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">Balance
    at March 31, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0517">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0518">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0519">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0520">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0521">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zeyDWHvNk9pd" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zXpgAkcbUUK1" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,833,059</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,833</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">86,721,672</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">70,520,119</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,230,387</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--StockIssuedDuringPeriodValueWarrantsExercised_znncrWJMFrhe" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Stock
    issued upon cash-exercise of warrants</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0535">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0536">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20210401__20210630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zM0tQY5kxYig" title="Stock issued upon cash-exercise of warrants, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0543">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0537">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_ecustom--StockIssuedDuringPeriodSharesWarrantsExercised_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zmHpeUbAtYpk" title="Stock issued upon cash-exercise of warrants, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodSharesWarrantsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">69,129</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,669</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueWarrantsExercised" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">49,738</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zrr4lSHjiJOd" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0547">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0548">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0550">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0551">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,286,926</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,286,926</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--NetIncomeLoss_zySogatBFls3" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">Net
    Loss</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0558">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0559">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0560">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0561">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0563">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,305,233</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,305,233</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr id="xdx_439_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zUE3ksxEntz9" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">Balance
    at June 30, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0569">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0570">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0572">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#8212;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; display: none; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif; display: none"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#8212;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; display: none; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif; display: none">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zZhjZVJRxvlj" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zT4fH54SCN5c" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">28,902,188</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">28,902</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">88,058,267</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">75,825,352</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 7pt Times New Roman, Times, Serif">&#160;</span>$</td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 7pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">12,261,818</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;&#160;</p>

<p style="margin: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series
    A Convertible</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series
    B Convertible</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series
    C Convertible</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series
    D Convertible</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series
    D-1 Convertible</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Series
    Alpha Convertible</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Additional</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Preferred
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Common
    Stock</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Paid-In</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">Accumulated</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount&#160;$</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount&#160;$</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount&#160;$</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount&#160;$</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount&#160;$</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount&#160;$</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Shares</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Amount
    $</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Capital</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-size: 7pt">Deficit</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-size: 10pt; font-weight: bold"><span style="font-size: 7pt">Total</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-size: 10pt; font-weight: bold"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td colspan="2" style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_43D_c20200101__20200331_eus-gaap--StockholdersEquity_iS_z7Vc7jx7Vvf3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 15%"><span style="font-size: 7pt">Balance at December 31, 2019</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zjymaFgMTc4i" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,412,887</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,129</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zaDgR4zr5oIa" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,707,736</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,077</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zXhkO4PaQvO6" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,300,715</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,007</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zbBa45UsNrj2" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,508,305</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,083</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zz4A7o68n3pl" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_custom_SeriesDOneConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">643,511</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_custom_SeriesDOneConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,435</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zuWrYyep20a1" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0605">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#8212;</span></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_987_eus-gaap--SharesOutstanding_iS_c20200101__20200331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zseg5FXzEQQh" title="Beginning balance, shares" style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,602,214</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,026</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,153,733</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="width: 1%"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">46,428,550</ix:nonFraction></span></td><td style="width: 1%; text-align: left"><span style="font-size: 7pt">)</span></td><td style="width: 1%; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="width: 2%; font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,063,060</ix:nonFraction></span></td><td style="width: 1%; font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zbpC7Sfu25R" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Stock-based compensation</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0609">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0610">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0611">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0612">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0613">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0614">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0615">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,866</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0617">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,866</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--NetIncomeLoss_zVBF8v9pJri3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">Net Loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0620">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0621">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0622">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0623">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0624">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0625">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0627">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">872,576</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">872,576</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_438_c20200401__20200630_eus-gaap--StockholdersEquity_iS_zbCvkdlbVwj6" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">Balance at March 31, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zV4T7EfVV4sa" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,412,887</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">24,129</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zVAdmJmJ2YKa" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,707,736</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,077</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zBqVd9UbeE77" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,300,715</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">33,007</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zg0dwDAyY7dc" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,508,305</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,083</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_z7oCnA5l9c1j" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_custom_SeriesDOneConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">643,511</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_custom_SeriesDOneConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,435</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zuUsuiiHaAZc" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0652">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0636">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zN6nz8P6zVN9" title="Beginning balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,602,214</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">56,026</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">45,161,599</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">47,301,126</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,927,770</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_zThnvDKWQoG2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Issuance of common stock for conversion of preferred stock</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zYQPXUcQYwui" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,412,887</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">24,129</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zI0P4ORSw0fi" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">7,707,736</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">77,077</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_985_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zm6ZXXkMewEj" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">3,300,715</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">33,007</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98E_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zPPWWZxiF4X" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,508,305</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">15,083</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98C_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_z4mQ7WlTle4l" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">643,511</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,435</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_987_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zE3tpSvNQBkd" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">740</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_982_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zAJADZIIN9N5" title="Issuance of common stock for conversion of preferred stock, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">7,042,660</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,042</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,690</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0664">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0665">&#8212;</span></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--ConversionOfStockAmountConverted1_zeQRO7JZ2SH8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Issuance of common stock for conversion of notes payable and accrued interest</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0681">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0682">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0683">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0684">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0685">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0686">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_980_eus-gaap--ConversionOfStockSharesConverted1_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z7HhFjUppcah" title="Issuance of common stock for conversion of notes payable and accrued interest, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,775,096</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,775</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,582,633</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0689">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:ConversionOfStockAmountConverted1" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,584,408</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zrPrgxWwuzRl" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Issuance of Series Alpha preferred shares upon closing of private placement</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0694">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0695">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0696">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0697">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0698">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_ziJEtHg5bEak" title="Issuance of Series Alpha preferred shares upon closing of private placement, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,010</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_986_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zz8UtVLQ3Zv3" title="Issuance of Series Alpha preferred shares upon closing of private placement, shares" style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0707">-</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,009,995</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0701">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0702">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,010,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_402_ecustom--StockIssuedDuringPeriodValueEffectOfReverseRecapitalization_zJsnpwPTQzjd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Effect of reverse recapitalization</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0709">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0710">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0711">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0712">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0713">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0714">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98F_ecustom--StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z41ecCCkTxQk" title="Effect of reverse recapitalization, shares" style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">2,095,826</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">52,519</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">863,405</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0717">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,886</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_400_ecustom--IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_zLEGu3FIaDH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Issuance of Series Alpha preferred stock for conversion of notes payable</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0722">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0723">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0724">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0725">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0726">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_987_ecustom--IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zot0pfDqlkYd" title="Issuance of Series Alpha preferred stock for conversion of notes payable, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">350</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0727">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_984_ecustom--IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zc8CVtnqDuec" title="Issuance of Series Alpha preferred stock for conversion of notes payable, shares" style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0735">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0730">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_40D_ecustom--SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_zpzNcFLD2Olg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Shares and warrants issued to advisor upon closing of private placement</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0737">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0738">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0739">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0740">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0741">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0742">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_985_ecustom--SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztyADHHEMFAi" title="Shares and warrants issued to advisor upon closing of private placement, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,217,147</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,217</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,103,891</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0745">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,105,108</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--AdjustmentsToAdditionalPaidInCapitalMarkToMarket_iN_pp0p0_di_zx3fBlsDmft6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Fair value of shares issued to advisor upon closing of private placement</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0750">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0751">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0752">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0753">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0754">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0755">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0756">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">902,250</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0758">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">902,250</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_401_eus-gaap--AdjustmentsToAdditionalPaidInCapitalWarrantIssued_iN_pp0p0_di_zw6nZIhXY3t7" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Fair value of warrants issued to advisor upon closing of private placement</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0761">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0762">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0763">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0764">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0765">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0766">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0767">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">202,858</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">)</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0769">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">202,858</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_404_eus-gaap--StockIssuedDuringPeriodValueIssuedForServices_zrRL2p7F5EG3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left"><span style="font-size: 7pt">Stock issued for professional services</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0772">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0773">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0774">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0775">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0776">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0777">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCJ6nkSrUtx4" title="Stock issued for professional services, shares" style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">46,967</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">47</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">239,953</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0780">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">240,000</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_zyqvgUc4YBu9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left"><span style="font-size: 7pt">Stock-based compensation</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0785">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0786">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0787">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0788">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0789">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0790">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0791">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,625</ix:nonFraction></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td><span style="font-size: 7pt">&#160;</span></td>
    <td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0793">&#8212;</span></span></td><td style="text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">358,625</ix:nonFraction></span></td><td style="font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_zFSoZJh54Bol" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">Net Loss</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0796">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0797">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0798">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0799">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0800">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0801">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0802">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0803">&#8212;</span></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 1.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,578,905</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 1.5pt; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,578,905</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  <tr id="xdx_43F_c20200401__20200630_eus-gaap--StockholdersEquity_iE_zeIQeZeiJetl" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; font-weight: bold"><span style="font-size: 7pt">Balance at June 30, 2020</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_985_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAConvertiblePreferredStockMember_zVDEwYrFeXZ8" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0818">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0807">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesBConvertiblePreferredStockMember_zNXTfMCfhLTl" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0820">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0808">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98E_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesCConvertiblePreferredStockMember_zxCY6nkZShB5" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0822">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0809">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_980_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesDConvertiblePreferredStockMember_zXuFfbHo8Dsd" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0824">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0810">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesDOneConvertiblePreferredStockMember_zkv5bTf5CFX3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0826">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><span style="-sec-ix-hidden: xdx2ixbrl0811">&#8212;</span></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementClassOfStockAxis__custom--SeriesAlphaConvertiblePreferredStockMember_zxqXWdvRFYi3" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,620</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z9bjAlGTBNv2" title="Ending balance, shares" style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,588,258</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,588</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 7pt"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">52,713,683</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 7pt">&#160;</span></td><td style="padding-bottom: 2.5pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">65,880,031</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font-size: 7pt">)</span></td><td style="padding-bottom: 2.5pt; font-size: 10pt"><span style="font-size: 7pt">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: left"><span style="font-size: 7pt">$</span></td><td style="border-bottom: Black 2.5pt double; font-size: 10pt; text-align: right"><span style="font-size: 7pt">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">13,152,756</ix:nonFraction></span></td><td style="padding-bottom: 2.5pt; font-size: 10pt; text-align: left"><span style="font-size: 7pt">)</span></td></tr>
  </table>

<p style="margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_005"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_300_112_z8HJe5kXVF84" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="display: none; text-align: left; padding-left: 10pt">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_498_20210101__20210630_z0u9hN1yqXLi" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td><td style="display: none">&#160;</td>
    <td style="display: none; text-align: left">&#160;</td><td id="xdx_49E_20200101__20200630_z6hFNCWU6EP5" style="display: none; text-align: right">&#160;</td><td style="display: none; text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the Six Months<br />
 Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB_z0qEdrCZ7Dri" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM OPERATING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_maCznmw_z8z9xcYdywf7" style="vertical-align: bottom; background-color: White">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,977,860</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">19,451,480</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B_zSWnMm2pvRy6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--DepreciationDepletionAndAmortization_i02_maCznmw_zmyFMIQepqSi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Depreciation and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">53,736</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">82,833</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--OperatingLeaseRightOfUseAssetAmortization_i02_maCznmw_zOqihyTBie6a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Amortization of right-of-use assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:OperatingLeaseRightOfUseAssetAmortization" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">109,719</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:OperatingLeaseRightOfUseAssetAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">50,318</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--ProvisionForDoubtfulAccounts_i02_maCznmw_zqDwRPDqdJL2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accounts receivable reserves and allowances</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,645</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProvisionForDoubtfulAccounts" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">19,951</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--InventoryWriteDown_i02_maCznmw_zNYLtRIz8ZH1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Inventory reserves</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">40,644</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InventoryWriteDown" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2,828</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_400_eus-gaap--ShareBasedCompensation_i02_maCznmw_zaISQPPE3JAj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Stock-based compensation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,549,049</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">366,491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--FairValueAdjustmentOfWarrants_i02_maCznmw_zindzz4kfsMc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">4,198,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">16,201,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i02B_z2pRi4C49OS2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncreaseDecreaseInAccountsReceivable_i03N_di_msCznmw_zL5lKJ7Yonma" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accounts receivable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">154,799</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">798,585</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--IncreaseDecreaseInInventoryAndEquipmentHeldForLease_i03_maCznmw_zPQqttHSTAn3" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Inventory and equipment held for lease</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLease" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">89,617</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLease" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">20,236</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--IncreaseDecreaseInPrepaidExpensesOther_i03N_di_msCznmw_zUZkfmfmoxe1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Prepaid expenses and other assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">746,787</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidExpensesOther" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,016,203</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--IncreaseDecreaseInAccountsPayable_i03_maCznmw_zp1PCQeK6ZRf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">283,706</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">188,840</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_i03_maCznmw_zmZZ1Utl6h0d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Accrued expenses and other current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,176,970</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,072,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_ecustom--IncreaseDecreaseInLeaseLiabilities_i03_maCznmw_zWU2xYtDXqgi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:IncreaseDecreaseInLeaseLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">122,780</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="QLGN:IncreaseDecreaseInLeaseLiabilities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">54,775</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--IncreaseDecreaseInContractWithCustomerLiability_i03_maCznmw_zxQ43XSquB15" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Deferred revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">206,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">57,668</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_mtCznmw_maCzgUG_zkSj9nExKmJi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,785,057</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">1,782,080</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB_zg2akIklg9Bg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM INVESTING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--PaymentsToAcquirePropertyPlantAndEquipment_i01N_di_msCzPkk_zNt17SrBzYGj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Purchases of property and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">107,798</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">110,427</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--PaymentsToAcquireIntangibleAssets_i01N_di_msCzPkk_zHfMmEZeb9Ma" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Payments for patents and licenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">382,732</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_mtCzPkk_maCzgUG_zGLC8wDmn1B3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">114,691</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">493,159</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB_zfmy7oBpsiB3" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">CASH FLOWS FROM FINANCING ACTIVITIES:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfPrivatePlacement_i01_maCzAZP_zdxJxAVrUtEk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from issuance of Series Alpha preferred shares upon closing of private placement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,010,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--ProceedsFromNotesPayable_i01_maCzAZP_z5OPu1aO8An5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Net proceeds from the issuance of notes payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,682,661</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ProceedsFromWarrantExercises_i01_maCzAZP_zvYMopEvcHTa" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Proceeds from warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,319</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0908">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RepaymentsOfNotesPayable_i01N_di_msCzAZP_zG8wPT2yMQDh" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Principal payments on notes payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">138,739</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,164,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_mtCzAZP_maCzgUG_z9lXel1Na7K6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">155,580</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,528,661</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_mtCzgUG_z7x8McqGgVud" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Net change in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,744,168</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,253,422</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_z83dvJfiNIZk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">CASH AND CASH EQUIVALENTS &#8211; beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">23,976,570</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">128,696</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_z6IJCubZVhlk" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">CASH AND CASH EQUIVALENTS &#8211; end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,232,402</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2,382,118</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--SupplementalCashFlowInformationAbstract_iB_zAB9T1CkF923" style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--CashPaidForAbstract_iB_z8snxev2pOwc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash paid for:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,683</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,487</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Taxes</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,200</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,014</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB_zs3cXkPhK87c" style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>NONCASH FINANCING AND INVESTING ACTIVITIES:</b></span></p></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_ecustom--IssuanceOfCommonStockForProfessionalServices_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt; text-align: left">Issuance of common stock for professional services</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:IssuanceOfCommonStockForProfessionalServices" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">101,750</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:IssuanceOfCommonStockForProfessionalServices" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">240,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DebtConversionOriginalDebtAmount1_i01_zUPMp0sfTyG5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Issuance of common stock for conversion of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0943">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:DebtConversionOriginalDebtAmount1" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,350,198</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_ecustom--IssuanceOfCommonStockForConversionOfAccruedInterest_i01_ziIdiK026Qg5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Issuance of common stock for conversion of accrued interest</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0946">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfAccruedInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">234,210</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--IssuanceOfCommonStockForConversionOfPreferredStock_i01_zZIwEErzIHu1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Issuance of common stock for conversion of preferred stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0949">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:IssuanceOfCommonStockForConversionOfPreferredStock" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">148,690</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_ecustom--IssuanceOfPreferredStockForConversionOfDebt_i01_znafzoXZiymd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Issuance of preferred stock for conversion of debt</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0952">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:IssuanceOfPreferredStockForConversionOfDebt" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">350,000</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement_i01_zbm734UsRpS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Fair value of shares issued to advisor upon closing of private placement</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0955">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">902,250</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_i01_zPExsA0GHR2e" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Fair value of warrants issued to advisor upon closing of private placement</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0958">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">202,858</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--EffectOfReverseRecapitalization_i01_z6R7MCd1yRei" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Effect of reverse recapitalization</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0961">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:EffectOfReverseRecapitalization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">810,886</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_402_ecustom--InitialMeasurementOfOperatingLeaseRightofuseAssets_i01_zytSOBuV6Tq2" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Initial measurement of operating lease right-of-use assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0964">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:InitialMeasurementOfOperatingLeaseRightofuseAssets" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">663,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_ecustom--NetTransfersToInventoryFromEquipmentHeldForLease_i01_zUCNn0iMJm3d" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt">Net transfers to inventory from equipment held for lease</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:NetTransfersToInventoryFromEquipmentHeldForLease" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,304</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0968">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_006"></span>QUALIGEN
THERAPEUTICS, INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Unaudited)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zzGqGWJYEpF2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1 &#8212; <span id="xdx_826_zjrCLcqTrMl">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:OrganizationPolicyTextBlock"><p id="xdx_843_ecustom--OrganizationPolicyTextBlock_zpwygdJ0lrG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zyZAFSLnlQQ3">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221;) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.&#8217;s capital stock were exchanged for Qualigen Therapeutics,
Inc.&#8217;s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol &#8220;RTTR,&#8221; commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol &#8220;QLGN&#8221; on May 26, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qualigen,
Inc. was determined to be the accounting acquirer in a reverse recapitalization based upon the terms of the merger and other factors.
All references to financial figures of the Company presented in the accompanying condensed consolidated financial statements and in these
Notes through May 22, 2020 are to those of Qualigen, Inc. All references to financial figures after May 22, 2020 are to those of Qualigen
Therapeutics, Inc. and Qualigen, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_845_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zmadOOwyuhVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_za6Kn8G6tyB7">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission
(&#8220;SEC&#8221;) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should
be read in conjunction with the audited financial statements and notes thereto contained in the Company&#8217;s Transition Report on
Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 31, 2021. In the opinion of management, the accompanying
condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading.
The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other
future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited
financial statements for the most recent fiscal year as reported in the Company&#8217;s Transition Report on Form 10-K have been omitted.
The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited balance sheet at December
31, 2020 contained in such Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zGTCw7etT4N1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zZUP69kkfxPb">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned
subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable
guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:UseOfEstimates"><p id="xdx_841_eus-gaap--UseOfEstimates_z0lSKQfjPQt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zTLxBTpfgUJe">Accounting
Estimates </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation,
write-off of patents and licenses, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and
warranty costs. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBSstpTFtg83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_znxLp2OVmSgc">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company maintains its cash and cash equivalents in bank deposits which at times may exceed federally insured limits. The Company has
not experienced any losses in such accounts and believes it is not exposed to any significant credit risks on cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:InventoryPolicyTextBlock"><p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z1J1S9bzyx6d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zxVC5aoFwVPe">Inventory,
Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records specific reserves for identified items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13Usu4O9oQ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zr72LivyHt9">Long-Lived
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three months and six months periods ended June 30, 2021
and 2020, <span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210101__20210630_zRrhw7o42pv8" title="Long-lived assets impairment losses"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200101__20200630_zDkes1HZANW7" title="Long-lived assets impairment losses"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210401__20210630_zVdcw2M5jRPh" title="Long-lived assets impairment losses"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200401__20200630_zoWZyNNnND6g" title="Long-lived assets impairment losses"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2020-01-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2021-04-012021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="From2020-04-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> such impairment losses have been recorded. All long-lived assets of the Company are located in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:TradeAndOtherAccountsReceivablePolicy"><p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zVpRYEku6J79" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zuyumM9NCDYg">Accounts
Receivable, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the creditworthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#8217;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">784,429</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableGrossCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">629,630</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,517</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,873</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Accounts receivable, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">766,911</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">615,757</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zZdyffaZrq1i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVtfKVLGbQuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zwc5fojeouqe">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company expenses research and development costs as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ShippingAndHandlingCostsPolicyTextBlock"><p id="xdx_844_ecustom--ShippingAndHandlingCostsPolicyTextBlock_ztZhHIaeTcDh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_z2BqBwkVfmMc">Shipping
and Handling Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zJGR7OcjBcs2" title="Shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630_zRxE5bOpJ6ef"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></span>, respectively, for the three
months ended June 30, 2021 and 2020, and approximately $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630_pp0p0" title="Shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,000</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630_pp0p0" title="Shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">56,000</ix:nonFraction></span>, respectively, for the six months ended June 30, 2021 and
2020. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing expenses
totaled approximately $<span id="xdx_90D_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z8nO35EuYhR4" title="Shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-04-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zFhWBbNeQGHc"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-04-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000</ix:nonFraction></span> for the three months ended June 30. 2021 and 2020, respectively, and approximately $<span id="xdx_90F_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2021-01-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span> and
$<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs"><ix:nonFraction name="us-gaap:CostOfGoodsAndServicesSold" contextRef="From2020-01-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000</ix:nonFraction></span> for the six months ended June 30, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zW2BUDsO4TJh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zbSF2phBMy89">Revenue
from Contracts with Customers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 1, 2020, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i>Revenue from Contracts with Customers
</i>(&#8220;ASC 606&#8221;), using the modified retrospective approach. The adoption of ASC 606 did not have a material impact on the
measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of the adoption date of April
1, 2020. Therefore, no cumulative adjustment has been made to the opening balance of accumulated deficit at April 1, 2020. The comparative
information has not been restated and continues to be reported under the accounting standards in effect for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Product
Sales</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs which are diagnostic tests for PSA, testosterone, thyroid disorders, pregnancy, and Vitamin
D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#8220;analyzer&#8221;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#8220;FOB&#8221;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#8217;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfil the promise to transfer the disposable products and not as a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#8217;s
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License
Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During the three months ended June 30, 2021 and 2020, the Company recognized
license revenue of $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zykC2i3HoA76" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1027">0</span></span> and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zHhXBTbPYKo2" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1028">0</span></span>, respectively, and during the six months ended June 30, 2021 and 2020, the Company recognized license revenue
of $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zed2L7Ioq7Bg" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_LicenseRevenueMember" format="ixt:numdotdecimal" decimals="-3" scale="0" unitRef="USD">479,000</ix:nonFraction></span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_z5jehxvl04df" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1032">0</span></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<ix:exclude><!-- Field: Page; Sequence: 9; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Collaborative
Research Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606, the Company recognized research revenue over the term of various agreements, as negotiated contracted amounts
were earned or reimbursable costs were incurred related to those agreements. Negotiated contracted amounts were earned in relative proportion
to the performance required under the applicable contracts. Any amounts received prior to satisfying these revenue recognition criteria
were recorded as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the
entity satisfies the relevant performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Collaborative
research revenue is recognized as research services are performed over the development periods for each agreement. During the three months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zGx3zEhB6eMa" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1034">0</span></span> and $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zxrpEkq22s" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1035">0</span></span>, respectively, and during the six months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zlTtTSiS0esc" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1037">0</span></span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_pp0p0" title="Revenues"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,000</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Contract
Balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
timing of the Company&#8217;s revenue recognition may differ from the timing of payment by the Company&#8217;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606 effective April 1, 2020 (using the modified retrospective approach), the Company accounted for its revenue
arrangements under ASC 605, Revenue Recognition (&#8220;ASC 605&#8221;). Under ASC 605, revenue arrangements with multiple deliverables
were evaluated for proper accounting treatment. In these arrangements, the Company recorded revenue as separate units of accounting if
the delivered items have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative
to the delivered items, and if delivery or performance of the undelivered items is considered probable and substantially within the Company&#8217;s
control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
ASC 605, revenues from product sales which included both the analyzer and various immunoassay products (&#8220;reagents&#8221;) were
generally recognized upon shipment, as no significant continuing performance obligations remained post shipment. Cash payments received
in advance were classified as deferred revenue and recorded as a liability. The Company was generally not contractually obligated to
accept returns, except for defective products. Revenue was recorded net of an allowance for estimated returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Multiple
element arrangements included contracts that combined both the Company&#8217;s analyzer and a customer&#8217;s future reagent purchases
under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was
maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated returns of approximately $<span id="xdx_905_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20210401__20210630_z7NYC0kl3Xm8" title="Estimated returns net of allowances"><ix:nonFraction name="QLGN:EstimatedReturnsNetOfAllowances" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>
and $<span id="xdx_90A_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20200401__20200630_za6TsZHWm2Ha"><ix:nonFraction name="QLGN:EstimatedReturnsNetOfAllowances" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000</ix:nonFraction></span>, respectively. During the six months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated
returns of approximately $<span id="xdx_901_ecustom--EstimatedReturnsNetOfAllowances_c20210101__20210630_pp0p0" title="Estimated returns net of allowances"><ix:nonFraction name="QLGN:EstimatedReturnsNetOfAllowances" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_903_ecustom--EstimatedReturnsNetOfAllowances_c20200101__20200630_pp0p0" title="Estimated returns net of allowances"><ix:nonFraction name="QLGN:EstimatedReturnsNetOfAllowances" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Deferred
Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606, payments received in advance from customers pursuant to certain collaborative research and license agreements,
deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current
deferred revenue liability based on the time from the balance sheet date to the future date of revenue recognition. The adoption of ASC
606 had no material effect on deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LesseeLeasesPolicyTextBlock"><p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zkwYxQRHfu7f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zhqJeuVqvP43">Operating
Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company adopted ASC Topic 842, <i>Leases</i> (&#8220;Topic 842&#8221;) in the nine-months transition period ended December 31, 2020.
In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding right-of-use-assets for all
leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for in a manner similar to the
guidance for operating leases prior to the adoption of Topic 842. Refer to Recent Accounting Pronouncements below and Note 8 for
more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPRki3wNZEde" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zj4qokND7Ib8">Property
and Equipment, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock"><p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zgbdMTw9LWNb" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"><span style="font: 10pt Times New Roman, Times, Serif">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2021-01-012021-06-30_us-gaap_MachineryAndEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2021-01-012021-06-30_us-gaap_ComputerEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">3</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2021-01-012021-06-30_us-gaap_ToolsDiesAndMoldsMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_OfficeFurnitureAndEquipmentMember" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife">5</ix:nonNumeric></span>
    years</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A8_zS4L8HTdKZI9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:IntangibleAssetsFiniteLivedPolicy"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5Rg8dVyuxn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zpmermdSsUy">Intangible
Assets, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Intangibles
consist of patent-related costs and costs for in-license agreements. Management reviews the carrying value of intangible assets that
are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment
exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends
and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected
to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MinimumMember_zfs2rfRygQn8" title="Estimated useful lives"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">5</ix:nonNumeric></span> to <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MaximumMember_zzq4DvoKUDMa" title="Estimated useful lives"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife">17</ix:nonNumeric></span>
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent has been obtained.
Patent and licenses costs are charged to operations if it is determined that the patent will not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the patents of approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">168,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">169,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at June 30, 2021 and December 31, 2020, respectively,
are stated net of accumulated amortization of approximately $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">303,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2021 and 2020 was approximately $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3v0zQLmdV6"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-04-012020-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each period, and for the six months ended
June 30, 2021 and 2020 was approximately $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each period. Total future estimated amortization
of patent costs for the five succeeding years is approximately $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znkm94YkiKci"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the remaining six months in the year
ending December 31, 2021, approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7shlPclUFP5"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,000</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each of the years ending December 31, 2022
through 2023, approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAEaHE3uqRK3" title="Future estimated amortization for year ending December 31, 2024"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for year 2024, approximately $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjz7njIiVoy" title="Future estimated amortization for year ending December 31, 2025"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for year 2025 and approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2j1ZVeBMoR4" title="Future estimated amortization, Thereafter"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" contextRef="AsOf2021-06-30_us-gaap_PatentsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">108,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the in-licenses of approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="AsOf2020-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,000</ix:nonFraction></span> at June 30, 2021 and December 31, 2020 are stated net of accumulated
amortization of approximately $<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">403,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="AsOf2020-12-31_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">400,000</ix:nonFraction></span>, respectively. Amortization of licenses charged to operations for the three months
ended June 30, 2021 and 2020 was approximately $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8YvYvtaC6Tj" title="Amortization expense"><span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxA8zHH8UQz7" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-04-012021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-04-012020-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></ix:nonFraction></span></span>, and for the six months ended June 30, 2021 and 2020 was approximately $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2021-01-012021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span> and
$<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdWTl5CE1vvf" title="Amortization expense"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" contextRef="From2020-01-012020-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000</ix:nonFraction></span>, respectively. Total future estimated amortization of license costs is approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zjy5zkQ7KGW" title="Future estimated amortization, remainder of fiscal year"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" contextRef="AsOf2021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000</ix:nonFraction></span> for the remaining six months in the
year ending December 31, 2021, approximately $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2022"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="AsOf2021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,000</ix:nonFraction></span> for the year ending December 31, 2022 and approximately $<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2023"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="AsOf2021-06-30_us-gaap_LicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span> for the year ending
December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock"><p id="xdx_849_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_zbwmhrCnUZxl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zI47w6nORUMl">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company
uses either the Black-Scholes option-pricing model or a Monte Carlo simulation to value the derivative instruments at inception and subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is re-assessed at the end of each reporting period (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zFzmkGcDqPof" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zbv4T442pOn8">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 - Inputs that are unobservable. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:FairValueOfFinancialInstrumentsPolicy"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztpH2j2FsKdg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zS8v1jlo1Eha">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt are carried at cost, which management believes
approximates fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CompensationRelatedCostsPolicyTextBlock"><p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zPt7xnUlRljk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zPl0T18VEjFi">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company-issued
stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation
expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zHrnRPHbJan3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_z2q0zNL63lLl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
The components of the deferred tax asset and liability are individually classified as current and noncurrent based on their characteristics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:SalesAndExciseTaxesPolicyTextBlock"><p id="xdx_844_ecustom--SalesAndExciseTaxesPolicyTextBlock_zjnO3gcEnz52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zOX37w6oIsXj">Sales
and Excise Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the balance sheet as cash is collected from customers and remitted to the
tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:WarrantyCostsPolicyTextBlock"><p id="xdx_849_ecustom--WarrantyCostsPolicyTextBlock_zaRanNxFwzwh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zzOJlFS5EOoe">Warranty
Costs </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#8217;s best estimates of analyzer failure rates
and costs to repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
warranty liabilities were approximately $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">48,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span>, respectively, for the periods ended June 30, 2021 and December 31, 2020
and are included in accrued expenses and other current liabilities on the balance sheets. Warranty costs were approximately $<span id="xdx_90E_ecustom--WarrantyCosts_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLArjq1M0zFg" title="Warranty costs"><ix:nonFraction name="QLGN:WarrantyCosts" contextRef="From2021-04-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span> and
$<span id="xdx_90C_ecustom--WarrantyCosts_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM9DQPsjm61b"><ix:nonFraction name="QLGN:WarrantyCosts" contextRef="From2020-04-012020-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">31,000</ix:nonFraction></span> for the three months ended June 30, 2021 and 2020, respectively, and approximately $<span id="xdx_906_ecustom--WarrantyCosts_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs"><ix:nonFraction name="QLGN:WarrantyCosts" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">41,000</ix:nonFraction></span> and $<span id="xdx_904_ecustom--WarrantyCosts_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs"><ix:nonFraction name="QLGN:WarrantyCosts" contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,000</ix:nonFraction></span> for the six months ended
June 30, 2021 and 2020, respectively, and are included in cost of product sales in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGsIPjhAUcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is calculated by dividing
the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.
Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents
outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, employee stock
purchase plan rights, restricted stock units, and warrants, and convertible preferred stock are considered to be common stock equivalents
but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be anti-dilutive.
The Company incurred net losses for all periods presented and there were no reconciling items for potentially dilutive securities. More
specifically, at June 30, 2021 and 2020, stock options, warrants, and convertible preferred stock exercisable
or convertible for approximately <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20210101__20210630_ztVfLrEYZEGd"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">13.9</ix:nonFraction>
</span>million shares and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20200101__20200630_zCvq2P9SIIMl"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="Shares">16.5</ix:nonFraction>
</span>million shares, respectively, were excluded from the calculation of diluted net loss per share as their effect would have been
anti-dilutive. Comprehensive loss is the same as net loss for all periods presented.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLVYGecyFne3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zhmEcnMuVYBd">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when
it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses
on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition
of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued
ASU No. 2019-10, Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842),
which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard
will be effective for the Company in the first quarter of the fiscal year beginning January 1, 2023, and early adoption is permitted.
The Company has not completed its review of the impact of this standard on its consolidated financial statements. However, based on the
Company&#8217;s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard
will have a material effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair
Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221;
an amendment to the accounting guidance on fair value measurements. The guidance modifies the disclosure requirements on fair value measurements,
including the removal of disclosures of the amount of and reasons for transfers between Level 1 of the fair value hierarchy, the policy
for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain
disclosure requirements related to Level 3 fair value measurements. The guidance is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019. The Company adopted ASU No. 2018-13 on April 1, 2020 and the adoption of this guidance
did not have a material impact on its financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major
separation models required under prior U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts
to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU
2020-06 is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the
beginning of the Company&#8217;s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric></ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:SubstantialDoubtAboutGoingConcernTextBlock"><p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zoiprZkNN32f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2 &#8212; <span id="xdx_82A_zXlWPEpBMtD2">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has incurred recurring losses from operations and has an accumulated deficit at June 30, 2021, and the Company expects to continue
to incur losses subsequent to the balance sheet date of June 30, 2021. The Company&#8217;s reverse recapitalization transaction with
Ritter closed in May 2020 together with an associated new equity capital raise of approximately $<span id="xdx_90A_ecustom--NewEquityCapitalRaise_pn5n6_c20200501__20200531_zqUoCRTS0LA" title="New equity capital raise"><ix:nonFraction name="QLGN:NewEquityCapitalRaise" contextRef="From2020-05-012020-05-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million, and approximately $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20200531_zFCoqLGzMJM1" title="Convertible notes payable"><ix:nonFraction name="us-gaap:ConvertibleNotesPayable" contextRef="AsOf2020-05-31" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span>
million in convertible notes payable were converted into shares of the Company&#8217;s capital stock. In July, August and December 2020,
the Company raised an additional $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z1vQOJCCNDjj" title="Proceeds from sale of equity"><span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200801__20200831__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zztW8WkqmUKh" title="Proceeds from sale of equity"><span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zzYgTIiBjor8" title="Proceeds from sale of equity"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-07-012020-07-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-08-012020-08-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" contextRef="From2020-12-012020-12-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">30.0</ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span> million through three Securities Purchase Agreements with a single institutional investor (see
Note 10). Based on the Company&#8217;s current cash position, currently planned expenditures and level of operations, the Company
believes it has sufficient capital to fund operations for the 12-month period subsequent to the issuance of the interim financial information.
However, there is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on a continuing basis.
Also, beyond such 12-month period, planned research and development activities, capital expenditures, clinical and pre-clinical testing,
and commercialization activities of the Company&#8217;s products are expected to require significant additional financing. Additional
financing may not be available on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:InventoryDisclosureTextBlock"><p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_ziy8oKxYjJPf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3 &#8212; <span id="xdx_82D_zb0217Ucayll">INVENTORY, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock"><p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zweDtfgSxQ6a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory,
net consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zyek1WxxDOR4" style="display: none">SCHEDULE
OF INVENTORY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210630_zddzIVsz88J6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20201231_zqmjVAirAkSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINz4Kh_z5xcwEDCHx25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">779,936</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:InventoryRawMaterials" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">579,765</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINz4Kh_zjdyDzKJfQQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">241,677</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">309,826</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINz4Kh_zYCMrqiKQ5a6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">51,722</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,867</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryNet_iTI_pp0p0_mtINz4Kh_zB9CNfzPsgB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Inventory net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,073,335</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:InventoryNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">953,458</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of June 30, 2021 and December 31, 2020, total inventory is recorded
net of inventory reserves of $149,000 and $108,000, respectively.</p>

</ix:nonNumeric><p id="xdx_8A6_z5oJsBpY1luf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>



</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock"><p id="xdx_80E_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zP6z8batpk9g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4 &#8212; <span id="xdx_822_zqEItuj9Liw8">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"><p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zTrCqblKHtn5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zw9lcaI91hWf" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210630_zTj5DmXdaem2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20201231_zfWuwFIvMfxg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzTBJ_zb3uxuB9si06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,916,387</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,307,864</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidManufacturingExpenses_iI_pp0p0_maPEAOAzTBJ_zsIu2p5Wbkgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:PrepaidManufacturingExpenses" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,617</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:PrepaidManufacturingExpenses" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,181,029</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--PrepaidInvestorRelationsExpenses_iI_pp0p0_maPEAOAzTBJ_zsBsOWTQ2nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid investor relations expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:PrepaidInvestorRelationsExpenses" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">49,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:PrepaidInvestorRelationsExpenses" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzTBJ_zjRQVQOU3ym1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,726</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,001</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzTBJ_zKLqbdsBQmw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,033,857</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,678,894</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A8_zzUszgzqVto6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXoWru4FyZyf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5 &#8212; <span id="xdx_824_zKY5Ri9mxDb1">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8vn5kLdV2Vj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment, net consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B3_zQPlJkdETztl" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zUN0RR2satU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zte766wi6Fr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhZDykO8MJs" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,409,946</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_MachineryAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,401,470</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_zNNg3LU1HtBc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Construction in progress&#8211;equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_custom_ConstructionInProgressEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,717</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_ConstructionInProgressEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">104,400</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTJvxMrKYNJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">472,094</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">443,865</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJsUcYOnRNW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">327,894</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">321,033</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zKCMD3ln1hQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Molds and tooling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_us-gaap_ToolsDiesAndMoldsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,002</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_us-gaap_ToolsDiesAndMoldsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">260,002</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_znB86KyBRn33" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30_custom_OfficeFurnitureAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">143,013</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31_custom_OfficeFurnitureAndEquipmentMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">138,699</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzgSC_z2npNgYtg1Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,707,666</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,669,469</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzgSC_zEl0k06NM36j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,454,405</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,422,146</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzgSC_zzGX836GFucc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">253,261</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">247,323</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zrTNH6DuEFlf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense relating to property and equipment was approximately $<span id="xdx_90A_eus-gaap--Depreciation_c20210401__20210630_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20200401__20200630_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,000</ix:nonFraction></span> for the three months ended June 30, 2021 and 2020, respectively,
and $<span id="xdx_90F_eus-gaap--Depreciation_c20210101__20210630_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">32,000</ix:nonFraction></span> and $<span id="xdx_902_eus-gaap--Depreciation_c20200101__20200630_pp0p0" title="Depreciation expense"><ix:nonFraction name="us-gaap:Depreciation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,000</ix:nonFraction></span> for the six months ended June 30, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zUZIrEOaPobk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6 &#8212; <span id="xdx_827_ziVLcjfC4Ea1">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zknWsIWftFY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zeLQwaM7pAPd" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210630_zNqkTzsNOZd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zi57gCz66qd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedCompensation_iI_pp0p0_maALCz4Fv_zM89Pg3c6Jc1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="QLGN:AccruedCompensation" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,776</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><ix:nonFraction name="QLGN:AccruedCompensation" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,091</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCz4Fv_zXu34xOTSRli" style="vertical-align: bottom; background-color: White">
    <td>Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">290,587</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedVacationCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230,457</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCz4Fv_zUnW6pFqF934" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedRoyaltiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">491</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCz4Fv_z1a9YqTVYZ1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">744,640</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedResearchAndDevelopmentCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">237,504</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCz4Fv_z3BwqWil0ZF9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">271,377</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">58,261</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedWarrantyCostsCurrent_iI_pp0p0_maALCz4Fv_z142s1ScbKS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warranty costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedWarrantyCostsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,854</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedWarrantyCostsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,871</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCz4Fv_zdf0hc56hNZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">176,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedPayrollTaxesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,566</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccruedPatentAndLicenseFeesCurrent_iI_pp0p0_maALCz4Fv_zVXXmR9dGz24" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent and license fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="QLGN:AccruedPatentAndLicenseFeesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,204</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maALCz4Fv_z0MM8Hb8QPr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Franchise, sales and use taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,130</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:SalesAndExciseTaxPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">30,353</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCz4Fv_zvdb97Z8BTwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,261</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedIncomeTaxesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,326</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCz4Fv_z6U54f6BSU4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">317,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">134,614</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCz4Fv_zLe38PjFctJg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Accrued expenses and
    other current liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,923,708</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">746,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A9_zcAuYlfE27Cg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:WarrantLiabilitiesTextBlock"><p id="xdx_80E_ecustom--WarrantLiabilitiesTextBlock_z6nQsV0augN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7 &#8211; <span id="xdx_822_zbIvoxysRFYe">WARRANT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#8220;Series C Warrants&#8221;). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted. The Series C Warrants were classified as liabilities, but had minimal fair value prior to the merger with Ritter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase an aggregate of
<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_pdd"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,713,490</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company&#8217;s common stock at
$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_pdd"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, subject to adjustment. As of June
30, 2021, the warrants received in exchange for the Series C Warrants have remaining terms ranging from <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MinimumMember_zYLP8QH5cbJ2"><ix:nonNumeric contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.4</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MaximumMember_zSZGUbFmXjU2"><ix:nonNumeric contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.0</ix:nonNumeric>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years. The warrants were determined to be
liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged ratchet provision for
subsequent dilutive issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" continuedAt="ConU001270-01" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-HVF_zIBruZ56MXte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants for the six months ended June
30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BF_zkvxIGOm7U5b" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock Warrants (received in exchange for the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Series C Warrants)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining<br /> Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zDaxPDbnKUl5" title="Number of Shares, Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,378,596</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zStbWShS2lMf" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zg9vSYTLyv0l" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCvou4jClwBf" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">542,737</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Forfeited" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">36,097</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1290">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1292">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcbNS4q2OtX" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,762</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCmR7vjK49T" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zkoYGshadwE9" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,799,762</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zfuT5h3k2XGa" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zgPYgZcHeZB7" title="Range of Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zRdhng9g0ri5" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">2.5</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zyjRbB8a89y9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Of
the <span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Shares issued upon the exercise of warrants"><ix:nonFraction name="QLGN:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">542,737</ix:nonFraction></span> shares issued upon the exercise of warrants (previously received in exchange for the Series C Warrants) during the six months
ended June 30, 2021, <span id="xdx_90C_ecustom--NumberOfWarrantExercisedOnCashlessBasis_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUTMA63LIrG8" title="Shares issued upon net-exercise of warrants"><ix:nonFraction name="QLGN:NumberOfWarrantExercisedOnCashlessBasis" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">156,861</ix:nonFraction></span> shares were issued upon net-exercises rather than upon exercises for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants activity for the six months ended
June 30, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<div id="xdx_C02_gL3SOSENWORTB-HVF_zmp4GprQzn33"><ix:continuation continuedAt="ConU001270-02" id="ConU001270-01"><table cellpadding="0" cellspacing="0" id="xdx_306_133_z9cZFuv8bvj9" summary="xdx: Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock Warrants (received in exchange for the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Series C Warrants)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211; Average Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total outstanding &#8211; December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z55WScidoXii" title="Number of Shares, Warrants Outstanding Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzg5D37vqJx9" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z5F2hAAfkbyg" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,713,490</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzYYlcEHss7g" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger" style="width: 12%; text-align: right"><ix:nonFraction name="QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Number of Shares, Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1328">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Granted" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1330">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCZPSOaRBzk5" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,713,490</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zrQKZTCBhAA6" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zNRnfOYyDl3" title="Number of Shares, Warrants Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,713,490</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zXoyCEVmqAse" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" title="Range of Exercise Price, Exercisable" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.72</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zQqW9Rqd8c3a" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">3.82</ix:nonNumeric></span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C07_gL3SOSENWORTB-HVF_zlWKVsXUPWPc"><ix:continuation id="ConU001270-02">&#160;</ix:continuation></span></span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock"><p id="xdx_896_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zci8YKS0KK1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents the Company&#8217;s fair value hierarchy for its warrant liabilities (all of which arise under the warrants
received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span id="xdx_8BB_zCeGJCyPl59i" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 2.5pt">Balance as of December 31. 2020</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcWsKV4o9Ecg" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ikU4uxxzNa" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeOj9aLw7l81" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,310,100</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231_zTuVPoyBlM0c" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2020-01-012020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,310,100</ix:nonFraction></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7Mj8rQWaWJj" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLbedbEb8mnf" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx8I03Rnxbyg" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,112,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630_zIKu76ZVXgH1" title="Fair value for warrant liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="QLGN:FairValueAdjustmentOfWarrant" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,112,100</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zj0RwQwpELYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were no transfers of financial assets or liabilities between category levels for the three and six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021 the Company recorded</span> <span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh2rXF5byK3b"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.2</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million gain
</span><span style="font: 10pt Times New Roman, Times, Serif">in other income because the fair value of the
warrant liabilities declined to $<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbs361zMjhj6"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.1</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvL4sTmvT0Pj"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.3</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million at December 31, 2020, primarily due to
a reduction in the stock price and to warrant exercises. For the six months ended June 30, 2020, change in fair value of warrant liabilities
was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zssDGYyspVSj"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">16.2</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million due to the reverse recapitalization transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock"><p id="xdx_898_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zlfJeT57pXwg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of June 30, 2021 and December
31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_z8MEEy2aESzg" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June
    30, 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December
    31, 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zK94R0DS9ZS1" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.34</ix:nonFraction></span>%
    &#8212; <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zntNlY0eUaI5" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.46</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%<span style="font: 10pt Times New Roman, Times, Serif"></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zwKTxpiUH5Yl" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.17</ix:nonFraction></span>%
    &#8212; <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zNCCsWNJwP7g" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.22</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    volatility (peer group)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_za9tyFt3yra7" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">82.00</ix:nonFraction></span>
    &#8212; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zATWqLnWH8ja" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">83.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOahHKARziM2" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">82.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Term
    of warrants (in years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zTGA01eevXn8" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.41</ix:nonNumeric></span>
    &#8212; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z7JuTZjNTKIf" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.99</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zomSgy8h899d" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">2.90</ix:nonNumeric></span>
    &#8212; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zb0kn7hRmcqc" title="Fair value assumptions, measurement input, term"><ix:nonNumeric contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember" format="ixt-sec:duryear" name="us-gaap:WarrantsAndRightsOutstandingTerm">3.49</ix:nonNumeric></span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zwf9yBh3xzkb" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2021-06-30_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCwGmmUYzigf" title="Fair value assumptions, measurement input, percentages"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AA_ztiBgY0ZQg81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LeasesOfLesseeDisclosureTextBlock"><p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zPErSFj5Pmdd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8 &#8212; <span id="xdx_825_zl6DYcI8hvDg">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock"><p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_zoVpgJ3yxoz7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases its facilities under a long-term operating lease agreement expiring in October 2022. The tables below show the operating
lease right-of-use assets and operating lease liabilities as of December 31, 2020 and June 30, 2021, including the changes during the
periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zxgSC1D22YA5" style="display: none">SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br />
 right-of-use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net right-of-use assets at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zB6B7GBLTW6e" title="Operating lease right-of-use assets" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">430,795</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amortization of operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9Hs7w4GqnMb" title="Less amortization of operating lease right-of-use assets" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="From2021-01-012021-06-30_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">109,719</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z8EMRGxbC3F9" title="Operating lease right-of-use assets" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">321,076</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br />
 liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">At December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zVGOAE31lqcf" title="Operating lease liabilities" style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">491,565</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less principal payments on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zz2UiEkr3aO1" title="Less principal payments on operating lease liabilities" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="From2021-01-012021-06-30_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">122,780</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zgVasBo025h4" title="Operating lease liabilities" style="text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,785</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z5OgPJ56SJpg" title="Less non-current portion" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">98,145</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Current portion at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_ztDMb9pI3DEf" title="Current portion at June 30, 2021" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">270,640</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zrdgvJmWKH7i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company&#8217;s operating leases have a weighted-average remaining lease term of <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210630_z2G09xQT506c" title="Weighted-average remaining lease term"><ix:nonNumeric contextRef="AsOf2021-06-30" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.3</ix:nonNumeric></span> years and a weighted-average
discount rate of <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20210630_zd13cRMMm1c6" title="Discount rate operating lease"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">8.9</ix:nonFraction></span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zdtcnbpO4Pt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, future minimum payments during the next five fiscal years and thereafter are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zJZzWsebBMSi" style="display: none">SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2021 (six months)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" title="2021 (nine months)" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">145,958</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" title="2022" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">246,650</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" title="Total" style="text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">392,608</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20210630_zjgjDCWWcQ73" title="Less present value discount" style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,823</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" title="Operating lease liabilities" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">368,785</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_ztPevmm4o3l9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
lease expense was approximately $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210401__20210630_zGiPFYxUxCE1" title="Lease expense"><span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20200401__20200630_zymfjyOG28S" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">86,000</ix:nonFraction></ix:nonFraction></span></span> for each of the three month periods ended June 30, 2021 and 2020, and approximately $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20210101__20210630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">172,000</ix:nonFraction></span>
and $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pp0p0" title="Lease expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">171,000</ix:nonFraction></span>, respectively, for the six month periods ended June 30, 2021 and 2020. Lease expense was recorded in cost of product sales,
general and administrative expenses, research and development and sales and marketing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ResearchAndLicenseAgreementsTextBlock"><p id="xdx_809_ecustom--ResearchAndLicenseAgreementsTextBlock_z2TONLNY0DLb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8212; <span id="xdx_822_zYKMu8rtYvdb">RESEARCH AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
University of Louisville Research Foundation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville Research
Foundation (&#8220;ULRF&#8221;) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements,
the Company will take over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance
of the related intellectual property portfolio. In return, ULRF received a $<span id="xdx_904_eus-gaap--RepaymentsOfConvertibleDebt_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Payment of convertible promissory note"><span id="xdx_90C_eus-gaap--RepaymentsOfConvertibleDebt_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Payment of convertible promissory note"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:RepaymentsOfConvertibleDebt" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></ix:nonFraction></span></span> convertible promissory note in payment of an upfront
license fee, which was subsequently converted into the Company&#8217;s common stock, and the Company agreed to reimburse ULRF for sponsored
research expenses of up to $<span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement of research expenses"><span id="xdx_905_ecustom--ReimbursementOfResearchExpenses_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement of research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">805,000</ix:nonFraction></ix:nonFraction></span></span> and prior patent costs of up to $<span id="xdx_908_ecustom--ReimbursementPatentCost_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"><span id="xdx_900_ecustom--ReimbursementPatentCost_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"><ix:nonFraction name="QLGN:ReimbursementPatentCost" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:ReimbursementPatentCost" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></ix:nonFraction></span></span>. <span id="xdx_907_ecustom--AgreementTermPaymentDescription_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"><span id="xdx_90E_ecustom--AgreementTermPaymentDescription_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"><ix:nonNumeric contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" name="QLGN:AgreementTermPaymentDescription"><ix:nonNumeric contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" name="QLGN:AgreementTermPaymentDescription">In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $<span id="xdx_902_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Milestone payment"><span id="xdx_90A_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></ix:nonFraction></span></span> to $<span id="xdx_900_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"><span id="xdx_908_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></ix:nonFraction></span></span>
upon the achievement of certain regulatory and commercial milestones.</ix:nonNumeric></ix:nonNumeric></span></span> Milestone payments for the first therapeutic indication would be
$<span id="xdx_90C_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"><span id="xdx_907_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></ix:nonFraction></span></span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_905_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"><span id="xdx_90D_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200,000</ix:nonFraction></ix:nonFraction></span></span> for first dosing in a Phase 2 clinical trial, $<span id="xdx_902_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_pp0p0" title="Milestone payment"><span id="xdx_90A_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">350,000</ix:nonFraction></ix:nonFraction></span></span> for first dosing
in a Phase 3 clinical trial, $<span id="xdx_90E_ecustom--MilestonePaymentForMarketingExpenses_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Milestone payment for marketing expenses"><span id="xdx_907_ecustom--MilestonePaymentForMarketingExpenses_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Milestone payment for marketing expenses"><ix:nonFraction name="QLGN:MilestonePaymentForMarketingExpenses" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:MilestonePaymentForMarketingExpenses" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></ix:nonFraction></span></span> for regulatory marketing approval and $5,000,000 upon achieving a cumulative $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction></ix:nonFraction></span></span> of Licensed
Product sales; the Company would also pay another $500,000 milestone payment for any additional regulatory marketing approval for each
additional therapeutic (or diagnostic) indication. The Company also must pay ULRF shortfall payments if the total amounts actually paid
with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_908_ecustom--ShortfallPayments_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"><span id="xdx_900_ecustom--ShortfallPayments_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></ix:nonFraction></span></span>
to $<span id="xdx_90E_ecustom--ShortfallPayments_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"><span id="xdx_906_ecustom--ShortfallPayments_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></ix:nonFraction></span></span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zb0w5Xuo576c" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">89,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zO7gH4LRXena" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></span>,
and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">152,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></span>, respectively, and these amounts are recorded
in research and development expenses in the statements of operations. Minimum annual royalties of $<span id="xdx_907_eus-gaap--RoyaltyExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z0AMNEA51QIc" title="Minimum annual royalties"><span id="xdx_90E_eus-gaap--RoyaltyExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zmAyy375iv96" title="Minimum annual royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> for each period related to these
agreements are included in research and development expenses in the statements of operations for the three months ended June 30, 2021
and 2020, respectively, and approximately $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Minimum annual royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Minimum annual royalties"><ix:nonFraction name="us-gaap:RoyaltyExpense" contextRef="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,000</ix:nonFraction></span> related to these agreements are included in research and development expenses
in the statements of operations for the six months ended June 30, 2021 and 2020, respectively. License costs were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zmIbooK5WE8e" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,000</ix:nonFraction></span>
and $<span id="xdx_907_ecustom--LicenseCost_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zpAVwl58omh9" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> related to these agreements for the three months ended June 30, 2021 and 2020, respectively, and approximately $<span id="xdx_903_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">53,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>
related to these agreements for the six months ended June 30, 2021 and 2020, respectively, and are included in research and development
expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company will reimburse ULRF
for sponsored research expenses of up to $<span id="xdx_909_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zTmRwYcmoSLb" title="Reimbursement of research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">693,000</ix:nonFraction></span> for this program. In February 2021, the Company extended the term of this agreement
for an additional 18 months (expires July 2022) and increased the amount that the Company will reimburse ULRF for sponsored research
expenses from $<span id="xdx_901_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zAiOMZgsBdNi" title="Reimbursement of research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">693,000</ix:nonFraction></span> to approximately $<span id="xdx_901_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLhai4x4by2j" title="Reimbursement of research expenses"><ix:nonFraction name="QLGN:ReimbursementOfResearchExpenses" contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million. In July 2020, the Company entered into an exclusive license agreement with ULRF
for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization
of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $<span id="xdx_903_ecustom--ReimbursementPatentCost_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"><ix:nonFraction name="QLGN:ReimbursementPatentCost" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,000</ix:nonFraction></span> for an upfront license fee and reimbursement of prior patent costs. <span id="xdx_90A_ecustom--AgreementTermPaymentDescription_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"><ix:nonNumeric contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" name="QLGN:AgreementTermPaymentDescription">In addition, the Company has agreed to pay
ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000)
or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not
covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first
two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and
30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated
with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging
from $<span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_zMxcihhstK06" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> to $<span id="xdx_90A_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon the achievement of certain regulatory and commercial milestones.</ix:nonNumeric></span> Milestone payments for the first therapeutic
indication would be $<span id="xdx_902_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_904_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> for first dosing in a Phase 2 clinical trial, $<span id="xdx_902_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zQHNLJQd862f" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span>
for first dosing in a Phase 3 clinical trial, $<span id="xdx_907_ecustom--RegulatoryMarketingApprovalExpenses_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> for regulatory marketing approval and $<span id="xdx_90C_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember_zbHNEPKe4Etg" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_LicensedProductSalesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon achieving a cumulative $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction></span>
of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties
and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_90A_ecustom--UpfrontLicenseFee_c20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,000</ix:nonFraction></span> to $<span id="xdx_908_ecustom--UpfrontLicenseFee_c20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span>) for such
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zRMOPwfKB9J3" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">99,000</ix:nonFraction></span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z2o9hA2osK7l"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">139,000</ix:nonFraction></span>,
respectively, and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">206,000</ix:nonFraction></span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">247,000</ix:nonFraction></span>, respectively, and are recorded
in research and development expenses in the statements of operations. License costs related to these agreements for the three months
ended June 30, 2021 and 2020 were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zlM5wazLFpze" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-04-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_908_ecustom--LicenseCost_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zsN5aApOJoc5" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-04-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively, and for the six months ended June 30, 2021 and 2020 were approximately
$<span id="xdx_904_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,000</ix:nonFraction></span> and $<span id="xdx_906_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-01-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively, and are included in research and development expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company will take over development, regulatory approval and commercialization of the
compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF
received approximately $<span id="xdx_90B_ecustom--UpfrontLicenseFee_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Upfront license fee"><ix:nonFraction name="QLGN:UpfrontLicenseFee" contextRef="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,000</ix:nonFraction></span> for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required
to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20200601__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span>. In November
2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-11-012020-11-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">430,000</ix:nonFraction></span> in research which satisfied this requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--UlrfLicenseAgreementDescription_c20200601__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="ULRF license agreement description"><ix:nonNumeric contextRef="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" name="QLGN:UlrfLicenseAgreementDescription">In
addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165
as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_zaVxo99JS9k5" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> to $<span id="xdx_902_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_zmeLZ2N0rXjb" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon the achievement of certain
regulatory and commercial milestones.</ix:nonNumeric></span> Milestone payments would be $<span id="xdx_907_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zx67h8sqwUq8" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zDduFHD1wgbl" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> for
first dosing in a Phase 2 clinical trial, $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zMeZ5djxENh3" title="Milestone payment"><ix:nonFraction name="QLGN:MilestonePayment" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">150,000</ix:nonFraction></span> for first dosing in a Phase 3 clinical trial, $<span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGhk9qPoZRy4" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">300,000</ix:nonFraction></span> for regulatory marketing approval
and $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember_zmcRsoIJtlJc" title="Regulatory marketing approval, expenses"><ix:nonFraction name="QLGN:RegulatoryMarketingApprovalExpenses" contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_LicensedProductSalesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></span> upon achieving a cumulative $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXQhklepvuTa" title="Licensed product sales, revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000,000</ix:nonFraction></span> of Licensed Product sales. The Company also must pay ULRF shortfall payments
if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable
annual minimum (ranging from $<span id="xdx_906_ecustom--ShortfallPayments_c20200627__20200630__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--RoyaltiesAndNonRoyaltySublicenseeIncomeMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2020-06-272020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span> to $<span id="xdx_907_ecustom--ShortfallPayments_c20200626__20200630__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--RoyaltiesAndNonRoyaltySublicenseeIncomeMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"><ix:nonFraction name="QLGN:ShortfallPayments" contextRef="From2020-06-262020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">50,000</ix:nonFraction></span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zx5DlN0F2SG4" title="Sponsored research expense"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> and $<span id="xdx_909_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQ8Acwmi7Gh2"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively,
and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_908_eus-gaap--OtherResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Sponsored research expense"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">94,000</ix:nonFraction></span> and $<span id="xdx_90A_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Sponsored research expense"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively, and are recorded in research and
development expenses in the statements of operations. License costs related to these agreements for the three months ended June 30, 2021
and 2020 were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zisYcJSjJYjd" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zepdM0Sfq5B1" title="Sponsored research expense"><ix:nonFraction name="us-gaap:OtherResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively, and for the six months ended June 30, 2021 and 2020 were approximately
$<span id="xdx_906_ecustom--LicenseCost_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zHEQM2T52lqf" title="Sponsored research expense"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">16,000</ix:nonFraction></span> and $<span id="xdx_900_ecustom--LicenseCost_pp0p0_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zgMqeQ8fymYd" title="Sponsored research expense"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 19; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Advanced
Cancer Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2018, <span id="xdx_906_ecustom--AgreementDescription_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember" title="Agreement description"><ix:nonNumeric contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" name="QLGN:AgreementDescription">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#8220;ACT&#8221;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $<span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Proceeds from convertible promissory note"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,000</ix:nonFraction></span> convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000)</ix:nonNumeric></span>,
until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $<span id="xdx_90E_ecustom--MilestoneMethodRevenueRecognized_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestoneMethodRevenueRecognized" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> for the Company raising a cumulative
total of $<span id="xdx_904_ecustom--CumulativeAmount_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Cumulative amount"><ix:nonFraction name="QLGN:CumulativeAmount" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000,000</ix:nonFraction></span> in new equity financing after the date of the ACT license agreement, $<span id="xdx_907_ecustom--MilestoneMethodRevenueRecognized_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember__srt--TitleOfIndividualAxis__custom--CEMarkMember_pp0p0" title="Milestone payment"><ix:nonFraction name="QLGN:MilestoneMethodRevenueRecognized" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember_custom_CEMarkMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> upon any first QN-165-based licensed
product receiving the CE Mark or similar FDA status, and $<span id="xdx_905_ecustom--CumulativeAmount_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember__srt--TitleOfIndividualAxis__custom--CEMarkMember_pp0p0" title="Cumulative amount"><ix:nonFraction name="QLGN:CumulativeAmount" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember_custom_CEMarkMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> upon cumulative worldwide QN-165-based licensed product net sales reaching
$<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Licensed product sales, revenue"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,000,000</ix:nonFraction></span>. For the three months ended June 30, 2021 and 2020, there were <span id="xdx_902_ecustom--LicenseCost_pp0p0_do_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zg9CsN29iKeb" title="License costs"><span id="xdx_90D_ecustom--LicenseCost_pp0p0_do_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zNFXdk20sTo7"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> license costs and for the six months ended June 30, 2021
and 2020, there were approximately $<span id="xdx_90B_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,000</ix:nonFraction></span> and $<span id="xdx_905_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="License costs"><ix:nonFraction name="QLGN:LicenseCost" contextRef="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span>, respectively, in license costs related to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Prediction
Biosciences</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture
diagnostic tests for use in the stroke point-of-care market. The Company recognizes development revenue and product sales over the performance
period of the contract. For the three months ended June 30, 2021 and 2020 there was $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_zfbLNyPJsNG5" title="Product sales"><span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_zf0cDJ875f29"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></ix:nonFraction></span></span> for each period, and for the six months ended
June 30, 2021 and 2020, there was $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_pp0p0" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">0</ix:nonFraction></span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_pp0p0" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,000</ix:nonFraction></span>, respectively, in collaborative research revenue related to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Sekisui
Diagnostics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended March 31, 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui Diagnostics, LLC (&#8220;Sekisui&#8221;)
until May 2022. The Company appointed Sekisui as its diagnostics commercial partner and exclusive worldwide distributor with the exception
of certain customer accounts retained by Qualigen. The agreement contains a right of first refusal for Sekisui against any potential
acquisition of the Company until May 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were product sales to Sekisui of approximately $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zuAfQmi6xC55" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-04-012021-06-30_custom_SekisuiDiagnosticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">701,000</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20200630__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zzH2MZnlYtFg"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-04-012020-06-30_custom_SekisuiDiagnosticsLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">420,000</ix:nonFraction></span> for the three months ended June 30, 2021 and 2020, and product sales
of approximately $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20210330__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zbjLj90fGz7e" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-03-30_custom_SekisuiDiagnosticsLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20200101__20200330__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zTlELjhDgs6e" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2020-01-012020-03-30_custom_SekisuiDiagnosticsLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.4</ix:nonFraction></span> million related to this agreement, for the six months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Yi
Xin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2020, the Company entered into a Technology Transfer Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#8220;Yi Xin&#8221;),
of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on the Company&#8217;s
core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to manufacture and sell the Company&#8217;s
current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Technology Transfer Agreement, the Company received net cash payments of $<span id="xdx_908_eus-gaap--DeferredRevenue_c20201231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2020-12-31_custom_YiXinZhenDuanJishuLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">250,000</ix:nonFraction></span> in the final quarter of the year ended December
31, 2020, classified as deferred revenue on the December 31, 2020 balance sheet, and a cash payment of $<span id="xdx_900_eus-gaap--DeferredRevenue_c20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">420,000</ix:nonFraction></span> during the first quarter
of 2021. The Company will also receive low- to mid-single-digit royalties on any future new-generations and current-generations product
sales by Yi Xin. Of these amounts, the Company recognized approximately $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">38,000</ix:nonFraction></span> in product sales and $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zIlApYx4eqLg" title="Product sales"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_LicenseRevenueMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">479,000</ix:nonFraction></span> in license revenue included
in the statement of operations for the six months ended June 30, 2021. On the balance sheet at June 30, 2021, the Company had
deferred revenue of approximately $<span id="xdx_90C_eus-gaap--DeferredRevenue_iI_c20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember__us-gaap--TypeOfArrangementAxis__custom--TechnologyTransferAgreementMember_zGuslToQocme" title="Deferred revenue"><ix:nonFraction name="us-gaap:DeferredRevenue" contextRef="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_TechnologyTransferAgreementMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">153,000</ix:nonFraction></span> related to this agreement. The Company provided technology transfer and patent/know-how
license rights to facilitate Yi Xin&#8217;s development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 20; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company gave Yi Xin the exclusive rights for China &#8211; which is a market the Company has not otherwise entered &#8211; both for Yi
Xin&#8217;s new generations of FastPack-based products and for Yi Xin-manufactured versions of the Company&#8217;s existing FastPack
product lines. Yi Xin will also have the right to sell its new generations of FastPack-based diagnostic test systems throughout the world
(but not to or toward current customers of the Company&#8217;s existing generations of FastPack products); any such non-China sales would,
until Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
need to be through Sekisui. In addition, after Spring 2022, Yi Xin will have the right to sell Yi Xin-manufactured versions of existing
FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US customers
of those products). Also, after Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
Yi Xin will have the right to buy Company-manufactured FastPack 1.0, IP and PRO products from the Company at distributor prices for resale
in and for the United States (but not to or toward current US customers of those products); the Company did not license Yi Xin to sell
in the United States market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines, even after Spring
</span><span style="font: 10pt Times New Roman, Times, Serif">2022. In the Technology Transfer Agreement, the
Company confirmed that it would not, after Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
seek new FastPack customers outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>STA
Pharmaceutical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, the Company&#8217;s lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials
in 2021. In connection with this agreement, the Company paid an upfront deposit of approximately $<span id="xdx_902_eus-gaap--DepositAssets_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zkKoViqNtT7j" title="Upfront deposit"><ix:nonFraction name="us-gaap:DepositAssets" contextRef="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million which was classified as
prepaid expenses on the December 31, 2020 balance sheet date, and all of which was included in research and development expenses in the
statement of operations for the six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses related to this agreement for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210401__20210630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zFZog1FdfL0k" title="Research and development"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million
and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200401__20200630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zE2xTb2IEZL3"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0</ix:nonFraction></span>, respectively, and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20210630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_znYKqu7syUGd"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-012021-06-30_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.1</ix:nonFraction></span> million and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200101__20200630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zLN83j6BoaRi"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30_custom_STAPharmaceuticalCoLtdMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0</ix:nonFraction></span>, respectively, and are
recorded in research and development expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zr30Mvgz6Y4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10 &#8212; <span id="xdx_822_z9AtyuwoVjm">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021 and December 31, 2020, the Company had two classes of capital stock: common stock and Series Alpha convertible preferred
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, as
of June 30, 2021 any remaining assets would be distributed ratably among the holders of the common stock and, on an as-if-converted basis,
the holders of Series Alpha convertible preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The
holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="QLGN:ScheduleOfReservedSharesTableTextBlock"><p id="xdx_893_ecustom--ScheduleOfReservedSharesTableTextBlock_zUhHeLMgL6ik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2021, the Company has reserved <span id="xdx_903_eus-gaap--CommonStockSharesSubscribedButUnissued_c20210630_pdd" title="Shares of authorized but unissued common stock">13,917,461</span> shares of authorized but unissued common stock for possible future issuance. At June
30, 2021, shares were reserved in connection with the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zhSYbgOdMeNk" style="display: none">SCHEDULE
OF RESERVED SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Exercise of outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockOptionsMember_zo3DUyEoEGa1" title="Total" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2021-06-30_custom_ExerciseOfOutstandingStockOptionsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,133,856</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise of outstanding stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockWarrantMember_zkXGif7XmMEi" style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2021-06-30_custom_ExerciseOfOutstandingStockWarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">9,540,187</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of outstanding Series Alpha preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--SerieAlphaPreferredStockMember_z5vjFpOt7Nbj" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2021-06-30_custom_SerieAlphaPreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">243,418</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630_zNi6r5qjfPCb" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CommonStockSharesSubscribedButUnissued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,917,461</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AE_zknFm4gi0Wpe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Series
Alpha Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the six-month period ended June 30, 2021, no shares of Series Alpha convertible preferred stock were converted into shares of the Company&#8217;s
common stock, and there were <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20210630_zasxxUu8l1P6" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">180</ix:nonFraction></span> shares of Series Alpha preferred stock outstanding at June 30, 2021 and December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 21; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Alpha
Securities Purchase Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 10, 2020, the Company closed a Securities Purchase Agreement (dated July 8, 2020) with a single institutional investor for the purchase
and sale for $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200709__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_z2z2McRF0pL7" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">8.0</ix:nonFraction></span> million for (i) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200709__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,140,570</ix:nonFraction></span> shares of Company common stock, (ii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,198</ix:nonFraction></span> pre-funded warrants (i.e., warrants to purchase
shares of Company common stock, for which the exercise price is almost entirely prepaid) and (iii) <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,920,768</ix:nonFraction></span> two-year warrants to purchase
shares of Company common stock for an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share. Both sets of warrants included a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQavFKjktyXf" title="Beneficial-ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% beneficial-ownership
blocker provision. The <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200721__20200722__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z0qHvXa5Kh33" title="Warrants exercise"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2020-07-212020-07-22_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,198</ix:nonFraction></span> pre-funded warrants were then exercised on July 21 and 22, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 4, 2020, the Company closed a Securities Purchase Agreement (dated August 2, 2020) with a single institutional investor for the
purchase and sale for $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_zzGVjp4ZZj7k" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million for (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,717,106</ix:nonFraction></span> shares of Company common stock, and (ii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,287,829</ix:nonFraction></span> two-year warrants to purchase
shares of Company common stock for an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share. The warrants included a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUiMLYXk3rqf" title="Beneficial-ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% beneficial-ownership blocker provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
December 18, 2020, the Company closed a Securities Purchase Agreement (dated December 16, 2020) with a single institutional investor
for the purchase and sale for $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20201216__20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_pp0p0" title="Sale of stock"><ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">12,000,000</ix:nonFraction></span> of (i) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201216__20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,370,786</ix:nonFraction></span> shares of Company common stock, (ii) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> pre-funded warrants (i.e.,
warrants to purchase shares of Company common stock, for which the exercise price is almost entirely prepaid) (iii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,348,314</ix:nonFraction></span> two-year
warrants to purchase shares of Company common stock for an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share, and (iv) <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">842,696</ix:nonFraction></span> warrants (first exercisable
6 months after issuance, and with an expiration date 30 months after issuance) to purchase shares of Company common stock for an exercise
price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share. The warrants included a <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFp8A21Vcndg" title="Beneficial-ownership percentage"><ix:nonFraction name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">9.99</ix:nonFraction></span>% beneficial-ownership blocker provision. The <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210203__20210204__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z1r3DXDwpAY4"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-02-032021-02-04_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> pre-funded warrants were
exercised on February 4, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock
Options and Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which provides for the granting of incentive
or nonstatutory common stock options to qualified employees, officers, directors, consultants and other service providers. At June 30,
2021 and December 31, 2020 there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,040,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zzk9s2D0LLhh"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-12-31_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,917,500</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">outstanding options respectively under the 2020
Plan and on those dates there were <span id="xdx_904_ecustom--StockOptionsSharesFutureGrant_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd"><ix:nonFraction name="QLGN:StockOptionsSharesFutureGrant" contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">17,157</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90A_ecustom--StockOptionsSharesFutureGrant_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd"><ix:nonFraction name="QLGN:StockOptionsSharesFutureGrant" contextRef="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">139,657</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">unused 2020 Plan shares available, respectively,
for future grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuuDS8dQT2fh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2021, and changes during the six-month period then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zsA2VITac1A7" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average <br />
    Exercise <br />
    Price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average Remaining <br />
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 39%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGZIeRguF763" title="Number of Shares, Options Outstanding, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,011,356</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNG1FtDfIxe7" title="Weighted Average Exercise Price, Outstanding, Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">7.05</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2TfsjjRSYHg" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.52</ix:nonFraction></span>&#8212;<span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zesHnaej9rr2" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,465.75</ix:nonFraction></span>
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3r0SiApwfxa" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">9.29</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" title="Number of Shares, Options Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">127,000</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" title="Weighted Average Exercise Price, Options Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Granted"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsGranted" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.80</ix:nonFraction></span>&#8212;<span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Granted"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsGranted" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.29</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4JC7iBSZbY5" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">9.83</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" title="Number of Shares, Options Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1734">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" title="Weighted Average Exercise Price, Options Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_ecustom--RangeOfExercisePriceOptionsExpired_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" title="Range of Exercise price, Options Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1738">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znlDhZ0qQq57" title="Number of Shares, Options Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,500</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" title="Weighted Average Exercise Price, Options Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.68</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsForfeited" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.52</ix:nonFraction></span>
    &#8212; <span id="xdx_90E_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Forfeited"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsForfeited" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGD3wHgiHYKk" title="Number of Shares, Options Outstanding at Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,133,856</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAPZM8OKVyme" title="Weighted Average Exercise Price, Outstanding at Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.90</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMjGUy7A2uP9" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.80</ix:nonFraction></span>
    &#8212; <span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEz1cL2XsGXl" title="Range of Exercise price, Options Outstanding"><ix:nonFraction name="QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,465.75</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHSjUCZ8a2k5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo">8.82</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable
    (vested)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSdZKQlVBMM6" title="Number of Shares, Options Exercisable (vested)" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,296,860</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zPjAvqCRwcjk" title="Weighted Average Exercise Price, Options Exercisable (vested)" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">11.50</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zo7WNz4ixrni" title="Range of Exercise price, Options Exercisable (vested)"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsExercisableVested" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.97</ix:nonFraction></span>
    &#8212; <span id="xdx_903_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Exercisable (vested)"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsExercisableVested" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1,465.75</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjcHVACkl421" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested">8.36</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable
    (non-vested)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zo6LEmEpSo6h" title="Number of Shares, Options Non-Exercisable (non-vested)" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,836,996</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjz5DW3HszD8" title="Weighted Average Exercise Price, Options Non-Exercisable (non-vested)" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.80</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsNonexercisableNonvested" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.80</ix:nonFraction></span>
    &#8212; <span id="xdx_905_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)"><ix:nonFraction name="QLGN:RangeOfExercisePriceOptionsNonexercisableNonvested" contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.13</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zfTNyjgx9T7e" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember" format="ixt-sec:duryear" name="QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">9.04</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AD_zaHrrgNTB7b4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20210401__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zI534eYSIuFd"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-04-012021-06-30_custom_StockOptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.3</ix:nonFraction></span> million and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20200401__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zlFjcxaJwUXa"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-04-012020-06-30_custom_StockOptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction></span> million of compensation cost related to outstanding options for the three months ended June
30, 2021 and 2020, respectively, and approximately</span><span style="font: 10pt Times New Roman, Times, Serif"> $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zCeyEiqPnoae"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zc3EyAilcMu9"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">0.4</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
of compensation cost related to outstanding options for the six months ended June 30, 2021 and 2020, respectively. As of June 30,
2021, there was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zd31GG43YY91"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2021-06-30_custom_StockOptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.3</ix:nonFraction> </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
of total unrecognized compensation cost related to unvested stock-based compensation arrangements. This cost is expected to be
recognized over a weighted average period of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zwTlKOzTCR61"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">1.98</ix:nonNumeric> </span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zggKq2xevmGe" title="Stock options exercised"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zaY3QnESTdOg" title="Stock options exercised"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">No</ix:nonFraction></ix:nonFraction></span></span>
stock options were exercised during the six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 22; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember" title="Stock options description"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</ix:nonNumeric></span> The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a ten-year
period. The weighted average grant date fair value per share of options granted during the six months ended June 30, 2021 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_pdd" title="Stock option granted exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.68</ix:nonFraction></span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fair
Value of Equity Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company utilizes the Black-Scholes option pricing model to value awards under its Plans. Key valuation assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
    dividend yield.</i> The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
    stock-price volatility.</i> The Company&#8217;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business
    over a period approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risk-free
    interest rate.</i> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the Securities
    and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual
    life of the options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zhMJCwb3Nvq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zypqMcSXiXa8" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the six months<br />
ended <br />
June 30, 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20210630_zgviF8xlXhVd" title="Expected dividend yield"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    stock-price volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20210630_z9MaedWULN8g" title="Expected stock-price volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">102</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20210101__20210630_zo1twREqmpi3" title="Risk-free interest rate, minimum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.84</ix:nonFraction></span>%
    &#8212; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20210101__20210630_zYGLh6nVGlX4" title="Risk-free interest rate, maximum"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.18</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Expected
    average term of options</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zp9wn2ZilkTe" title="Average expected remaining years of life of options"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">6.0</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharePrice_c20210630_pdd" title="Stock price"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.12</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A6_zp2HEeIYtp13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"><p id="xdx_890_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zLcG6bpugaBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zMdYUrsZNdyf" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7egFqhcBdBd" title="Total" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,201,499</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqhAcfvZcEHd" title="Total" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">277,807</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zK7inVm28ael" title="Total" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">347,550</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqCUHEU4Ifq3" title="Total" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">88,684</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_zG9rAHPnEZF8" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,549,049</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630_zTaUiVSIXXF6" title="Total" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">366,491</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zJun7vuJdv3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 23; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Equity
Classified Compensatory Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the $<span id="xdx_901_ecustom--EquityCapitalRaise_iI_pn5n6_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_z6D4WpaEl8r3" title="Equity capital raise"><ix:nonFraction name="QLGN:EquityCapitalRaise" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">811,431</ix:nonFraction></span> shares of the Company&#8217;s common stock at an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span> per share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense
on the Company&#8217;s statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20171231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">668,024</ix:nonFraction></span> shares
of Company common stock at a weighted average exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20171231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.34</ix:nonFraction></span> per share. These are to be differentiated from the Series C Warrants
described in Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
compensatory warrants were issued during the six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" continuedAt="ConU001832-01" escape="true" name="QLGN:SummaryOfWarrantActivityTableTextBlock"><p id="xdx_89B_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_gL3SOWATTB-XCNSZ_ze9Cvv2uEijh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zz0DeCBA5H5k" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br />
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;<br />
    Average<br />
    Remaining <br />
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztJPt0tKB5W6" title="Number of Shares, Warrants Outstanding Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,294,217</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVYkjfKsgOLd" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.66</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zC5KDPgMmXHe" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1JG4rJahtKh" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1840">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Legacy
    Ritter warrants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRQw9aW18Ec" title="Number of Shares, Warrants Legacy Ritter warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvMc2kCuqEc" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1844">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1846">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">38,390</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.09</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1856">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">65,179</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RYTQiEnCDj" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,190,648</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zi0WH4YIOGwa" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.62</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR2z8g3LZho7" title="Number of Shares, Warrants Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,187,052</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbnSiTJp3qKh" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.62</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span>
    &#8212; <span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdYAqANed95k" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">3.75</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbVhuLk43Bvf" title="Number of shares, warrants non-exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,596</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zSFTVvAFI1a6" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction>
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_989_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4JSgNsnKVm" title="Weighted Average Remaining Life (Years) Non-Exercisable"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">5.23</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8A4_zqKyYscW9vy4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Of
the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zxXv4Ufjrzi5" title="Stock issued upon exercise of  stock options"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">38,390</ix:nonFraction></span> shares issued upon the exercise of equity classified compensatory warrants during the six months ended June 30, 2021, <span id="xdx_90D_ecustom--SharesIssuedUponNetExercises_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zZIvYPIG1rA8" title="Shares issued on net exercises"><ix:nonFraction name="QLGN:SharesIssuedUponNetExercises" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">35,512</ix:nonFraction></span>
shares were issued upon net-exercises rather than upon exercises for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<div id="xdx_C03_gL3SOWATTB-XCNSZ_zqsVpz8dwtRh"><ix:continuation continuedAt="ConU001832-02" id="ConU001832-01"><table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zNtEjVZ5xzkf" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br />
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life
    (Years)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRPgZtofBdl" title="Number of Shares, Warrants Outstanding Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z66E65pFepNc" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2019-12-31_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.99</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3F0agyTu3oi" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">668,024</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zFzKhwhNafmh" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.34</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Legacy
    Ritter warrants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zEptr09bcs83" title="Number of Shares, Warrants Legacy Ritter warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1896">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7etL0b2V5ml" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">811,431</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMmPCwmC2Pi" title="Weighted Average Exercise Price Per Share Warrants Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1904">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zLL0Ke1UL8u5" title="Weighted Average Exercise Price Per Share Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1906">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1908">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RloP4fvTyi" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zZQm2lRUhPCc" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,479,455</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za9epGDPPV0c" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.67</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfRQiexHvsB3" title="Number of Shares, Warrants Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">660,832</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMrKiLC8mghj" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.34</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.07</ix:nonFraction></span>
    &#8212; <span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmD95OhSynA2" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">3.82</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9tnexDfrbBa" title="Number of shares, warrants non-exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">818,623</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1roXZzS8sub" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.12</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Non-Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span>
    &#8212; <span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Non-Exercisable"><ix:nonFraction name="QLGN:RangeOfExercisePriceNonexercisableNonvested" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.54</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziEKMWF29x0k" title="Weighted Average Remaining Life (Years) Non-Exercisable"><ix:nonNumeric contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">4.91</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C0B_gL3SOWATTB-XCNSZ_zirtWBfn8c79"><ix:continuation id="ConU001832-02">&#160;</ix:continuation></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_do_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zIVFZT7Rn6ac" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span> compensation cost related to outstanding equity classified compensatory warrants for the six months ended June 30, 2021 and approximately
$<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zpsuktLGUBi4" title="Stock based compensation expense"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,000</ix:nonFraction></span> for the six months ended June 30, 2020. As of June 30, 2021 and 2020, there was <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_do_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_znWMFDVOZkh4" title="Unrecognized compensation cost"><span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zJxXVuX0Wen" title="Unrecognized compensation cost"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></span></span> unrecognized compensation cost related to nonvested
equity classified compensatory warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 24; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Noncompensatory
Equity Classified Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to an investor for the purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200531__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">270,478</ix:nonFraction></span>
shares of Company common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200531__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction></span> per share (of which warrants for <span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_c20201201__20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Shares issued upon the exercise of warrants"><ix:nonFraction name="QLGN:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" contextRef="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">200,000</ix:nonFraction></span> shares were subsequently exercised
in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to such investor for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200731__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">780,198</ix:nonFraction></span>
shares of Company common stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200731__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per share (which were subsequently exercised in July 2020), and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,920,678</ix:nonFraction></span>
shares of Company common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.25</ix:nonFraction></span> per share. In August 2020 the Company issued noncompensatory equity classified
warrants to such investor for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,287,829</ix:nonFraction></span> shares of Company common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.00</ix:nonFraction></span> per share. Lastly,
in December 2020, the Company issued noncompensatory equity classified warrants to such investor for the purchase of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,000,000</ix:nonFraction></span> shares
of Company common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span> per share (which were exercised in February 2021) and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Purchase of stock warrants"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,191,010</ix:nonFraction></span> shares of Company
common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Warrant exercise price"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.07</ix:nonFraction></span> per share. No noncompensatory equity classified warrants were issued during the six months
ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" escape="true" name="QLGN:SummaryOfWarrantActivityTableTextBlock"><p id="xdx_89E_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zhvZKGrwksr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B5_zz92liI2luSj" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br />
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;<br />
    Average<br />
    Remaining <br />
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zQhwqpdEym8e" title="Number of Shares, Warrants Outstanding Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">6,549,777</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zxtC0XknraS7" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.37</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="Shares">1,000,000</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Exercised" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.01</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1980">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Granted" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1984">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Expired" style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1986">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Number of Shares, Warrants Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1988">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Weighted Average Exercise Price Per Share Warrants Forfeited" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zL1FaaiiJEb1" title="Number of Shares, Warrants Outstanding Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,549,777</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zYEbzYgcSMki" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.15</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z8ZdcQ0BJeE1" title="Number of Shares, Warrants Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,549,777</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zXGXhpg0ZWM5" title="Weighted Average Exercise Price Per Share Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">5.15</ix:nonFraction></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" style="font: 10pt Times New Roman, Times, Serif"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MinimumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.11</ix:nonFraction>
    </span><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span><span style="font: 10pt Times New Roman, Times, Serif">
    <span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd"><ix:nonFraction name="QLGN:RangeOfExercisePriceExercisableVested" contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MaximumMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2,325.00</ix:nonFraction></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zGzT4vMFUq6h" title="Weighted Average Remaining Life (Years) Exercisable"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember" format="ixt-sec:duryear" name="QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">1.33</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zZFK6wpzMyj8" title="Number of shares, warrants non-exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2004">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zC4ecpj8SH0i" title="Weighted Average Exercise Price Per Share Non-Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2006">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" title="Range of Exercise Price, Non-Exercisable" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl2008">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</ix:nonNumeric><p id="xdx_8AE_zpSLrAfjVjGb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zSOynDE0cNL3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11 &#8212; <span id="xdx_82C_zF4iUwfgZ5xg">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2017, Sekisui purchased all outstanding shares of the Company&#8217;s Series D and Series D-1 preferred stock from Gen-Probe
Incorporated. As such, Sekisui became a related party as of October 2017. These Series D and Series D-1 preferred stock shares were converted
into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20200501__20200531__us-gaap--StatementClassOfStockAxis__custom--SeriesDAndSeriesDOnePreferredStockMember_pdd" title="Conversion of preferred stock"><ix:nonFraction name="us-gaap:ConversionOfStockSharesConverted1" contextRef="From2020-05-012020-05-31_custom_SeriesDAndSeriesDOnePreferredStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,980,233</ix:nonFraction></span> shares of the Company&#8217;s common stock in connection with the reverse recapitalization transaction in May 2020. During
the nine-months transition period ended December 31, 2020, Sekisui ceased to be a related party as to the Company. In the attached financial
statements, information for 2020 periods and dates is presented without distinct &#8220;related party&#8221; treatment for items pertaining
to Sekisui.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:SubsequentEventsTextBlock"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zEBEXoJeaHil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12 &#8212; <span id="xdx_827_zdZwxWRj39Ta">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management
has evaluated subsequent events pursuant to the requirements of ASC Topic 855, <i>Subsequent Events</i>, from the balance sheet date
through the date the financial statements were available to be issued, and has determined that there are no material subsequent events
that require disclosure in these financial statements, except that effective July 1, 2021, the Company and Sekisui amended the scheduled
termination date of the Sekisui Distribution and Development Agreement (see Note 9) to be March 31, 2022 instead of May 1, 2022, and by virtue
of a 2020 Plan amendment approved by the Company&#8217;s stockholders on August 9, 2021, the number of shares of common stock available
for issuance under the 2020 Plan was increased by <span id="xdx_90B_ecustom--CommonStockSharesAvailableForFutureIssuance_iI_c20210809__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwpThousandTwentyPlanMember_z0bf0S2psDA8"><ix:nonFraction name="QLGN:CommonStockSharesAvailableForFutureIssuance" contextRef="AsOf2021-08-09_us-gaap_SubsequentEventMember_custom_TwpThousandTwentyPlanMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,500,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

</ix:nonNumeric><p id="xdx_817_zr435Fvqzo54" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_007"></span>ITEM
2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>The
following discussion and analysis should be read in conjunction with our interim unaudited condensed consolidated financial statements
and related notes included in this Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) and the audited financial statements
and notes thereto as of and for the nine-months transition period ended December 31, 2020, which are contained in our Transition Report
on Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 31, 2021. As used in this Quarterly Report,
unless the context suggests otherwise, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; or &#8220;Qualigen&#8221; refer to Qualigen
Therapeutics, Inc. In addition to historical information, this discussion and analysis contains forward-looking statements that involve
risks, uncertainties and assumptions.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Cautionary
Note Regarding Forward Looking Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
Quarterly Report contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company&#8217;s
judgment as of the date of this Report. These statements generally relate to future events or the Company&#8217;s future financial or
operating performance. In some cases, you can identify forward-looking statements because they contain words such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;could,&#8221;
&#8220;intends,&#8221; &#8220;target,&#8221; or &#8220;continue&#8221; or the negative of these words or other similar terms or expressions
that concern the Company&#8217;s expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among other
things, potential future development, testing and launch of products and product candidates. Actual events or results may differ from
our expectations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Some
of the factors that we believe could cause actual results to differ from those anticipated or predicted include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that we will successfully develop any drugs or therapeutic devices;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that preclinical or clinical development of our candidate drugs or therapeutic devices will be successful;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that clinical trials will be approved to begin by or will actually begin by or will proceed as contemplated by
    any projected timeline;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that clinical trials will complete enrollment as contemplated by any projected timeline;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that future clinical trial data will be favorable or that such trials will confirm any improvements over other
    products or lack negative impacts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that any drugs or therapeutic devices will receive required regulatory approvals or that they will be commercially
    successful;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that we will be able to procure or earn sufficient working capital to complete the development, testing and launch
    of our prospective therapeutic products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that patents will issue on our owned and in-licensed patent applications;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that such patents, if any, and our current owned and in-licensed patents would prevent competition;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that we will be able to maintain or expand market demand and/or market share for our diagnostic products generally,
    particularly in view of COVID-19-related deferral of patients&#8217; physician-office visits and in view of FastPack reimbursement
    pricing challenges.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that adoption and placement of FastPack PRO System analyzers will be widespread; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">there
    can be no assurance that we will be able to manufacture our FastPack PRO System analyzers successfully.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
stock price could be harmed if any of the events or trends contemplated by the forward-looking statements fails to occur or is delayed
or if any actual future event otherwise differs from expectations. Additional information concerning these and other risk factors affecting
our business (including events beyond our control, such as epidemics and resulting changes) can be found in our prior filings with the
SEC (including our Transition Report on Form 10-K for the nine-months transition period ended December 31, 2020), available at www.sec.gov.
Any forward-looking statement that we make in this Quarterly Report speaks only as of the date of this Quarterly Report, and we disclaim
any intent or obligation to update these forward-looking statements beyond the date of this Quarterly Report, except as required by law.
This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">By
their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare,
regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement
contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that
our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial
condition and liquidity, and the development of the industry in which we operate, are consistent in some future periods with the forward-looking
statements contained in this Quarterly Report, they may not be predictive of results or developments in other future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Future
filings with the SEC, future press releases and future oral or written statements made by us or with our approval, which are not statements
of historical fact, may also contain forward-looking statements. Because such statements include risks and uncertainties, many of which
are beyond our control, actual results may differ materially from those expressed or implied by such forward-looking statements. The
forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements
to reflect events that occur or circumstances that exist after the date on which they are made.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
are a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, as well as operating
our core FDA-approved FastPack&#174; System, which has been used successfully in diagnostics for 20 years. Our cancer therapeutics
pipeline includes QN-247, RAS-F and STARS. QN-247 (formerly referred to as ALAN or AS1411-GNP) is a DNA coated gold
nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects; the
nanoparticle coating technology is similar to the core nanoparticle coating technology used in our blood-testing diagnostic
products. The foundational aptamer of QN-247, QN-165 (formerly referred to as AS1411), is also a drug candidate for treating
 viral-based infectious diseases. RAS-F is a family of RAS oncogene protein-protein interaction inhibitor small
molecules for preventing mutated RAS genes&#8217; proteins from binding to their effector proteins; preventing this binding could
stop tumor growth, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device candidate for
removal from circulating blood of precisely targeted tumor-produced and viral compounds.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0; margin-bottom: 0">On July 13, 2021, we filed
an Investigational New Drug (IND) application with the FDA to seek approval to commence Phase 1b/2a clinical studies with QN-165 in hospitalized
COVID-19 patients, but on August 11, 2021 the FDA informed us that additional preclinical studies would be required in order for such
application to be cleared. There can be no assurance when (if ever) the FDA would clear this
IND application or any other IND application we may file. We have decided to deprioritize this QN-165
program.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Because
our therapeutic candidates are still in the development stage, our only products that are currently commercially available are the FastPack
System diagnostic instruments and test kits. The FastPack System menu includes rapid point-of-care diagnostic tests for cancer, men&#8217;s
health, hormone function and vitamin D status. Since inception, our sales of FastPack products have exceeded $100 million. We have always
utilized a &#8220;razor and blades&#8221; pricing strategy, providing analyzers to our customers (physician offices, clinics and small
hospitals) at low cost in order to increase sales volumes of higher-margin test kits. Pursuant to a distribution agreement, we are required
to rely on our diagnostics distribution partner Sekisui Diagnostics, LLC (&#8220;Sekisui&#8221;) for most FastPack distribution worldwide
until March 31, 2022. We maintain direct distribution for certain house accounts, including selling our total testosterone test kits
to Low T Center, Inc. (&#8220;Low T&#8221;), the largest men&#8217;s health group in the US, with 44 locations. We have licensed and
technology-transferred our FastPack System technology to Yi Xin Zhen Duan Jishu (Suzhou) Ltd., for the China diagnostics market.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
do not expect to be profitable before products from our therapeutics pipeline are commercialized, because we foresee that research and
development expenses on the therapeutics programs will significantly exceed the profits, if any, that we might have from our diagnostics
products. To experience losses while therapeutic products are still under development is, of course, typical for biotechnology companies.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
condensed consolidated financial statements do not separate out our diagnostics-related activities and our therapeutics-related activities.
Although to date all our reported revenue is diagnostics-related, our reported expenses represent the total of our therapeutics-related
and diagnostics-related expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Completion
of Reverse Recapitalization Transaction with Ritter</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On
May 22, 2020, we completed a &#8220;reverse recapitalization&#8221; transaction with Qualigen, Inc. (not to be confused with the Company);
the Company&#8217;s merger subsidiary merged with and into Qualigen, Inc. with Qualigen, Inc. surviving as a wholly owned subsidiary
of the Company. The Company, which had previously been known as Ritter Pharmaceuticals, Inc., was renamed Qualigen Therapeutics, Inc.,
and the former stockholders of Qualigen, Inc. acquired, via the recapitalization, a substantial majority of the shares of the Company.
Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol &#8220;RTTR,&#8221;
commenced trading on Nasdaq, on a post-reverse-stock-split adjusted basis, under the ticker symbol &#8220;QLGN&#8221; on May 26, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Because
Qualigen, Inc. was the accounting acquirer in the reverse recapitalization transaction, all references to financial figures of &#8220;the
Company&#8221; presented in the accompanying condensed consolidated financial statements and Notes are those of Qualigen, Inc.; the corresponding
figures of Ritter Pharmaceuticals, Inc. have been disregarded. Moreover, references in this Quarterly Report to &#8220;our&#8221; pre-May
22, 2020-merger history, securities and agreements are references to the pre-May 22, 2020-merger history, securities and agreements of
Qualigen, Inc., except where otherwise expressly specified.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
are no longer pursuing the gastrointestinal disease treatment business on which Ritter Pharmaceuticals, Inc. had focused before the reverse
recapitalization transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Distribution
and Development Agreement with Sekisui</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2016, through our wholly-owned diagnostics subsidiary Qualigen, Inc., we entered into a Distribution and Development Agreement (the
&#8220;Distribution Agreement&#8221;) with Sekisui. Under the Distribution Agreement, Sekisui serves as the exclusive worldwide distributor
for FastPack products (although we retain certain specific accounts for direct transactions). Sekisui&#8217;s exclusive distribution
arrangements are effective until March 31, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Distribution Agreement, we began development of a proposed &#8220;FastPack 2.0&#8221; product line, which if successfully introduced
by us would have been distributed by Sekisui. Between May 2016 and January 2018, Sekisui paid us a total of approximately $5.5 million
upon the achievement of specified development milestones.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Under
this program, we developed a FastPack 2.0 diagnostic test for a new whole blood vitamin D assay, and we then conducted a clinical trial
of it in March 2019. We determined in May 2019 that it was uncertain whether the results of the trial would enable the test to receive
FDA approval, and our FastPack 2.0 project with Sekisui was discontinued. Currently no further FastPack 2.0 analyzer or test development
is ongoing, and we have licensed and transferred our FastPack 2.0 technology to Yi Xin Zhen Duan Jishu (Suzhou) Ltd. for them to further
develop and commercialize.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
became obligated to pay Sekisui $0.9 million for $0.5 million in research and development costs advanced by Sekisui to us and for the
reimbursement of $0.4 million in certain out-of-pocket development and preclinical study expenses incurred by Sekisui. We satisfied these
amounts (plus interest) by payment in full on July 21, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
expectation is that upon regaining FastPack distribution rights from Sekisui, we would be able to improve the profitability of our diagnostics
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Technology
Transfer Agreement with Yi Xin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Through
our wholly-owned diagnostics subsidiary Qualigen, Inc., we entered into a Technology Transfer Agreement dated as of October 7, 2020 with
Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#8220;Yi Xin&#8221;), of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations
of diagnostic test systems based on our core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to
manufacture and sell our current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Technology Transfer Agreement, we received net cash payments of $250,000 in the final quarter of calendar 2020, classified as deferred
revenue as of the balance sheet date of December 31, 2020, and a cash payment of $420,000 during the first quarter of 2021. In addition,
we will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin. Of
these amounts, we recognized approximately $38,000 in product sales and $479,000 in license revenue included in the statement of operations
for the six months ended June 30, 2021, but none in the three months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
provided technology transfer and patent/know-how license rights to facilitate Yi Xin&#8217;s development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the Technology Transfer Agreement (as amended in August 2021), we gave Yi Xin the exclusive rights for China &#8211; which is a market
we have not otherwise entered &#8211; both for Yi Xin&#8217;s new generations of FastPack-based products and for Yi Xin-manufactured
versions of our existing FastPack product lines. Yi Xin will also have the right to sell its new generations of FastPack-based diagnostic
test systems throughout the world (but not to or toward current customers of our existing generations of FastPack products); any such
non-China sales would, until Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
need to be through Sekisui. In addition, after Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
Yi Xin will have the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than
in the United States and other than to or toward current non-US customers of those products). Also, after Spring
</span><span style="font: 10pt Times New Roman, Times, Serif">2022, Yi Xin will have the right to buy Qualigen-manufactured
FastPack 1.0, IP and PRO products from us at distributor prices for resale in and for the United States (but not to or toward current
US customers of those products); we did not license Yi Xin to sell in the United States market any Yi Xin-manufactured versions of those
legacy FastPack product lines, even after Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the Technology Transfer Agreement, we also confirmed that we would not, after Spring</span>
<span style="font: 10pt Times New Roman, Times, Serif">2022, the expiration of the Sekisui Distribution Agreement,
seek new FastPack customers outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Yi
Xin is a newly-formed company and is subject to many risks. There can be no assurance that Yi Xin will successfully commercialize any
products or that we will receive any royalties from Yi Xin.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Warrant
Liabilities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
2004, Qualigen, Inc. issued a series of Series C preferred stock warrants to investors and brokers in connection with a private placement.
These warrants were subsequently extended and survived the May 2020 Ritter reverse recapitalization transaction and are now exercisable
for Qualigen Therapeutics common stock. These warrants were so-called &#8220;exploding warrants&#8221; &#8211; they contained a provision
that if Qualigen, Inc. issued shares (except in certain defined scenarios) at a price below the warrants&#8217; exercise price, the exercise
price would be re-set to such new price and the number of shares underlying the warrants would be increased in the same proportion as
the exercise price decrease. For accounting purposes, such &#8220;exploding warrants&#8221; give rise to &#8220;warrant liabilities&#8221;
(even though there is not any &#8220;liability&#8221; in the sense that we would be obligated to pay any cash sum to anyone). Although
the fair value of the warrants was immaterial at March 31, 2020, the operation of the &#8220;double-ratchet&#8221; provisions in these
&#8220;exploding warrants&#8221; in connection with the reverse-recapitalization transaction now allow the holders to exercise for a
significantly higher number of shares than before and at a significantly lower price than the current market price of our shares. Accounting
principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;) require us to recognize the fair value of these warrants
as warrant liabilities on our balance sheets and to reflect period-to-period changes in the fair value of the warrant liabilities on
our statements of operations. The size of these warrant liabilities at June 30, 2021 was quite large ($4.1 million) and caused a significant
distortion of our balance sheet at June 30, 2021 and our results of operations for the three months and six month periods ended June
30, 2021. Because this fair value will be determined each quarter on a &#8220;mark-to-market&#8221; basis, this item will usually result
in significant variability in our future quarterly and annual statements of operations and balance sheets based on changes in our public
market common stock price. Pursuant to U.S. GAAP, a quarter-to-quarter increase in our stock price would result in a (possibly quite
large) increase in the fair value of the warrant liabilities and a quarter-to-quarter decrease in our stock price would result in a (possibly
quite large) decrease in the fair value of the warrant liabilities. Approximately 41% of these &#8220;exploding warrants&#8221; were
exercised or forfeited through June 30, 2021, which will tend to reduce the amplitude of this variability. (There were 2,799,762 and
3,378,596 of these &#8220;exploding warrants&#8221; outstanding at June 30, 2021 and December 31, 2020, respectively.) We will continue
to encourage the holders of these warrants to exercise them, and if the number of outstanding &#8220;exploding warrants&#8221; is further
reduced the potential amplitude of the changes in the warrant liabilities will correspondingly be further reduced.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Comparison
of the Three Months Ended June 30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes our results of operations for the three months ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the Three Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net product sales</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">1,117,935</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right">904,067</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,117,935</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">904,067</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">916,624</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">807,922</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,952,100</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,979,614</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,508,466</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">597,345</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Sales and marketing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">135,543</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">88,844</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8,512,733</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,473,725</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,394,798</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,569,658</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss (gain) on change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,075,100</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,201,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(12,718</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,364</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,352</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(250,114</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,090,170</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,008,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(5,304,628</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,578,308</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">PROVISION FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">605</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">597</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(5,305,233</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(18,578,905</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
product sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
product sales are primarily generated from sales of diagnostic tests. <span style="background-color: white">Net product sales during
the three-month periods ended June 30, 2021 and 2020 were approximately $1.1 million and $0.9 million, respectively, representing an
increase of approximately $0.2 million, or 24%. </span>This improvement was due to a recovery from the effects of the COVID-19 pandemic
experienced during the prior year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">However,
net product sales for the second quarter of 2021 declined sequentially from the approximately $1.4 million figure of the first quarter
of 2021, and our year-over-year increase in quarterly net product sales was restrained, in part as a result of sporadic problems with
our manufacturing equipment during the second quarter of 2021 which affected our ability to supply.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the three months ended June 30, 2021, sales of
our Testosterone test kits to end users exceeded sales of our Total PSA test kits to end users;
in no previous calendar quarter had this occurred.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost
of Product Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of product sales increased during the three months ended June 30, 2021, to $916,000, or 82% of net product sales, versus approximately
$808,000, or 89% of net product sales, during the three months ended June 30, 2020. This increase of $109,000 was primarily due to higher
manufacturing labor costs and higher allocated manufacturing-support costs of research and development personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">General
and administrative expenses increased sharply from $2.0 million, during the three months ended June 30, 2020, to $3.0 million during
the three months ended June 30, 2021. This increase was primarily due to $0.8 million in employee/director stock-based compensation expense,
and a $0.2 million increase in payroll and insurance expenses, all primarily related to our public-company status during the three
months ended June 30, 2021 in contrast to our private-company status during most of the three months ended June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs include therapeutic and diagnostic research and product development costs. We have shifted our focus in this category
toward therapeutics. Research and development costs increased from $0.6 million for the three months ended June 30, 2020 to $4.5 million
for the three months ended June 30, 2021. Of the $0.6 million of research and development costs for the three months ended June 30, 2020,
$0.34 million (58%) was attributable to therapeutics and $0.25 million (42%) was attributable to diagnostics. Of the $4.5 million of
research and development costs for the three months ended June 30, 2021, $4.2 million (93%) was attributable to therapeutics and $0.3
million (7%) was attributable to diagnostics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
increase in therapeutics research and development costs was primarily due to $3.4 million in expenses related to the potential
application of QN-165 to treatment of COVID-19 ($2.5 million in drug compound manufacturing costs, and $0.9 million in other pre-clinical
research costs for the three months ended June 30, 2021, as compared to $0.2 million in pre-clinical research costs for the three months
ended June 30, 2020), as well as pre-clinical research and development cost increases of about $0.2 million for QN-247, and an increase
of about $0.5 million in payroll and professional service expenses. Of the $2.5 million in drug compound manufacturing costs during the
three months ended June 30, 2021, $1.9 million consisted of expenses incurred with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi
AppTec, our manufacturer of QN-165 for our anticipated clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
the future, we expect our therapeutic research and development costs to continue to increase and to significantly outweigh our diagnostic
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Sales
and Marketing Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing expenses during the three months ended June 30, 2021 increased to approximately $136,000 as compared to approximately $89,000
during the three months ended June 30, 2020, primarily due to an increase in payroll and recruiting expenses related to our diagnostics
business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Other
Expense (Income)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Change
in Fair Value of Warrant Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2021 we experienced (primarily due to a decrease in our stock price during the period) a $2.1
million gain on change in the fair value of the warrant liabilities arising from our &#8220;exploding warrants&#8221; series
(containing a &#8220;double-ratchet&#8221; provision) issued by Qualigen, Inc. many years ago to brokers and investors in connection
with a 2004 private placement. By contrast, for the three months ended June 30, 2020, we experienced a $16.2 million loss on change
in fair value of warrant liabilities, due to the reverse recapitalization transaction and an associated increase in the market price
of our common stock. Typically a decline in our stock price would result in a decline in the fair value of our warrant liabilities,
generating an item of income; but an increase in our stock price would result in an increase in the fair value of our warrant
liabilities, generating a loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Because
the fair value of the warrant liabilities will be determined each quarter on a &#8220;mark-to-market&#8221; basis, this item is likely
to continue to result in significant variability in our future quarterly and annual statements of operations based on unpredictable changes
in our public market common stock price and the number of warrants outstanding at the end of each quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
(Income) Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">There
was approximately $13,000 in net interest income during the three months ended June 30, 2021 versus net interest expense of approximately
$57,000 during the three months ended June 30, 2020. Interest on $1.7 million principal amount of convertible notes payable ceased to
accrue when they automatically converted in May 2020 upon the closing of the reverse recapitalization transaction. In addition, between
April 1, 2020 and December 31, 2020 we paid off our revolving factoring line of credit facility and repaid approximately $0.9 million
to Sekisui. During the second quarter of 2021 we paid off our Equipment Financing Agreements which eliminated all of our outstanding
notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
(Income), Net </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">There
was approximately $2,000 in other income during the three months ended June 30, 2021, compared to approximately $250,000
in other income during the three months ended June 30, 2020, of which $250,000 resulted from a li<span style="background-color: white">cense
option fee for our FastPack 2.0 technology during the prior period</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Comparison
of the Six Months Ended June 30, 2021 and 2020</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes our results of operations for the six months ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the Six Months Ended </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">REVENUES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 60%; text-align: left; padding-left: 10pt">Net product sales</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,538,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,315,823</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">License revenue</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">478,654</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Collaborative research revenue</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#8212;</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">45,000</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,017,430</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,360,823</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold">EXPENSES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Cost of product sales</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,119,103</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,799,574</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">General and administrative</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">5,826,038</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,897,993</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">8,007,840</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">835,403</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Sales and marketing</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">272,129</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">181,106</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,225,110</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,714,076</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS FROM OPERATIONS</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(13,207,680</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,353,253</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">OTHER EXPENSE (INCOME), NET</td><td style="font-weight: bold">&#160;</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; text-align: right">&#160;</td><td style="font-weight: bold; text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Loss (gain) on change in fair value of warrant liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(4,198,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,201,400</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Interest (income) expense, net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,061</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">148,121</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Other (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,894</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(251,272</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total other expense (income), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4,230,955</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">16,098,249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">LOSS BEFORE PROVISION FOR INCOME TAXES</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(8,976,725</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(19,451,502</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">PROVISION (BENEFIT) FOR INCOME TAXES</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,135</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(22</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt">NET LOSS</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(8,977,860</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(19,451,480</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenues</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
operating revenues are primarily generated from sales of diagnostic tests. Revenues during the six months ended June 30, 2021 were $3.0
million compared to $2.4 million during the six months ended June 30, 2020, an increase of $0.6 million. This increase was primarily
due to recognition of license revenue from Yi Xin under the Technology Transfer Agreement, an item which had no counterpart in the six
months ended June 30, 2020, as well as an increase in diagnostic product sales.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
product sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Net
product sales are primarily generated from sales of diagnostic tests. <span style="background-color: white">Net product sales during
the six-month periods ended June 30, 2021 and 2020 were approximately $2.5 million and $2.3 million, respectively, representing an increase
of approximately $0.2 million, or 10%. </span>This improvement was due to a recovery from the effects of the COVID-19 pandemic
during the prior year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>License
revenue </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">License
revenue during the six months ended June 30, 2021 was $479,000, due to the recognition of revenue from Yi Xin under the Technology Transfer
Agreement in the first quarter of 2021. There was no license revenue during the six months ended June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Collaborative
research revenue</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Collaborative
research revenue is recognized as research services are performed over the development period for each agreement. There was no collaborative
research revenue during the six months ended June 30, 2021, as compared to $45,000 during the six months ended June 30, 2020, which arose
from our development work toward a cellular fibronectin assay for Prediction BioSciences SAS.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Cost
of Product Sales</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cost
of product sales increased during the six months ended June 30, 2021, to $2.1 million, or 83% of net product sales, versus approximately
$1.8 million, or 78% of net product sales, during the six months ended June 30, 2020. This increase of $0.3 million, and increase in
percentage, were primarily due to higher manufacturing labor costs and higher allocated manufacturing-support costs of research and development
personnel.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">General
and administrative expenses increased sharply from $2.9 million, during the six months ended June 30, 2020, to $5.8 million during the
six months ended June 30, 2021. This increase was primarily due to $1.9 million in employee/director stock-based compensation expense,
a $0.5 million increase in insurance expenses, and a $0.5 million increase in payroll expenses, all primarily related to our public-company
status during the six months ended June 30, 2021 in contrast to our private-company status during most of the six months ended June 30,
2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Costs</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development costs include therapeutic and diagnostic research and product development costs. We have shifted our focus in this category
toward therapeutics. Research and development costs increased from $0.8 million for the six months ended June 30, 2020 to $8.0 million
for the six months ended June 30, 2021. Of the $0.8 million of research and development costs for the six months ended June 30, 2020,
$0.5 million (60%) was attributable to therapeutics and $0.3 million (40%) was attributable to diagnostics. Of the $8.0 million of research
and development costs for the six months ended June 30, 2021, $7.3 million (91%) was attributable to therapeutics and $0.7 million (9%)
was attributable to diagnostics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
increase in diagnostic research and development costs was primarily due to increased stock-based compensation expense related to our
public-company status, and wind-down costs related to the withdrawn COVID-19 antibody diagnostic test during the six months ended June
30, 2021. The increase in therapeutics research and development costs was primarily due to $5.9 million in expenses related to the potential
application of QN-165 to treatment of COVID-19 ($4.2 million in drug compound manufacturing costs, and $1.6 million in other pre-clinical
research costs for the six months ended June 30, 2021, as compared to $0.2 million in pre-clinical research costs for the six
months ended June 30, 2020), as well as pre-clinical research and development cost increases of about $0.3 million for QN-247
and about $0.2 million for RAS. Of the $4.2 million in drug compound manufacturing costs during the six months ended June 30,
2021, $3.1 million consisted of payments made to STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, our manufacturer of QN-165
for our anticipated clinical trials.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">For
the future, we expect our therapeutic research and development costs to continue to increase and to significantly outweigh our diagnostic
research and development costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Sales
and Marketing Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and marketing expenses during the six months ended June 30, 2021 increased to approximately $272,000 as compared to $181,000 during the
six months ended June 30, 2020, primarily due to an increase in payroll and recruiting expenses related to our diagnostics business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Other
Expense (Income)</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Change
in Fair Value of Warrant Liabilities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021 we experienced (primarily due to a decrease in our stock price during the period) $4.2 million in
other income because the fair value of the warrant liabilities arising from our &#8220;exploding warrants&#8221; series (containing a
&#8220;double-ratchet&#8221; provision) issued by Qualigen, Inc. many years ago to brokers and investors in connection with a 2004 private
placement declined to $4.1 million from $8.3 million at December 31, 2020. For the six months ended June 30, 2020, loss on change in
fair value of warrant liabilities was $16.2 million due to the reverse recapitalization transaction and an associated increase in the
market price of our common stock. Typically a decline in our stock price would result in a decline in the fair value of our warrant liabilities,
generating an item of income; but an increase in our stock price would result in an increase in the fair value of our warrant liabilities,
generating a loss.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Because
the fair value of the warrant liabilities will be determined each quarter on a &#8220;mark-to-market&#8221; basis, this item is likely
to continue to result in significant variability in our future quarterly and annual statements of operations based on unpredictable changes
in our public market common stock price and the number of warrants outstanding at the end of each quarter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
(Income) Expense, Net</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">There
was about $30,000 in net interest income during the six months ended June 30, 2021 versus net interest expense of approximately $148,000
during the six months ended June 30, 2020. Interest on $1.7 million principal amount of convertible notes payable ceased to accrue when
they automatically converted in May 2020 upon the closing of the reverse recapitalization transaction. In addition, between April 1,
2020 and December 31, 2020 we paid off our revolving factoring line of credit facility and repaid approximately $0.9 million to Sekisui.
During the second quarter of 2021 we paid off our Equipment Financing Agreements which eliminated all of our notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other
(Income), Net </i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">There
was approximately $3,000 in other income during the six months ended June 30, 2021, and approximately $251,000 in other income
during the first six months of 2020, of which $250,000 resulted from a li<span style="background-color: white">cense option fee for our
FastPack 2.0 technology</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, we had $15.2 million of cash and cash equivalents. However, we have suffered recurring losses from operations and expect
to continue to do so. Based on our current cash position, and assuming currently planned expenditures and level of operations, we believe
we have sufficient capital to fund operations for the twelve-month period subsequent to the date of this Quarterly Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
a development-stage therapeutics biotechnology company, we expect to continue to have net losses and negative cash flow from operations,
which over time will challenge our liquidity. There is no assurance that profitable operations will ever be achieved, or, if achieved,
could be sustained on a continuing basis. In order to fully execute our business plan, including full clinical trials of therapeutic
drug candidates, we will require additional financing. There can be no assurance that further financing can be obtained on favorable
terms, or at all. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development programs,
product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Our
balance sheet at June 30, 2021 included $4.1 million of warrant liabilities. We do not consider that the warrant liabilities constrain
our liquidity, as a practical matter. Our current liabilities at June 30, 2021 included $0.8 million of accounts payable and $1.9
million of accrued expenses and other current liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Cash
Flows</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the significant sources and uses of cash and cash equivalents for the periods set forth below:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For the Six Months Ended</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June 30,</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Net cash provided by (used in):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 56%; text-align: left; padding-left: 10pt">Operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(8,785,057</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">(1,782,080</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(114,691</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(493,159</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">155,580</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,528,661</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Net increase (decrease) in cash and cash equivalents</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">(8,744,168</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">)</td><td style="font-weight: bold; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">2,253,422</td><td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Cash Used in (Provided by) Operating Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021, operating activities used $8.8 million of cash, primarily resulting from a net loss of $9.0 million.
Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2021 benefitted from the $0.7 million
decrease in prepaid expenses and other assets, a $2.5 million increase in employee/director stock-based compensation expense, a $1.2
million increase in accrued expenses and other current liabilities and a $0.3 million increase in accounts payable, due to higher costs
related to therapeutics research and development. On the other hand, cash flows from operating activities (as opposed to net loss) for
the six months ended June 30, 2021 were disadvantaged by a $4.2 million decrease in fair value of warrant liabilities and a $0.2 million
increase in accounts receivable. The decrease in prepaid expenses was primarily due to the expensing during the period of $1.1 million
of previous prepayments to STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, our manufacturer of QN-165 for our anticipated
clinical trials, but was offset in part by an approximately $0.6 million increase of prepaid expenses for director and officer liability
insurance.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2020, operating activities used $1.8 million of cash, primarily resulting from a net loss of $19.5
million. Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2020 benefitted from a $16.2
million increase in fair value of warrant liabilities due to the reverse-recapitalization and an associated increase in the market price
of our common stock, a $0.4 million increase in employee/director stock-based compensation expense, a $0.8 million decrease in accounts
receivable, a $1.1 million increase in accrued expenses and other current liabilities and a $0.2 million increase in accounts
payable, due primarily to higher costs related to therapeutics research and development. Cash flows from operating activities (as opposed
to net loss) for the six months ended June 30, 2020 were negatively impacted by a $1 million increase in prepaid expenses, primarily
due to <span style="background-color: white">prepaid director and officer liability insurance policies purchased in connection with the
reverse-recapitalization transaction.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Cash Used in Investing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021, net cash used in investing activities was approximately $0.1 million, primarily related to the purchase
of property and equipment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2020, net cash used in investing activities was approximately $0.5 million, primarily related to payments
for patents and licenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><i>Net
Cash Provided by (Used in) Financing Activities</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash provided by financing activities for the six months ended June 30, 2021 was approximately $0.2 million, due to about $0.3 million
of net proceeds from exercise of warrants, offset by approximately $0.1 million in principal payments on notes payable. Net cash provided
by financing activities for the six months ended June 30, 2020 was $4.5 million, primarily due to $4.0 million in proceeds from the issuance
of Series Alpha Preferred Stock and $1.7 million in proceeds from the issuance of notes payable, offset by $1.2 million in principal
payments on notes payable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_008"></span>3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
reporting companies are not required to respond to this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_009"></span>4.
CONTROLS AND PROCEDURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Evaluation
of Disclosure Controls and Procedures</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of
our disclosure controls and procedures as of June 30, 2021, the end of the period covered by this Quarterly Report.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Based
on this evaluation, our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures
as of June 30, 2021 were effective to provide reasonable assurance that the information required to be disclosed by us in reports filed
under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified
in the SEC&#8217;s rules and forms, and that such information is accumulated and communicated to our management, including our principal
executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. We believe
that a disclosure controls system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of
the disclosure controls system are met, and no evaluation of disclosure controls can provide absolute assurance that all disclosure control
issues, if any, within a company have been detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Changes
in Internal Control over Financial Reporting</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f)
and 15d-15(f) under the Securities Exchange Act. Internal control over financial reporting is a process designed under the supervision
and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes
in accordance with U.S. GAAP. As of December 31, 2020, our management assessed the effectiveness of our internal control over financial
reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated
Framework, or 2013 Framework. Based on this assessment, our management concluded that, as of December 31, 2020, our internal control
over financial reporting was not effective because of a material weakness in our internal control over financial reporting related to
the lack of accounting department resources and/or policies and procedures to ensure recording and disclosure of items in compliance
with generally accepted accounting principles. We have taken and are taking steps to remediate the material weakness, including implementing
additional procedures and utilizing external consulting resources with experience and expertise in U.S. GAAP and public company accounting
and reporting requirements to assist management with its accounting and reporting of complex and/or non-recurring transactions and related
disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that during the quarter ended June 30, 2021 the remediation steps described above had a positive effect and have materially improved
our internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Notwithstanding
the identified material weakness, our management believes that the condensed consolidated financial statements included in this Quarterly
Report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods
presented in accordance with U.S. GAAP. Nonetheless, we also believe that an internal control system, no matter how well designed and
operated, cannot provide absolute assurance that the objectives of the internal control system are met, and no evaluation of internal
control can provide absolute assurance that all internal control issues and instances of fraud, if any, within a company are detected.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_010"></span>PART
II - OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_011"></span>ITEM
1. LEGAL PROCEEDINGS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
are not currently involved in any legal matters. From time to time, we could become involved in disputes and various litigation matters
that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract
law and employee relations matters.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_012"></span>ITEM
1A. RISK FACTORS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
reporting companies are not required to respond to this Item.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Please
refer to the Risk Factors section of our Transition Report on Form 10-K for the nine-months transition period ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_013"></span>ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Unregistered
Sales of Equity Securities</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Purchases
of Equity Securities by the Issuer and Affiliated Purchasers</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_014"></span>ITEM
3. DEFAULTS UPON SENIOR SECURITIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_015"></span>ITEM
4. MINE SAFETY DISCLOSURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Not
Applicable</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_016"></span>ITEM
5. OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">None</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="a_017"></span>ITEM
6. EXHIBITS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: center">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: bottom; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; vertical-align: top">&#160;</td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><b>Incorporated by Reference</b></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 38%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Form</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 10%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>File
    No.</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 9%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 16%"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Filing</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000157104915005411/t1501532_ex3-1.htm" style="-sec-extract: exhibit">Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">July
    1, 2015</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315217010647/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">September
    15, 2017</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315218003738/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Amended and Restated Certificate of Incorporation</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">001-37428</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">March
    22, 2018</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-1.htm" style="-sec-extract: exhibit">Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 20, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">May
    29, 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.5</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-2.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">May
    29, 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.6</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-3.htm" style="-sec-extract: exhibit">Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.3</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">May
    29, 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.7</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><a href="https://www.sec.gov/Archives/edgar/data/1460702/000149315220010166/ex3-4.htm" style="-sec-extract: exhibit">Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [name change]</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">8-K</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.4</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">May
    29, 2020</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">3.8</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex3-8.htm"><span style="font: 10pt Times New Roman, Times, Serif">Amended and Restated Bylaws of the Company, through August 10, 2021 </span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><a href="ex10-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Hire offer letter from the Company to Tariq Arshad, dated April 22, 2021</span></a></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">10.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex10-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Letter dated June 22, 2021 to A.G.P./Alliance Global Partners giving notice of termination of Sales Agreement</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">31.1
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">31.2
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex31-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. </span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">32.1
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><a href="ex32-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. </span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%"><span style="font: 10pt Times New Roman, Times, Serif">101.INS#
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 88%"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH#
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Schema Document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL#
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Calculation Linkbase Document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF#
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Definition Linkbase Document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB#
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Label Linkbase Document. </span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE#
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Taxonomy Extension Presentation Linkbase Document. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">#
XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement
or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the
Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">August
    16,</span><span style="font: 10pt Times New Roman, Times, Serif"> 2021</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>QUALIGEN
    THERAPEUTICS, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Michael S. Poirier &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Name:&#160;
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Michael
    S. Poirier</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- 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 -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.8
<SEQUENCE>2
<FILENAME>ex3-8.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
3.8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>AMENDED
AND RESTATED BYLAWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OF</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUALIGEN
THERAPEUTICS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
1</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
OFFICES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
1.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Offices</I>. The Corporation shall have a registered
office (and address) within the State of Delaware and may also have offices at such other places both within and without the State of
Delaware as the board of directors of the Corporation (the &ldquo;<U>Board of Directors</U>&rdquo;) may from time to time determine or
the business of the Corporation may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
1.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Books</I>. The books of the Corporation may
be kept within or without the State of Delaware as the Board of Directors may from time to time determine or the business of the Corporation
may require.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
2</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
MEETINGS OF STOCKHOLDERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Time and Place of Meetings</I>. All meetings
of the stockholders shall be held at such place, if any, either within or without the State of Delaware, on such date and at such time
as may be determined from time to time by the Board of Directors (or the Chairman in the absence of a designation by the Board of Directors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Annual Meetings</I>. An annual meeting of the
stockholders shall be held for the election of directors and to transact such other business as may properly be brought before the meeting.
Any other proper business may be transacted at the annual meeting. The Board of Directors may postpone, reschedule or cancel any annual
meeting of stockholders previously scheduled by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.03. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special Meetings</I>. Special meetings of the
stockholders for any purpose or purposes may be called by the Board of Directors, the Chairman of the Board of Directors, the Chief Executive
Officer or the President of the Corporation, and may not be called by any other person. Business transacted at any special meeting of
the stockholders shall be limited to the purposes stated in the notice. The Board of Directors may postpone, reschedule or cancel any
special meeting of stockholders previously scheduled by the Board of Directors. Notwithstanding the foregoing, whenever holders of one
or more classes or series of preferred stock shall have the right, voting separately as a class or series, to elect directors, such holders
may call, pursuant to the terms of the resolution or resolutions adopted by the Board of Directors, special meetings of holders of such
Preferred Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.04. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notice of Meetings and Adjourned Meetings;
Waivers of Notice</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Whenever stockholders are required or permitted to take
any action at a meeting, a written notice of the meeting shall be given which shall state the place, if any, date and hour of the meeting,
the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at
such meeting, the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record
date for stockholders entitled to notice of the meeting) and, in the case of a special meeting, the purpose or purposes for which the
meeting is called. Unless otherwise provided by the General Corporation Law of the State of Delaware as the same exists or may hereafter
be amended (&ldquo;<U>Delaware Law</U>&rdquo;), the Certificate of Incorporation or these Bylaws, such notice of any meeting shall be
given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder of record entitled to vote
at such meeting. Except as otherwise provided herein or permitted by applicable law, notice of stockholders shall be in writing and delivered
personally or mailed to the stockholders at their address appearing on the books of the Corporation. Without limiting the manner by which
notice otherwise may be given effectively to stockholders, notice of meetings may be given to stockholders by means of electronic transmission
in accordance with applicable law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any meeting of the stockholders, annual or special,
may be adjourned from time to time to reconvene at the same or some other place, if any. Unless these Bylaws otherwise require, when
a meeting is adjourned to another time or place (whether or not a quorum is present), notice need not be given of the adjourned meeting
if the time, place, if any, thereof and the means of remote communications, if any, by which stockholders and proxy holders may be deemed
to be present in person and vote at such meeting, are announced at the meeting at which the adjournment is taken. At the adjourned meeting,
the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than
thirty (30) days, or after the adjournment a new record date is fixed for the adjourned meeting, a notice of the adjourned meeting shall
be given to each stockholder of record entitled to vote at the meeting as of the record date for determining the stockholders entitled
to notice of the meeting. If mailed, such notice shall be deemed to be given when deposited in the United States mail, postage prepaid,
directed to the stockholder at such stockholder&rsquo;s address as it appears on the records of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A written waiver of any such notice signed by the person
entitled thereto, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time stated therein,
shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of notice of such meeting, except
when the person attends the meeting for the express purpose of objecting, at the beginning of the meeting, to the transaction of any
business because the meeting is not lawfully called or convened. Any stockholder so waiving notice of the meeting shall be bound by the
proceedings of the meeting in all respects as if due notice thereof had been given. Business transacted at any special meeting of stockholders
shall be limited to the purposes stated in the notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.05. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quorum</I>. Unless otherwise provided in the
Certificate of Incorporation or these Bylaws, and subject to Delaware Law, the presence, in person or by proxy, of the holders of shares
of the outstanding capital stock of the Corporation representing at least 35% of the votes entitled to be voted at a meeting of stockholders
shall constitute a quorum for the transaction of business. If, however, such quorum shall not be present or represented at any meeting
of the stockholders, the chairman of the meeting may adjourn the meeting in the manner provided in Section 2.04, without notice other
than announcement at the meeting, until a quorum shall be present or represented. A quorum once established, shall not be broken by the
subsequent withdrawal of enough votes to leave less than a quorum. At such adjourned meeting at which a quorum shall be present or represented,
any business may be transacted which might have been transacted at the meeting as originally notified. Shares of stock of the Corporation
belonging to the Corporation or to another corporation, if a majority of the shares entitled to vote in the election of directors of
such other corporation is held, directly or indirectly, by the Corporation, shall neither be entitled to vote nor be counted for quorum
purposes; provided, however, that the foregoing shall not limit the right of the Corporation, or any subsidiary of the Corporation, to
vote stock, including but not limited to its own stock, held by it in a fiduciary capacity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.06. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting; Proxies</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unless otherwise provided in the Certificate of Incorporation
and subject to Delaware Law, each stockholder shall be entitled to one vote for each outstanding share of capital stock of the Corporation
held by such stockholder. Any share of capital stock of the Corporation held by the Corporation shall have no voting rights. Except as
otherwise provided by law, the Certificate of Incorporation or these Bylaws, in all matters other than the election of directors, the
affirmative vote of the majority of the votes cast by the shares of capital stock of the Corporation present in person or represented
by proxy at the meeting and entitled to vote on the subject matter shall be the act of the stockholders, provided a quorum is present.
Subject to the rights of the holders of any series of preferred stock to elect additional directors under specific circumstances, directors
shall be elected by a plurality of the votes cast at a meeting of the stockholders by the holders of stock entitled to vote in the election
of directors, provided a quorum is present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each stockholder entitled to vote at a meeting of stockholders,
or to express consent or dissent to a corporate action in writing without a meeting, may authorize another person or persons to act for
such stockholder by proxy, appointed by an instrument in writing, subscribed by such stockholder or by his attorney thereunto authorized,
or by proxy sent by cable, telegram or by any means of electronic communication permitted by law, which results in a writing from such
stockholder or by his attorney, and delivered to the secretary of the meeting. No proxy shall be voted or acted upon after three (3)
years from its date, unless said proxy provides for a longer period. A proxy shall be irrevocable if it states that it is irrevocable
and if, and only as long as, it is coupled with an interest sufficient in law to support an irrevocable power. A stockholder may revoke
any proxy which is not irrevocable by attending the meeting and voting in person or by delivering to the Secretary of the Corporation
a revocation of the proxy or a new proxy bearing a later date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voting at meetings of stockholders need not be by written
ballot. Votes may be cast by any stockholder entitled to vote in person or by his proxy. In determining the number of votes cast for
or against a proposal or nominee, shares abstaining from voting on a matter (including elections) will not be treated as a vote cast,
but will be counted for purposes of determining a quorum. A non-vote by a broker will be counted for purposes of determining a quorum
but not for purposes of determining the number of votes cast.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.07. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Inspector of Elections; Opening and Closing
the Polls</I>. The Board of Directors by resolution shall appoint one or more inspectors, which inspector or inspectors may include individuals
who serve the Corporation in other capacities, including, without limitation, as officers, employees, agents or representatives, to act
at the meetings of stockholders and make a written report thereof. One or more persons may be designated as alternate inspectors to replace
any inspector who fails to act. If no inspector or alternate has been appointed to act or is able to act at a meeting of stockholders,
the presiding officer of the meeting shall appoint one or more inspectors to act at the meeting. Each inspector, before discharging his
or her duties, shall take and sign an oath faithfully to execute the duties of inspector with strict impartiality and according to the
best of his or her ability. The inspectors shall have the duties prescribed by law. The presiding officer of the meeting shall fix and
announce at the meeting the date and time of the opening and the closing of the polls for each matter upon which the stockholders will
vote at a meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.08. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Written Consent of Stockholders Without a Meeting</I>.
Any action to be taken at any annual or special meeting of stockholders may be taken without a meeting, without prior notice and without
a vote, if a consent or consents in writing, setting forth the action to be so taken, shall be signed by the holders of outstanding stock
having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares
entitled to vote thereon were present and voted and shall be delivered (by hand or by certified or registered mail, return receipt requested)
to the Corporation by delivery to its registered office in the State of Delaware, its principal place of business or an officer or agent
of the Corporation having custody of the book in which proceedings of meetings of stockholders are recorded. Every written consent shall
bear the date of signature of each stockholder who signs the consent, and no written consent shall be effective to take the corporate
action referred to therein unless, within 60 days of the earliest dated consent delivered in the manner required by this Section 2.08,
written consents signed by a sufficient number of holders to take action are delivered to the Corporation as aforesaid. Prompt notice
of the taking of the corporate action without a meeting by less than unanimous written consent shall, to the extent required by applicable
law, be given to those stockholders who have not consented in writing, and who, if the action had been taken at a meeting, would have
been entitled to notice of the meeting if the record date for notice of such meeting had been the date that written consents signed by
a sufficient number of holders to take the action were delivered to the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.09. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Organization</I>. At each meeting of stockholders,
the Chairman of the Board, if one shall have been elected, or in the Chairman&rsquo;s absence or if one shall not have been elected,
the director designated by the vote of the majority of the directors present at such meeting, shall act as chairman of, and preside at,
the meeting. The Secretary, or in the Secretary&rsquo;s absence or inability to act, the person whom the chairman of the meeting shall
appoint secretary of the meeting, shall act as secretary of the meeting and keep the minutes thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.10. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Order of Business</I>. The order of business
at all meetings of stockholders shall be as determined by the chairman of the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.11. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nomination of Directors</I>. Only persons who
are nominated in accordance with the procedures set forth in these Bylaws shall be eligible to serve as directors. Nominations of persons
for election to the Board of Directors of the Corporation may be made at an annual meeting of stockholders (a) by or at the direction
of the Board of Directors or (b) by any stockholder of the Corporation who is a stockholder of record at the time of giving of notice
provided for in this Section 2.11, who shall be entitled to vote for the election of directors at the meeting and who complies with the
notice procedures set forth in this Section 2.11. Such nominations, other than those made by or at the direction of the Board of Directors,
shall be made pursuant to timely notice in writing to the secretary of the Corporation. To be timely, a stockholder&rsquo;s notice shall
be delivered to or mailed and received at the principal executive offices of the Corporation not later than the close of business on
the ninetieth (90<SUP>th</SUP>) day, nor earlier than the close of business on the one hundred twentieth (120<SUP>th</SUP>) day in advance
of the first anniversary of the preceding year&rsquo;s annual meeting of stockholders; provided, however, that in the event that the
date of the annual meeting is advanced more than thirty (30) days prior to such anniversary date or delayed more than sixty (60) days
after such anniversary date then to be timely such notice must be received by the Corporation notice not earlier than the close of business
on the one hundred twentieth (120th) day prior to such annual meeting and not later than the close of business on the later of the ninetieth
(90th) day prior to such annual meeting or the tenth (10th) day following the day on which public announcement of the date of such meeting
is first made by the Corporation. In no event shall the public announcement of the new meeting date commence a new notice time period
(or extend any notice time period).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
stockholder notice delivered pursuant to this Section 2.11 shall set forth (a) as to each person whom the stockholder proposes to nominate
for election or reelection as a director, (i) all information relating to such person as would be required to be disclosed in solicitations
of proxies for the election of such nominees as directors pursuant to Regulation 14A under the Exchange Act; (ii) such person&rsquo;s
written consent to serve as a director if elected; (iii) a description of all direct and indirect compensation or other material monetary
agreements, arrangements and understandings during the past three years, and any other material relationships, between or among such
stockholder of record and beneficial owner or owners, if any, and their respective affiliates and associates, or other persons acting
in concert therewith, on the one hand, and each proposed nominee and his or her respective affiliates and associates or other persons
acting in concert therewith, on the other hand, including without limitation all information that would be required to be disclosed pursuant
to Rule 404 promulgated under Regulation S-K if the stockholder of record making the nomination and any beneficial owner or owners, if
any, or other person on whose behalf the nomination is made, or any affiliate or associate thereof or other person acting in concert
therewith, were the &ldquo;registrant&rdquo; for purposes of such rule and the nominee were a director or executive officer of such registrant;
and (iv) a completed and signed questionnaire, representation or agreement as may be required by the Corporation pursuant to Section
3.03 of Article 3 of these Bylaws, and (b) as to the stockholder giving the notice (i) the name and address, as they appear on the Corporation&rsquo;s
books, of such stockholder, and of the beneficial owner, if any, on whose behalf the nomination is being made, (ii) the class and number
of shares of the Corporation which are owned (beneficially and of record) by such stockholder and owned by the beneficial owner, if any,
on whose behalf the nomination is being made, as of the date of the stockholder&rsquo;s notice, and a representation that the stockholder
will notify the Corporation in writing of the class and number of such shares owned of record and beneficially as of the record date
for the meeting promptly following the later of the record date or the date notice of the record date is first publicly disclosed, (iii)
a description of any agreement, arrangement or understanding with respect to such nomination between or among the stockholder and any
of its affiliates or associates, and any others (including their names) acting in concert with any of the foregoing, and a representation
that the stockholder will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the record
date for the meeting promptly following the later of the record date or the date notice of the record date is first publicly disclosed,
(iv) a description of any agreement, arrangement or understanding (including, regardless of the form of settlement, any derivative, long
or short positions, profit interests, forwards, futures, swaps, options, warrants, convertible securities, stock appreciation or similar
rights, hedging transactions and borrowed or loaned shares) that has been entered into as of the date of the proposing stockholder&rsquo;s
notice, by or on behalf of such stockholder with respect to the Corporation&rsquo;s securities, or any other agreement, arrangement or
understanding that has been made, the effect or intent of which is to create or mitigate loss to, manage risk or benefit of share price
changes for, or increase or decrease the voting power of, such stockholder with respect to the Corporation&rsquo;s securities, and a
representation that the stockholder will notify the Corporation in writing of any such agreement, arrangement or understanding in effect
as of the record date for the meeting promptly following the later of the record date or the date notice of the record date is first
publicly disclosed; (v) a representation that the proposing stockholder is a holder of record of the shares of the Corporation entitled
to vote at the meeting and intends to appear in person or by proxy at the meeting to nominate the person or persons specified in the
notice, and (vi) a representation whether the proposing stockholder intends to deliver a proxy statement and/or form of proxy to holders
of at least the percentage of the Corporation&rsquo;s outstanding capital stock required to approve the nomination and/or otherwise to
solicit proxies from the stockholders in support of the nomination. For purposes of these Bylaws, a person shall be deemed to be acting
in concert with another person if such person knowingly acts toward a common goal relating to the management, governance or control of
the corporation in parallel with such other person where (A) each person is conscious of the other person&rsquo;s conduct or intent and
this awareness is an element in their decision-making process and (B) at least one additional factor suggests that persons intend to
act in parallel, which additional factors may include attending meetings, conducting discussions or making or soliciting invitations
to act in parallel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Corporation may require any proposed nominee to furnish such other information as it may reasonably require to determine the eligibility
of such proposed nominee to serve as an independent director of the Corporation or that could be material to a reasonable stockholder&rsquo;s
understanding of the independence, or lack thereof, of such nominee. No person shall be eligible to serve as a director of the Corporation
unless nominated in accordance with the procedures set forth in this bylaw. The chairman of the meeting shall, if the facts warrant,
determine and declare to the meeting that a nomination was not made in accordance with the procedures prescribed by the Bylaws, and if
he should so determine, he shall so declare to the meeting and the defective nomination shall be disregarded. Notwithstanding the foregoing
provisions of this Section 2.11, a stockholder shall also comply with all applicable requirements of the Securities Exchange Act of 1934,
as amended, and the rules and regulations thereunder with respect to the matters set forth in this Section 2.11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.12. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Notice of Business</I>. At any meeting of the
stockholders, only such business shall be conducted as shall have been brought before the meeting (a) by or at the direction of the Board
of Directors or (b) solely with respect to annual meetings, by any stockholder of the Corporation who is a stockholder of record at the
time of giving of the notice provided for in this Section 2.12, who shall be entitled to vote at such meeting and who complies with the
notice procedures set forth in this Section 2.12. In addition, any proposal of business must be a proper matter for stockholder action.
For business to be properly brought before a stockholder meeting by a stockholder, the stockholder must have given timely notice thereof
in writing to the secretary of the Corporation. To be timely, a stockholder&rsquo;s notice shall be delivered to or mailed and received
at the principal executive offices of the Corporation not later than the close of business on the ninetieth (90<SUP>th</SUP>) day, nor
earlier than the close of business on the one hundred twentieth (120<SUP>th</SUP>) day in advance of the first anniversary of the preceding
year&rsquo;s annual meeting of stockholders; provided, however, that in the event that the date of the annual meeting is advanced more
than thirty (30) days prior to such anniversary date or delayed more than sixty (60) days after such anniversary date then to be timely
such notice must be received by the Corporation no later than the later of the close of business on the seventieth (70<SUP>th</SUP>)
day prior to the date of the meeting or the close of business on the tenth (10<SUP>th</SUP>) day following the day on which public announcement
of the date of the meeting was made. In no event shall the public announcement of the new meeting date commence a new notice time period
(or extend any notice time period). A stockholder&rsquo;s notice to the secretary shall set forth as to each matter the stockholder proposes
to bring before the meeting (a) a brief description of the business desired to be brought before the meeting and the reasons for conducting
such business at the meeting, (b) the name and address, as they appear on the Corporation&rsquo;s books, of the stockholder proposing
such business and of the beneficial owner, if any, on whose behalf the proposal is being made, (c) the class and number of shares of
the Corporation which are owned (beneficially and of record) by such stockholder and owned by the beneficial owner, if any, on whose
behalf the proposal is being made, as of the date of the stockholder&rsquo;s notice, and a representation that the stockholder will notify
the Corporation in writing of the class and number of such shares owned of record and beneficially as of the record date for the meeting
promptly following the later of the record date or the date notice of the record date is first publicly disclosed, (d) a description
of any agreement, arrangement or understanding with respect to such nomination between or among the stockholder and any of its affiliates
or associates, and any others (including their names) acting in concert with any of the foregoing, and a representation that the stockholder
will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the record date for the meeting
promptly following the later of the record date or the date notice of the record date is first publicly disclosed, (e) a description
of any agreement, arrangement or understanding (including, regardless of the form of settlement, any derivative, long or short positions,
profit interests, forwards, futures, swaps, options, warrants, convertible securities, stock appreciation or similar rights, hedging
transactions and borrowed or loaned shares) that has been entered into as of the date of the proposing stockholder&rsquo;s notice, by
or on behalf of such stockholder with respect to the Corporation&rsquo;s securities, or any other agreement, arrangement or understanding
that has been made, the effect or intent of which is to create or mitigate loss to, manage risk or benefit of share price changes for,
or increase or decrease the voting power of, such stockholder with respect to the Corporation&rsquo;s securities, and a representation
that the stockholder will notify the Corporation in writing of any such agreement, arrangement or understanding in effect as of the record
date for the meeting promptly following the later of the record date or the date notice of the record date is first publicly disclosed,
(f) a representation that the proposing stockholder is a holder of record of the shares of the Corporation entitled to vote at the meeting
and intends to appear in person or by proxy at the meeting to propose the business specified in the notice, (g) a representation whether
the proposing stockholder intends to deliver a proxy statement and/or form of proxy to holders of at least the percentage of the Corporation&rsquo;s
outstanding capital stock required to approve the proposal and/or otherwise to solicit proxies from the stockholders in support of the
proposal, (h) any material interest of the stockholder in such business, and (i) any other information relating to such stockholder and
beneficial owner, if any, on whose behalf the proposal is being made, required to be disclosed in a proxy statement or other filings
required to be made in connection with solicitations of proxies for the proposal and pursuant to and in accordance with Regulation 14A
under the Securities Exchange Act of 1934. Notwithstanding anything in the Bylaws to the contrary, no business shall be conducted at
a stockholder meeting except in accordance with the procedures set forth in this Section 2.12. The chairman of the meeting shall, if
the facts warrant, determine and declare to the meeting that business was not properly brought before the meeting and in accordance with
the provisions of the Bylaws, and if he should so determine, he shall so declare to the meeting and any such business not properly brought
before the meeting shall not be transacted. Notwithstanding the foregoing, provisions of this Section 2.12, a stockholder shall also
comply with all applicable requirements of the Securities Exchange Act of 1934, and the rules and regulations thereunder with respect
to the matters set forth in this Section 2.12.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.13. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Proxy Rules</I>. The foregoing notice requirements
of Section 2.12 shall be deemed satisfied by a stockholder with respect to business other than a nomination if the stockholder has notified
the Corporation of his, her or its intention to present a proposal at an annual meeting in compliance with the applicable rules and regulations
promulgated under Regulation 14A under the Securities Exchange Act of 1934 and such stockholder&rsquo;s proposal has been included in
a proxy statement that has been prepared by the Corporation to solicit proxies for such annual meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
2.14. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Effect of Noncompliance</I>. Notwithstanding
anything in these Bylaws to the contrary: (i) no nominations shall be made or business shall be conducted at any annual meeting except
in accordance with the procedures set forth in this Article 2, and (ii) unless otherwise required by law, if a stockholder intending
to propose business or make nominations at an annual meeting pursuant to this Article 2 does not provide the information required under
this Article 2 to the Corporation promptly following the later of the record date or the date notice of the record date is first publicly
disclosed, or the proposing stockholder (or a qualified representative of the proposing stockholder) does not appear at the meeting to
present the proposed business or nominations, such business or nominations shall not be considered, notwithstanding that proxies in respect
of such business or nominations may have been received by the Corporation. The requirements of this Article 2 shall apply to any business
or nominations to be brought before an annual meeting by a stockholder whether such business or nomination are to be included in the
Corporation&rsquo;s proxy statement pursuant to Rule 14a-8 of the Exchange Act or presented to stockholders by means of an independently
financed proxy solicitation. The requirements of this Article 2 are included to provide the Corporation notice of a stockholder&rsquo;s
intention to bring business or nominations before an annual meeting and shall in no event be construed as imposing upon any stockholder
the requirement to seek approval from the Corporation as a condition precedent to bringing any such business or making such nominations
before an annual meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
3</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
DIRECTORS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>General Powers</I>. Except as otherwise provided
by Delaware Law or the Certificate of Incorporation, the business and affairs of the Corporation shall be managed by or under the direction
of the Board of Directors. The Board of Directors may adopt such rules and procedures, not inconsistent with the Certificate of Incorporation,
these Bylaws, Delaware Law or other applicable law as it may deem proper for the conduct of its meetings and the management of the Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Number, Election and Term of Office.</I> The
Board of Directors shall consist of not less than three (3) nor more than eleven (11) directors, with the exact number of directors to
be determined from time to time solely by resolution adopted by the affirmative vote of a majority of the entire Board of Directors.
Except as otherwise provided in the Certificate of Incorporation, each director shall serve for a term ending on the date of the annual
meeting of stockholders next following the annual meeting at which such director was elected. Notwithstanding the foregoing, each director
shall hold office until such director&rsquo;s successor shall have been duly elected and qualified or until such director&rsquo;s earlier
death, resignation or removal. Directors need not be stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.03. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Eligibility for Nomination as a Director</I>.
To be eligible to be a nominee for election or reelection as a director of the Corporation, a person must deliver (in accordance with
the time periods prescribed for delivery of notice under Section 2.11 of Article 2 of these Bylaws or such period as the Board of Directors
may specify) to the Secretary at the principal executive offices of the Corporation a written questionnaire with respect to the background
and qualification of such person and the background of any other person or entity on whose behalf the nomination is being made (which
form of questionnaire shall be provided by the Secretary upon written request) and a written representation and agreement (in the form
provided by the Secretary upon written request) that such person (a) is not and will not become a party to (i) any agreement, arrangement
or understanding with, and has not given any commitment or assurance to, any person or entity as to how such person, if elected as a
director of the Corporation, will act or vote on any issue or question (a &ldquo;<U>Voting Commitment</U>&rdquo;) that has not been disclosed
in writing to the Corporation or (ii) any Voting Commitment that could limit or interfere with such person&rsquo;s ability to comply,
if elected as a director of the Corporation, with such person&rsquo;s fiduciary duties under applicable law, (b) is not and will not
become a party to any agreement, arrangement or understanding with any person or entity other than the Corporation with respect to any
direct or indirect compensation, reimbursement or indemnification in connection with service or action as a director that has not been
disclosed therein, and (c) in such person&rsquo;s individual capacity and on behalf of any person or entity on whose behalf the nomination
is being made, would be in compliance, if elected as a director of the Corporation, and will comply with all applicable publicly disclosed
corporate governance, conflict of interest, confidentiality and stock ownership and trading policies and guidelines of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.04. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Quorum and Manner of Acting</I>. Unless the
Certificate of Incorporation or these Bylaws require a greater number, the presence of a majority of the total number of directors shall
constitute a quorum for the transaction of business, and the affirmative vote of a majority of the directors present at a meeting at
which a quorum is present shall be the act of the Board of Directors. When a meeting is adjourned to another time or place (whether or
not a quorum is present), notice need not be given of the adjourned meeting if the time and place thereof are announced at the meeting
at which the adjournment is taken. At the adjourned meeting, the Board of Directors may transact any business which might have been transacted
at the original meeting. If a quorum shall not be present at any meeting of the Board of Directors, the directors present thereat shall
adjourn the meeting, from time to time, without notice other than announcement at the meeting, until a quorum shall be present.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.05. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Time and Place of Meetings</I>. The Board of
Directors shall hold its meetings at such place, either within or without the State of Delaware, and at such time as may be determined
from time to time by the Board of Directors (or the Chairman in the absence of a determination by the Board of Directors).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.06. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Annual Meeting.</I> The Board of Directors
shall meet for the purpose of organization, the election of officers and the transaction of other business, as soon as practicable after
each annual meeting of stockholders, on the same day and at the same place where such annual meeting shall be held. Notice of such meeting
need not be given. In the event such annual meeting is not so held, the annual meeting of the Board of Directors may be held at such
place either within or without the State of Delaware, on such date and at such time as shall be specified in a notice thereof given as
hereinafter provided in Section 3.08 herein or in a waiver of notice thereof signed by any director who chooses to waive the requirement
of notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.07. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Regular Meetings</I>. After the place and time
of regular meetings of the Board of Directors shall have been determined and notice thereof shall have been once given to each member
of the Board of Directors, regular meetings may be held without further notice being given.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.08. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Special Meetings</I>. Special meetings of the
Board of Directors may be called by the Chairman of the Board, the Chief Executive Officer or the President and shall be called by the
Chairman of the Board, the Chief Executive Officer, President or Secretary on the written request of three or more directors. Notice
of special meetings of the Board of Directors shall be given to each director at least two days before the date of the meeting in such
manner as is determined by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.09. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Committees</I>. The Board of Directors may
designate one or more committees, each committee to consist of one or more of the directors of the Corporation. The Board may designate
one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of the
committee. In the absence or disqualification of a member of a committee, the member or members present at any meeting and not disqualified
from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of the Board of Directors
to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in the resolution
of the Board of Directors or by applicable law, shall have and may exercise all the powers and authority of the Board of Directors in
the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers
which may require it; but no such committee shall have the power or authority in reference to the following matter: (a) approving or
adopting, or recommending to the stockholders, any action or matter expressly required by Delaware Law to be submitted to the stockholders
for approval or (b) adopting, amending or repealing any bylaw of the Corporation. Unless the Board of Directors provides otherwise, at
all meetings of such committee, a majority of the then authorized members of the committee shall constitute a quorum for the transaction
of business, and the vote of a majority of the members of the committee present at the meeting at which there is a quorum shall be the
act of the Committee. Each committee shall keep regular minutes of its meetings and report the same to the Board of Directors when required.
Except as otherwise provided in the Certificate of Incorporation, these Bylaws, or the resolution of the Board of Directors designating
the committee, a committee may create one or more subcommittees, each subcommittee to consist of one or more members of the committee,
and delegate to a subcommittee any or all of the powers and authority of the committee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.10. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Action by Consent</I>. Unless otherwise restricted
by the Certificate of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors
or of any committee thereof may be taken without a meeting, if all members of the Board or such committee, as the case may be, consent
thereto in writing or by electronic transmission, and the writing or writings or electronic transmission or transmissions, are filed
with the minutes of proceedings of the Board of Directors or such committee. Such filing shall be in paper form if the minutes are maintained
in paper form and shall be in electronic form if the minutes are maintained in electronic form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.11. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Telephonic Meetings</I>. Unless otherwise restricted
by the Certificate of Incorporation or these Bylaws, members of the Board of Directors, or any committee designated by the Board of Directors,
may participate in a meeting of the Board of Directors, or such committee, as the case may be, by means of conference telephone or other
communications equipment by means of which all persons participating in the meeting can hear each other, and such participation in a
meeting shall constitute presence in person at the meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.12. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Resignation</I>. Any director may resign at
any time by giving notice in writing or by electronic transmission to the Board of Directors or to the Secretary of the Corporation.
The resignation of any director shall take effect upon receipt of notice thereof or at such later time as shall be specified in such
notice; and unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.13. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Vacancies</I>. Unless otherwise provided in
the Certificate of Incorporation, vacancies on the Board of Directors resulting from death, resignation, removal or otherwise and newly
created directorships resulting from any increase in the number of directors may be filled solely by the affirmative vote of a majority
of the remaining directors then in office (although less than a quorum) or by the sole remaining director. Each director so elected shall
hold office until the earlier of the expiration of the term of office of the director whom he or she has replaced, a successor is duly
elected and qualified or the earlier of such director&rsquo;s death, resignation or removal. If there are no directors in office, then
an election of directors may be held in accordance with Delaware Law. Unless otherwise provided in the Certificate of Incorporation,
when one or more directors shall resign from the Board, effective at a future date, a majority of the directors then in office, including
those who have so resigned, shall have the power to fill such future vacancy or vacancies, the vote thereon to take effect when such
resignation or resignations shall become effective, and each director so chosen shall hold office as provided in the filling of the other
vacancies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.14. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal</I>. Except as may otherwise be provided
by the DGCL, any director or the entire Board of Directors may be removed, with or without cause, at an annual meeting or at a special
meeting called for that purpose, by the holders of a majority of the shares then entitled to vote at an election of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.15. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Compensation</I>. Unless otherwise restricted
by the Certificate of Incorporation or these Bylaws, the Board of Directors shall have authority to fix the compensation of directors,
including fees and reimbursement of expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
3.16. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Preferred Stock Directors</I>. Notwithstanding
anything else contained herein, whenever the holders of one or more classes or series of Preferred Stock shall have the right, voting
separately as a class or series, to elect directors, the election, term of office, filing of vacancies, removal and other features of
such directorships shall be governed by the terms of the resolutions applicable thereto adopted by the Board of Directors pursuant to
the Certificate of Incorporation, and such directors so elected shall not be subject to the provisions of Sections 3.02, 3.12 and 3.13
of this Article 3 unless otherwise provided therein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
OFFICERS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Principal Officers</I>. The officers of the
Corporation shall be elected by the Board of Directors and shall include a Chief Executive Officer, a President, a Treasurer and a Secretary.
The Board of Directors, in its discretion, may also elect a chairman (who must be a director), one or more vice chairmen (who must be
directors) and one or more vice presidents, assistant treasurers, assistant secretaries and other officers. Any two or more offices may
be held by the same person.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Chief Executive Officer</I>. The Chief Executive
Officer shall, when present, preside at all meetings of the stockholders and, unless a Chairman of the Board of Directors has been elected
and is present, shall preside at all meetings of the Board of Directors. He or she shall also have general and active management of the
business of the Corporation and shall see that all orders and resolutions of the Board of Directors are put into effect. The Chief Executive
Officer, unless some other person is specifically authorized by resolution of the Board of Directors, shall sign all bonds, deeds, mortgages,
leases, and other contracts of the Corporation. He or she shall have the power to hire and discharge agents and employees who are not
Officers of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>President</I>. The President shall be the chief operating
and administrative officer of the Corporation. He or she shall have general responsibility for the management and control of the operations
and administration of the Corporation and shall perform all duties and have all powers which are commonly incident to the office of chief
operating officer or which are delegated to him or her by the Board of Directors. Subject to the direction of the Board of Directors
and the Chief Executive Officer, the President shall have power to sign all stock certificates, contracts, bonds, mortgages and other
instruments of the Corporation and shall have general supervision and direction of all of the other officers (other than the Chief Executive
Officer), employees and agents of the Corporation, subject in all cases to the orders and resolutions of the Board of Directors and to
the direction of the Chief Executive Officer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(c)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Treasurer</I>. The Treasurer shall supervise and
be responsible for all the funds and securities of the Corporation, the deposit of all moneys and other valuables to the credit of the
Corporation in depositories of the Corporation, borrowings and compliance with the provisions of all indentures, agreements and instruments
governing such borrowings to which the Corporation is a party, the disbursement of funds of the Corporation and the investment of its
funds, and in general shall perform all of the duties incident to the office of the Treasurer. The Treasurer shall, when requested, counsel
with and advise the other officers of the Corporation and shall perform such other duties as such officer may agree with the Chief Executive
Officer, President or as the Board of Directors may from time to time determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(d)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Secretary</I>. The powers and duties of the Secretary
are: (i) to act as Secretary at all meetings of the Board of Directors, of the committees of the Board of Directors and of the stockholders
and to record the proceedings of such meetings in a book or books to be kept for that purpose; (ii) to see that all notices required
to be given by the Corporation are duly given and served; (iii) to act as custodian of the seal of the Corporation and affix the seal
or cause it to be affixed to all certificates of stock of the Corporation and to all documents, the execution of which on behalf of the
Corporation under its seal is duly authorized in accordance with the provisions of these Bylaws; (iv) to have charge of the books, records
and papers of the Corporation and see that the reports, statements and other documents required by law to be kept and filed are properly
kept and filed; and (v) to perform all of the duties incident to the office of Secretary. The Secretary shall, when requested, counsel
with and advise the other officers of the Corporation and shall perform such other duties as such officer may agree with the Chief Executive
Officer, President or as the Board of Directors may from time to time determine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Term of Office; Vacancy; and Remuneration</I>.
Each officer shall hold office until his or her successor is elected and qualified, or until his or her earlier death, resignation or
removal. Any vacancy in any office shall be filled in such manner as the Board of Directors shall determine. The remuneration of all
officers of the Corporation shall be fixed by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.03. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Subordinate Officers</I>. The Board of Directors
may delegate to any principal officer the power to appoint and to remove any such subordinate officers, agents or employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.04. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Removal</I>. Except as otherwise permitted
with respect to subordinate officers, any officer may be removed, with or without cause, at any time, by the majority vote of the members
of the Board of Directors then in office.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.05. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Resignations</I>. Any officer may resign at
any time by giving written notice to the Board of Directors (or to a principal officer if the Board of Directors has delegated to such
principal officer the power to appoint and to remove such officer) of such person&rsquo;s resignation. The resignation of any officer
shall take effect upon receipt of notice thereof or at such later time as shall be specified in such notice; and unless otherwise specified
therein, the acceptance of such resignation shall not be necessary to make it effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
4.06. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Powers and Duties</I>. The officers of the
Corporation shall have such powers and perform such duties incident to each of their respective offices and such other duties as may
from time to time be conferred upon or assigned to them by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
5</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
CAPITAL STOCK</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Certificates for Stock; Uncertificated Shares</I>.
The shares of the Corporation shall be represented by certificates, provided that the Board of Directors of the Corporation may provide
by resolution or resolutions that some or all of any or all classes or series of its stock shall be uncertificated shares that may be
evidenced by a book entry system maintained by the registrar of such stock. Any such resolution shall not apply to shares represented
by a certificate until such certificate is surrendered to the Corporation. Except as otherwise provided by law, the rights and obligations
of the holders of uncertificated shares and the rights and obligations of the holders of shares represented by certificates of the same
class and series shall be identical. Every holder of stock represented by certificates shall be entitled to have a certificate signed
by, or in the name of the Corporation by the Chairman or Vice Chairman of the Board of Directors, or the President or Vice President,
and by the Treasurer or an Assistant Treasurer or the Secretary or an assistant Secretary of such Corporation representing the number
of shares registered in certificate form. Any or all of the signatures on the certificate may be a facsimile. In case any officer, transfer
agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer,
transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person
were such officer, transfer agent or registrar at the date of issue. A Corporation shall not have power to issue a certificate in bearer
form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Transfer of Shares</I>. Shares of the stock
of the Corporation may be transferred on the record of stockholders of the Corporation by the holder thereof or by such holder&rsquo;s
duly authorized attorney upon surrender of a certificate therefor properly endorsed or upon receipt of proper transfer instructions from
the registered holder of uncertificated shares or by such holder&rsquo;s duly authorized attorney and upon compliance with appropriate
procedures for transferring shares in uncertificated form, unless waived by the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.03. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Authority for Additional Rules Regarding Transfer.
</I>The Board of Directors shall have the power and authority to make all such rules and regulations as they may deem expedient concerning
the issue, transfer and registration of certificated or uncertificated shares of the stock of the Corporation, as well as for the issuance
of new certificates in lieu of those which may be lost or destroyed, and may require of any stockholder requesting replacement of lost
or destroyed certificates, bond in such amount and in such form as they may deem expedient to indemnify the Corporation, and/or the transfer
agents, and/or the registrars of its stock against any claims arising in connection therewith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
5.04. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Lost, Stolen or Destroyed Stock Certificates;
Issuance of New Certificates.</I> The Corporation may issue a new certificate of stock in the place of any certificate theretofore issued
by it, alleged to have been lost, stolen or destroyed, and the Corporation may require the owner of the lost, stolen or destroyed certificate,
or such owner&rsquo;s legal representative, to give the Corporation a bond sufficient to indemnify it against any claim that may be made
against it on account of the alleged loss, theft or destruction of any such certificate or the issuance of such new certificate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
6</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
INDEMNIFICATION AND ADVANCEMENT OF EXPENSES</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Right to Indemnification</I>. The Corporation
shall indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter be amended,
any person (a &ldquo;<U>Covered Person</U>&rdquo;) who was or is made or is threatened to be made a party or is otherwise involved in
any action, suit or proceeding, whether civil, criminal, administrative or investigative (a &ldquo;proceeding&rdquo;), by reason of the
fact that he or she, or a person for whom he or she is the legal representative, is or was a director or officer of the Corporation or,
while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee
or agent of another Corporation or of a partnership, joint venture, trust, enterprise or nonprofit entity, including service with respect
to employee benefit plans, against all liability and loss suffered and expenses (including attorneys&rsquo; fees) reasonably incurred
by such Covered Person. Notwithstanding the preceding sentence, except as otherwise provided in Section 6.03, the Corporation shall be
required to indemnify a Covered Person in connection with a proceeding (or part thereof) commenced by such Covered Person only if the
commencement of such proceeding (or part thereof) by the Covered Person was authorized in the specific case by the Board of Directors
of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Prepayment of Expenses</I>. The Corporation
shall to the fullest extent not prohibited by applicable law pay the expenses (including attorneys&rsquo; fees) incurred by a Covered
Person in defending any proceeding in advance of its final disposition, provided, however, that, to the extent required by law, such
payment of expenses in advance of the final disposition of the proceeding shall be made only upon receipt of an undertaking by the Covered
Person to repay all amounts advanced if it should be ultimately determined that the Covered Person is not entitled to be indemnified
under this Article 6 or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.03. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nonexclusivity of Rights</I>. The rights conferred
on any Covered Person by this Article 6 shall not be exclusive of any other rights which such Covered Person may have or hereafter acquire
under any statute, provision of the Certificate of Incorporation, these Bylaws, agreement, vote of stockholders or disinterested directors
or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.04. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other Sources</I>. The Corporation&rsquo;s
obligation, if any, to indemnify or to advance expenses to any Covered Person who was or is serving at its request as a director, officer,
employee or agent of another Corporation, partnership, joint venture, trust, enterprise or nonprofit entity shall be reduced by any amount
such Covered Person may collect as indemnification or advancement of expenses from such other Corporation, partnership, joint venture,
trust, enterprise or non-profit enterprise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.05. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendment or Repeal</I>. Any right to indemnification
or to advancement of expenses of any Covered Person arising hereunder shall not be eliminated or impaired by an amendment to or repeal
of these Bylaws after the occurrence of the act or omission that is the subject of the civil, criminal, administrative or investigative
action, suit or proceeding for which indemnification or advancement of expenses is sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
6.06. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Other Indemnification and Advancement of Expenses</I>.
This Article 6 shall not limit the right of the Corporation, to the extent and in the manner permitted by law, to indemnify and to advance
expenses to persons other than Covered Persons when and as authorized by appropriate corporate action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase; color: #010000">ARTICLE
7</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><BR>
GENERAL PROVISIONS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.01. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Fixing the Record Date</I>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(a)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order that the Corporation may determine the stockholders
entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board of Directors may fix a record date,
which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and
which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If the Board of Directors
so fixes a date, such date shall also be the record date for determining the stockholders entitled to vote at such meeting unless the
Board of Directors determines, at the time it fixes the record date, that a later date on or before the date of the meeting shall be
the date for making such determination. If no record date is fixed by the Board of Directors, the record date for determining stockholders
entitled to notice of or to vote at a meeting of stockholders shall be at the close of business on the day next preceding the day on
which notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held.
A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting; provided that the Board of Directors may fix a new record date for the determination of stockholders entitled to vote
at the adjourned meeting and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting
the same or an earlier date as that fixed for the determination of stockholders entitled to vote therewith at the adjourned meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">(b)
</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In order that the Corporation may determine the stockholders
entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise
any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors
may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and
which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining
stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution
relating thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.02. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I>. Subject to limitations contained
in Delaware Law and the Certificate of Incorporation, the Board of Directors may declare and pay dividends upon the shares of capital
stock of the Corporation, which dividends may be paid either in cash, in property or in shares of the capital stock of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.03. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Year</I>. The fiscal year of the Corporation
shall commence on January 1 and end on December 31 of each year. The fiscal year of the Corporation may be changed by the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.04. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Corporate Seal</I>. The corporate seal shall
have inscribed thereon the name of the Corporation, the year of its organization and the words &ldquo;Corporate Seal, Delaware&rdquo;.
The seal may be used by causing it or a facsimile thereof to be impressed, affixed or otherwise reproduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.05. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Voting of Stock Owned by the Corporation</I>.
The Board of Directors may authorize any person, on behalf of the Corporation, to attend, vote at and grant proxies to be used at any
meeting of stockholders of any Corporation (except this Corporation) in which the Corporation may hold stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; color: #010000"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.06. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Form of Records</I>. Any records maintained
by the Corporation in the regular course of its business, including its stock ledger, books of account, and minute books, may be kept
on, or by means of, or be in the form of, any information storage device or method, provided that the records so kept can be converted
into clearly legible paper form within a reasonable time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: #010000">Section
7.07. </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Amendments</I>. These Bylaws or any of them,
may be altered, amended or repealed, or new Bylaws may be made, by the stockholders entitled to vote thereon at any annual or special
meeting thereof or by the Board of Directors. Unless a higher percentage is required by the Certificate of Incorporation as to any matter
which is the subject of these Bylaws, all such amendments must be approved by the affirmative vote of the holders of the majority of
the total voting power of all outstanding securities of the Corporation then entitled to vote generally in the election of directors,
voting together as a single class or by a majority of the Board of Directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Section
7.08.&#9;<I>Forum for Adjudication of Disputes</I>. Unless the Corporation consents in writing to the selection of an alternative forum,
the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Corporation, (ii) any action asserting
a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s
stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the Certificate
of Incorporation or Bylaws (as either may be amended from time to time), or (iv) any action asserting a claim governed by the internal
affairs doctrine shall be the Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the
federal district court for the District of Delaware). If any action the subject matter of which is within the scope of the preceding
sentence is filed in a court other than a court located within the State of Delaware (a &ldquo;<U>Foreign Action</U>&rdquo;) in the name
of any stockholder, such stockholder shall be deemed to have consented to (i) the personal jurisdiction of the state and federal courts
located within the State of Delaware in connection with any action brought in any such court to enforce the preceding sentence and (ii)
having service of process made upon such stockholder in any such action by service upon such stockholder&rsquo;s counsel in the Foreign
Action as agent for such stockholder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
amended and restated through August 10, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ex10-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_001.jpg" ALT="A close up of a logo&#10;&#10;Description automatically generated" STYLE="height: 84px; width: 168px"><BR STYLE="clear: both"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">April
22, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tariq
Arshad, MD</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1545
Bayberry View Lane</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">San
Ramon, CA 94582</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">drtariqarshad@outlook.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(908)
240-7602</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 153pt; text-align: justify; text-indent: -153pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Full-Time
Employment Offer</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 153pt; text-align: justify; text-indent: -153pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Dr. Arshad,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 153pt; text-align: justify; text-indent: -153pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are pleased to offer you the position of Senior Vice President &amp; Chief Medical Officer with Qualigen Therapeutics, Inc. (the &ldquo;Company&rdquo;).
This position and its responsibilities will utilize your talents, education and experience to meet the Company&rsquo;s needs in this
important area. (You would also serve in the same capacity, without additional compensation, for the Company&rsquo;s wholly-owned subsidiary
Qualigen, Inc.) We are confident that you will find the position to be a challenging and enjoyable career opportunity. The position is
being offered to you on the following terms:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Position:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Senior
    Vice President &amp; Chief Medical Officer </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Reports
    to:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amy
    Broidrick, Executive Vice President/Chief Strategy Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Start
    Date:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
    mutually anticipate your employment start date will be May 17, 2021 (the actual start date, the &ldquo;Start Date&rdquo;).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Compensation:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
    initial annualized base salary will be at the rate of $400,000 per year, payable bi-weekly according to the Company&rsquo;s payroll
    practices. The base salary will be reviewed annually as part of the Company&rsquo;s normal salary review process. You will be eligible
    for annual performance-based cash bonuses as may be awarded by the Board of Directors and its Compensation Committee based upon your
    performance and the achievement of objectives established for the year by the Board of Directors and its Compensation Committee,
    with the annual target bonus being expressed as a percentage, established each year by the Board of Directors and its Compensation
    Committee, of your base salary. For 2021, your bonus target will be 40% of your annualized base salary.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, you shall be entitled to reimbursement for reasonable travel and other business expenses that adhere to the Company&rsquo;s
    travel and expense documentation and other policies. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Signing
    Bonus:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
    cash signing bonus of $25,000 will be paid on the first regular bi-weekly pay date after the Start Date.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Insurance
    Benefits:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
    of July 1, 2021, you and your eligible dependents will be eligible to participate in the Company&rsquo;s group medical, dental, vision,
    disability and life insurance plans. The Company reserves the right to (on a nondiscriminatory basis) terminate, replace or change
    these plans and all other benefit plans and programs.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Paid
    Vacation:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vacation
    accrues at the rate of 6.15 hours per bi-weekly pay period (4 weeks per year) according to the Company&rsquo;s standard policies,
    subject to any and all accrual caps imposed by such policies (as they may be revised from time to time).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>401(k)
    Plan:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
    completing three months of employment, you are entitled to participate in the Company&rsquo;s 401(k) retirement savings plan, subject
    to IRS contribution limits. The Company presently matches 50% of employee contributions (subject to IRS matching limits), provided
    that no further matching is provided in a year after the employee has contributed 6% of total actual annual salary/bonus.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Stock
    Options</U>:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Company&rsquo;s management will recommend to the Board of Directors and its Compensation Committee that the Company grant to you,
    on the Start Date, stock options under the Company&rsquo;s 2020 Stock Incentive Plan to purchase 100,000 shares of the Company&rsquo;s
    common stock, at an exercise price per share equal to the fair market value on the grant date, with the scheduled expiration date
    of the stock options to be the 10th anniversary of the Start Date. The stock options would be documented on and subject to the terms
    and conditions of the Company&rsquo;s standard form of Stock Option Agreement, and would be subject to equal annual vesting on each
    of the first three anniversaries of the Start Date (in each case vesting would depend on your being in the service of the Company
    on the vesting date).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition, upon satisfactory completion of the first 90 days of employment, the Company&rsquo;s management will recommend to the Board
    of Directors and its Compensation Committee that the Company grant to you stock options under the Company&rsquo;s 2020 Stock Incentive
    Plan to purchase an additional 300,000 shares of the Company&rsquo;s common stock, at an exercise price per share equal to the fair
    market value on the grant date, with the scheduled expiration date of the additional stock options to be the 10th anniversary of
    the Start Date. The additional stock options would be documented on and subject to the terms and conditions of the Company&rsquo;s
    standard form of Stock Option Agreement, and would be subject to equal annual vesting on each of the first three anniversaries of
    the Start Date (in each case vesting would depend on your being in the service of the Company on the vesting date). It is understood
    that the Company&rsquo;s ability to grant any such additional options is subject to approval, at the Company&rsquo;s July 15, 2021
    Annual Meeting of Stockholders, of the proposal to expand the 2020 Stock Incentive Plan.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Other
    Benefits:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
    addition to the benefits listed above, you also will be eligible for paid sick-leave as and to the extent outlined in the Employee
    Handbook and be entitled to participate in other benefit programs adopted by the Company from time to time for its employees generally.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Severance:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    shall not be entitled to any severance or separation benefits except under the following circumstances: </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    (after the first 90 days of your employment, which is your probationary period) your employment is terminated without Cause or you
    resign for Good Reason, then if and only if within 30 days after such termination without Cause or resignation with Good Reason you
    execute and deliver a customary and satisfactory general release of all claims (with a nondisparagement provision) in favor of the
    Company and its related persons, you will be entitled to 180 days of salary continuation plus (should you timely elect to continue
    coverage pursuant to COBRA) the cost of COBRA coverage continuation for such 180 day period. </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Cause&rdquo;
    means any of the following: (i) a material breach by you of any of the trade secret/proprietary information, confidential information
    or intellectual property ownership sections of your Confidential Information and Invention Assignment Agreement; (ii) a material
    breach by you of any other provision of the Employment Agreement, if such material breach (if susceptible to cure) has continued
    uncured for a period of at least 15 days following delivery by the Company to you of written notice of such material breach; (iii)
    fraud, dishonesty or other breach of trust whereby you obtain personal gain or benefit at the expense of or to the detriment of the
    Company or any of the Company&rsquo;s subsidiaries or affiliates; (iv) a conviction of or plea of nolo contendere or similar plea
    by you of any felony; (v) a conviction of or plea of nolo contendere or similar plea by you of any other crime involving theft, misappropriation
    of property, dishonesty or moral turpitude; (vi) a willful and material violation of applicable law by you in connection with the
    performance of your employment duties; (vii) chronic or repeated substance abuse, or any other use of alcohol, drugs or illegal substances
    in such a manner as to interfere with the performance of your material employment duties; or (viii) failure to comply with the lawful
    directions of the Board of Directors which are otherwise consistent with the terms of your employment under this letter agreement,
    which failure has continued for a period of at least 10 days after delivery by the Company to you of written demand by the Board
    of Directors. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;Good
    Reason&rdquo; means the occurrence of any of the following circumstances, without your express consent: you resign due to (i) a material
    reduction of your title or authority, (ii) a material reduction in your salary or benefits (other than a reduction that generally
    applies to the officers at your level in the Company or, as applicable, after a transaction in which the Company or substantially
    all its assets is acquired, in the successor entity at that time), (iii) any material breach of this Agreement by the Company which
    is not cured within 30 days after written notice by you; or (iv) a change of the principal non-temporary location in which you are
    <U>required</U> to perform your services to any location exceeding 35 miles from Carlsbad, California (it being understood that at
    present you will be working primarily from a remote location). In no event shall a resignation be considered to be with Good Reason
    unless the resignation occurs after but within 30 days after the initiation of the item of Good Reason. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">It
    is the intention of both the Company and you that the benefits and rights to which you could be entitled pursuant to this letter
    agreement comply with Section 409A of the Internal Revenue Code and the Treasury Regulations and other guidance promulgated or issued
    thereunder (&ldquo;Section 409A&rdquo;), to the extent that the requirements of Section 409A are applicable thereto; and the provisions
    of this letter agreement shall be construed in a manner consistent with that intention. Without limitation, if (and only to the extent)
    any amounts payable to you on account of separation from service are considered deferred compensation under Section 409A and/or not
    within any specified exception from Section 409A, and you are a &ldquo;specified employee&rdquo; at the time of separation from service,
    then no payment or benefit shall be made before the date that is six months after your separation from service. If you or the Company
    believes, at any time, that any such benefit or right that is subject to Section 409A does not so comply, it shall promptly advise
    the other and shall negotiate reasonably and in good faith to amend the terms of such benefits and rights such that they comply with
    Section 409A (with the most limited possible economic effect on you and on the Company).</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Arbitration:</U></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    and the Company agree to arbitrate before a neutral arbitrator (at JAMS, unless the parties otherwise agree) any and all claims or
    disputes arising out of this letter agreement and any and all claims arising from or relating to your employment with the Company,
    claims of wrongful termination, retaliation, discrimination, harassment, breach of contract, breach of the covenant of good faith
    and fair dealing, defamation, invasion of privacy, fraud, misrepresentation, constructive discharge or failure to provide a leave
    of absence, or claims regarding stock options or bonuses, commissions, infliction of emotional distress or unfair business practices.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    arbitrator&rsquo;s decision must be written and must include the findings of fact and law that support the decision. The arbitrator&rsquo;s
    decision will be final and binding on both parties, except to the extent applicable law allows for judicial review of arbitration
    awards. The arbitrator may award any remedies that would otherwise be available to the parties if they were to bring the dispute
    in court. The arbitration will be conducted in accordance with JAMS&rsquo; employment disputes arbitration rules. The arbitration
    will take place in San Diego, California and be governed by California procedural law. </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
    and the Company will share the costs of arbitration equally, except that the Company will bear the cost of any administrative fee
    of the tribunal, the arbitrator&rsquo;s fee and any other type of expense or cost that you would not be required to bear if you were
    to bring the dispute or claim in court. Both the Company and you will be responsible for their own attorneys&rsquo; fees, and the
    arbitrator may not award attorneys&rsquo; fees unless a statute or contract at issue specifically authorizes such an award.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    foregoing notwithstanding, this arbitration provision does not apply to (a)&nbsp;workers&rsquo; compensation or unemployment insurance
    claims, (b) stock appraisal rights under the Delaware General Corporation Law, (c)&nbsp;any other claims that an employer cannot,
    in accordance with applicable state law, require (either pursuant to an arbitration agreement or otherwise) an employee to arbitrate,
    or (d) claims concerning the ownership, validity, infringement, misappropriation, disclosure, misuse or enforceability of any confidential
    information, patent right, copyright, mask work, trademark or any other trade secret or intellectual property held or sought by either
    you or the Company (whether or not arising under the Confidential Information and Invention Assignment Agreement).</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    an arbitrator or court of competent jurisdiction (the &ldquo;<U>Neutral</U>&rdquo;) determines that any provision of this arbitration
    provision is illegal or unenforceable, then the Neutral shall modify or replace the language of this arbitration provision with a
    valid and enforceable provision, but only to the minimum extent necessary to render this arbitration provision legal and enforceable.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment is &ldquo;At Will&rdquo;, meaning that either you or the Company may terminate your employment at any time for any reason
or no reason, without further contractual obligation or contractual liability (except as may be expressly set forth in Section 11 of
this letter agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
offer is subject to approval by the Board of Directors and its Compensation Committee as well as the successful completion of the Company&rsquo;s
pre-employment background check. Prior to commencement of employment, you will be required to complete the Company&rsquo;s Employment
Application, sign the Company&rsquo;s standard form of Confidential Information and Invention Assignment Agreement, and complete a drug
screening test. For purposes of federal immigration law, you will be required to provide to the Company documentary evidence of your
identity and eligibility for employment in the United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are excited about your future with our Company and the talents and background you add to our team. Please acknowledge your acceptance
of this offer by signing and returning a copy of this letter to me by Friday April 23, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
look forward to working with you!</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Chris Lotz</I></FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 48%">&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chris
    Lotz</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Vice
    President</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Acceptance</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted
and agreed to this 22<SUP>nd</SUP> day of April, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 4%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 48%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Tariq Arshad</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tariq
    Arshad, MD</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ex10-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
10.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">June
22, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>VIA
FEDEX</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A.G.P./Alliance
Global Partners</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">590
Madison Avenue</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
Tom Higgins</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:
Termination of Sales Agreement with Ritter Pharmaceuticals, Inc. (nka Qualigen Therapeutics, Inc.)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gentlemen,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 11(b) of the Sales Agreement dated November 6, 2019 between you and Ritter Pharmaceuticals, Inc. (now known as Qualigen Therapeutics,
Inc.), we hereby notify you that we are terminating such Sales Agreement. Allowing for the required advance-notice period, the effective
date of the termination will be July 3, 2021. It would be convenient and much appreciated if we could agree that the date of termination
could be accelerated to June 25; please email if this is acceptable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman,
    Chief Executive Officer and President, </FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Qualigen
    Therapeutics, Inc.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 15%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">cc
    (via FedEx):</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mintz,
    Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">666
    Third Avenue</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
    York, New York 10017</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention:
    Anthony J. Marsico, Esq.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">C<B>ERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Michael S. Poirier, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of Qualigen Therapeutics, Inc., a Delaware corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial
statements for external purposes with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons
performing the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 56.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    16,</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Christopher L. Lotz, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
I have reviewed this quarterly report on Form 10-Q of Qualigen Therapeutics, Inc., a Delaware corporation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the
period covered by this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
Based on my knowledge, the condensed consolidated financial statements, and other financial information included in this report, fairly
present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
The registrant&rsquo;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures
(as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act
Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during
the period in which this report is being prepared;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Designed such control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of condensed consolidated financial
statements for external purposes with generally accepted accounting principles;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)
Evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)
Disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected,
or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 56.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
The registrant&rsquo;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial
reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors (or persons performing
the equivalent functions):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 56.1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
    16,</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher L. Lotz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS
PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the undersigned, Michael S. Poirier, Chief Executive Officer of Qualigen Therapeutics, Inc., a Delaware corporation (the &ldquo;Company&rdquo;),
and Christopher L. Lotz, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant
to Section 906 of the Sarbanes- Oxley Act of 2002, that, to his knowledge (1) the quarterly report on Form 10-Q of the Company for the
six months ended June 30, 2021, as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), fully
complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
16,</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Michael S. Poirier</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Michael
    S. Poirier</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer (Principal Executive Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
16,</FONT> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 45%; border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Christopher L. Lotz</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Christopher
    L. Lotz</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial Officer)</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>These
certifications accompanying and being &ldquo;furnished&rdquo; with this Report, shall not be deemed &ldquo;filed&rdquo; by the Company
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and
shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation
language contained in such filing.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 27.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image_001.jpg
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 *@# 2(  A$! Q$!_\0
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MTW')('<^]7***AN[NRTK*R"BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>qlgn-20210630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWamAqbP9z5Z8aekhvWB3bfnKHy4kSOZxAi7gPnvGYVMK -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:QLGN="http://qualigeninc.com/20210630" elementFormDefault="qualified" targetNamespace="http://qualigeninc.com/20210630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://qualigeninc.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates">
	  <link:definition>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000008 - Disclosure - LIQUIDITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/InventoryNet" id="InventoryNet">
	  <link:definition>00000009 - Disclosure - INVENTORY, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
	  <link:definition>00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
	  <link:definition>00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" id="AccruedExpensesAndOtherCurrentLiabilities">
	  <link:definition>00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/WarrantLiabilities" id="WarrantLiabilities">
	  <link:definition>00000013 - Disclosure - WARRANT LIABILITIES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/Leases" id="Leases">
	  <link:definition>00000014 - Disclosure - LEASES</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" id="ResearchAndLicenseAgreements">
	  <link:definition>00000015 - Disclosure - RESEARCH AND LICENSE AGREEMENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000016 - Disclosure - STOCKHOLDERS&#8217; EQUITY</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000017 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000018 - Disclosure - SUBSEQUENT EVENTS</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies">
	  <link:definition>00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables">
	  <link:definition>00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/InventoryNetTables" id="InventoryNetTables">
	  <link:definition>00000021 - Disclosure - INVENTORY, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
	  <link:definition>00000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
	  <link:definition>00000023 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" id="AccruedExpensesAndOtherCurrentLiabilitiesTables">
	  <link:definition>00000024 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" id="WarrantLiabilitiesTables">
	  <link:definition>00000025 - Disclosure - WARRANT LIABILITIES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000026 - Disclosure - LEASES (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" id="ScheduleOfAccountsReceivableDetails">
	  <link:definition>00000028 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" id="ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails">
	  <link:definition>00000029 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" id="OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative">
	  <link:definition>00000030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000031 - Disclosure - LIQUIDITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" id="ScheduleOfInventoryDetails">
	  <link:definition>00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails">
	  <link:definition>00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" id="ScheduleOfPropertyAndEquipmentDetails">
	  <link:definition>00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" id="PropertyAndEquipmentNetDetailsNarrative">
	  <link:definition>00000035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" id="ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails">
	  <link:definition>00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" id="ScheduleOfWarrantsActivityDetails">
	  <link:definition>00000037 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" id="ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails">
	  <link:definition>00000038 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" id="ScheduleOfAssumptionsOfWarrantLiabilitiesDetails">
	  <link:definition>00000039 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" id="WarrantLiabilitiesDetailsNarrative">
	  <link:definition>00000040 - Disclosure - WARRANT LIABILITIES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" id="ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000041 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
	  <link:definition>00000042 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000043 - Disclosure - LEASES (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" id="ResearchAndLicenseAgreementsDetailsNarrative">
	  <link:definition>00000044 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" id="ScheduleOfReservedSharesDetails">
	  <link:definition>00000045 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000046 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" id="ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails">
	  <link:definition>00000047 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" id="ScheduleOfShare-basedCompensationExpenseDetails">
	  <link:definition>00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" id="ScheduleOfWarrantActivityDetails">
	  <link:definition>00000049 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000050 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000051 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="qlgn-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="QLGN_NetProductSalesMember" name="NetProductSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseRevenueMember" name="LicenseRevenueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CollaborativeResearchRevenueMember" name="CollaborativeResearchRevenueMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesBConvertiblePreferredStockMember" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesCConvertiblePreferredStockMember" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesDConvertiblePreferredStockMember" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesDOneConvertiblePreferredStockMember" name="SeriesDOneConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesAlphaConvertiblePreferredStockMember" name="SeriesAlphaConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" name="GeneralAdministrativeResearchAndDevelopmentExpensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PatentsAndLicensesMember" name="PatentsAndLicensesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ConstructionInProgressEquipmentMember" name="ConstructionInProgressEquipmentMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesCWarrantsMember" name="SeriesCWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LongtermOperatingLeaseAgreementMember" name="LongtermOperatingLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseAndSponsoredResearchAgreementsMember" name="LicenseAndSponsoredResearchAgreementsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UniversityOfLouisvilleResearchFoundationMember" name="UniversityOfLouisvilleResearchFoundationMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseOneClinicalTrialMember" name="PhaseOneClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseTwoClinicalTrialMember" name="PhaseTwoClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PhaseThreeClinicalTrialMember" name="PhaseThreeClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SponsoredResearchAgreementAndLicenseMember" name="SponsoredResearchAgreementAndLicenseMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicensedProductSalesMember" name="LicensedProductSalesMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" name="RoyaltiesAndNonRoyaltySublicenseeIncomeMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AdvancedCancerTherapeuticsLLCMember" name="AdvancedCancerTherapeuticsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CEMarkMember" name="CEMarkMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PredictionBiosciencesSASMember" name="PredictionBiosciencesSASMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SekisuiDiagnosticsLLCMember" name="SekisuiDiagnosticsLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_YiXinZhenDuanJishuLtdMember" name="YiXinZhenDuanJishuLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TechnologyTransferAgreementMember" name="TechnologyTransferAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_STAPharmaceuticalCoLtdMember" name="STAPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ExerciseOfOutstandingStockOptionsMember" name="ExerciseOfOutstandingStockOptionsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ExerciseOfOutstandingStockWarrantMember" name="ExerciseOfOutstandingStockWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SerieAlphaPreferredStockMember" name="SerieAlphaPreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SingleInstitutionalInvestorMember" name="SingleInstitutionalInvestorMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrefundedWarrantsMember" name="PrefundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwoYearWarrantsMember" name="TwoYearWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockOptionsAndWarrantsMember" name="StockOptionsAndWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwoThousandTwentyStockIncentivePlanMember" name="TwoThousandTwentyStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EmployeesAndNonemployeeServiceProviderMember" name="EmployeesAndNonemployeeServiceProviderMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CompensatoryWarrantsMember" name="CompensatoryWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CompensatoryWarrantActivityMember" name="CompensatoryWarrantActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" name="NoncompensatoryEquityClassifiedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NonCompensatoryWarrantActivityMember" name="NonCompensatoryWarrantActivityMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SeriesDAndSeriesDOnePreferredStockMember" name="SeriesDAndSeriesDOnePreferredStockMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwpThousandTwentyPlanMember" name="TwpThousandTwentyPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EquipmentHeldForLeaseNet" name="EquipmentHeldForLeaseNet" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CostOfProductSales" name="CostOfProductSales" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValueWarrantsExercised" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" name="StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" name="StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" name="StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" name="StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" name="IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" name="IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" name="SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" name="SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_OperatingLeaseRightOfUseAssetAmortization" name="OperatingLeaseRightOfUseAssetAmortization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" name="IncreaseDecreaseInInventoryAndEquipmentHeldForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IncreaseDecreaseInLeaseLiabilities" name="IncreaseDecreaseInLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CashPaidForAbstract" name="CashPaidForAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfCommonStockForProfessionalServices" name="IssuanceOfCommonStockForProfessionalServices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest" name="IssuanceOfCommonStockForConversionOfAccruedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" name="IssuanceOfCommonStockForConversionOfPreferredStock" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_IssuanceOfPreferredStockForConversionOfDebt" name="IssuanceOfPreferredStockForConversionOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" name="FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" name="FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EffectOfReverseRecapitalization" name="EffectOfReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets" name="InitialMeasurementOfOperatingLeaseRightofuseAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease" name="NetTransfersToInventoryFromEquipmentHeldForLease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" name="DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosureWarrantLiabilitiesAbstract" name="DisclosureWarrantLiabilitiesAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantLiabilitiesTextBlock" name="WarrantLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" name="DisclosureResearchAndLicenseAgreementsAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ResearchAndLicenseAgreementsTextBlock" name="ResearchAndLicenseAgreementsTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_OrganizationPolicyTextBlock" name="OrganizationPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShippingAndHandlingCostsPolicyTextBlock" name="ShippingAndHandlingCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" name="DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SalesAndExciseTaxesPolicyTextBlock" name="SalesAndExciseTaxesPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantyCostsPolicyTextBlock" name="WarrantyCostsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" name="ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" name="ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" name="ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" name="ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ScheduleOfReservedSharesTableTextBlock" name="ScheduleOfReservedSharesTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SummaryOfWarrantActivityTableTextBlock" name="SummaryOfWarrantActivityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EstimatedReturnsNetOfAllowances" name="EstimatedReturnsNetOfAllowances" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WarrantyCosts" name="WarrantyCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NewEquityCapitalRaise" name="NewEquityCapitalRaise" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrepaidManufacturingExpenses" name="PrepaidManufacturingExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_PrepaidInvestorRelationsExpenses" name="PrepaidInvestorRelationsExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedCompensation" name="AccruedCompensation" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedResearchAndDevelopmentCurrent" name="AccruedResearchAndDevelopmentCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedWarrantyCostsCurrent" name="AccruedWarrantyCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AccruedPatentAndLicenseFeesCurrent" name="AccruedPatentAndLicenseFeesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" name="NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" name="WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceExercisableVested" name="RangeOfExercisePriceExercisableVested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_FairValueAdjustmentOfWarrant" name="FairValueAdjustmentOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" name="ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NumberOfWarrantExercisedOnCashlessBasis" name="NumberOfWarrantExercisedOnCashlessBasis" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementOfResearchExpenses" name="ReimbursementOfResearchExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ReimbursementPatentCost" name="ReimbursementPatentCost" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AgreementTermPaymentDescription" name="AgreementTermPaymentDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestonePayment" name="MilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestonePaymentForMarketingExpenses" name="MilestonePaymentForMarketingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShortfallPayments" name="ShortfallPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_LicenseCost" name="LicenseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RegulatoryMarketingApprovalExpenses" name="RegulatoryMarketingApprovalExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UpfrontLicenseFee" name="UpfrontLicenseFee" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_UlrfLicenseAgreementDescription" name="UlrfLicenseAgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_AgreementDescription" name="AgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_MilestoneMethodRevenueRecognized" name="MilestoneMethodRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CumulativeAmount" name="CumulativeAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOptionsGranted" name="RangeOfExercisePriceOptionsGranted" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOptionsExpired" name="RangeOfExercisePriceOptionsExpired" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOptionsForfeited" name="RangeOfExercisePriceOptionsForfeited" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOptionsExercisableVested" name="RangeOfExercisePriceOptionsExercisableVested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" name="WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" name="RangeOfExercisePriceOptionsNonexercisableNonvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" name="WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" name="NumberOfSharesWarrantsLegacyRitterWarrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" name="WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_RangeOfExercisePriceNonexercisableNonvested" name="RangeOfExercisePriceNonexercisableNonvested" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_StockOptionsSharesFutureGrant" name="StockOptionsSharesFutureGrant" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_EquityCapitalRaise" name="EquityCapitalRaise" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesIssuedUponNetExercises" name="SharesIssuedUponNetExercises" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_CommonStockSharesAvailableForFutureIssuance" name="CommonStockSharesAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_NetRightofuseAsset" name="NetRightofuseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_SharesIssuedOnNetExercise" name="SharesIssuedOnNetExercise" nillable="true" xbrli:periodType="instant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="QLGN_TwoThousandTwentyPlanMember" name="TwoThousandTwentyPlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>qlgn-20210630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheets" xlink:href="qlgn-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfOperations" xlink:href="qlgn-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20210630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:href="qlgn-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Liquidity" xlink:href="qlgn-20210630.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNet" xlink:href="qlgn-20210630.xsd#InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20210630.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilities" xlink:href="qlgn-20210630.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Leases" xlink:href="qlgn-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20210630.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquity" xlink:href="qlgn-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:href="qlgn-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEvents" xlink:href="qlgn-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNetTables" xlink:href="qlgn-20210630.xsd#InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20210630.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20210630.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LeasesTables" xlink:href="qlgn-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityTables" xlink:href="qlgn-20210630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityDetailsNarrative" xlink:href="qlgn-20210630.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20210630.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LeasesDetailsNarrative" xlink:href="qlgn-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20210630.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20210630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EquipmentHeldForLeaseNet" xlink:label="loc_QLGNEquipmentHeldForLeaseNet" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_QLGNEquipmentHeldForLeaseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="loc_us-gaapHedgingLiabilitiesCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapHedgingLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CostOfProductSales" xlink:label="loc_QLGNCostOfProductSales" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_QLGNCostOfProductSales" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OperatingLeaseRightOfUseAssetAmortization" xlink:label="loc_QLGNOperatingLeaseRightOfUseAssetAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNOperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:label="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLease" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:calculationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_QLGNIncreaseDecreaseInLeaseLiabilities" />
      <link:calculationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_QLGNIncreaseDecreaseInLeaseLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Liquidity" xlink:title="00000008 - Disclosure - LIQUIDITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNet" xlink:title="00000009 - Disclosure - INVENTORY, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:title="00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilities" xlink:title="00000013 - Disclosure - WARRANT LIABILITIES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Leases" xlink:title="00000014 - Disclosure - LEASES" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:title="00000015 - Disclosure - RESEARCH AND LICENSE AGREEMENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNetTables" xlink:title="00000021 - Disclosure - INVENTORY, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:title="00000023 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000024 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:title="00000025 - Disclosure - WARRANT LIABILITIES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LeasesTables" xlink:title="00000026 - Disclosure - LEASES (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccountsReceivableNetCurrent" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityDetailsNarrative" xlink:title="00000031 - Disclosure - LIQUIDITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapInventoryNet" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidManufacturingExpenses" xlink:label="loc_QLGNPrepaidManufacturingExpenses" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_QLGNPrepaidManufacturingExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidInvestorRelationsExpenses" xlink:label="loc_QLGNPrepaidInvestorRelationsExpenses" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_QLGNPrepaidInvestorRelationsExpenses" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedCompensation" xlink:label="loc_QLGNAccruedCompensation" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_QLGNAccruedResearchAndDevelopmentCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedResearchAndDevelopmentCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedWarrantyCostsCurrent" xlink:label="loc_QLGNAccruedWarrantyCostsCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedWarrantyCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedPatentAndLicenseFeesCurrent" xlink:label="loc_QLGNAccruedPatentAndLicenseFeesCurrent" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_QLGNAccruedPatentAndLicenseFeesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000040 - Disclosure - WARRANT LIABILITIES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LeasesDetailsNarrative" xlink:title="00000043 - Disclosure - LEASES (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000044 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000051 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>qlgn-20210630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheets" xlink:href="qlgn-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfOperations" xlink:href="qlgn-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20210630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:href="qlgn-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Liquidity" xlink:href="qlgn-20210630.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNet" xlink:href="qlgn-20210630.xsd#InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20210630.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilities" xlink:href="qlgn-20210630.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Leases" xlink:href="qlgn-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20210630.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquity" xlink:href="qlgn-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:href="qlgn-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEvents" xlink:href="qlgn-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNetTables" xlink:href="qlgn-20210630.xsd#InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20210630.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20210630.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LeasesTables" xlink:href="qlgn-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityTables" xlink:href="qlgn-20210630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityDetailsNarrative" xlink:href="qlgn-20210630.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20210630.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LeasesDetailsNarrative" xlink:href="qlgn-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20210630.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20210630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NetProductSalesMember" xlink:label="loc_QLGNNetProductSalesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNNetProductSalesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="loc_QLGNCollaborativeResearchRevenueMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNCollaborativeResearchRevenueMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract_170" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CostOfProductSales" xlink:label="loc_QLGNCostOfProductSales_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_170" xlink:to="loc_QLGNCostOfProductSales_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_170" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_170" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_170" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract_170" xlink:to="loc_us-gaapOperatingExpenses_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_170" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_170" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_170" xlink:to="loc_us-gaapInterestIncomeExpenseNet_170" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_170" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense_170" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract_170" xlink:to="loc_us-gaapNonoperatingIncomeExpense_170" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_170" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit_170" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_170" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted_170" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted_170" xlink:type="arc" order="18" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesAConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAConvertiblePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAConvertiblePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesBConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesBConvertiblePreferredStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesBConvertiblePreferredStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesCConvertiblePreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCConvertiblePreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesDConvertiblePreferredStockMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesDConvertiblePreferredStockMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDOneConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesDOneConvertiblePreferredStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesDOneConvertiblePreferredStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAlphaConvertiblePreferredStockMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesAlphaConvertiblePreferredStockMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercised_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercised_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" xlink:label="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_110" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" xlink:label="loc_QLGNStockIssuedDuringPeriodValueEffectOfReverseRecapitalization_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueEffectOfReverseRecapitalization_110" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" xlink:label="loc_QLGNStockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" xlink:label="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" xlink:label="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" xlink:label="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_110" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_110" xlink:type="arc" order="24" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Liquidity" xlink:title="00000008 - Disclosure - LIQUIDITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNet" xlink:title="00000009 - Disclosure - INVENTORY, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:title="00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilities" xlink:title="00000013 - Disclosure - WARRANT LIABILITIES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Leases" xlink:title="00000014 - Disclosure - LEASES" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:title="00000015 - Disclosure - RESEARCH AND LICENSE AGREEMENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS&#8217; EQUITY" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - RELATED PARTY TRANSACTIONS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNetTables" xlink:title="00000021 - Disclosure - INVENTORY, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:title="00000023 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000024 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:title="00000025 - Disclosure - WARRANT LIABILITIES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LeasesTables" xlink:title="00000026 - Disclosure - LEASES (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="loc_QLGNScheduleOfReservedSharesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNScheduleOfReservedSharesTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_QLGNSummaryOfWarrantActivityTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSummaryOfWarrantActivityTableTextBlock_40" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeaseDescriptionLineItems" xlink:label="loc_us-gaapLessorLeaseDescriptionLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLessorLeaseDescriptionLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaapToolsDiesAndMoldsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapToolsDiesAndMoldsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OfficeFurnitureAndEquipmentMember" xlink:label="loc_QLGNOfficeFurnitureAndEquipmentMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNOfficeFurnitureAndEquipmentMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLessorLeaseDescriptionLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:label="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="loc_QLGNCollaborativeResearchRevenueMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNCollaborativeResearchRevenueMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PatentsAndLicensesMember" xlink:label="loc_QLGNPatentsAndLicensesMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNPatentsAndLicensesMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember_210" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember_210" xlink:type="arc" order="211" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_270" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_270" xlink:type="arc" order="271" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse_340" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold_340" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_340" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EstimatedReturnsNetOfAllowances" xlink:label="loc_QLGNEstimatedReturnsNetOfAllowances_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_QLGNEstimatedReturnsNetOfAllowances_340" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife_340" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet_340" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization_340" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets_340" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_340" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_340" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_340" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree_340" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour_340" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_340" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent_340" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantyCosts" xlink:label="loc_QLGNWarrantyCosts_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_QLGNWarrantyCosts_340" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_340" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityDetailsNarrative" xlink:title="00000031 - Disclosure - LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NewEquityCapitalRaise" xlink:label="loc_QLGNNewEquityCapitalRaise_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_QLGNNewEquityCapitalRaise_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity_60" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ConstructionInProgressEquipmentMember" xlink:label="loc_QLGNConstructionInProgressEquipmentMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNConstructionInProgressEquipmentMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaapToolsDiesAndMoldsMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapToolsDiesAndMoldsMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OfficeFurnitureAndEquipmentMember" xlink:label="loc_QLGNOfficeFurnitureAndEquipmentMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNOfficeFurnitureAndEquipmentMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_150" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_150" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_150" xlink:type="arc" order="2" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CommonStockWarrantsMember" xlink:label="loc_QLGNCommonStockWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCommonStockWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_70" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant_90" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput_140" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_140" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000040 - Disclosure - WARRANT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNSeriesCWarrantsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:label="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfWarrantExercisedOnCashlessBasis" xlink:label="loc_QLGNNumberOfWarrantExercisedOnCashlessBasis_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNNumberOfWarrantExercisedOnCashlessBasis_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LongtermOperatingLeaseAgreementMember" xlink:label="loc_QLGNLongtermOperatingLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLongtermOperatingLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent_40" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LeasesDetailsNarrative" xlink:title="00000043 - Disclosure - LEASES (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000044 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="loc_QLGNLicenseAndSponsoredResearchAgreementsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAndSponsoredResearchAgreementsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementAndLicenseMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementAndLicenseMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseAgreementMember" xlink:label="loc_QLGNLicenseAgreementMember_240" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAgreementMember_240" xlink:type="arc" order="241" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TechnologyTransferAgreementMember" xlink:label="loc_QLGNTechnologyTransferAgreementMember_580" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNTechnologyTransferAgreementMember_580" xlink:type="arc" order="582" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="loc_QLGNUniversityOfLouisvilleResearchFoundationMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNUniversityOfLouisvilleResearchFoundationMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:label="loc_QLGNAdvancedCancerTherapeuticsLLCMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNAdvancedCancerTherapeuticsLLCMember_400" xlink:type="arc" order="402" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PredictionBiosciencesSASMember" xlink:label="loc_QLGNPredictionBiosciencesSASMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNPredictionBiosciencesSASMember_460" xlink:type="arc" order="462" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SekisuiDiagnosticsLLCMember" xlink:label="loc_QLGNSekisuiDiagnosticsLLCMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNSekisuiDiagnosticsLLCMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_YiXinZhenDuanJishuLtdMember" xlink:label="loc_QLGNYiXinZhenDuanJishuLtdMember_540" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNYiXinZhenDuanJishuLtdMember_540" xlink:type="arc" order="541" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_STAPharmaceuticalCoLtdMember" xlink:label="loc_QLGNSTAPharmaceuticalCoLtdMember_590" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNSTAPharmaceuticalCoLtdMember_590" xlink:type="arc" order="591" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="loc_QLGNPhaseOneClinicalTrialMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseOneClinicalTrialMember_60" xlink:type="arc" order="63" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="loc_QLGNPhaseTwoClinicalTrialMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseTwoClinicalTrialMember_80" xlink:type="arc" order="83" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="loc_QLGNPhaseThreeClinicalTrialMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseThreeClinicalTrialMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicensedProductSalesMember" xlink:label="loc_QLGNLicensedProductSalesMember_230" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicensedProductSalesMember_230" xlink:type="arc" order="233" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" xlink:label="loc_QLGNRoyaltiesAndNonRoyaltySublicenseeIncomeMember_340" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNRoyaltiesAndNonRoyaltySublicenseeIncomeMember_340" xlink:type="arc" order="342" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="loc_QLGNCollaborativeResearchRevenueMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNCollaborativeResearchRevenueMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember_570" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember_570" xlink:type="arc" order="572" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CEMarkMember" xlink:label="loc_QLGNCEMarkMember_410" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNCEMarkMember_410" xlink:type="arc" order="413" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt_650" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="loc_QLGNReimbursementOfResearchExpenses_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNReimbursementOfResearchExpenses_650" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ReimbursementPatentCost" xlink:label="loc_QLGNReimbursementPatentCost_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNReimbursementPatentCost_650" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="loc_QLGNAgreementTermPaymentDescription_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNAgreementTermPaymentDescription_650" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestonePayment" xlink:label="loc_QLGNMilestonePayment_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNMilestonePayment_650" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestonePaymentForMarketingExpenses" xlink:label="loc_QLGNMilestonePaymentForMarketingExpenses_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNMilestonePaymentForMarketingExpenses_650" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax_650" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShortfallPayments" xlink:label="loc_QLGNShortfallPayments_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNShortfallPayments_650" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense_650" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRoyaltyExpense_650" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseCost" xlink:label="loc_QLGNLicenseCost_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNLicenseCost_650" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpenses_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpenses_650" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UpfrontLicenseFee" xlink:label="loc_QLGNUpfrontLicenseFee_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNUpfrontLicenseFee_650" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UlrfLicenseAgreementDescription" xlink:label="loc_QLGNUlrfLicenseAgreementDescription_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNUlrfLicenseAgreementDescription_650" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense_650" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AgreementDescription" xlink:label="loc_QLGNAgreementDescription_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNAgreementDescription_650" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt_650" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestoneMethodRevenueRecognized" xlink:label="loc_QLGNMilestoneMethodRevenueRecognized_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNMilestoneMethodRevenueRecognized_650" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CumulativeAmount" xlink:label="loc_QLGNCumulativeAmount_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNCumulativeAmount_650" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax_650" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapDeferredRevenue_650" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets_650" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapDepositAssets_650" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapScheduleOfStockByClassTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ExerciseOfOutstandingStockOptionsMember" xlink:label="loc_QLGNExerciseOfOutstandingStockOptionsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNExerciseOfOutstandingStockOptionsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ExerciseOfOutstandingStockWarrantMember" xlink:label="loc_QLGNExerciseOfOutstandingStockWarrantMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNExerciseOfOutstandingStockWarrantMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SerieAlphaPreferredStockMember" xlink:label="loc_QLGNSerieAlphaPreferredStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSerieAlphaPreferredStockMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued_50" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:label="loc_QLGNShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsGranted" xlink:label="loc_QLGNRangeOfExercisePriceOptionsGranted_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsGranted_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsExpired" xlink:label="loc_QLGNRangeOfExercisePriceOptionsExpired_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsExpired_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_100" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsForfeited" xlink:label="loc_QLGNRangeOfExercisePriceOptionsForfeited_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsForfeited_100" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_100" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_100" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceOptionsExercisableVested_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsExercisableVested_100" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_100" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_100" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_100" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceOptionsNonexercisableNonvested_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsNonexercisableNonvested_100" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_100" xlink:type="arc" order="25" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_110" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_110" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant_110" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_110" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_110" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_110" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_110" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_110" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_110" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_110" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_110" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_110" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_110" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_110" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_110" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_110" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_110" xlink:type="arc" order="23" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SingleInstitutionalInvestorMember" xlink:label="loc_QLGNSingleInstitutionalInvestorMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNSingleInstitutionalInvestorMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember_400" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember_400" xlink:type="arc" order="402" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrefundedWarrantsMember" xlink:label="loc_QLGNPrefundedWarrantsMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantsMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="loc_QLGNCompensatoryWarrantsMember_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantsMember_260" xlink:type="arc" order="261" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember_290" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember_290" xlink:type="arc" order="291" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_360" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_360" xlink:type="arc" order="361" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoYearWarrantsMember" xlink:label="loc_QLGNTwoYearWarrantsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNTwoYearWarrantsMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockOptionsAndWarrantsMember" xlink:label="loc_QLGNStockOptionsAndWarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNStockOptionsAndWarrantsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_420" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_420" xlink:type="arc" order="421" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_QLGNTwoThousandTwentyStockIncentivePlanMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwoThousandTwentyStockIncentivePlanMember_180" xlink:type="arc" order="182" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_320" xlink:type="arc" order="322" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_330" xlink:type="arc" order="332" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding_440" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_440" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_440" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_440" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_440" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage_440" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_440" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_440" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockOptionsSharesFutureGrant" xlink:label="loc_QLGNStockOptionsSharesFutureGrant_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNStockOptionsSharesFutureGrant_440" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation_440" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_440" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_440" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_440" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_440" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_440" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EquityCapitalRaise" xlink:label="loc_QLGNEquityCapitalRaise_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNEquityCapitalRaise_440" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesIssuedUponNetExercises" xlink:label="loc_QLGNSharesIssuedUponNetExercises_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSharesIssuedUponNetExercises_440" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_440" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_440" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_440" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_440" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant_440" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_440" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_440" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_440" xlink:type="arc" order="24" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_440" xlink:type="arc" order="25" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_440" xlink:type="arc" order="26" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_440" xlink:type="arc" order="27" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_440" xlink:type="arc" order="28" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_440" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_440" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested_440" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_440" xlink:type="arc" order="34" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_440" xlink:type="arc" order="35" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_440" xlink:type="arc" order="36" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested_440" xlink:type="arc" order="37" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_440" xlink:type="arc" order="38" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:label="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_440" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_440" xlink:type="arc" order="39" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000051 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliateCollateralizedSecurityLineItems" xlink:label="loc_srtAffiliateCollateralizedSecurityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDAndSeriesDOnePreferredStockMember" xlink:label="loc_QLGNSeriesDAndSeriesDOnePreferredStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesDAndSeriesDOnePreferredStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1_20" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_us-gaapSubsequentEventTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwpThousandTwentyPlanMember" xlink:label="loc_QLGNTwpThousandTwentyPlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwpThousandTwentyPlanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CommonStockSharesAvailableForFutureIssuance" xlink:label="loc_QLGNCommonStockSharesAvailableForFutureIssuance_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNCommonStockSharesAvailableForFutureIssuance_20" xlink:type="arc" order="0" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>qlgn-20210630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NetProductSalesMember" xlink:label="QLGN_NetProductSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetProductSalesMember" xlink:to="QLGN_NetProductSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NetProductSalesMember_lbl" xml:lang="en-US">Net Product Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="QLGN_LicenseRevenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseRevenueMember" xlink:to="QLGN_LicenseRevenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseRevenueMember_lbl" xml:lang="en-US">License Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="QLGN_CollaborativeResearchRevenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CollaborativeResearchRevenueMember" xlink:to="QLGN_CollaborativeResearchRevenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CollaborativeResearchRevenueMember_lbl" xml:lang="en-US">Collaborative Research Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesAConvertiblePreferredStockMember" xlink:label="QLGN_SeriesAConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAConvertiblePreferredStockMember" xlink:to="QLGN_SeriesAConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesAConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesBConvertiblePreferredStockMember" xlink:label="QLGN_SeriesBConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesBConvertiblePreferredStockMember" xlink:to="QLGN_SeriesBConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesBConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCConvertiblePreferredStockMember" xlink:label="QLGN_SeriesCConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCConvertiblePreferredStockMember" xlink:to="QLGN_SeriesCConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesCConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDConvertiblePreferredStockMember" xlink:label="QLGN_SeriesDConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesDConvertiblePreferredStockMember" xlink:to="QLGN_SeriesDConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesDConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDOneConvertiblePreferredStockMember" xlink:label="QLGN_SeriesDOneConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesDOneConvertiblePreferredStockMember" xlink:to="QLGN_SeriesDOneConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesDOneConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series D One Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="QLGN_SeriesAlphaConvertiblePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:to="QLGN_SeriesAlphaConvertiblePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesAlphaConvertiblePreferredStockMember_lbl" xml:lang="en-US">Series Alpha Convertible Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:label="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:to="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_lbl" xml:lang="en-US">General, Administrative, Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="us-gaap_MachineryAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MachineryAndEquipmentMember" xlink:to="us-gaap_MachineryAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MachineryAndEquipmentMember_lbl" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="us-gaap_ToolsDiesAndMoldsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ToolsDiesAndMoldsMember" xlink:to="us-gaap_ToolsDiesAndMoldsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ToolsDiesAndMoldsMember_lbl" xml:lang="en-US">Tools, Dies and Molds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OfficeFurnitureAndEquipmentMember" xlink:label="QLGN_OfficeFurnitureAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OfficeFurnitureAndEquipmentMember" xlink:to="QLGN_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_OfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Office Furniture And Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PatentsAndLicensesMember" xlink:label="QLGN_PatentsAndLicensesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentsAndLicensesMember" xlink:to="QLGN_PatentsAndLicensesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PatentsAndLicensesMember_lbl" xml:lang="en-US">Patents and Licenses [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="us-gaap_PatentsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PatentsMember" xlink:to="us-gaap_PatentsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PatentsMember_lbl" xml:lang="en-US">Patents [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LicenseMember_lbl" xml:lang="en-US">License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="QLGN_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SecuritiesPurchaseAgreementMember" xlink:to="QLGN_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_TitleOfIndividualAxis_lbl" xml:lang="en-US">Title of Individual [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="us-gaap_InvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestorMember" xlink:to="us-gaap_InvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestorMember_lbl" xml:lang="en-US">Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ConstructionInProgressEquipmentMember" xlink:label="QLGN_ConstructionInProgressEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConstructionInProgressEquipmentMember" xlink:to="QLGN_ConstructionInProgressEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ConstructionInProgressEquipmentMember_lbl" xml:lang="en-US">Construction In Progress Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCWarrantsMember" xlink:label="QLGN_SeriesCWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCWarrantsMember" xlink:to="QLGN_SeriesCWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesCWarrantsMember_lbl" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CommonStockWarrantsMember" xlink:label="QLGN_CommonStockWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockWarrantsMember" xlink:to="QLGN_CommonStockWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommonStockWarrantsMember_lbl" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember_lbl" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedTermMember_lbl" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember_lbl" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LongtermOperatingLeaseAgreementMember" xlink:label="QLGN_LongtermOperatingLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LongtermOperatingLeaseAgreementMember" xlink:to="QLGN_LongtermOperatingLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LongtermOperatingLeaseAgreementMember_lbl" xml:lang="en-US">Longterm Operating Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:to="QLGN_LicenseAndSponsoredResearchAgreementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember_lbl" xml:lang="en-US">License And Sponsored Research Agreements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:to="QLGN_UniversityOfLouisvilleResearchFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember_lbl" xml:lang="en-US">University Of Louisville Research Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="QLGN_PhaseOneClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseOneClinicalTrialMember" xlink:to="QLGN_PhaseOneClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseOneClinicalTrialMember_lbl" xml:lang="en-US">Phase One Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="QLGN_PhaseTwoClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseTwoClinicalTrialMember" xlink:to="QLGN_PhaseTwoClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseTwoClinicalTrialMember_lbl" xml:lang="en-US">Phase Two Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="QLGN_PhaseThreeClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseThreeClinicalTrialMember" xlink:to="QLGN_PhaseThreeClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PhaseThreeClinicalTrialMember_lbl" xml:lang="en-US">Phase Three Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementAndLicenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember_lbl" xml:lang="en-US">Sponsored Research Agreement And License [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicensedProductSalesMember" xlink:label="QLGN_LicensedProductSalesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensedProductSalesMember" xlink:to="QLGN_LicensedProductSalesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicensedProductSalesMember_lbl" xml:lang="en-US">Licensed Product Sales [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseAgreementMember" xlink:label="QLGN_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAgreementMember" xlink:to="QLGN_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" xlink:label="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" xlink:to="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_lbl" xml:lang="en-US">Royalties And Non Royalty Sublicensee Income [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:label="QLGN_AdvancedCancerTherapeuticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:to="QLGN_AdvancedCancerTherapeuticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AdvancedCancerTherapeuticsLLCMember_lbl" xml:lang="en-US">Advanced Cancer Therapeutics L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CEMarkMember" xlink:label="QLGN_CEMarkMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CEMarkMember" xlink:to="QLGN_CEMarkMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CEMarkMember_lbl" xml:lang="en-US">C E Mark [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PredictionBiosciencesSASMember" xlink:label="QLGN_PredictionBiosciencesSASMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PredictionBiosciencesSASMember" xlink:to="QLGN_PredictionBiosciencesSASMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PredictionBiosciencesSASMember_lbl" xml:lang="en-US">Prediction Biosciences S A S [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SekisuiDiagnosticsLLCMember" xlink:label="QLGN_SekisuiDiagnosticsLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SekisuiDiagnosticsLLCMember" xlink:to="QLGN_SekisuiDiagnosticsLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SekisuiDiagnosticsLLCMember_lbl" xml:lang="en-US">Sekisui Diagnostics L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_YiXinZhenDuanJishuLtdMember" xlink:label="QLGN_YiXinZhenDuanJishuLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_YiXinZhenDuanJishuLtdMember" xlink:to="QLGN_YiXinZhenDuanJishuLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_YiXinZhenDuanJishuLtdMember_lbl" xml:lang="en-US">Yi Xin Zhen Duan Jishu Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TechnologyTransferAgreementMember" xlink:label="QLGN_TechnologyTransferAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TechnologyTransferAgreementMember" xlink:to="QLGN_TechnologyTransferAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TechnologyTransferAgreementMember_lbl" xml:lang="en-US">Technology Transfer Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_STAPharmaceuticalCoLtdMember" xlink:label="QLGN_STAPharmaceuticalCoLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_STAPharmaceuticalCoLtdMember" xlink:to="QLGN_STAPharmaceuticalCoLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_STAPharmaceuticalCoLtdMember_lbl" xml:lang="en-US">S T A Pharmaceutical Co Ltd [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ExerciseOfOutstandingStockOptionsMember" xlink:label="QLGN_ExerciseOfOutstandingStockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ExerciseOfOutstandingStockOptionsMember" xlink:to="QLGN_ExerciseOfOutstandingStockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ExerciseOfOutstandingStockOptionsMember_lbl" xml:lang="en-US">Exercise Of Outstanding Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ExerciseOfOutstandingStockWarrantMember" xlink:label="QLGN_ExerciseOfOutstandingStockWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ExerciseOfOutstandingStockWarrantMember" xlink:to="QLGN_ExerciseOfOutstandingStockWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ExerciseOfOutstandingStockWarrantMember_lbl" xml:lang="en-US">Exercise Of Outstanding Stock Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SerieAlphaPreferredStockMember" xlink:label="QLGN_SerieAlphaPreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SerieAlphaPreferredStockMember" xlink:to="QLGN_SerieAlphaPreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SerieAlphaPreferredStockMember_lbl" xml:lang="en-US">Serie Alpha Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SingleInstitutionalInvestorMember" xlink:label="QLGN_SingleInstitutionalInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SingleInstitutionalInvestorMember" xlink:to="QLGN_SingleInstitutionalInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SingleInstitutionalInvestorMember_lbl" xml:lang="en-US">Single Institutional Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrefundedWarrantsMember" xlink:label="QLGN_PrefundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantsMember" xlink:to="QLGN_PrefundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrefundedWarrantsMember_lbl" xml:lang="en-US">Prefunded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoYearWarrantsMember" xlink:label="QLGN_TwoYearWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoYearWarrantsMember" xlink:to="QLGN_TwoYearWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwoYearWarrantsMember_lbl" xml:lang="en-US">Two Year Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockOptionsAndWarrantsMember" xlink:label="QLGN_StockOptionsAndWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockOptionsAndWarrantsMember" xlink:to="QLGN_StockOptionsAndWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockOptionsAndWarrantsMember_lbl" xml:lang="en-US">Stock Options And Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:to="QLGN_TwoThousandTwentyStockIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember_lbl" xml:lang="en-US">Two Thousand Twenty Stock Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:to="QLGN_EmployeesAndNonemployeeServiceProviderMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember_lbl" xml:lang="en-US">Employees And Nonemployee Service Provider [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="QLGN_CompensatoryWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantsMember" xlink:to="QLGN_CompensatoryWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CompensatoryWarrantsMember_lbl" xml:lang="en-US">Compensatory Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="QLGN_CompensatoryWarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantActivityMember" xlink:to="QLGN_CompensatoryWarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CompensatoryWarrantActivityMember_lbl" xml:lang="en-US">Compensatory Warrant Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:to="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_lbl" xml:lang="en-US">Noncompensatory Equity Classified Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="QLGN_NonCompensatoryWarrantActivityMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NonCompensatoryWarrantActivityMember" xlink:to="QLGN_NonCompensatoryWarrantActivityMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NonCompensatoryWarrantActivityMember_lbl" xml:lang="en-US">Non Compensatory Warrant Activity [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDAndSeriesDOnePreferredStockMember" xlink:label="QLGN_SeriesDAndSeriesDOnePreferredStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesDAndSeriesDOnePreferredStockMember" xlink:to="QLGN_SeriesDAndSeriesDOnePreferredStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SeriesDAndSeriesDOnePreferredStockMember_lbl" xml:lang="en-US">Series D And Series D One Preferred Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwpThousandTwentyPlanMember" xlink:label="QLGN_TwpThousandTwentyPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwpThousandTwentyPlanMember" xlink:to="QLGN_TwpThousandTwentyPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_TwpThousandTwentyPlanMember_lbl" xml:lang="en-US">Twp Thousand Twenty Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryNet_lbl" xml:lang="en-US">Inventory, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EquipmentHeldForLeaseNet" xlink:label="QLGN_EquipmentHeldForLeaseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EquipmentHeldForLeaseNet" xlink:to="QLGN_EquipmentHeldForLeaseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EquipmentHeldForLeaseNet_lbl" xml:lang="en-US">Equipment held for lease, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xml:lang="en-US">Intangible assets, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="us-gaap_DeferredIncomeCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeCurrent" xlink:to="us-gaap_DeferredIncomeCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeCurrent_lbl" xml:lang="en-US">Deferred revenue, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Operating lease liability, current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="us-gaap_HedgingLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HedgingLiabilitiesCurrent" xlink:to="us-gaap_HedgingLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HedgingLiabilitiesCurrent_lbl" xml:lang="en-US">Warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="us-gaap_LongTermNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermNotesPayable" xlink:to="us-gaap_LongTermNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermNotesPayable_lbl" xml:lang="en-US">Notes payable, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Operating lease liability, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Series Alpha convertible preferred stock, $0.001 par value; 7,000 shares authorized; 180 shares issued and outstanding as of June 30, 2021 and December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.001 par value; 225,000,000 shares authorized; 28,902,188 and 27,296,061 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Series Alpha convertible preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Series Alpha convertible preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Series Alpha convertible preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Series Alpha convertible preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenuesAbstract_lbl" xml:lang="en-US">REVENUES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xml:lang="en-US">Total revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract_lbl" xml:lang="en-US">EXPENSES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CostOfProductSales" xlink:label="QLGN_CostOfProductSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CostOfProductSales" xlink:to="QLGN_CostOfProductSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CostOfProductSales_lbl" xml:lang="en-US">Cost of product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="us-gaap_MarketingAndAdvertisingExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl" xml:lang="en-US">Sales and marketing</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">LOSS FROM OPERATIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">OTHER (INCOME) EXPENSE, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Loss (gain) on change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="us-gaap_InterestIncomeExpenseNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest (income) expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Other (income), net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other (income) expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">LOSS BEFORE PROVISION FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">PROVISION (BENEFIT) FOR INCOME TAXES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">NET LOSS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per common share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted&#8212;average number of shares outstanding, basic and diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Beginning balance, value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Beginning balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="QLGN_StockIssuedDuringPeriodValueWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="QLGN_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValueWarrantsExercised_lbl" xml:lang="en-US">Stock issued upon cash-exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised_lbl" xml:lang="en-US">Stock issued upon cash-exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" xlink:label="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" xlink:to="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_lbl" xml:lang="en-US">Stock issued upon net-exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" xlink:label="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" xlink:to="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_lbl" xml:lang="en-US">Stock issued upon net-exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xml:lang="en-US">Stock issued for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Stock issued for professional services, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xml:lang="en-US">Issuance of common stock for conversion of notes payable and accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="us-gaap_ConversionOfStockSharesConverted1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockSharesConverted1_lbl" xml:lang="en-US">Issuance of common stock for conversion of notes payable and accrued interest, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of Series Alpha preferred shares upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of Series Alpha preferred shares upon closing of private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" xlink:label="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" xlink:to="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization_lbl" xml:lang="en-US">Effect of reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" xlink:label="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" xlink:to="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_lbl" xml:lang="en-US">Effect of reverse recapitalization, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" xlink:label="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" xlink:to="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_lbl" xml:lang="en-US">Issuance of Series Alpha preferred stock for conversion of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" xlink:label="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" xlink:to="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_lbl" xml:lang="en-US">Issuance of Series Alpha preferred stock for conversion of notes payable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:to="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_lbl" xml:lang="en-US">Shares and warrants issued to advisor upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" xlink:label="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" xlink:to="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_lbl" xml:lang="en-US">Shares and warrants issued to advisor upon closing of private placement, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_lbl" xml:lang="en-US">Fair value of shares issued to advisor upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Fair value of warrants issued to advisor upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net Loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Ending balance, value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Ending balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_3_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OperatingLeaseRightOfUseAssetAmortization" xlink:label="QLGN_OperatingLeaseRightOfUseAssetAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OperatingLeaseRightOfUseAssetAmortization" xlink:to="QLGN_OperatingLeaseRightOfUseAssetAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_OperatingLeaseRightOfUseAssetAmortization_lbl" xml:lang="en-US">Amortization of right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="us-gaap_ProvisionForDoubtfulAccounts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProvisionForDoubtfulAccounts" xlink:to="us-gaap_ProvisionForDoubtfulAccounts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProvisionForDoubtfulAccounts_lbl" xml:lang="en-US">Accounts receivable reserves and allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWriteDown_lbl" xml:lang="en-US">Inventory reserves</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xml:lang="en-US">Accounts receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:to="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease_lbl" xml:lang="en-US">Inventory and equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_lbl" xml:lang="en-US">Prepaid expenses and other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IncreaseDecreaseInLeaseLiabilities" xlink:label="QLGN_IncreaseDecreaseInLeaseLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInLeaseLiabilities" xlink:to="QLGN_IncreaseDecreaseInLeaseLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IncreaseDecreaseInLeaseLiabilities_lbl" xml:lang="en-US">Lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl" xml:lang="en-US">Payments for patents and licenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Proceeds from issuance of Series Alpha preferred shares upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Net proceeds from the issuance of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS &#8211; beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">CASH AND CASH EQUIVALENTS &#8211; end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CashPaidForAbstract" xlink:label="QLGN_CashPaidForAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CashPaidForAbstract" xlink:to="QLGN_CashPaidForAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CashPaidForAbstract_lbl" xml:lang="en-US">Cash paid for:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">&#160; NONCASH FINANCING AND INVESTING ACTIVITIES:</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfCommonStockForProfessionalServices" xlink:label="QLGN_IssuanceOfCommonStockForProfessionalServices" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForProfessionalServices" xlink:to="QLGN_IssuanceOfCommonStockForProfessionalServices_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfCommonStockForProfessionalServices_lbl" xml:lang="en-US">Issuance of common stock for professional services</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionOriginalDebtAmount1" xlink:to="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtConversionOriginalDebtAmount1_lbl" xml:lang="en-US">Issuance of common stock for conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest_lbl" xml:lang="en-US">Issuance of common stock for conversion of accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_lbl" xml:lang="en-US">Issuance of common stock for conversion of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfPreferredStockForConversionOfDebt" xlink:label="QLGN_IssuanceOfPreferredStockForConversionOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfPreferredStockForConversionOfDebt" xlink:to="QLGN_IssuanceOfPreferredStockForConversionOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfPreferredStockForConversionOfDebt_lbl" xml:lang="en-US">Issuance of preferred stock for conversion of debt</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:to="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement_lbl" xml:lang="en-US">Fair value of shares issued to advisor upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:to="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_lbl" xml:lang="en-US">Fair value of warrants issued to advisor upon closing of private placement</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EffectOfReverseRecapitalization" xlink:label="QLGN_EffectOfReverseRecapitalization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectOfReverseRecapitalization" xlink:to="QLGN_EffectOfReverseRecapitalization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_EffectOfReverseRecapitalization_lbl" xml:lang="en-US">Effect of reverse recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets" xlink:label="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets" xlink:to="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets_lbl" xml:lang="en-US">Initial measurement of operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NetTransfersToInventoryFromEquipmentHeldForLease" xlink:label="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease" xlink:to="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease_lbl" xml:lang="en-US">Net transfers to inventory from equipment held for lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">LIQUIDITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="us-gaap_InventoryDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureAbstract_lbl" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryDisclosureTextBlock_lbl" xml:lang="en-US">INVENTORY, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_lbl" xml:lang="en-US">Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xml:lang="en-US">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="QLGN_DisclosureWarrantLiabilitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:to="QLGN_DisclosureWarrantLiabilitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosureWarrantLiabilitiesAbstract_lbl" xml:lang="en-US">Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantLiabilitiesTextBlock" xlink:label="QLGN_WarrantLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesTextBlock" xlink:to="QLGN_WarrantLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantLiabilitiesTextBlock_lbl" xml:lang="en-US">WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:to="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesOfLesseeDisclosureTextBlock_lbl" xml:lang="en-US">LEASES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:to="QLGN_DisclosureResearchAndLicenseAgreementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DisclosureResearchAndLicenseAgreementsAbstract_lbl" xml:lang="en-US">Research And License Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:to="QLGN_ResearchAndLicenseAgreementsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock_lbl" xml:lang="en-US">RESEARCH AND LICENSE AGREEMENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&#8217; EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">RELATED PARTY TRANSACTIONS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OrganizationPolicyTextBlock" xlink:label="QLGN_OrganizationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OrganizationPolicyTextBlock" xlink:to="QLGN_OrganizationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_OrganizationPolicyTextBlock_lbl" xml:lang="en-US">Organization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Accounting Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl" xml:lang="en-US">Inventory, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Long-Lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TradeAndOtherAccountsReceivablePolicy_lbl" xml:lang="en-US">Accounts Receivable, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="QLGN_ShippingAndHandlingCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="QLGN_ShippingAndHandlingCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShippingAndHandlingCostsPolicyTextBlock_lbl" xml:lang="en-US">Shipping and Handling Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue from Contracts with Customers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xml:lang="en-US">Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IntangibleAssetsFiniteLivedPolicy_lbl" xml:lang="en-US">Intangible Assets, Net</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" xlink:to="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_lbl" xml:lang="en-US">Derivative Financial Instruments and Warrant Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value Measurements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:label="QLGN_SalesAndExciseTaxesPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:to="QLGN_SalesAndExciseTaxesPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SalesAndExciseTaxesPolicyTextBlock_lbl" xml:lang="en-US">Sales and Excise Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantyCostsPolicyTextBlock" xlink:label="QLGN_WarrantyCostsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantyCostsPolicyTextBlock" xlink:to="QLGN_WarrantyCostsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantyCostsPolicyTextBlock_lbl" xml:lang="en-US">Warranty Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCOUNTS RECEIVABLE</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF INVENTORY</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">SCHEDULE OF PROPERTY AND EQUIPMENT</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANTS ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:to="QLGN_ScheduleOfReservedSharesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF RESERVED SHARES</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF STOCK OPTION ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:to="QLGN_SummaryOfWarrantActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock_lbl" xml:lang="en-US">SCHEDULE OF WARRANT ACTIVITY</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xml:lang="en-US">Accounts Receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_lbl" xml:lang="en-US">Less Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccountsReceivableNetCurrent_2_lbl" xml:lang="en-US">Accounts receivable, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeaseDescriptionLineItems" xlink:label="us-gaap_LessorLeaseDescriptionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LessorLeaseDescriptionLineItems" xlink:to="us-gaap_LessorLeaseDescriptionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LessorLeaseDescriptionLineItems_lbl" xml:lang="en-US">Lessor, Lease, Description [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Property and equipment, useful life</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl" xml:lang="en-US">Long-lived assets impairment losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CostOfGoodsAndServicesSold_lbl" xml:lang="en-US">Shipping and handling costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EstimatedReturnsNetOfAllowances" xlink:label="QLGN_EstimatedReturnsNetOfAllowances" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EstimatedReturnsNetOfAllowances" xlink:to="QLGN_EstimatedReturnsNetOfAllowances_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EstimatedReturnsNetOfAllowances_lbl" xml:lang="en-US">Estimated returns net of allowances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet_lbl" xml:lang="en-US">Carrying value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_lbl" xml:lang="en-US">Accumulated amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xml:lang="en-US">Amortization expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_lbl" xml:lang="en-US">Future estimated amortization, remainder of fiscal year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_lbl" xml:lang="en-US">Future estimated amortization for year ending December 31, 2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_lbl" xml:lang="en-US">Future estimated amortization for year ending December 31, 2023</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_lbl" xml:lang="en-US">Future estimated amortization for year ending December 31, 2024</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_lbl" xml:lang="en-US">Future estimated amortization for year ending December 31, 2025</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_lbl" xml:lang="en-US">Future estimated amortization, Thereafter</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Accrued liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantyCosts" xlink:label="QLGN_WarrantyCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantyCosts" xlink:to="QLGN_WarrantyCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WarrantyCosts_lbl" xml:lang="en-US">Warranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NewEquityCapitalRaise" xlink:label="QLGN_NewEquityCapitalRaise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NewEquityCapitalRaise" xlink:to="QLGN_NewEquityCapitalRaise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NewEquityCapitalRaise_lbl" xml:lang="en-US">New equity capital raise</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="us-gaap_ConvertibleNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleNotesPayable" xlink:to="us-gaap_ConvertibleNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertibleNotesPayable_lbl" xml:lang="en-US">Convertible notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity_lbl" xml:lang="en-US">Proceeds from sale of equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="us-gaap_InventoryRawMaterials" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryRawMaterials_lbl" xml:lang="en-US">Raw materials</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="us-gaap_InventoryWorkInProcess" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryWorkInProcess_lbl" xml:lang="en-US">Work in process</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="us-gaap_InventoryFinishedGoods" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InventoryFinishedGoods_lbl" xml:lang="en-US">Finished goods</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_InventoryNet_2_lbl" xml:lang="en-US">Inventory net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract_2_lbl" xml:lang="en-US">Schedule Of Prepaid Expenses And Other Current Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidInsurance_lbl" xml:lang="en-US">Prepaid insurance</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidManufacturingExpenses" xlink:label="QLGN_PrepaidManufacturingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidManufacturingExpenses" xlink:to="QLGN_PrepaidManufacturingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrepaidManufacturingExpenses_lbl" xml:lang="en-US">Prepaid manufacturing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidInvestorRelationsExpenses" xlink:label="QLGN_PrepaidInvestorRelationsExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidInvestorRelationsExpenses" xlink:to="QLGN_PrepaidInvestorRelationsExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_PrepaidInvestorRelationsExpenses_lbl" xml:lang="en-US">Prepaid investor relations expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="us-gaap_OtherPrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPrepaidExpenseCurrent" xlink:to="us-gaap_OtherPrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPrepaidExpenseCurrent_lbl" xml:lang="en-US">Other prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less Accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Depreciation_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedCompensation" xlink:label="QLGN_AccruedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedCompensation" xlink:to="QLGN_AccruedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedCompensation_lbl" xml:lang="en-US">Board compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="us-gaap_AccruedVacationCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedVacationCurrent" xlink:to="us-gaap_AccruedVacationCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedVacationCurrent_lbl" xml:lang="en-US">Vacation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="us-gaap_AccruedRoyaltiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedRoyaltiesCurrent" xlink:to="us-gaap_AccruedRoyaltiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedRoyaltiesCurrent_lbl" xml:lang="en-US">Royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xml:lang="en-US">Professional fees</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedWarrantyCostsCurrent" xlink:label="QLGN_AccruedWarrantyCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedWarrantyCostsCurrent" xlink:to="QLGN_AccruedWarrantyCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_AccruedWarrantyCostsCurrent_lbl" xml:lang="en-US">Warranty costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="us-gaap_AccruedPayrollTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedPayrollTaxesCurrent" xlink:to="us-gaap_AccruedPayrollTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedPayrollTaxesCurrent_lbl" xml:lang="en-US">Payroll</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedPatentAndLicenseFeesCurrent" xlink:label="QLGN_AccruedPatentAndLicenseFeesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedPatentAndLicenseFeesCurrent" xlink:to="QLGN_AccruedPatentAndLicenseFeesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedPatentAndLicenseFeesCurrent_lbl" xml:lang="en-US">Patent and license fees</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SalesAndExciseTaxPayableCurrent_lbl" xml:lang="en-US">Franchise, sales and use taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="us-gaap_AccruedIncomeTaxesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedIncomeTaxesCurrent" xlink:to="us-gaap_AccruedIncomeTaxesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedIncomeTaxesCurrent_lbl" xml:lang="en-US">Income taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_3_lbl" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_lbl" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:to="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_lbl" xml:lang="en-US">Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:to="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Number of Shares, Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Number of Shares, Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Number of Shares, Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Number of Shares, Warrants Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Warrants Outstanding Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Warrants Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="QLGN_RangeOfExercisePriceExercisableVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_lbl" xml:lang="en-US">Range of Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years) Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_lbl" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="QLGN_FairValueAdjustmentOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_FairValueAdjustmentOfWarrant_lbl" xml:lang="en-US">Fair value for warrant liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput_lbl" xml:lang="en-US">Fair value assumptions, measurement input, percentages</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US">Fair value assumptions, measurement input, term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm_2_lbl" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:label="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:to="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_lbl" xml:lang="en-US">Shares issued upon the exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfWarrantExercisedOnCashlessBasis" xlink:label="QLGN_NumberOfWarrantExercisedOnCashlessBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfWarrantExercisedOnCashlessBasis" xlink:to="QLGN_NumberOfWarrantExercisedOnCashlessBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NumberOfWarrantExercisedOnCashlessBasis_lbl" xml:lang="en-US">Shares issued upon net-exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_2_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_lbl" xml:lang="en-US">Less amortization of operating lease right-of-use assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_3_lbl" xml:lang="en-US">Operating lease right-of-use assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US">Less principal payments on operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_OperatingLeaseLiability_2_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_2_lbl" xml:lang="en-US">Less non-current portion</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_2_lbl" xml:lang="en-US">Current portion at June 30, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2021 (nine months)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US">Less present value discount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_3_lbl" xml:lang="en-US">Operating lease liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">Weighted-average remaining lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">Discount rate operating lease</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Lease expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="us-gaap_RepaymentsOfConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfConvertibleDebt" xlink:to="us-gaap_RepaymentsOfConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfConvertibleDebt_lbl" xml:lang="en-US">Payment of convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="QLGN_ReimbursementOfResearchExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfResearchExpenses" xlink:to="QLGN_ReimbursementOfResearchExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementOfResearchExpenses_lbl" xml:lang="en-US">Reimbursement of research expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ReimbursementPatentCost" xlink:label="QLGN_ReimbursementPatentCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementPatentCost" xlink:to="QLGN_ReimbursementPatentCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ReimbursementPatentCost_lbl" xml:lang="en-US">Reimbursement patent cost</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="QLGN_AgreementTermPaymentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementTermPaymentDescription" xlink:to="QLGN_AgreementTermPaymentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AgreementTermPaymentDescription_lbl" xml:lang="en-US">Agreement term payment, description</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestonePayment" xlink:label="QLGN_MilestonePayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePayment" xlink:to="QLGN_MilestonePayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestonePayment_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestonePaymentForMarketingExpenses" xlink:label="QLGN_MilestonePaymentForMarketingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePaymentForMarketingExpenses" xlink:to="QLGN_MilestonePaymentForMarketingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestonePaymentForMarketingExpenses_lbl" xml:lang="en-US">Milestone payment for marketing expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_lbl" xml:lang="en-US">Licensed product sales, revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShortfallPayments" xlink:label="QLGN_ShortfallPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShortfallPayments" xlink:to="QLGN_ShortfallPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShortfallPayments_lbl" xml:lang="en-US">Shortfall payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Minimum annual royalties</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseCost" xlink:label="QLGN_LicenseCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseCost" xlink:to="QLGN_LicenseCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_LicenseCost_lbl" xml:lang="en-US">License costs</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpenses" xlink:to="QLGN_RegulatoryMarketingApprovalExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses_lbl" xml:lang="en-US">Regulatory marketing approval, expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UpfrontLicenseFee" xlink:label="QLGN_UpfrontLicenseFee" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontLicenseFee" xlink:to="QLGN_UpfrontLicenseFee_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UpfrontLicenseFee_lbl" xml:lang="en-US">Upfront license fee</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UlrfLicenseAgreementDescription" xlink:label="QLGN_UlrfLicenseAgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UlrfLicenseAgreementDescription" xlink:to="QLGN_UlrfLicenseAgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_UlrfLicenseAgreementDescription_lbl" xml:lang="en-US">ULRF license agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Sponsored research expense</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AgreementDescription" xlink:label="QLGN_AgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementDescription" xlink:to="QLGN_AgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AgreementDescription_lbl" xml:lang="en-US">Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromConvertibleDebt_lbl" xml:lang="en-US">Proceeds from convertible promissory note</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestoneMethodRevenueRecognized" xlink:label="QLGN_MilestoneMethodRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestoneMethodRevenueRecognized" xlink:to="QLGN_MilestoneMethodRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_MilestoneMethodRevenueRecognized_lbl" xml:lang="en-US">Milestone payment</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CumulativeAmount" xlink:label="QLGN_CumulativeAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CumulativeAmount" xlink:to="QLGN_CumulativeAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CumulativeAmount_lbl" xml:lang="en-US">Cumulative amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3_lbl" xml:lang="en-US">Product sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredRevenue_lbl" xml:lang="en-US">Deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="us-gaap_DepositAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositAssets" xlink:to="us-gaap_DepositAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositAssets_lbl" xml:lang="en-US">Upfront deposit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US">Class of Stock [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable_lbl" xml:lang="en-US">Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems_lbl" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Options Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:label="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:to="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsGranted" xlink:label="QLGN_RangeOfExercisePriceOptionsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsGranted" xlink:to="QLGN_RangeOfExercisePriceOptionsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOptionsGranted_lbl" xml:lang="en-US">Range of Exercise price, Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of Shares, Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsExpired" xlink:label="QLGN_RangeOfExercisePriceOptionsExpired" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsExpired" xlink:to="QLGN_RangeOfExercisePriceOptionsExpired_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOptionsExpired_lbl" xml:lang="en-US">Range of Exercise price, Options Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of Shares, Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsForfeited" xlink:label="QLGN_RangeOfExercisePriceOptionsForfeited" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsForfeited" xlink:to="QLGN_RangeOfExercisePriceOptionsForfeited_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOptionsForfeited_lbl" xml:lang="en-US">Range of Exercise price, Options Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of Shares, Options Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding at Ending</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:to="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_2_lbl" xml:lang="en-US">Range of Exercise price, Options Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Options Exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsExercisableVested" xlink:label="QLGN_RangeOfExercisePriceOptionsExercisableVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsExercisableVested" xlink:to="QLGN_RangeOfExercisePriceOptionsExercisableVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOptionsExercisableVested_lbl" xml:lang="en-US">Range of Exercise price, Options Exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Number of Shares, Options Non-Exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Options Non-Exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" xlink:label="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested_lbl" xml:lang="en-US">Range of Exercise price, Options Non-Exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_lbl" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected stock-price volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Average expected remaining years of life of options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Stock price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:to="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_2_lbl" xml:lang="en-US">Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:to="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_2_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:label="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:to="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant_lbl" xml:lang="en-US">Number of Shares, Warrants Legacy Ritter warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:to="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_lbl" xml:lang="en-US">Number of shares, warrants non-exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_lbl" xml:lang="en-US">Weighted Average Exercise Price Per Share Non-Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceNonexercisableNonvested_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested_lbl" xml:lang="en-US">Range of Exercise Price, Non-Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Life (Years) Non-Exercisable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_2_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Sale of stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Number of shares common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_2_lbl" xml:lang="en-US">Purchase of stock warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Warrant exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xml:lang="en-US">Beneficial-ownership percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Warrants exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockOptionsSharesFutureGrant" xlink:label="QLGN_StockOptionsSharesFutureGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockOptionsSharesFutureGrant" xlink:to="QLGN_StockOptionsSharesFutureGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_StockOptionsSharesFutureGrant_lbl" xml:lang="en-US">[custom:StockOptionsSharesFutureGrant]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_3_lbl" xml:lang="en-US">Stock based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xml:lang="en-US">Unrecognized compensation cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Stock issued upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_lbl" xml:lang="en-US">Stock options description</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Stock option granted exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EquityCapitalRaise" xlink:label="QLGN_EquityCapitalRaise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EquityCapitalRaise" xlink:to="QLGN_EquityCapitalRaise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EquityCapitalRaise_lbl" xml:lang="en-US">Equity capital raise</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesIssuedUponNetExercises" xlink:label="QLGN_SharesIssuedUponNetExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedUponNetExercises" xlink:to="QLGN_SharesIssuedUponNetExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_SharesIssuedUponNetExercises_lbl" xml:lang="en-US">Shares issued on net exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliateCollateralizedSecurityLineItems" xlink:label="srt_AffiliateCollateralizedSecurityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AffiliateCollateralizedSecurityLineItems" xlink:to="srt_AffiliateCollateralizedSecurityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_AffiliateCollateralizedSecurityLineItems_lbl" xml:lang="en-US">Affiliate, Collateralized Security [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockSharesConverted1" xlink:to="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ConversionOfStockSharesConverted1_2_lbl" xml:lang="en-US">Conversion of preferred stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US">Subsequent Event [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CommonStockSharesAvailableForFutureIssuance" xlink:label="QLGN_CommonStockSharesAvailableForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockSharesAvailableForFutureIssuance" xlink:to="QLGN_CommonStockSharesAvailableForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_CommonStockSharesAvailableForFutureIssuance_lbl" xml:lang="en-US">[custom:CommonStockSharesAvailableForFutureIssuance-0]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EquipmentHeldForLeaseNet" xlink:to="QLGN_EquipmentHeldForLeaseNet_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EquipmentHeldForLeaseNet_doc" xml:lang="en-US">Equipment held for lease net.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CostOfProductSales" xlink:to="QLGN_CostOfProductSales_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CostOfProductSales_doc" xml:lang="en-US">Cost of product sales.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetProductSalesMember" xlink:to="QLGN_NetProductSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NetProductSalesMember_doc" xml:lang="en-US">Net Product Sales [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseRevenueMember" xlink:to="QLGN_LicenseRevenueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseRevenueMember_doc" xml:lang="en-US">License Revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CollaborativeResearchRevenueMember" xlink:to="QLGN_CollaborativeResearchRevenueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CollaborativeResearchRevenueMember_doc" xml:lang="en-US">Collaborative Research Revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OperatingLeaseRightOfUseAssetAmortization" xlink:to="QLGN_OperatingLeaseRightOfUseAssetAmortization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_OperatingLeaseRightOfUseAssetAmortization_doc" xml:lang="en-US">Operating lease right of use asset amortization.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:to="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease_doc" xml:lang="en-US">Inventory and equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IncreaseDecreaseInLeaseLiabilities" xlink:to="QLGN_IncreaseDecreaseInLeaseLiabilities_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IncreaseDecreaseInLeaseLiabilities_doc" xml:lang="en-US">Change during the period in carrying value of lease liabilities.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest_doc" xml:lang="en-US">Issuance of common stock for conversion of debt and accrued interest.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_doc" xml:lang="en-US">Issuance of common stock for conversion of preferred stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfPreferredStockForConversionOfDebt" xlink:to="QLGN_IssuanceOfPreferredStockForConversionOfDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfPreferredStockForConversionOfDebt_doc" xml:lang="en-US">Issuance of Preferred Stock for Conversion of Debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:to="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement_doc" xml:lang="en-US">Fair value of shares issued to advisor upon closing of private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:to="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_doc" xml:lang="en-US">Fair value of warrants issued to advisor upon closing of private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectOfReverseRecapitalization" xlink:to="QLGN_EffectOfReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EffectOfReverseRecapitalization_doc" xml:lang="en-US">Stock issued during period effect of reverse recapitalization transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets" xlink:to="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets_doc" xml:lang="en-US">Initial Measurement of Operating Lease Right of use Assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease" xlink:to="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NetTransfersToInventoryFromEquipmentHeldForLease_doc" xml:lang="en-US">Net transfers to inventory from equipment held for lease.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CashPaidForAbstract" xlink:to="QLGN_CashPaidForAbstract_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CashPaidForAbstract_doc" xml:lang="en-US">Cash Paid For [Abstract]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForProfessionalServices" xlink:to="QLGN_IssuanceOfCommonStockForProfessionalServices_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfCommonStockForProfessionalServices_doc" xml:lang="en-US">Issuance common stock for professional services.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAConvertiblePreferredStockMember" xlink:to="QLGN_SeriesAConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesAConvertiblePreferredStockMember_doc" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="QLGN_StockIssuedDuringPeriodValueWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValueWarrantsExercised_doc" xml:lang="en-US">Warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" xlink:to="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis_doc" xml:lang="en-US">Warrants exercised on a net basis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:to="QLGN_SeriesAlphaConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesAlphaConvertiblePreferredStockMember_doc" xml:lang="en-US">Series Alpha Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodSharesWarrantsExercised_doc" xml:lang="en-US">Warrants exercised, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" xlink:to="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis_doc" xml:lang="en-US">Warrants exercised on a net basis, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock_doc" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantLiabilitiesTextBlock" xlink:to="QLGN_WarrantLiabilitiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantLiabilitiesTextBlock_doc" xml:lang="en-US">Warrant Liabilities [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:to="QLGN_ResearchAndLicenseAgreementsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ResearchAndLicenseAgreementsTextBlock_doc" xml:lang="en-US">Research and license agreements [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OrganizationPolicyTextBlock" xlink:to="QLGN_OrganizationPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_OrganizationPolicyTextBlock_doc" xml:lang="en-US">Organization [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:to="QLGN_ShippingAndHandlingCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShippingAndHandlingCostsPolicyTextBlock_doc" xml:lang="en-US">Shipping and handling costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" xlink:to="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_doc" xml:lang="en-US">Derivative Financial Instruments and Warrant Liabilities [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:to="QLGN_SalesAndExciseTaxesPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SalesAndExciseTaxesPolicyTextBlock_doc" xml:lang="en-US">Sales and excise taxes [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantyCostsPolicyTextBlock" xlink:to="QLGN_WarrantyCostsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantyCostsPolicyTextBlock_doc" xml:lang="en-US">Warranty costs [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:to="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_doc" xml:lang="en-US">Schedule of Useful Lives of Property and Equipment [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_doc" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Fair Value Hierarchy for Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Assumptions of Warrant Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:to="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_doc" xml:lang="en-US">Schedule of Operating Lease Right of Use Assets and Liabilities [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:to="QLGN_ScheduleOfReservedSharesTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ScheduleOfReservedSharesTableTextBlock_doc" xml:lang="en-US">Schedule of Reserved Shares [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:to="QLGN_SummaryOfWarrantActivityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SummaryOfWarrantActivityTableTextBlock_doc" xml:lang="en-US">Summary of Warrant Activity [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantActivityMember" xlink:to="QLGN_CompensatoryWarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CompensatoryWarrantActivityMember_doc" xml:lang="en-US">Compensatory Warrant Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NonCompensatoryWarrantActivityMember" xlink:to="QLGN_NonCompensatoryWarrantActivityMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NonCompensatoryWarrantActivityMember_doc" xml:lang="en-US">Non Compensatory Warrant Activity [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesBConvertiblePreferredStockMember" xlink:to="QLGN_SeriesBConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesBConvertiblePreferredStockMember_doc" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCConvertiblePreferredStockMember" xlink:to="QLGN_SeriesCConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesCConvertiblePreferredStockMember_doc" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesDConvertiblePreferredStockMember" xlink:to="QLGN_SeriesDConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesDConvertiblePreferredStockMember_doc" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesDOneConvertiblePreferredStockMember" xlink:to="QLGN_SeriesDOneConvertiblePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesDOneConvertiblePreferredStockMember_doc" xml:lang="en-US">Series D One Convertible Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" xlink:to="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization_doc" xml:lang="en-US">Stock issued during period effect of reverse recapitalization transaction.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" xlink:to="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares_doc" xml:lang="en-US">Stock issued during period effect of reverse recapitalization transaction, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" xlink:to="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable_doc" xml:lang="en-US">Issuance of Series Alpha preferred stock for conversion of notes payable.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" xlink:to="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares_doc" xml:lang="en-US">Issuance of Series Alpha preferred stock for conversion of notes payable, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:to="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement_doc" xml:lang="en-US">Shares and warrants issued to advisor upon closing of private placement.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" xlink:to="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares_doc" xml:lang="en-US">Shares and warrants issued to advisor upon closing of private placement, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:to="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember_doc" xml:lang="en-US">General, Administrative, Research and Development Expense [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EstimatedReturnsNetOfAllowances" xlink:to="QLGN_EstimatedReturnsNetOfAllowances_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EstimatedReturnsNetOfAllowances_doc" xml:lang="en-US">Estimated Returns Net of allowances.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PatentsAndLicensesMember" xlink:to="QLGN_PatentsAndLicensesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PatentsAndLicensesMember_doc" xml:lang="en-US">Patents and Licenses [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WarrantyCosts" xlink:to="QLGN_WarrantyCosts_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WarrantyCosts_doc" xml:lang="en-US">Warranty costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_OfficeFurnitureAndEquipmentMember" xlink:to="QLGN_OfficeFurnitureAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_OfficeFurnitureAndEquipmentMember_doc" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NewEquityCapitalRaise" xlink:to="QLGN_NewEquityCapitalRaise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NewEquityCapitalRaise_doc" xml:lang="en-US">New equity capital raise,</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SecuritiesPurchaseAgreementMember" xlink:to="QLGN_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidManufacturingExpenses" xlink:to="QLGN_PrepaidManufacturingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrepaidManufacturingExpenses_doc" xml:lang="en-US">Prepaid manufacturing expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrepaidInvestorRelationsExpenses" xlink:to="QLGN_PrepaidInvestorRelationsExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrepaidInvestorRelationsExpenses_doc" xml:lang="en-US">Prepaid investor relations expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ConstructionInProgressEquipmentMember" xlink:to="QLGN_ConstructionInProgressEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ConstructionInProgressEquipmentMember_doc" xml:lang="en-US">Construction In Progress Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedCompensation" xlink:to="QLGN_AccruedCompensation_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedCompensation_doc" xml:lang="en-US">Board compensation.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_doc" xml:lang="en-US">Research and development.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedWarrantyCostsCurrent" xlink:to="QLGN_AccruedWarrantyCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedWarrantyCostsCurrent_doc" xml:lang="en-US">Warranty costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedPatentAndLicenseFeesCurrent" xlink:to="QLGN_AccruedPatentAndLicenseFeesCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AccruedPatentAndLicenseFeesCurrent_doc" xml:lang="en-US">Patent and license fees.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesCWarrantsMember" xlink:to="QLGN_SeriesCWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesCWarrantsMember_doc" xml:lang="en-US">Series C Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:to="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_doc" xml:lang="en-US">Number of warrant exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfWarrantExercisedOnCashlessBasis" xlink:to="QLGN_NumberOfWarrantExercisedOnCashlessBasis_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NumberOfWarrantExercisedOnCashlessBasis_doc" xml:lang="en-US">Number of warrant exercised on cashless basis.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockWarrantsMember" xlink:to="QLGN_CommonStockWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommonStockWarrantsMember_doc" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_doc" xml:lang="en-US">The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share warrants exercised.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share warrants forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_doc" xml:lang="en-US">Weighted average exercise price per share exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceExercisableVested" xlink:to="QLGN_RangeOfExercisePriceExercisableVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceExercisableVested_doc" xml:lang="en-US">Range of exercise price, exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:to="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_doc" xml:lang="en-US">Sttock warrant exchanged for common stock warrant upon reverse merger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:to="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_doc" xml:lang="en-US">Weighted average exercise price per share warrants series c preferred stock warrant exchanged for common stock warrant upon reverse merger.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_FairValueAdjustmentOfWarrant" xlink:to="QLGN_FairValueAdjustmentOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_FairValueAdjustmentOfWarrant_doc" xml:lang="en-US">Amount of expense (income) related to adjustment to fair value of warrant liability.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NetRightofuseAsset" xlink:label="QLGN_NetRightofuseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NetRightofuseAsset" xlink:to="QLGN_NetRightofuseAsset_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NetRightofuseAsset_doc" xml:lang="en-US">Net right-of-use assets.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LongtermOperatingLeaseAgreementMember" xlink:to="QLGN_LongtermOperatingLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LongtermOperatingLeaseAgreementMember_doc" xml:lang="en-US">Conversion of Outstanding Series Alpha Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:to="QLGN_LicenseAndSponsoredResearchAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseAndSponsoredResearchAgreementsMember_doc" xml:lang="en-US">License and Sponsored Research Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:to="QLGN_UniversityOfLouisvilleResearchFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UniversityOfLouisvilleResearchFoundationMember_doc" xml:lang="en-US">University of Louisville Research Foundation [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementOfResearchExpenses" xlink:to="QLGN_ReimbursementOfResearchExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementOfResearchExpenses_doc" xml:lang="en-US">Reimbursement of research expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ReimbursementPatentCost" xlink:to="QLGN_ReimbursementPatentCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ReimbursementPatentCost_doc" xml:lang="en-US">Reimbursement patent cost.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementTermPaymentDescription" xlink:to="QLGN_AgreementTermPaymentDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AgreementTermPaymentDescription_doc" xml:lang="en-US">Agreement term payment, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePayment" xlink:to="QLGN_MilestonePayment_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestonePayment_doc" xml:lang="en-US">Milestone payment.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseOneClinicalTrialMember" xlink:to="QLGN_PhaseOneClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseOneClinicalTrialMember_doc" xml:lang="en-US">Phase 1 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseTwoClinicalTrialMember" xlink:to="QLGN_PhaseTwoClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseTwoClinicalTrialMember_doc" xml:lang="en-US">Phase 2 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PhaseThreeClinicalTrialMember" xlink:to="QLGN_PhaseThreeClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PhaseThreeClinicalTrialMember_doc" xml:lang="en-US">Phase 3 Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RegulatoryMarketingApprovalExpenses" xlink:to="QLGN_RegulatoryMarketingApprovalExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RegulatoryMarketingApprovalExpenses_doc" xml:lang="en-US">Regulatory marketing approval, expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicensedProductSalesMember" xlink:to="QLGN_LicensedProductSalesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicensedProductSalesMember_doc" xml:lang="en-US">Licensed Product Sales [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShortfallPayments" xlink:to="QLGN_ShortfallPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShortfallPayments_doc" xml:lang="en-US">Shortfall payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestonePaymentForMarketingExpenses" xlink:to="QLGN_MilestonePaymentForMarketingExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestonePaymentForMarketingExpenses_doc" xml:lang="en-US">Milestone payment for marketing expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:to="QLGN_SponsoredResearchAgreementAndLicenseMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SponsoredResearchAgreementAndLicenseMember_doc" xml:lang="en-US">Sponsored Research and License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseCost" xlink:to="QLGN_LicenseCost_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseCost_doc" xml:lang="en-US">License costs.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UpfrontLicenseFee" xlink:to="QLGN_UpfrontLicenseFee_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UpfrontLicenseFee_doc" xml:lang="en-US">Upfront license fee.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_LicenseAgreementMember" xlink:to="QLGN_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_UlrfLicenseAgreementDescription" xlink:to="QLGN_UlrfLicenseAgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_UlrfLicenseAgreementDescription_doc" xml:lang="en-US">ULRF license agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" xlink:to="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_doc" xml:lang="en-US">Royalties and Non-royalty Sublicensee Income [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AgreementDescription" xlink:to="QLGN_AgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AgreementDescription_doc" xml:lang="en-US">Agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:to="QLGN_AdvancedCancerTherapeuticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_AdvancedCancerTherapeuticsLLCMember_doc" xml:lang="en-US">Advanced Cancer Therapeutics, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestoneMethodRevenueRecognized" xlink:to="QLGN_MilestoneMethodRevenueRecognized_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_MilestoneMethodRevenueRecognized_doc" xml:lang="en-US">Milestone method revenue recognized.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CumulativeAmount" xlink:to="QLGN_CumulativeAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CumulativeAmount_doc" xml:lang="en-US">Cumulative amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CEMarkMember" xlink:to="QLGN_CEMarkMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CEMarkMember_doc" xml:lang="en-US">CE Mark [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PredictionBiosciencesSASMember" xlink:to="QLGN_PredictionBiosciencesSASMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PredictionBiosciencesSASMember_doc" xml:lang="en-US">Prediction Biosciences SAS [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SekisuiDiagnosticsLLCMember" xlink:to="QLGN_SekisuiDiagnosticsLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SekisuiDiagnosticsLLCMember_doc" xml:lang="en-US">Sekisui Diagnostics, LLC [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_YiXinZhenDuanJishuLtdMember" xlink:to="QLGN_YiXinZhenDuanJishuLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_YiXinZhenDuanJishuLtdMember_doc" xml:lang="en-US">Yi Xin Zhen Duan Jishu Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_STAPharmaceuticalCoLtdMember" xlink:to="QLGN_STAPharmaceuticalCoLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_STAPharmaceuticalCoLtdMember_doc" xml:lang="en-US">STA Pharmaceutical Co Ltd [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TechnologyTransferAgreementMember" xlink:to="QLGN_TechnologyTransferAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TechnologyTransferAgreementMember_doc" xml:lang="en-US">Technology Transfer Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SingleInstitutionalInvestorMember" xlink:to="QLGN_SingleInstitutionalInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SingleInstitutionalInvestorMember_doc" xml:lang="en-US">Single Institutional Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_PrefundedWarrantsMember" xlink:to="QLGN_PrefundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_PrefundedWarrantsMember_doc" xml:lang="en-US">Pre-funded Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoYearWarrantsMember" xlink:to="QLGN_TwoYearWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwoYearWarrantsMember_doc" xml:lang="en-US">Two-year Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockOptionsAndWarrantsMember" xlink:to="QLGN_StockOptionsAndWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockOptionsAndWarrantsMember_doc" xml:lang="en-US">Stock Options and Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:to="QLGN_TwoThousandTwentyStockIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwoThousandTwentyStockIncentivePlanMember_doc" xml:lang="en-US">2020 Stock Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_StockOptionsSharesFutureGrant" xlink:to="QLGN_StockOptionsSharesFutureGrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_StockOptionsSharesFutureGrant_doc" xml:lang="en-US">Stock options shares future grant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EquityCapitalRaise" xlink:to="QLGN_EquityCapitalRaise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EquityCapitalRaise_doc" xml:lang="en-US">Equity capital raise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CompensatoryWarrantsMember" xlink:to="QLGN_CompensatoryWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CompensatoryWarrantsMember_doc" xml:lang="en-US">Compensatory Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesIssuedOnNetExercise" xlink:label="QLGN_SharesIssuedOnNetExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedOnNetExercise" xlink:to="QLGN_SharesIssuedOnNetExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesIssuedOnNetExercise_doc" xml:lang="en-US">Shares Issued On Net Exercise.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:to="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NoncompensatoryEquityClassifiedWarrantsMember_doc" xml:lang="en-US">Noncompensatory Equity Classified Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharesIssuedUponNetExercises" xlink:to="QLGN_SharesIssuedUponNetExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharesIssuedUponNetExercises_doc" xml:lang="en-US">Shares issued upon net exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ExerciseOfOutstandingStockOptionsMember" xlink:to="QLGN_ExerciseOfOutstandingStockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ExerciseOfOutstandingStockOptionsMember_doc" xml:lang="en-US">Exercise of Outstanding Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ExerciseOfOutstandingStockWarrantMember" xlink:to="QLGN_ExerciseOfOutstandingStockWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ExerciseOfOutstandingStockWarrantMember_doc" xml:lang="en-US">Exercise of Outstanding Stock Warrant Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SerieAlphaPreferredStockMember" xlink:to="QLGN_SerieAlphaPreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SerieAlphaPreferredStockMember_doc" xml:lang="en-US">Series Alpha Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:to="QLGN_EmployeesAndNonemployeeServiceProviderMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_EmployeesAndNonemployeeServiceProviderMember_doc" xml:lang="en-US">Employees and Non-employee Service Provider [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average exercise price, options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:to="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_doc" xml:lang="en-US">Range of exercise price, options outstanding.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsGranted" xlink:to="QLGN_RangeOfExercisePriceOptionsGranted_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOptionsGranted_doc" xml:lang="en-US">Range of exercise price, options granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsExpired" xlink:to="QLGN_RangeOfExercisePriceOptionsExpired_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOptionsExpired_doc" xml:lang="en-US">Range of exercise price, options expired.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsForfeited" xlink:to="QLGN_RangeOfExercisePriceOptionsForfeited_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOptionsForfeited_doc" xml:lang="en-US">Range of exercise price, options forfeited.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsExercisableVested" xlink:to="QLGN_RangeOfExercisePriceOptionsExercisableVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOptionsExercisableVested_doc" xml:lang="en-US">Range of exercise price, options exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested_doc" xml:lang="en-US">Range of exercise price, options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_doc" xml:lang="en-US">Weighted- Average Remaining Contractual Life (in Years), Options Granted.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" xlink:to="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_doc" xml:lang="en-US">Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_doc" xml:lang="en-US">Weighted- average remaining contractual life (in years), options exercisable (vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:to="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_doc" xml:lang="en-US">Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_doc" xml:lang="en-US">Number of shares, warrants non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_doc" xml:lang="en-US">Weighted average exercise price per share non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:to="QLGN_RangeOfExercisePriceNonexercisableNonvested_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_RangeOfExercisePriceNonexercisableNonvested_doc" xml:lang="en-US">Range of exercise price, non-exercisable (non-vested).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_doc" xml:lang="en-US">Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:to="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_NumberOfSharesWarrantsLegacyRitterWarrant_doc" xml:lang="en-US">Number of Shares, Warrants Legacy Ritter warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:to="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_doc" xml:lang="en-US">Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_SeriesDAndSeriesDOnePreferredStockMember" xlink:to="QLGN_SeriesDAndSeriesDOnePreferredStockMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_SeriesDAndSeriesDOnePreferredStockMember_doc" xml:lang="en-US">Series D and Series D-1 Preferred Stock [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_CommonStockSharesAvailableForFutureIssuance" xlink:to="QLGN_CommonStockSharesAvailableForFutureIssuance_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_CommonStockSharesAvailableForFutureIssuance_doc" xml:lang="en-US">Common stock shares available for future issuance.</link:label>
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoThousandTwentyPlanMember" xlink:label="QLGN_TwoThousandTwentyPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_TwoThousandTwentyPlanMember" xlink:to="QLGN_TwoThousandTwentyPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="QLGN_TwoThousandTwentyPlanMember_doc" xml:lang="en-US">2020 Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_2_lbl" xml:lang="en-US">Interest Income (Expense), Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Fair Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpensesOther_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expenses, Other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_2_lbl" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:to="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_IssuanceOfCommonStockForConversionOfPreferredStock_3_lbl" xml:lang="en-US">IssuanceOfCommonStockForConversionOfPreferredStock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_EffectOfReverseRecapitalization" xlink:to="QLGN_EffectOfReverseRecapitalization_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_EffectOfReverseRecapitalization_3_lbl" xml:lang="en-US">EffectOfReverseRecapitalization</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_2_lbl" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedResearchAndDevelopmentCurrent" xlink:to="QLGN_AccruedResearchAndDevelopmentCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedResearchAndDevelopmentCurrent_3_lbl" xml:lang="en-US">AccruedResearchAndDevelopmentCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_AccruedWarrantyCostsCurrent" xlink:to="QLGN_AccruedWarrantyCostsCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_AccruedWarrantyCostsCurrent_3_lbl" xml:lang="en-US">AccruedWarrantyCostsCurrent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_4_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_2_lbl" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_2_lbl" xml:lang="en-US">Operating Lease, Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_MilestoneMethodRevenueRecognized" xlink:to="QLGN_MilestoneMethodRevenueRecognized_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_MilestoneMethodRevenueRecognized_3_lbl" xml:lang="en-US">MilestoneMethodRevenueRecognized</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenue_2_lbl" xml:lang="en-US">Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesSubscribedButUnissued" xlink:to="us-gaap_CommonStockSharesSubscribedButUnissued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesSubscribedButUnissued_2_lbl" xml:lang="en-US">Common Stock, Shares Subscribed but Unissued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:to="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_4_lbl" xml:lang="en-US">ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:to="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>qlgn-20210630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://qualigeninc.com/role/Cover" xlink:href="qlgn-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheets" xlink:href="qlgn-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:href="qlgn-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfOperations" xlink:href="qlgn-20210630.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="qlgn-20210630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:href="qlgn-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Liquidity" xlink:href="qlgn-20210630.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNet" xlink:href="qlgn-20210630.xsd#InventoryNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:href="qlgn-20210630.xsd#PrepaidExpensesAndOtherCurrentAssets" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNet" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:href="qlgn-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilities" xlink:href="qlgn-20210630.xsd#WarrantLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/Leases" xlink:href="qlgn-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:href="qlgn-20210630.xsd#ResearchAndLicenseAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquity" xlink:href="qlgn-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:href="qlgn-20210630.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEvents" xlink:href="qlgn-20210630.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/InventoryNetTables" xlink:href="qlgn-20210630.xsd#InventoryNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="qlgn-20210630.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNetTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:href="qlgn-20210630.xsd#AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:href="qlgn-20210630.xsd#WarrantLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LeasesTables" xlink:href="qlgn-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityTables" xlink:href="qlgn-20210630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAccountsReceivableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:href="qlgn-20210630.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LiquidityDetailsNarrative" xlink:href="qlgn-20210630.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfInventoryDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:href="qlgn-20210630.xsd#PropertyAndEquipmentNetDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfWarrantsActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:href="qlgn-20210630.xsd#WarrantLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/LeasesDetailsNarrative" xlink:href="qlgn-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:href="qlgn-20210630.xsd#ResearchAndLicenseAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfReservedSharesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfShare-basedCompensationExpenseDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:href="qlgn-20210630.xsd#ScheduleOfWarrantActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:href="qlgn-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="qlgn-20210630.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:href="qlgn-20210630.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EquipmentHeldForLeaseNet" xlink:label="loc_QLGNEquipmentHeldForLeaseNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_QLGNEquipmentHeldForLeaseNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapIntangibleAssetsNetExcludingGoodwill" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeCurrent" xlink:label="loc_us-gaapDeferredIncomeCurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredIncomeCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingLiabilitiesCurrent" xlink:label="loc_us-gaapHedgingLiabilitiesCurrent" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapHedgingLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaapLongTermNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaapDeferredRevenueNoncurrent" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRevenueNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NetProductSalesMember" xlink:label="loc_QLGNNetProductSalesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNNetProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="loc_QLGNCollaborativeResearchRevenueMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNCollaborativeResearchRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaapRevenuesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenuesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="loc_us-gaapOperatingCostsAndExpensesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CostOfProductSales" xlink:label="loc_QLGNCostOfProductSales" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_QLGNCostOfProductSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="loc_us-gaapMarketingAndAdvertisingExpense" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapMarketingAndAdvertisingExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingCostsAndExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaapInterestIncomeExpenseNet" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="100" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesAConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAConvertiblePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesAConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesBConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesBConvertiblePreferredStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesBConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesCConvertiblePreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesCConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesDConvertiblePreferredStockMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesDConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDOneConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesDOneConvertiblePreferredStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesDOneConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesAlphaConvertiblePreferredStockMember" xlink:label="loc_QLGNSeriesAlphaConvertiblePreferredStockMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_QLGNSeriesAlphaConvertiblePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueWarrantsExercised" xlink:label="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" xlink:label="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" xlink:label="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="loc_us-gaapConversionOfStockAmountConverted1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockAmountConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization" xlink:label="loc_QLGNStockIssuedDuringPeriodValueEffectOfReverseRecapitalization" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodValueEffectOfReverseRecapitalization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" xlink:label="loc_QLGNStockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNStockIssuedDuringPeriodEffectOfReverseRecapitalizationShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" xlink:label="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" xlink:label="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNIssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" xlink:label="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_QLGNSharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalMarkToMarket" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaapDepreciationDepletionAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationDepletionAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OperatingLeaseRightOfUseAssetAmortization" xlink:label="loc_QLGNOperatingLeaseRightOfUseAssetAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_QLGNOperatingLeaseRightOfUseAssetAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProvisionForDoubtfulAccounts" xlink:label="loc_us-gaapProvisionForDoubtfulAccounts" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapProvisionForDoubtfulAccounts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaapInventoryWriteDown" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapInventoryWriteDown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsReceivable" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsReceivable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:label="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLease" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_QLGNIncreaseDecreaseInInventoryAndEquipmentHeldForLease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpensesOther" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpensesOther" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IncreaseDecreaseInLeaseLiabilities" xlink:label="loc_QLGNIncreaseDecreaseInLeaseLiabilities" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_QLGNIncreaseDecreaseInLeaseLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaapPaymentsToAcquireIntangibleAssets" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireIntangibleAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CashPaidForAbstract" xlink:label="loc_QLGNCashPaidForAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_QLGNCashPaidForAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNCashPaidForAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNCashPaidForAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfCommonStockForProfessionalServices" xlink:label="loc_QLGNIssuanceOfCommonStockForProfessionalServices" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNIssuanceOfCommonStockForProfessionalServices" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionOriginalDebtAmount1" xlink:label="loc_us-gaapDebtConversionOriginalDebtAmount1" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDebtConversionOriginalDebtAmount1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest" xlink:label="loc_QLGNIssuanceOfCommonStockForConversionOfAccruedInterest" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNIssuanceOfCommonStockForConversionOfAccruedInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfCommonStockForConversionOfPreferredStock" xlink:label="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStock" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNIssuanceOfCommonStockForConversionOfPreferredStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_IssuanceOfPreferredStockForConversionOfDebt" xlink:label="loc_QLGNIssuanceOfPreferredStockForConversionOfDebt" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNIssuanceOfPreferredStockForConversionOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="loc_QLGNFairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNFairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:label="loc_QLGNFairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNFairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EffectOfReverseRecapitalization" xlink:label="loc_QLGNEffectOfReverseRecapitalization" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNEffectOfReverseRecapitalization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets" xlink:label="loc_QLGNInitialMeasurementOfOperatingLeaseRightofuseAssets" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNInitialMeasurementOfOperatingLeaseRightofuseAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NetTransfersToInventoryFromEquipmentHeldForLease" xlink:label="loc_QLGNNetTransfersToInventoryFromEquipmentHeldForLease" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_QLGNNetTransfersToInventoryFromEquipmentHeldForLease" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates" xlink:title="00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Liquidity" xlink:title="00000008 - Disclosure - LIQUIDITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNet" xlink:title="00000009 - Disclosure - INVENTORY, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaapInventoryDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets" xlink:title="00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_QLGNPrepaidExpensesAndOtherCurrentAssetsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_QLGNPrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNet" xlink:title="00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities" xlink:title="00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilities" xlink:title="00000013 - Disclosure - WARRANT LIABILITIES">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantLiabilitiesTextBlock" xlink:label="loc_QLGNWarrantLiabilitiesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNWarrantLiabilitiesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/Leases" xlink:title="00000014 - Disclosure - LEASES">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLeasesOfLesseeDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreements" xlink:title="00000015 - Disclosure - RESEARCH AND LICENSE AGREEMENTS">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ResearchAndLicenseAgreementsTextBlock" xlink:label="loc_QLGNResearchAndLicenseAgreementsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" xlink:to="loc_QLGNResearchAndLicenseAgreementsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquity" xlink:title="00000016 - Disclosure - STOCKHOLDERS&#8217; EQUITY">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactions" xlink:title="00000017 - Disclosure - RELATED PARTY TRANSACTIONS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEvents" xlink:title="00000018 - Disclosure - SUBSEQUENT EVENTS">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies" xlink:title="00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OrganizationPolicyTextBlock" xlink:label="loc_QLGNOrganizationPolicyTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNOrganizationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaapConsolidationPolicyTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapConsolidationPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaapInventoryPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapInventoryPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapTradeAndOtherAccountsReceivablePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShippingAndHandlingCostsPolicyTextBlock" xlink:label="loc_QLGNShippingAndHandlingCostsPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNShippingAndHandlingCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaapRevenueRecognitionPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapRevenueRecognitionPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaapLesseeLeasesPolicyTextBlock" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapLesseeLeasesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIntangibleAssetsFiniteLivedPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" xlink:label="loc_QLGNDerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNDerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapCompensationRelatedCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SalesAndExciseTaxesPolicyTextBlock" xlink:label="loc_QLGNSalesAndExciseTaxesPolicyTextBlock" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNSalesAndExciseTaxesPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantyCostsPolicyTextBlock" xlink:label="loc_QLGNWarrantyCostsPolicyTextBlock" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNWarrantyCostsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables" xlink:title="00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:label="loc_QLGNScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_QLGNScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/InventoryNetTables" xlink:title="00000021 - Disclosure - INVENTORY, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="00000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="loc_QLGNScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_QLGNScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetTables" xlink:title="00000023 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables" xlink:title="00000024 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesTables" xlink:title="00000025 - Disclosure - WARRANT LIABILITIES (Tables)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_QLGNScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LeasesTables" xlink:title="00000026 - Disclosure - LEASES (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_QLGNScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_QLGNScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityTables" xlink:title="00000027 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ScheduleOfReservedSharesTableTextBlock" xlink:label="loc_QLGNScheduleOfReservedSharesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNScheduleOfReservedSharesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SummaryOfWarrantActivityTableTextBlock" xlink:label="loc_QLGNSummaryOfWarrantActivityTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSummaryOfWarrantActivityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails" xlink:title="00000028 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaapAccountsReceivableGrossCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAccountsReceivableGrossCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaapAccountsReceivableNetCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapAccountsReceivableNetCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails" xlink:title="00000029 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeaseDescriptionLineItems" xlink:label="loc_us-gaapLessorLeaseDescriptionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapLessorLeaseDescriptionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaapToolsDiesAndMoldsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapToolsDiesAndMoldsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OfficeFurnitureAndEquipmentMember" xlink:label="loc_QLGNOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLessorLeaseDescriptionLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative" xlink:title="00000030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:label="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_QLGNGeneralAdministrativeResearchAndDevelopmentExpensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="loc_QLGNCollaborativeResearchRevenueMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNCollaborativeResearchRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PatentsAndLicensesMember" xlink:label="loc_QLGNPatentsAndLicensesMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_QLGNPatentsAndLicensesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PatentsMember" xlink:label="loc_us-gaapPatentsMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapPatentsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaapLicenseMember" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="loc_us-gaapLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaapCostOfGoodsAndServicesSold" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapCostOfGoodsAndServicesSold" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EstimatedReturnsNetOfAllowances" xlink:label="loc_QLGNEstimatedReturnsNetOfAllowances" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_QLGNEstimatedReturnsNetOfAllowances" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaapAmortizationOfIntangibleAssets" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAmortizationOfIntangibleAssets" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:label="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapFiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WarrantyCosts" xlink:label="loc_QLGNWarrantyCosts" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_QLGNWarrantyCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LiquidityDetailsNarrative" xlink:title="00000031 - Disclosure - LIQUIDITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NewEquityCapitalRaise" xlink:label="loc_QLGNNewEquityCapitalRaise" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_QLGNNewEquityCapitalRaise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertibleNotesPayable" xlink:label="loc_us-gaapConvertibleNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapConvertibleNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfInventoryDetails" xlink:title="00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaapInventoryDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaapInventoryRawMaterials" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryRawMaterials" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaapInventoryWorkInProcess" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryWorkInProcess" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaapInventoryFinishedGoods" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryFinishedGoods" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaapInventoryNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInventoryDisclosureAbstract" xlink:to="loc_us-gaapInventoryNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaapPrepaidInsurance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidInsurance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidManufacturingExpenses" xlink:label="loc_QLGNPrepaidManufacturingExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_QLGNPrepaidManufacturingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrepaidInvestorRelationsExpenses" xlink:label="loc_QLGNPrepaidInvestorRelationsExpenses" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_QLGNPrepaidInvestorRelationsExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaapOtherPrepaidExpenseCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapOtherPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails" xlink:title="00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaapMachineryAndEquipmentMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapMachineryAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ConstructionInProgressEquipmentMember" xlink:label="loc_QLGNConstructionInProgressEquipmentMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNConstructionInProgressEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaapComputerEquipmentMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapComputerEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ToolsDiesAndMoldsMember" xlink:label="loc_us-gaapToolsDiesAndMoldsMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapToolsDiesAndMoldsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_OfficeFurnitureAndEquipmentMember" xlink:label="loc_QLGNOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_QLGNOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative" xlink:title="00000035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaapDepreciation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapDepreciation" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails" xlink:title="00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedCompensation" xlink:label="loc_QLGNAccruedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedVacationCurrent" xlink:label="loc_us-gaapAccruedVacationCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedVacationCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent" xlink:label="loc_us-gaapAccruedRoyaltiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedRoyaltiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedResearchAndDevelopmentCurrent" xlink:label="loc_QLGNAccruedResearchAndDevelopmentCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedResearchAndDevelopmentCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaapAccruedProfessionalFeesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedProfessionalFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedWarrantyCostsCurrent" xlink:label="loc_QLGNAccruedWarrantyCostsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedWarrantyCostsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaapAccruedPayrollTaxesCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedPayrollTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AccruedPatentAndLicenseFeesCurrent" xlink:label="loc_QLGNAccruedPatentAndLicenseFeesCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_QLGNAccruedPatentAndLicenseFeesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent" xlink:label="loc_us-gaapSalesAndExciseTaxPayableCurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapSalesAndExciseTaxPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesCurrent" xlink:label="loc_us-gaapAccruedIncomeTaxesCurrent" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedIncomeTaxesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails" xlink:title="00000037 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CommonStockWarrantsMember" xlink:label="loc_QLGNCommonStockWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCommonStockWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails" xlink:title="00000038 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_FairValueAdjustmentOfWarrant" xlink:label="loc_QLGNFairValueAdjustmentOfWarrant" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_QLGNFairValueAdjustmentOfWarrant" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails" xlink:title="00000039 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="loc_us-gaapMeasurementInputTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_us-gaapMeasurementInputTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="loc_us-gaapMeasurementInputTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeAxis" xlink:to="loc_us-gaapMeasurementInputTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputRiskFreeInterestRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="loc_us-gaapMeasurementInputPriceVolatilityMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputPriceVolatilityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="loc_us-gaapMeasurementInputExpectedTermMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedTermMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="loc_us-gaapMeasurementInputExpectedDividendRateMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMeasurementInputTypeDomain" xlink:to="loc_us-gaapMeasurementInputExpectedDividendRateMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative" xlink:title="00000040 - Disclosure - WARRANT LIABILITIES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureWarrantLiabilitiesAbstract" xlink:label="loc_QLGNDisclosureWarrantLiabilitiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureWarrantLiabilitiesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesCWarrantsMember" xlink:label="loc_QLGNSeriesCWarrantsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNSeriesCWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingTerm" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingTerm" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:label="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfWarrantExercisedOnCashlessBasis" xlink:label="loc_QLGNNumberOfWarrantExercisedOnCashlessBasis" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_QLGNNumberOfWarrantExercisedOnCashlessBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails" xlink:title="00000041 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LongtermOperatingLeaseAgreementMember" xlink:label="loc_QLGNLongtermOperatingLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLongtermOperatingLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_2" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaapOperatingLeasePayments" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeasePayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_2" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityNoncurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityNoncurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaapOperatingLeaseLiabilityCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapOperatingLeaseLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="00000042 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/LeasesDetailsNarrative" xlink:title="00000043 - Disclosure - LEASES (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaapLeasesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeasesAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative" xlink:title="00000044 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_DisclosureResearchAndLicenseAgreementsAbstract" xlink:label="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_QLGNDisclosureResearchAndLicenseAgreementsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseAndSponsoredResearchAgreementsMember" xlink:label="loc_QLGNLicenseAndSponsoredResearchAgreementsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAndSponsoredResearchAgreementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SponsoredResearchAgreementAndLicenseMember" xlink:label="loc_QLGNSponsoredResearchAgreementAndLicenseMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSponsoredResearchAgreementAndLicenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseAgreementMember" xlink:label="loc_QLGNLicenseAgreementMember" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TechnologyTransferAgreementMember" xlink:label="loc_QLGNTechnologyTransferAgreementMember" />
      <link:presentationArc order="590" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNTechnologyTransferAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UniversityOfLouisvilleResearchFoundationMember" xlink:label="loc_QLGNUniversityOfLouisvilleResearchFoundationMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNUniversityOfLouisvilleResearchFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AdvancedCancerTherapeuticsLLCMember" xlink:label="loc_QLGNAdvancedCancerTherapeuticsLLCMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNAdvancedCancerTherapeuticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PredictionBiosciencesSASMember" xlink:label="loc_QLGNPredictionBiosciencesSASMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNPredictionBiosciencesSASMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SekisuiDiagnosticsLLCMember" xlink:label="loc_QLGNSekisuiDiagnosticsLLCMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNSekisuiDiagnosticsLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_YiXinZhenDuanJishuLtdMember" xlink:label="loc_QLGNYiXinZhenDuanJishuLtdMember" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNYiXinZhenDuanJishuLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_STAPharmaceuticalCoLtdMember" xlink:label="loc_QLGNSTAPharmaceuticalCoLtdMember" />
      <link:presentationArc order="600" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_QLGNSTAPharmaceuticalCoLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseOneClinicalTrialMember" xlink:label="loc_QLGNPhaseOneClinicalTrialMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseOneClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseTwoClinicalTrialMember" xlink:label="loc_QLGNPhaseTwoClinicalTrialMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseTwoClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PhaseThreeClinicalTrialMember" xlink:label="loc_QLGNPhaseThreeClinicalTrialMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNPhaseThreeClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtProductOrServiceAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicensedProductSalesMember" xlink:label="loc_QLGNLicensedProductSalesMember" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicensedProductSalesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember" xlink:label="loc_QLGNRoyaltiesAndNonRoyaltySublicenseeIncomeMember" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNRoyaltiesAndNonRoyaltySublicenseeIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CollaborativeResearchRevenueMember" xlink:label="loc_QLGNCollaborativeResearchRevenueMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNCollaborativeResearchRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseRevenueMember" xlink:label="loc_QLGNLicenseRevenueMember" />
      <link:presentationArc order="580" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_QLGNLicenseRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtTitleOfIndividualAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CEMarkMember" xlink:label="loc_QLGNCEMarkMember" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNCEMarkMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfConvertibleDebt" xlink:label="loc_us-gaapRepaymentsOfConvertibleDebt" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRepaymentsOfConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ReimbursementOfResearchExpenses" xlink:label="loc_QLGNReimbursementOfResearchExpenses" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNReimbursementOfResearchExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ReimbursementPatentCost" xlink:label="loc_QLGNReimbursementPatentCost" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNReimbursementPatentCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AgreementTermPaymentDescription" xlink:label="loc_QLGNAgreementTermPaymentDescription" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNAgreementTermPaymentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestonePayment" xlink:label="loc_QLGNMilestonePayment" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNMilestonePayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestonePaymentForMarketingExpenses" xlink:label="loc_QLGNMilestonePaymentForMarketingExpenses" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNMilestonePaymentForMarketingExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShortfallPayments" xlink:label="loc_QLGNShortfallPayments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNShortfallPayments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_LicenseCost" xlink:label="loc_QLGNLicenseCost" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNLicenseCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RegulatoryMarketingApprovalExpenses" xlink:label="loc_QLGNRegulatoryMarketingApprovalExpenses" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNRegulatoryMarketingApprovalExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UpfrontLicenseFee" xlink:label="loc_QLGNUpfrontLicenseFee" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNUpfrontLicenseFee" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_UlrfLicenseAgreementDescription" xlink:label="loc_QLGNUlrfLicenseAgreementDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNUlrfLicenseAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense" xlink:label="loc_us-gaapOtherResearchAndDevelopmentExpense" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapOtherResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_AgreementDescription" xlink:label="loc_QLGNAgreementDescription" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaapProceedsFromConvertibleDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapProceedsFromConvertibleDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_MilestoneMethodRevenueRecognized" xlink:label="loc_QLGNMilestoneMethodRevenueRecognized" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNMilestoneMethodRevenueRecognized" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CumulativeAmount" xlink:label="loc_QLGNCumulativeAmount" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_QLGNCumulativeAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaapDeferredRevenue" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapDeferredRevenue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaapDepositAssets" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapDepositAssets" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfReservedSharesDetails" xlink:title="00000045 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaapScheduleOfStockByClassTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockByClassTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaapClassOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapClassOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfStockByClassTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ExerciseOfOutstandingStockOptionsMember" xlink:label="loc_QLGNExerciseOfOutstandingStockOptionsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNExerciseOfOutstandingStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ExerciseOfOutstandingStockWarrantMember" xlink:label="loc_QLGNExerciseOfOutstandingStockWarrantMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNExerciseOfOutstandingStockWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SerieAlphaPreferredStockMember" xlink:label="loc_QLGNSerieAlphaPreferredStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSerieAlphaPreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesSubscribedButUnissued" xlink:label="loc_us-gaapCommonStockSharesSubscribedButUnissued" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockLineItems" xlink:to="loc_us-gaapCommonStockSharesSubscribedButUnissued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000046 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:label="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:label="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtTitleOfIndividualAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EmployeesAndNonemployeeServiceProviderMember" xlink:label="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNEmployeesAndNonemployeeServiceProviderMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:label="loc_QLGNShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsGranted" xlink:label="loc_QLGNRangeOfExercisePriceOptionsGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsExpired" xlink:label="loc_QLGNRangeOfExercisePriceOptionsExpired" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsExpired" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsForfeited" xlink:label="loc_QLGNRangeOfExercisePriceOptionsForfeited" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsForfeited" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange" xlink:label="loc_QLGNShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_2" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" xlink:label="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceOptionsExercisableVested" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceOptionsNonexercisableNonvested" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNRangeOfExercisePriceOptionsNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:label="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems" xlink:to="loc_QLGNWeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails" xlink:title="00000047 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails" xlink:title="00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails" xlink:title="00000049 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NonCompensatoryWarrantActivityMember" xlink:label="loc_QLGNNonCompensatoryWarrantActivityMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNonCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000050 - Disclosure - STOCKHOLDERS&#8217; EQUITY (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SecuritiesPurchaseAgreementMember" xlink:label="loc_QLGNSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_QLGNSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srtTitleOfIndividualAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtTitleOfIndividualAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualAxis" xlink:to="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SingleInstitutionalInvestorMember" xlink:label="loc_QLGNSingleInstitutionalInvestorMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_QLGNSingleInstitutionalInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestorMember" xlink:label="loc_us-gaapInvestorMember" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtTitleOfIndividualWithRelationshipToEntityDomain" xlink:to="loc_us-gaapInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_PrefundedWarrantsMember" xlink:label="loc_QLGNPrefundedWarrantsMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNPrefundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantsMember" xlink:label="loc_QLGNCompensatoryWarrantsMember" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CompensatoryWarrantActivityMember" xlink:label="loc_QLGNCompensatoryWarrantActivityMember" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNCompensatoryWarrantActivityMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoYearWarrantsMember" xlink:label="loc_QLGNTwoYearWarrantsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNTwoYearWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockOptionsAndWarrantsMember" xlink:label="loc_QLGNStockOptionsAndWarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNStockOptionsAndWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NoncompensatoryEquityClassifiedWarrantsMember" xlink:label="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_2" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_QLGNNoncompensatoryEquityClassifiedWarrantsMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapPlanNameAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwoThousandTwentyStockIncentivePlanMember" xlink:label="loc_QLGNTwoThousandTwentyStockIncentivePlanMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwoThousandTwentyStockIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEquityMethodInvestmentOwnershipPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_StockOptionsSharesFutureGrant" xlink:label="loc_QLGNStockOptionsSharesFutureGrant" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNStockOptionsSharesFutureGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_EquityCapitalRaise" xlink:label="loc_QLGNEquityCapitalRaise" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNEquityCapitalRaise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SharesIssuedUponNetExercises" xlink:label="loc_QLGNSharesIssuedUponNetExercises" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNSharesIssuedUponNetExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_NumberOfSharesWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNNumberOfSharesWarrantsLegacyRitterWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:label="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNWeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceExercisableVested" xlink:label="loc_QLGNRangeOfExercisePriceExercisableVested" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceExercisableVested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_RangeOfExercisePriceNonexercisableNonvested" xlink:label="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNRangeOfExercisePriceNonexercisableNonvested" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:label="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_QLGNClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000051 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_AffiliateCollateralizedSecurityLineItems" xlink:label="loc_srtAffiliateCollateralizedSecurityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtAffiliateCollateralizedSecurityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_SeriesDAndSeriesDOnePreferredStockMember" xlink:label="loc_QLGNSeriesDAndSeriesDOnePreferredStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_QLGNSeriesDAndSeriesDOnePreferredStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaapConversionOfStockSharesConverted1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtAffiliateCollateralizedSecurityLineItems" xlink:to="loc_us-gaapConversionOfStockSharesConverted1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://qualigeninc.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaapSubsequentEventTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaapSubsequentEventLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_TwpThousandTwentyPlanMember" xlink:label="loc_QLGNTwpThousandTwentyPlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_QLGNTwpThousandTwentyPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="qlgn-20210630.xsd#QLGN_CommonStockSharesAvailableForFutureIssuance" xlink:label="loc_QLGNCommonStockSharesAvailableForFutureIssuance" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventLineItems" xlink:to="loc_QLGNCommonStockSharesAvailableForFutureIssuance" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:QLGN="http://qualigeninc.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="qlgn-20210630.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2021-08-12</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_NetProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_NetProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_NetProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_NetProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:NetProductSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SeriesBConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SeriesCConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SeriesDConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SeriesDOneConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDOneConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesAlphaConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">QLGN:GeneralAdministrativeResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_ToolsDiesAndMoldsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">QLGN:PatentsAndLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_PatentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2020-07-012020-07-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="From2020-08-012020-08-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_ConstructionInProgressEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:ConstructionInProgressEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_ConstructionInProgressEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:ConstructionInProgressEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ComputerEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_ToolsDiesAndMoldsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_ToolsDiesAndMoldsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ToolsDiesAndMoldsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_OfficeFurnitureAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">QLGN:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesCWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_LongtermOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LongtermOperatingLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SponsoredResearchAgreementAndLicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseOneClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseTwoClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:PhaseThreeClinicalTrialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_LicensedProductSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicensedProductSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAndSponsoredResearchAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-11-012020-11-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-06-272020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:RoyaltiesAndNonRoyaltySublicenseeIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-27</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-06-262020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:RoyaltiesAndNonRoyaltySublicenseeIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-26</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:UniversityOfLouisvilleResearchFoundationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember_custom_CEMarkMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:CEMarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:AdvancedCancerTherapeuticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:CollaborativeResearchRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:PredictionBiosciencesSASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_SekisuiDiagnosticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_SekisuiDiagnosticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-30_custom_SekisuiDiagnosticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-03-30_custom_SekisuiDiagnosticsLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:SekisuiDiagnosticsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_YiXinZhenDuanJishuLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_LicenseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">QLGN:LicenseRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_TechnologyTransferAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:TechnologyTransferAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:YiXinZhenDuanJishuLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_STAPharmaceuticalCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">QLGN:STAPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_ExerciseOfOutstandingStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:ExerciseOfOutstandingStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_ExerciseOfOutstandingStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:ExerciseOfOutstandingStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_SerieAlphaPreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SerieAlphaPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SingleInstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-09</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-09</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:TwoYearWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="From2020-07-212020-07-22_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-21</startDate>
            <endDate>2020-07-22</endDate>
        </period>
    </context>
    <context id="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SingleInstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-03</startDate>
            <endDate>2020-08-04</endDate>
        </period>
    </context>
    <context id="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:TwoYearWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-04</instant>
        </period>
    </context>
    <context id="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-04</instant>
        </period>
    </context>
    <context id="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:SingleInstitutionalInvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-16</startDate>
            <endDate>2020-12-18</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-18</instant>
        </period>
    </context>
    <context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:TwoYearWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-18</instant>
        </period>
    </context>
    <context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-18</instant>
        </period>
    </context>
    <context id="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-18</instant>
        </period>
    </context>
    <context id="From2021-02-032021-02-04_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:PrefundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">QLGN:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-03</startDate>
            <endDate>2021-02-04</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwoThousandTwentyStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">QLGN:EmployeesAndNonemployeeServiceProviderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_StockOptionsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_StockOptionsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockOptionsAndWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:StockOptionsAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2017-12-31_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2019-12-31_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CompensatoryWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:CompensatoryWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">us-gaap:InvestorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">QLGN:NoncompensatoryEquityClassifiedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">QLGN:NonCompensatoryWarrantActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-05-012020-05-31_custom_SeriesDAndSeriesDOnePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">QLGN:SeriesDAndSeriesDOnePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-09_us-gaap_SubsequentEventMember_custom_TwpThousandTwentyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001460702</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">QLGN:TwpThousandTwentyPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-09</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-06-30">0001460702</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-06-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:NotesPayableCurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0091"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermNotesPayable
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0106"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_LicenseRevenueMember"
      id="xdx2ixbrl0181"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30_custom_LicenseRevenueMember"
      id="xdx2ixbrl0182"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30_custom_LicenseRevenueMember"
      id="xdx2ixbrl0184"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember"
      id="xdx2ixbrl0186"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember"
      id="xdx2ixbrl0187"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember"
      id="xdx2ixbrl0188"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0282"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0284"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0285"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0296"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0297"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0301"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0304"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0307"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0311"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0312"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0314"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0319"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0320"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0322"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0326"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0327"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0328"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0329"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0337"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0497"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0498"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0499"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0500"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0501"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0503"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0506"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0507"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0508"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0509"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0510"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0511"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0513"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0517"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0518"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0519"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0520"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0521"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0535"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0536"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0537"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0543"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0547"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0550"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0551"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0558"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0559"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0560"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0561"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0563"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0569"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0570"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0572"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0605"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0609"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0610"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0611"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0612"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0613"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0614"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0615"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0617"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0620"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0621"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0622"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0623"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0624"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0625"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0627"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0636"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0652"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0664"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0665"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0681"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0682"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0683"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0684"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0685"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0686"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0689"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0694"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0695"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0696"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0697"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0698"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0701"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0702"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0707"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0709"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0710"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0711"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0712"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0713"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0714"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0717"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0722"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0723"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0724"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0725"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0726"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0727"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0730"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0735"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0737"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0738"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0740"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0741"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0742"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0745"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0750"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0751"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0752"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0753"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0754"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0755"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0756"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0758"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0761"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0762"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0763"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0764"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0765"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0766"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0767"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0769"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0772"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0773"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0774"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0775"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0776"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0777"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0780"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0785"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0786"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0787"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0788"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0789"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0790"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0791"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0793"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0796"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0797"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0798"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0799"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0800"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      id="xdx2ixbrl0801"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0802"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0803"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0807"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0808"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0809"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0810"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0811"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      id="xdx2ixbrl0818"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      id="xdx2ixbrl0820"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      id="xdx2ixbrl0822"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      id="xdx2ixbrl0824"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      id="xdx2ixbrl0826"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0901"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0904"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0908"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0943"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfCommonStockForConversionOfAccruedInterest
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0946"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0949"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:IssuanceOfPreferredStockForConversionOfDebt
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0952"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0955"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0958"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:EffectOfReverseRecapitalization
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0961"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:InitialMeasurementOfOperatingLeaseRightofuseAssets
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0964"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NetTransfersToInventoryFromEquipmentHeldForLease
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0968"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_LicenseRevenueMember"
      id="xdx2ixbrl1027"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30_custom_LicenseRevenueMember"
      id="xdx2ixbrl1028"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30_custom_LicenseRevenueMember"
      id="xdx2ixbrl1032"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember"
      id="xdx2ixbrl1034"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember"
      id="xdx2ixbrl1035"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember"
      id="xdx2ixbrl1037"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:AccruedPatentAndLicenseFeesCurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl1247"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1276"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1278"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1288"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1290"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1292"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1294"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1312"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1314"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1320"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1322"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1324"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1326"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1328"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      id="xdx2ixbrl1330"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1346"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1348"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl1354"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl1356"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1734"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1736"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceOptionsExpired
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      id="xdx2ixbrl1738"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1838"
      unitRef="USD"
      xsi:nil="true"/>
    <QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1840"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:NumberOfSharesWarrantsLegacyRitterWarrant
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1842"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1844"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1846"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1848"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1854"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1856"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2019-12-31_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1888"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:NumberOfSharesWarrantsLegacyRitterWarrant
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1896"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1898"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1904"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1906"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1908"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      id="xdx2ixbrl1910"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1980"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1982"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1984"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1986"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1988"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl1990"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2004"
      unitRef="Shares"
      xsi:nil="true"/>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2006"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      id="xdx2ixbrl2008"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-06-30">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-06-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-06-30">Qualigen Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-06-30">001-37428</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-06-30">26-3474527</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-06-30">2042 Corte Del Nogal</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-06-30">Carlsbad</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-06-30">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-06-30">92011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-06-30">760</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-06-30">918-9165</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-06-30">Common Stock, par value $.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-06-30">QLGN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-08-12" decimals="INF" unitRef="Shares">28998831</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">15232402</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">23976570</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">766911</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">615757</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1073335</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">953458</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2033857</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2678894</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">19106505</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">28224679</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">321076</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">430795</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">253261</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">247323</us-gaap:PropertyPlantAndEquipmentNet>
    <QLGN:EquipmentHeldForLeaseNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">5821</QLGN:EquipmentHeldForLeaseNet>
    <QLGN:EquipmentHeldForLeaseNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">17947</QLGN:EquipmentHeldForLeaseNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">183933</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">187694</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">18334</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18334</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">19888930</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">29126772</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">784474</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">500768</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1923708</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">746738</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">131766</us-gaap:NotesPayableCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">325988</us-gaap:DeferredIncomeCurrent>
    <us-gaap:DeferredIncomeCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">486031</us-gaap:DeferredIncomeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">270640</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">254739</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:HedgingLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">4112100</us-gaap:HedgingLiabilitiesCurrent>
    <us-gaap:HedgingLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">8310100</us-gaap:HedgingLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">7416910</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">10430142</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermNotesPayable contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6973</us-gaap:LongTermNotesPayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">98145</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">236826</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">112057</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">158271</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">7627112</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">10832212</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">7000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">7000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">180</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">180</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">180</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">180</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">28902188</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">28902188</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">27296061</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">27296061</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">28902</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">27296</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">88058267</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">85114755</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-75825352</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-66847492</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">12261818</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18294560</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">19888930</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">29126772</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_NetProductSalesMember"
      decimals="0"
      unitRef="USD">1117935</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30_custom_NetProductSalesMember"
      decimals="0"
      unitRef="USD">904067</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_NetProductSalesMember"
      decimals="0"
      unitRef="USD">2538776</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30_custom_NetProductSalesMember"
      decimals="0"
      unitRef="USD">2315823</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_LicenseRevenueMember"
      decimals="0"
      unitRef="USD">478654</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember"
      decimals="0"
      unitRef="USD">45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1117935</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">904067</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3017430</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">2360823</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <QLGN:CostOfProductSales
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">916624</QLGN:CostOfProductSales>
    <QLGN:CostOfProductSales
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">807922</QLGN:CostOfProductSales>
    <QLGN:CostOfProductSales
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">2119103</QLGN:CostOfProductSales>
    <QLGN:CostOfProductSales
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1799574</QLGN:CostOfProductSales>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2952100</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1979614</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">5826038</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">2897993</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">4508466</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">597345</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">8007840</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">835403</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">135543</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">88844</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">272129</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">181106</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">8512733</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">3473725</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">16225110</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5714076</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-7394798</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-2569658</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-13207680</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-3353253</us-gaap:OperatingIncomeLoss>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2075100</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">16201400</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-4198000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">16201400</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">12718</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-57364</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">30061</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-148121</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2352</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">250114</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">2894</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">251272</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2090170</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-16008650</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">4230955</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-16098249</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-5304628</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-18578308</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-8976725</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-19451502</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">605</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">597</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1135</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-22</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-5305233</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-18578905</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-8977860</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-19451480</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.18</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.12</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.31</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-2.71</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">28850451</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">8746250</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">28510014</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">7174233</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">180</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">27296061</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">27296</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">85114755</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-66847492</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18294560</us-gaap:StockholdersEquity>
    <QLGN:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1319625</QLGN:StockIssuedDuringPeriodSharesWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1320</QLGN:StockIssuedDuringPeriodValueWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">243261</QLGN:StockIssuedDuringPeriodValueWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">244581</QLGN:StockIssuedDuringPeriodValueWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">192373</QLGN:StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">192</QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-192</QLGN:StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">25</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">101725</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">101750</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1262123</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1262123</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-3672627</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-3672627</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">180</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">28833059</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">28833</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">86721672</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-70520119</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">16230387</us-gaap:StockholdersEquity>
    <QLGN:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">69129</QLGN:StockIssuedDuringPeriodSharesWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">69</QLGN:StockIssuedDuringPeriodValueWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">49669</QLGN:StockIssuedDuringPeriodValueWarrantsExercised>
    <QLGN:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">49738</QLGN:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1286926</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1286926</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-5305233</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-5305233</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">180</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">28902188</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">28902</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">88058267</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-75825352</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">12261818</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">2412887</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">24129</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">7707736</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">77077</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_custom_SeriesCConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">3300715</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SeriesCConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">33007</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1508305</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15083</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_custom_SeriesDOneConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">643511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_custom_SeriesDOneConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">6435</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5602214</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">56026</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">45153733</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-46428550</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">-1063060</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">7866</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">7866</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-872576</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-03-31"
      decimals="0"
      unitRef="USD">-872576</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">2412887</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">24129</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">7707736</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">77077</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_custom_SeriesCConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">3300715</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_SeriesCConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">33007</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1508305</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">15083</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">643511</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_custom_SeriesDOneConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">6435</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">5602214</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">56026</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">45161599</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-47301126</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">-1927770</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-2412887</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesAConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-24129</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-7707736</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesBConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-77077</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-3300715</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesCConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-33007</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-1508305</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesDConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-15083</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-643511</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesDOneConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-6435</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">-740</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">-1</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">7042660</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7042</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">148690</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1775096</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1775</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1582633</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1584408</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">5010</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">5</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4009995</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">4010000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <QLGN:StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">-2095826</QLGN:StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">-52519</QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">863405</QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization>
    <QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">810886</QLGN:StockIssuedDuringPeriodValueEffectOfReverseRecapitalization>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares
      contextRef="From2020-04-012020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">350</QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">350000</QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable>
    <QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">350000</QLGN:IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1217147</QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1217</QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">1103891</QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement>
    <QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1105108</QLGN:SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">902250</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">902250</us-gaap:AdjustmentsToAdditionalPaidInCapitalMarkToMarket>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">202858</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">202858</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">46967</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">47</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">239953</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">240000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">358625</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">358625</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-18578905</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-18578905</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="INF"
      unitRef="Shares">4620</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_custom_SeriesAlphaConvertiblePreferredStockMember"
      decimals="0"
      unitRef="USD">4</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13588258</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">13588</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">52713683</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-65880031</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">-13152756</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-8977860</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-19451480</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">53736</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">82833</us-gaap:DepreciationDepletionAndAmortization>
    <QLGN:OperatingLeaseRightOfUseAssetAmortization
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">109719</QLGN:OperatingLeaseRightOfUseAssetAmortization>
    <QLGN:OperatingLeaseRightOfUseAssetAmortization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">50318</QLGN:OperatingLeaseRightOfUseAssetAmortization>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3645</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">19951</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:InventoryWriteDown
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">40644</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-2828</us-gaap:InventoryWriteDown>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">2549049</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">366491</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-4198000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">16201400</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">154799</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-798585</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLease
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-89617</QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLease>
    <QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLease
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">20236</QLGN:IncreaseDecreaseInInventoryAndEquipmentHeldForLease>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-746787</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInPrepaidExpensesOther
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1016203</us-gaap:IncreaseDecreaseInPrepaidExpensesOther>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">283706</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">188840</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1176970</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1072220</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
    <QLGN:IncreaseDecreaseInLeaseLiabilities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-122780</QLGN:IncreaseDecreaseInLeaseLiabilities>
    <QLGN:IncreaseDecreaseInLeaseLiabilities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-54775</QLGN:IncreaseDecreaseInLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-206257</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-57668</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-8785057</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-1782080</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">107798</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">110427</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">6893</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">382732</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-114691</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-493159</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4010000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1682661</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">294319</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">138739</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1164000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">155580</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4528661</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-8744168</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">2253422</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">23976570</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">128696</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">15232402</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">2382118</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1683</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">25487</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">2200</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3014</us-gaap:IncomeTaxesPaidNet>
    <QLGN:IssuanceOfCommonStockForProfessionalServices
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">101750</QLGN:IssuanceOfCommonStockForProfessionalServices>
    <QLGN:IssuanceOfCommonStockForProfessionalServices
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">240000</QLGN:IssuanceOfCommonStockForProfessionalServices>
    <us-gaap:DebtConversionOriginalDebtAmount1
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1350198</us-gaap:DebtConversionOriginalDebtAmount1>
    <QLGN:IssuanceOfCommonStockForConversionOfAccruedInterest
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">234210</QLGN:IssuanceOfCommonStockForConversionOfAccruedInterest>
    <QLGN:IssuanceOfCommonStockForConversionOfPreferredStock
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">148690</QLGN:IssuanceOfCommonStockForConversionOfPreferredStock>
    <QLGN:IssuanceOfPreferredStockForConversionOfDebt
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">350000</QLGN:IssuanceOfPreferredStockForConversionOfDebt>
    <QLGN:FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">902250</QLGN:FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement>
    <QLGN:FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">202858</QLGN:FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement>
    <QLGN:EffectOfReverseRecapitalization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">810886</QLGN:EffectOfReverseRecapitalization>
    <QLGN:InitialMeasurementOfOperatingLeaseRightofuseAssets
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">663110</QLGN:InitialMeasurementOfOperatingLeaseRightofuseAssets>
    <QLGN:NetTransfersToInventoryFromEquipmentHeldForLease
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1304</QLGN:NetTransfersToInventoryFromEquipmentHeldForLease>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zzGqGWJYEpF2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
1 &#x2014; &lt;span id="xdx_826_zjrCLcqTrMl"&gt;ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_ecustom--OrganizationPolicyTextBlock_zpwygdJ0lrG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zyZAFSLnlQQ3"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the &#x201c;Company&#x201d;) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (&#x201c;Ritter&#x201d;) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.&#x2019;s capital stock were exchanged for Qualigen Therapeutics,
Inc.&#x2019;s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol &#x201c;RTTR,&#x201d; commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol &#x201c;QLGN&#x201d; on May 26, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Qualigen,
Inc. was determined to be the accounting acquirer in a reverse recapitalization based upon the terms of the merger and other factors.
All references to financial figures of the Company presented in the accompanying condensed consolidated financial statements and in these
Notes through May 22, 2020 are to those of Qualigen, Inc. All references to financial figures after May 22, 2020 are to those of Qualigen
Therapeutics, Inc. and Qualigen, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_845_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zmadOOwyuhVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_za6Kn8G6tyB7"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and the rules of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should
be read in conjunction with the audited financial statements and notes thereto contained in the Company&#x2019;s Transition Report on
Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 31, 2021. In the opinion of management, the accompanying
condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading.
The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other
future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited
financial statements for the most recent fiscal year as reported in the Company&#x2019;s Transition Report on Form 10-K have been omitted.
The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited balance sheet at December
31, 2020 contained in such Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zGTCw7etT4N1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zZUP69kkfxPb"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned
subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable
guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--UseOfEstimates_z0lSKQfjPQt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zTLxBTpfgUJe"&gt;Accounting
Estimates &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation,
write-off of patents and licenses, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and
warranty costs. Actual results could vary from the estimates that were used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBSstpTFtg83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_znxLp2OVmSgc"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company maintains its cash and cash equivalents in bank deposits which at times may exceed federally insured limits. The Company has
not experienced any losses in such accounts and believes it is not exposed to any significant credit risks on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z1J1S9bzyx6d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zxVC5aoFwVPe"&gt;Inventory,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records specific reserves for identified items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13Usu4O9oQ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zr72LivyHt9"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three months and six months periods ended June 30, 2021
and 2020, &lt;span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210101__20210630_zRrhw7o42pv8" title="Long-lived assets impairment losses"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200101__20200630_zDkes1HZANW7" title="Long-lived assets impairment losses"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210401__20210630_zVdcw2M5jRPh" title="Long-lived assets impairment losses"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200401__20200630_zoWZyNNnND6g" title="Long-lived assets impairment losses"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; such impairment losses have been recorded. All long-lived assets of the Company are located in the U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zVpRYEku6J79" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zuyumM9NCDYg"&gt;Accounts
Receivable, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the creditworthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#x2019;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
receivable is comprised of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;784,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;629,630&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,517&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;766,911&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;615,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zZdyffaZrq1i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVtfKVLGbQuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zwc5fojeouqe"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expenses research and development costs as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--ShippingAndHandlingCostsPolicyTextBlock_ztZhHIaeTcDh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z2BqBwkVfmMc"&gt;Shipping
and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $&lt;span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zJGR7OcjBcs2" title="Shipping and handling costs"&gt;28,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630_zRxE5bOpJ6ef"&gt;26,000&lt;/span&gt;, respectively, for the three
months ended June 30, 2021 and 2020, and approximately $&lt;span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630_pp0p0" title="Shipping and handling costs"&gt;58,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630_pp0p0" title="Shipping and handling costs"&gt;56,000&lt;/span&gt;, respectively, for the six months ended June 30, 2021 and
2020. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing expenses
totaled approximately $&lt;span id="xdx_90D_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z8nO35EuYhR4" title="Shipping and handling costs"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zFhWBbNeQGHc"&gt;6,000&lt;/span&gt; for the three months ended June 30. 2021 and 2020, respectively, and approximately $&lt;span id="xdx_90F_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs"&gt;5,000&lt;/span&gt; and
$&lt;span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs"&gt;6,000&lt;/span&gt; for the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zW2BUDsO4TJh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zbSF2phBMy89"&gt;Revenue
from Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
April 1, 2020, the Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i&gt;Revenue from Contracts with Customers
&lt;/i&gt;(&#x201c;ASC 606&#x201d;), using the modified retrospective approach. The adoption of ASC 606 did not have a material impact on the
measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of the adoption date of April
1, 2020. Therefore, no cumulative adjustment has been made to the opening balance of accumulated deficit at April 1, 2020. The comparative
information has not been restated and continues to be reported under the accounting standards in effect for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Product
Sales&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs which are diagnostic tests for PSA, testosterone, thyroid disorders, pregnancy, and Vitamin
D.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#x201c;analyzer&#x201d;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#x201c;FOB&#x201d;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#x2019;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfil the promise to transfer the disposable products and not as a separate performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#x2019;s
contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;License
Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During the three months ended June 30, 2021 and 2020, the Company recognized
license revenue of $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zykC2i3HoA76" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1027"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zHhXBTbPYKo2" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively, and during the six months ended June 30, 2021 and 2020, the Company recognized license revenue
of $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zed2L7Ioq7Bg" title="Revenues"&gt;479,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_z5jehxvl04df" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Collaborative
Research Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to the adoption of ASC 606, the Company recognized research revenue over the term of various agreements, as negotiated contracted amounts
were earned or reimbursable costs were incurred related to those agreements. Negotiated contracted amounts were earned in relative proportion
to the performance required under the applicable contracts. Any amounts received prior to satisfying these revenue recognition criteria
were recorded as deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;To
determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the
entity satisfies the relevant performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Collaborative
research revenue is recognized as research services are performed over the development periods for each agreement. During the three months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zGx3zEhB6eMa" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1034"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zxrpEkq22s" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1035"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively, and during the six months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zlTtTSiS0esc" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_pp0p0" title="Revenues"&gt;45,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Contract
Balances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
timing of the Company&#x2019;s revenue recognition may differ from the timing of payment by the Company&#x2019;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to the adoption of ASC 606 effective April 1, 2020 (using the modified retrospective approach), the Company accounted for its revenue
arrangements under ASC 605, Revenue Recognition (&#x201c;ASC 605&#x201d;). Under ASC 605, revenue arrangements with multiple deliverables
were evaluated for proper accounting treatment. In these arrangements, the Company recorded revenue as separate units of accounting if
the delivered items have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative
to the delivered items, and if delivery or performance of the undelivered items is considered probable and substantially within the Company&#x2019;s
control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
ASC 605, revenues from product sales which included both the analyzer and various immunoassay products (&#x201c;reagents&#x201d;) were
generally recognized upon shipment, as no significant continuing performance obligations remained post shipment. Cash payments received
in advance were classified as deferred revenue and recorded as a liability. The Company was generally not contractually obligated to
accept returns, except for defective products. Revenue was recorded net of an allowance for estimated returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Multiple
element arrangements included contracts that combined both the Company&#x2019;s analyzer and a customer&#x2019;s future reagent purchases
under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was
maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated returns of approximately $&lt;span id="xdx_905_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20210401__20210630_z7NYC0kl3Xm8" title="Estimated returns net of allowances"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90A_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20200401__20200630_za6TsZHWm2Ha"&gt;12,000&lt;/span&gt;, respectively. During the six months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated
returns of approximately $&lt;span id="xdx_901_ecustom--EstimatedReturnsNetOfAllowances_c20210101__20210630_pp0p0" title="Estimated returns net of allowances"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--EstimatedReturnsNetOfAllowances_c20200101__20200630_pp0p0" title="Estimated returns net of allowances"&gt;24,000&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Deferred
Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to the adoption of ASC 606, payments received in advance from customers pursuant to certain collaborative research and license agreements,
deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current
deferred revenue liability based on the time from the balance sheet date to the future date of revenue recognition. The adoption of ASC
606 had no material effect on deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zkwYxQRHfu7f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zhqJeuVqvP43"&gt;Operating
Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company adopted ASC Topic 842, &lt;i&gt;Leases&lt;/i&gt; (&#x201c;Topic 842&#x201d;) in the nine-months transition period ended December 31, 2020.
In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding right-of-use-assets for all
leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for in a manner similar to the
guidance for operating leases prior to the adoption of Topic 842. Refer to Recent Accounting Pronouncements below and Note 8 for
more information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPRki3wNZEde" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zj4qokND7Ib8"&gt;Property
and Equipment, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zgbdMTw9LWNb" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life"&gt;3&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Molds
    and tooling&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zS4L8HTdKZI9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5Rg8dVyuxn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zpmermdSsUy"&gt;Intangible
Assets, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangibles
consist of patent-related costs and costs for in-license agreements. Management reviews the carrying value of intangible assets that
are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment
exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends
and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected
to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MinimumMember_zfs2rfRygQn8" title="Estimated useful lives"&gt;5&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MaximumMember_zzq4DvoKUDMa" title="Estimated useful lives"&gt;17&lt;/span&gt;
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent has been obtained.
Patent and licenses costs are charged to operations if it is determined that the patent will not be obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
carrying value of the patents of approximately $&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;168,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;169,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at June 30, 2021 and December 31, 2020, respectively,
are stated net of accumulated amortization of approximately $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;311,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;303,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2021 and 2020 was approximately $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3v0zQLmdV6"&gt;3,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for each period, and for the six months ended
June 30, 2021 and 2020 was approximately $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;6,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for each period. Total future estimated amortization
of patent costs for the five succeeding years is approximately $&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znkm94YkiKci"&gt;8,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the remaining six months in the year
ending December 31, 2021, approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7shlPclUFP5"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;15,000&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for each of the years ending December 31, 2022
through 2023, approximately $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAEaHE3uqRK3" title="Future estimated amortization for year ending December 31, 2024"&gt;11,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for year 2024, approximately $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjz7njIiVoy" title="Future estimated amortization for year ending December 31, 2025"&gt;11,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for year 2025 and approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2j1ZVeBMoR4" title="Future estimated amortization, Thereafter"&gt;108,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thereafter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
carrying value of the in-licenses of approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value"&gt;19,000&lt;/span&gt; at June 30, 2021 and December 31, 2020 are stated net of accumulated
amortization of approximately $&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization"&gt;403,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization"&gt;400,000&lt;/span&gt;, respectively. Amortization of licenses charged to operations for the three months
ended June 30, 2021 and 2020 was approximately $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8YvYvtaC6Tj" title="Amortization expense"&gt;&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxA8zHH8UQz7" title="Amortization expense"&gt;2,000&lt;/span&gt;&lt;/span&gt;, and for the six months ended June 30, 2021 and 2020 was approximately $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Amortization expense"&gt;4,000&lt;/span&gt; and
$&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdWTl5CE1vvf" title="Amortization expense"&gt;3,000&lt;/span&gt;, respectively. Total future estimated amortization of license costs is approximately $&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zjy5zkQ7KGW" title="Future estimated amortization, remainder of fiscal year"&gt;4,000&lt;/span&gt; for the remaining six months in the
year ending December 31, 2021, approximately $&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2022"&gt;7,000&lt;/span&gt; for the year ending December 31, 2022 and approximately $&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2023"&gt;5,000&lt;/span&gt; for the year ending
December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_zbwmhrCnUZxl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zI47w6nORUMl"&gt;Derivative
Financial Instruments and Warrant Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company
uses either the Black-Scholes option-pricing model or a Monte Carlo simulation to value the derivative instruments at inception and subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is re-assessed at the end of each reporting period (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zFzmkGcDqPof" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zbv4T442pOn8"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 - Inputs that are unobservable. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztpH2j2FsKdg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zS8v1jlo1Eha"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt are carried at cost, which management believes
approximates fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zPt7xnUlRljk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zPl0T18VEjFi"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company-issued
stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation
expense to employees and non-employees determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zHrnRPHbJan3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z2q0zNL63lLl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
The components of the deferred tax asset and liability are individually classified as current and noncurrent based on their characteristics.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_844_ecustom--SalesAndExciseTaxesPolicyTextBlock_zjnO3gcEnz52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zOX37w6oIsXj"&gt;Sales
and Excise Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the balance sheet as cash is collected from customers and remitted to the
tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_849_ecustom--WarrantyCostsPolicyTextBlock_zaRanNxFwzwh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zzOJlFS5EOoe"&gt;Warranty
Costs &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#x2019;s best estimates of analyzer failure rates
and costs to repair.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued
warranty liabilities were approximately $&lt;span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities"&gt;48,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities"&gt;25,000&lt;/span&gt;, respectively, for the periods ended June 30, 2021 and December 31, 2020
and are included in accrued expenses and other current liabilities on the balance sheets. Warranty costs were approximately $&lt;span id="xdx_90E_ecustom--WarrantyCosts_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLArjq1M0zFg" title="Warranty costs"&gt;20,000&lt;/span&gt; and
$&lt;span id="xdx_90C_ecustom--WarrantyCosts_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM9DQPsjm61b"&gt;31,000&lt;/span&gt; for the three months ended June 30, 2021 and 2020, respectively, and approximately $&lt;span id="xdx_906_ecustom--WarrantyCosts_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs"&gt;41,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--WarrantyCosts_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs"&gt;58,000&lt;/span&gt; for the six months ended
June 30, 2021 and 2020, respectively, and are included in cost of product sales in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/&gt;

&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGsIPjhAUcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is calculated by dividing
the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.
Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents
outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, employee stock
purchase plan rights, restricted stock units, and warrants, and convertible preferred stock are considered to be common stock equivalents
but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be anti-dilutive.
The Company incurred net losses for all periods presented and there were no reconciling items for potentially dilutive securities. More
specifically, at June 30, 2021 and 2020, stock options, warrants, and convertible preferred stock exercisable
or convertible for approximately &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20210101__20210630_ztVfLrEYZEGd"&gt;13.9
&lt;/span&gt;million shares and &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20200101__20200630_zCvq2P9SIIMl"&gt;16.5
&lt;/span&gt;million shares, respectively, were excluded from the calculation of diluted net loss per share as their effect would have been
anti-dilutive. Comprehensive loss is the same as net loss for all periods presented.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLVYGecyFne3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zhmEcnMuVYBd"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when
it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses
on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition
of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued
ASU No. 2019-10, Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842),
which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard
will be effective for the Company in the first quarter of the fiscal year beginning January 1, 2023, and early adoption is permitted.
The Company has not completed its review of the impact of this standard on its consolidated financial statements. However, based on the
Company&#x2019;s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard
will have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued ASU No. 2018-13, &#x201c;Fair
Value Measurement (Topic 820): Disclosure Framework &#x2014; Changes to the Disclosure Requirements for Fair Value Measurement,&#x201d;
an amendment to the accounting guidance on fair value measurements. The guidance modifies the disclosure requirements on fair value measurements,
including the removal of disclosures of the amount of and reasons for transfers between Level 1 of the fair value hierarchy, the policy
for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain
disclosure requirements related to Level 3 fair value measurements. The guidance is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019. The Company adopted ASU No. 2018-13 on April 1, 2020 and the adoption of this guidance
did not have a material impact on its financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major
separation models required under prior U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts
to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU
2020-06 is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the
beginning of the Company&#x2019;s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated
financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#x2019;s
condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <QLGN:OrganizationPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_843_ecustom--OrganizationPolicyTextBlock_zpwygdJ0lrG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_865_zyZAFSLnlQQ3"&gt;Organization&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the &#x201c;Company&#x201d;) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (&#x201c;Ritter&#x201d;) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.&#x2019;s capital stock were exchanged for Qualigen Therapeutics,
Inc.&#x2019;s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol &#x201c;RTTR,&#x201d; commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol &#x201c;QLGN&#x201d; on May 26, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Qualigen,
Inc. was determined to be the accounting acquirer in a reverse recapitalization based upon the terms of the merger and other factors.
All references to financial figures of the Company presented in the accompanying condensed consolidated financial statements and in these
Notes through May 22, 2020 are to those of Qualigen, Inc. All references to financial figures after May 22, 2020 are to those of Qualigen
Therapeutics, Inc. and Qualigen, Inc.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:OrganizationPolicyTextBlock>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_845_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zmadOOwyuhVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_za6Kn8G6tyB7"&gt;Basis
of Presentation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and the rules of the Securities and Exchange Commission
(&#x201c;SEC&#x201d;) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should
be read in conjunction with the audited financial statements and notes thereto contained in the Company&#x2019;s Transition Report on
Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 31, 2021. In the opinion of management, the accompanying
condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading.
The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other
future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited
financial statements for the most recent fiscal year as reported in the Company&#x2019;s Transition Report on Form 10-K have been omitted.
The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited balance sheet at December
31, 2020 contained in such Form 10-K.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zGTCw7etT4N1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zZUP69kkfxPb"&gt;Principles
of Consolidation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned
subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable
guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_841_eus-gaap--UseOfEstimates_z0lSKQfjPQt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zTLxBTpfgUJe"&gt;Accounting
Estimates &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation,
write-off of patents and licenses, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and
warranty costs. Actual results could vary from the estimates that were used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBSstpTFtg83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_znxLp2OVmSgc"&gt;Cash
and Cash Equivalents&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company maintains its cash and cash equivalents in bank deposits which at times may exceed federally insured limits. The Company has
not experienced any losses in such accounts and believes it is not exposed to any significant credit risks on cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z1J1S9bzyx6d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zxVC5aoFwVPe"&gt;Inventory,
Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records specific reserves for identified items.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13Usu4O9oQ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_zr72LivyHt9"&gt;Long-Lived
Assets&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three months and six months periods ended June 30, 2021
and 2020, &lt;span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210101__20210630_zRrhw7o42pv8" title="Long-lived assets impairment losses"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200101__20200630_zDkes1HZANW7" title="Long-lived assets impairment losses"&gt;&lt;span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210401__20210630_zVdcw2M5jRPh" title="Long-lived assets impairment losses"&gt;&lt;span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200401__20200630_zoWZyNNnND6g" title="Long-lived assets impairment losses"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; such impairment losses have been recorded. All long-lived assets of the Company are located in the U.S.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zVpRYEku6J79" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_862_zuyumM9NCDYg"&gt;Accounts
Receivable, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the creditworthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#x2019;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
receivable is comprised of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;784,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;629,630&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,517&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;766,911&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;615,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zZdyffaZrq1i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounts
receivable is comprised of the following at:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none"&gt;SCHEDULE
OF ACCOUNTS RECEIVABLE&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Accounts Receivable&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;784,429&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;629,630&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(17,517&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(13,873&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;766,911&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;615,757&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">784429</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AccountsReceivableGrossCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">629630</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">17517</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">13873</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">766911</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">615757</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVtfKVLGbQuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zwc5fojeouqe"&gt;Research
and Development&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company expenses research and development costs as incurred.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <QLGN:ShippingAndHandlingCostsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_ecustom--ShippingAndHandlingCostsPolicyTextBlock_ztZhHIaeTcDh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_z2BqBwkVfmMc"&gt;Shipping
and Handling Costs&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $&lt;span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zJGR7OcjBcs2" title="Shipping and handling costs"&gt;28,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630_zRxE5bOpJ6ef"&gt;26,000&lt;/span&gt;, respectively, for the three
months ended June 30, 2021 and 2020, and approximately $&lt;span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630_pp0p0" title="Shipping and handling costs"&gt;58,000&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630_pp0p0" title="Shipping and handling costs"&gt;56,000&lt;/span&gt;, respectively, for the six months ended June 30, 2021 and
2020. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing expenses
totaled approximately $&lt;span id="xdx_90D_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z8nO35EuYhR4" title="Shipping and handling costs"&gt;4,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zFhWBbNeQGHc"&gt;6,000&lt;/span&gt; for the three months ended June 30. 2021 and 2020, respectively, and approximately $&lt;span id="xdx_90F_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs"&gt;5,000&lt;/span&gt; and
$&lt;span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs"&gt;6,000&lt;/span&gt; for the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ShippingAndHandlingCostsPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">28000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">26000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">58000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">56000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-04-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-04-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember"
      decimals="0"
      unitRef="USD">6000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2021-01-012021-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="From2020-01-012020-06-30_custom_GeneralAdministrativeResearchAndDevelopmentExpensesMember"
      decimals="0"
      unitRef="USD">6000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zW2BUDsO4TJh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zbSF2phBMy89"&gt;Revenue
from Contracts with Customers&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
April 1, 2020, the Company adopted Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, &lt;i&gt;Revenue from Contracts with Customers
&lt;/i&gt;(&#x201c;ASC 606&#x201d;), using the modified retrospective approach. The adoption of ASC 606 did not have a material impact on the
measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of the adoption date of April
1, 2020. Therefore, no cumulative adjustment has been made to the opening balance of accumulated deficit at April 1, 2020. The comparative
information has not been restated and continues to be reported under the accounting standards in effect for the periods presented.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Product
Sales&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs which are diagnostic tests for PSA, testosterone, thyroid disorders, pregnancy, and Vitamin
D.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#x201c;analyzer&#x201d;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#x201c;FOB&#x201d;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#x2019;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfil the promise to transfer the disposable products and not as a separate performance obligation.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#x2019;s
contracts.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;License
Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During the three months ended June 30, 2021 and 2020, the Company recognized
license revenue of $&lt;span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zykC2i3HoA76" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1027"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zHhXBTbPYKo2" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1028"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively, and during the six months ended June 30, 2021 and 2020, the Company recognized license revenue
of $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zed2L7Ioq7Bg" title="Revenues"&gt;479,000&lt;/span&gt; and $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_z5jehxvl04df" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1032"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Collaborative
Research Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to the adoption of ASC 606, the Company recognized research revenue over the term of various agreements, as negotiated contracted amounts
were earned or reimbursable costs were incurred related to those agreements. Negotiated contracted amounts were earned in relative proportion
to the performance required under the applicable contracts. Any amounts received prior to satisfying these revenue recognition criteria
were recorded as deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;To
determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the
entity satisfies the relevant performance obligations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Collaborative
research revenue is recognized as research services are performed over the development periods for each agreement. During the three months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $&lt;span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zGx3zEhB6eMa" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1034"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zxrpEkq22s" title="::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1035"&gt;0&lt;/span&gt;&lt;/span&gt;, respectively, and during the six months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $&lt;span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zlTtTSiS0esc" title="Revenues::XDX::-"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1037"&gt;0&lt;/span&gt;&lt;/span&gt; and $&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_pp0p0" title="Revenues"&gt;45,000&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Contract
Balances&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
timing of the Company&#x2019;s revenue recognition may differ from the timing of payment by the Company&#x2019;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to the adoption of ASC 606 effective April 1, 2020 (using the modified retrospective approach), the Company accounted for its revenue
arrangements under ASC 605, Revenue Recognition (&#x201c;ASC 605&#x201d;). Under ASC 605, revenue arrangements with multiple deliverables
were evaluated for proper accounting treatment. In these arrangements, the Company recorded revenue as separate units of accounting if
the delivered items have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative
to the delivered items, and if delivery or performance of the undelivered items is considered probable and substantially within the Company&#x2019;s
control.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
ASC 605, revenues from product sales which included both the analyzer and various immunoassay products (&#x201c;reagents&#x201d;) were
generally recognized upon shipment, as no significant continuing performance obligations remained post shipment. Cash payments received
in advance were classified as deferred revenue and recorded as a liability. The Company was generally not contractually obligated to
accept returns, except for defective products. Revenue was recorded net of an allowance for estimated returns.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Multiple
element arrangements included contracts that combined both the Company&#x2019;s analyzer and a customer&#x2019;s future reagent purchases
under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was
maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated returns of approximately $&lt;span id="xdx_905_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20210401__20210630_z7NYC0kl3Xm8" title="Estimated returns net of allowances"&gt;0&lt;/span&gt;
and $&lt;span id="xdx_90A_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20200401__20200630_za6TsZHWm2Ha"&gt;12,000&lt;/span&gt;, respectively. During the six months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated
returns of approximately $&lt;span id="xdx_901_ecustom--EstimatedReturnsNetOfAllowances_c20210101__20210630_pp0p0" title="Estimated returns net of allowances"&gt;0&lt;/span&gt; and $&lt;span id="xdx_903_ecustom--EstimatedReturnsNetOfAllowances_c20200101__20200630_pp0p0" title="Estimated returns net of allowances"&gt;24,000&lt;/span&gt; respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="text-decoration: underline"&gt;Deferred
Revenue&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prior
to the adoption of ASC 606, payments received in advance from customers pursuant to certain collaborative research and license agreements,
deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current
deferred revenue liability based on the time from the balance sheet date to the future date of revenue recognition. The adoption of ASC
606 had no material effect on deferred revenue.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_LicenseRevenueMember"
      decimals="-3"
      unitRef="USD">479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember"
      decimals="0"
      unitRef="USD">45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <QLGN:EstimatedReturnsNetOfAllowances
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</QLGN:EstimatedReturnsNetOfAllowances>
    <QLGN:EstimatedReturnsNetOfAllowances
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">12000</QLGN:EstimatedReturnsNetOfAllowances>
    <QLGN:EstimatedReturnsNetOfAllowances
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">0</QLGN:EstimatedReturnsNetOfAllowances>
    <QLGN:EstimatedReturnsNetOfAllowances
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">24000</QLGN:EstimatedReturnsNetOfAllowances>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zkwYxQRHfu7f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zhqJeuVqvP43"&gt;Operating
Leases&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company adopted ASC Topic 842, &lt;i&gt;Leases&lt;/i&gt; (&#x201c;Topic 842&#x201d;) in the nine-months transition period ended December 31, 2020.
In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding right-of-use-assets for all
leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for in a manner similar to the
guidance for operating leases prior to the adoption of Topic 842. Refer to Recent Accounting Pronouncements below and Note 8 for
more information.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPRki3wNZEde" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zj4qokND7Ib8"&gt;Property
and Equipment, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zgbdMTw9LWNb" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life"&gt;3&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Molds
    and tooling&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A8_zS4L8HTdKZI9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zgbdMTw9LWNb" style="display: none"&gt;SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Machinery
    and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Computer
    equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life"&gt;3&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Molds
    and tooling&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Office
    furniture and equipment&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life"&gt;5&lt;/span&gt;
    years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-06-30_us-gaap_MachineryAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-06-30_us-gaap_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-06-30_us-gaap_ToolsDiesAndMoldsMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2021-01-012021-06-30_custom_OfficeFurnitureAndEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5Rg8dVyuxn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zpmermdSsUy"&gt;Intangible
Assets, Net&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Intangibles
consist of patent-related costs and costs for in-license agreements. Management reviews the carrying value of intangible assets that
are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment
exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends
and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;If
the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected
to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally &lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MinimumMember_zfs2rfRygQn8" title="Estimated useful lives"&gt;5&lt;/span&gt; to &lt;span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MaximumMember_zzq4DvoKUDMa" title="Estimated useful lives"&gt;17&lt;/span&gt;
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent has been obtained.
Patent and licenses costs are charged to operations if it is determined that the patent will not be obtained.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
carrying value of the patents of approximately $&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;168,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;169,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;at June 30, 2021 and December 31, 2020, respectively,
are stated net of accumulated amortization of approximately $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;311,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;303,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2021 and 2020 was approximately $&lt;span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3v0zQLmdV6"&gt;3,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for each period, and for the six months ended
June 30, 2021 and 2020 was approximately $&lt;span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;6,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for each period. Total future estimated amortization
of patent costs for the five succeeding years is approximately $&lt;span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znkm94YkiKci"&gt;8,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for the remaining six months in the year
ending December 31, 2021, approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7shlPclUFP5"&gt;&lt;span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0"&gt;15,000&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for each of the years ending December 31, 2022
through 2023, approximately $&lt;span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAEaHE3uqRK3" title="Future estimated amortization for year ending December 31, 2024"&gt;11,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for year 2024, approximately $&lt;span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjz7njIiVoy" title="Future estimated amortization for year ending December 31, 2025"&gt;11,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;for year 2025 and approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2j1ZVeBMoR4" title="Future estimated amortization, Thereafter"&gt;108,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;thereafter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
carrying value of the in-licenses of approximately $&lt;span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value"&gt;19,000&lt;/span&gt; at June 30, 2021 and December 31, 2020 are stated net of accumulated
amortization of approximately $&lt;span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization"&gt;403,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization"&gt;400,000&lt;/span&gt;, respectively. Amortization of licenses charged to operations for the three months
ended June 30, 2021 and 2020 was approximately $&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8YvYvtaC6Tj" title="Amortization expense"&gt;&lt;span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxA8zHH8UQz7" title="Amortization expense"&gt;2,000&lt;/span&gt;&lt;/span&gt;, and for the six months ended June 30, 2021 and 2020 was approximately $&lt;span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Amortization expense"&gt;4,000&lt;/span&gt; and
$&lt;span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdWTl5CE1vvf" title="Amortization expense"&gt;3,000&lt;/span&gt;, respectively. Total future estimated amortization of license costs is approximately $&lt;span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zjy5zkQ7KGW" title="Future estimated amortization, remainder of fiscal year"&gt;4,000&lt;/span&gt; for the remaining six months in the
year ending December 31, 2021, approximately $&lt;span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2022"&gt;7,000&lt;/span&gt; for the year ending December 31, 2022 and approximately $&lt;span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2023"&gt;5,000&lt;/span&gt; for the year ending
December 31, 2023.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IntangibleAssetsFiniteLivedPolicy>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MinimumMember">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="From2021-01-012021-06-30_custom_PatentsAndLicensesMember_srt_MaximumMember">P17Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">168000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">169000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">311000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">303000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-04-012020-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">3000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">6000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">8000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">15000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">15000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">11000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">11000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
      contextRef="AsOf2021-06-30_us-gaap_PatentsMember"
      decimals="0"
      unitRef="USD">108000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">16000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2020-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">19000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">403000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2020-12-31_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-04-012021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-04-012020-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2020-01-012020-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">3000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="AsOf2021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">4000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="AsOf2021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">7000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="AsOf2021-06-30_us-gaap_LicenseMember"
      decimals="0"
      unitRef="USD">5000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_849_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_zbwmhrCnUZxl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86F_zI47w6nORUMl"&gt;Derivative
Financial Instruments and Warrant Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company
uses either the Black-Scholes option-pricing model or a Monte Carlo simulation to value the derivative instruments at inception and subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is re-assessed at the end of each reporting period (see Note 7).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zFzmkGcDqPof" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86C_zbv4T442pOn8"&gt;Fair
Value Measurements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 - Inputs that are unobservable. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztpH2j2FsKdg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86B_zS8v1jlo1Eha"&gt;Fair
Value of Financial Instruments&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt are carried at cost, which management believes
approximates fair value due to the short-term nature of these instruments.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zPt7xnUlRljk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86E_zPl0T18VEjFi"&gt;Stock-Based
Compensation&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company-issued
stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation
expense to employees and non-employees determined at the date of grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CompensationRelatedCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zHrnRPHbJan3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_864_z2q0zNL63lLl"&gt;Income
Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
The components of the deferred tax asset and liability are individually classified as current and noncurrent based on their characteristics.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxPolicyTextBlock>
    <QLGN:SalesAndExciseTaxesPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_ecustom--SalesAndExciseTaxesPolicyTextBlock_zjnO3gcEnz52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_866_zOX37w6oIsXj"&gt;Sales
and Excise Taxes&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the balance sheet as cash is collected from customers and remitted to the
tax authority.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:SalesAndExciseTaxesPolicyTextBlock>
    <QLGN:WarrantyCostsPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_849_ecustom--WarrantyCostsPolicyTextBlock_zaRanNxFwzwh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_868_zzOJlFS5EOoe"&gt;Warranty
Costs &lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#x2019;s best estimates of analyzer failure rates
and costs to repair.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued
warranty liabilities were approximately $&lt;span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities"&gt;48,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities"&gt;25,000&lt;/span&gt;, respectively, for the periods ended June 30, 2021 and December 31, 2020
and are included in accrued expenses and other current liabilities on the balance sheets. Warranty costs were approximately $&lt;span id="xdx_90E_ecustom--WarrantyCosts_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLArjq1M0zFg" title="Warranty costs"&gt;20,000&lt;/span&gt; and
$&lt;span id="xdx_90C_ecustom--WarrantyCosts_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM9DQPsjm61b"&gt;31,000&lt;/span&gt; for the three months ended June 30, 2021 and 2020, respectively, and approximately $&lt;span id="xdx_906_ecustom--WarrantyCosts_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs"&gt;41,000&lt;/span&gt; and $&lt;span id="xdx_904_ecustom--WarrantyCosts_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs"&gt;58,000&lt;/span&gt; for the six months ended
June 30, 2021 and 2020, respectively, and are included in cost of product sales in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/&gt;

</QLGN:WarrantyCostsPolicyTextBlock>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">48000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:AccruedLiabilitiesCurrent>
    <QLGN:WarrantyCosts
      contextRef="From2021-04-012021-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">20000</QLGN:WarrantyCosts>
    <QLGN:WarrantyCosts
      contextRef="From2020-04-012020-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">31000</QLGN:WarrantyCosts>
    <QLGN:WarrantyCosts
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">41000</QLGN:WarrantyCosts>
    <QLGN:WarrantyCosts
      contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">58000</QLGN:WarrantyCosts>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGsIPjhAUcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Basic net loss per share is calculated by dividing
the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.
Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents
outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, employee stock
purchase plan rights, restricted stock units, and warrants, and convertible preferred stock are considered to be common stock equivalents
but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be anti-dilutive.
The Company incurred net losses for all periods presented and there were no reconciling items for potentially dilutive securities. More
specifically, at June 30, 2021 and 2020, stock options, warrants, and convertible preferred stock exercisable
or convertible for approximately &lt;span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20210101__20210630_ztVfLrEYZEGd"&gt;13.9
&lt;/span&gt;million shares and &lt;span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20200101__20200630_zCvq2P9SIIMl"&gt;16.5
&lt;/span&gt;million shares, respectively, were excluded from the calculation of diluted net loss per share as their effect would have been
anti-dilutive. Comprehensive loss is the same as net loss for all periods presented.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-01to2021-06-30"
      decimals="-5"
      unitRef="Shares">13900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-06-30"
      decimals="-5"
      unitRef="Shares">16500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLVYGecyFne3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&lt;span id="xdx_86A_zhmEcnMuVYBd"&gt;Recent
Accounting Pronouncements&lt;/span&gt;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2016, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-13,
Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when
it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses
on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition
of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued
ASU No. 2019-10, Financial Instruments &#x2013; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842),
which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard
will be effective for the Company in the first quarter of the fiscal year beginning January 1, 2023, and early adoption is permitted.
The Company has not completed its review of the impact of this standard on its consolidated financial statements. However, based on the
Company&#x2019;s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard
will have a material effect on the Company&#x2019;s consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;In August 2018, the FASB issued ASU No. 2018-13, &#x201c;Fair
Value Measurement (Topic 820): Disclosure Framework &#x2014; Changes to the Disclosure Requirements for Fair Value Measurement,&#x201d;
an amendment to the accounting guidance on fair value measurements. The guidance modifies the disclosure requirements on fair value measurements,
including the removal of disclosures of the amount of and reasons for transfers between Level 1 of the fair value hierarchy, the policy
for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain
disclosure requirements related to Level 3 fair value measurements. The guidance is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019. The Company adopted ASU No. 2018-13 on April 1, 2020 and the adoption of this guidance
did not have a material impact on its financial statements.&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
August 2020, the FASB issued ASU No. 2020-06, &#x201c;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#x2019;s Own Equity&#x201d; (&#x201c;ASU 2020-06&#x201d;), which simplifies accounting for convertible instruments by removing major
separation models required under prior U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts
to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU
2020-06 is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the
beginning of the Company&#x2019;s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated
financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#x2019;s
condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zoiprZkNN32f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
2 &#x2014; &lt;span id="xdx_82A_zXlWPEpBMtD2"&gt;LIQUIDITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has incurred recurring losses from operations and has an accumulated deficit at June 30, 2021, and the Company expects to continue
to incur losses subsequent to the balance sheet date of June 30, 2021. The Company&#x2019;s reverse recapitalization transaction with
Ritter closed in May 2020 together with an associated new equity capital raise of approximately $&lt;span id="xdx_90A_ecustom--NewEquityCapitalRaise_pn5n6_c20200501__20200531_zqUoCRTS0LA" title="New equity capital raise"&gt;4.0&lt;/span&gt; million, and approximately $&lt;span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20200531_zFCoqLGzMJM1" title="Convertible notes payable"&gt;1.9&lt;/span&gt;
million in convertible notes payable were converted into shares of the Company&#x2019;s capital stock. In July, August and December 2020,
the Company raised an additional $&lt;span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z1vQOJCCNDjj" title="Proceeds from sale of equity"&gt;&lt;span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200801__20200831__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zztW8WkqmUKh" title="Proceeds from sale of equity"&gt;&lt;span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zzYgTIiBjor8" title="Proceeds from sale of equity"&gt;30.0&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; million through three Securities Purchase Agreements with a single institutional investor (see
Note 10). Based on the Company&#x2019;s current cash position, currently planned expenditures and level of operations, the Company
believes it has sufficient capital to fund operations for the 12-month period subsequent to the issuance of the interim financial information.
However, there is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on a continuing basis.
Also, beyond such 12-month period, planned research and development activities, capital expenditures, clinical and pre-clinical testing,
and commercialization activities of the Company&#x2019;s products are expected to require significant additional financing. Additional
financing may not be available on acceptable terms or at all.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <QLGN:NewEquityCapitalRaise
      contextRef="From2020-05-012020-05-31"
      decimals="-5"
      unitRef="USD">4000000.0</QLGN:NewEquityCapitalRaise>
    <us-gaap:ConvertibleNotesPayable contextRef="AsOf2020-05-31" decimals="-5" unitRef="USD">1900000</us-gaap:ConvertibleNotesPayable>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-07-012020-07-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember"
      decimals="-5"
      unitRef="USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-08-012020-08-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember"
      decimals="-5"
      unitRef="USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="From2020-12-012020-12-31_custom_SecuritiesPurchaseAgreementMember_us-gaap_InvestorMember"
      decimals="-5"
      unitRef="USD">30000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_ziy8oKxYjJPf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
3 &#x2014; &lt;span id="xdx_82D_zb0217Ucayll"&gt;INVENTORY, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zweDtfgSxQ6a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory,
net consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zyek1WxxDOR4" style="display: none"&gt;SCHEDULE
OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210630_zddzIVsz88J6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20201231_zqmjVAirAkSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINz4Kh_z5xcwEDCHx25" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;779,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;579,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINz4Kh_zjdyDzKJfQQ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINz4Kh_zYCMrqiKQ5a6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;63,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryNet_iTI_pp0p0_mtINz4Kh_zB9CNfzPsgB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Inventory net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,073,335&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;953,458&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;As of June 30, 2021 and December 31, 2020, total inventory is recorded
net of inventory reserves of $149,000 and $108,000, respectively.&lt;/p&gt;

&lt;p id="xdx_8A6_z5oJsBpY1luf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zweDtfgSxQ6a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Inventory,
net consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_zyek1WxxDOR4" style="display: none"&gt;SCHEDULE
OF INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20210630_zddzIVsz88J6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_491_20201231_zqmjVAirAkSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINz4Kh_z5xcwEDCHx25" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;779,936&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;579,765&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINz4Kh_zjdyDzKJfQQ9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Work in process&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;241,677&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;309,826&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINz4Kh_zYCMrqiKQ5a6" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Finished goods&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;51,722&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;63,867&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--InventoryNet_iTI_pp0p0_mtINz4Kh_zB9CNfzPsgB7" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Inventory net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,073,335&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;953,458&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;As of June 30, 2021 and December 31, 2020, total inventory is recorded
net of inventory reserves of $149,000 and $108,000, respectively.&lt;/p&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">779936</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">579765</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">241677</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">309826</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">51722</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">63867</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1073335</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">953458</us-gaap:InventoryNet>
    <QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80E_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zP6z8batpk9g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
4 &#x2014; &lt;span id="xdx_822_zqEItuj9Liw8"&gt;PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zTrCqblKHtn5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zw9lcaI91hWf" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210630_zTj5DmXdaem2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20201231_zfWuwFIvMfxg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzTBJ_zb3uxuB9si06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;1,916,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;1,307,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidManufacturingExpenses_iI_pp0p0_maPEAOAzTBJ_zsIu2p5Wbkgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,181,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--PrepaidInvestorRelationsExpenses_iI_pp0p0_maPEAOAzTBJ_zsBsOWTQ2nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid investor relations expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzTBJ_zjRQVQOU3ym1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,726&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,001&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzTBJ_zKLqbdsBQmw5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,033,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,678,894&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zzUszgzqVto6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zTrCqblKHtn5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Prepaid
expenses and other current assets consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zw9lcaI91hWf" style="display: none"&gt;SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210630_zTj5DmXdaem2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20201231_zfWuwFIvMfxg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzTBJ_zb3uxuB9si06" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Prepaid insurance&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;1,916,387&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;1,307,864&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--PrepaidManufacturingExpenses_iI_pp0p0_maPEAOAzTBJ_zsIu2p5Wbkgb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Prepaid manufacturing expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,617&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,181,029&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--PrepaidInvestorRelationsExpenses_iI_pp0p0_maPEAOAzTBJ_zsBsOWTQ2nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Prepaid investor relations expenses&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;49,127&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;150,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzTBJ_zjRQVQOU3ym1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Other prepaid expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;18,726&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;40,001&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzTBJ_zKLqbdsBQmw5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,033,857&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,678,894&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1916387</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1307864</us-gaap:PrepaidInsurance>
    <QLGN:PrepaidManufacturingExpenses contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">49617</QLGN:PrepaidManufacturingExpenses>
    <QLGN:PrepaidManufacturingExpenses contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1181029</QLGN:PrepaidManufacturingExpenses>
    <QLGN:PrepaidInvestorRelationsExpenses contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">49127</QLGN:PrepaidInvestorRelationsExpenses>
    <QLGN:PrepaidInvestorRelationsExpenses contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">150000</QLGN:PrepaidInvestorRelationsExpenses>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">18726</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">40001</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2033857</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2678894</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXoWru4FyZyf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
5 &#x2014; &lt;span id="xdx_824_zKY5Ri9mxDb1"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8vn5kLdV2Vj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment, net consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B3_zQPlJkdETztl" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210630_zUN0RR2satU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20201231_zte766wi6Fr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhZDykO8MJs" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;2,409,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;2,401,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_zNNg3LU1HtBc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Construction in progress&#x2013;equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTJvxMrKYNJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;472,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJsUcYOnRNW8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;327,894&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zKCMD3ln1hQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Molds and tooling&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_znB86KyBRn33" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzgSC_z2npNgYtg1Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,707,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,669,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzgSC_zEl0k06NM36j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,454,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,422,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzgSC_zzGX836GFucc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;253,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;247,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zrTNH6DuEFlf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Depreciation
expense relating to property and equipment was approximately $&lt;span id="xdx_90A_eus-gaap--Depreciation_c20210401__20210630_pp0p0" title="Depreciation expense"&gt;17,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--Depreciation_c20200401__20200630_pp0p0" title="Depreciation expense"&gt;9,000&lt;/span&gt; for the three months ended June 30, 2021 and 2020, respectively,
and $&lt;span id="xdx_90F_eus-gaap--Depreciation_c20210101__20210630_pp0p0" title="Depreciation expense"&gt;32,000&lt;/span&gt; and $&lt;span id="xdx_902_eus-gaap--Depreciation_c20200101__20200630_pp0p0" title="Depreciation expense"&gt;18,000&lt;/span&gt; for the six months ended June 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8vn5kLdV2Vj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Property
and equipment, net consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B3_zQPlJkdETztl" style="display: none"&gt;SCHEDULE
OF PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210630_zUN0RR2satU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20201231_zte766wi6Fr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhZDykO8MJs" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Machinery and equipment&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;2,409,946&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;2,401,470&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_zNNg3LU1HtBc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Construction in progress&#x2013;equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;94,717&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;104,400&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTJvxMrKYNJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computer equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;472,094&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;443,865&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJsUcYOnRNW8" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Leasehold improvements&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;327,894&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;321,033&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zKCMD3ln1hQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Molds and tooling&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;260,002&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_znB86KyBRn33" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;143,013&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;138,699&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzgSC_z2npNgYtg1Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,707,666&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,669,469&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzgSC_zEl0k06NM36j" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,454,405&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(3,422,146&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzgSC_zzGX836GFucc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="display: none; font-family: Times New Roman, Times, Serif"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;253,261&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;247,323&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">2409946</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_MachineryAndEquipmentMember"
      decimals="0"
      unitRef="USD">2401470</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_custom_ConstructionInProgressEquipmentMember"
      decimals="0"
      unitRef="USD">94717</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_ConstructionInProgressEquipmentMember"
      decimals="0"
      unitRef="USD">104400</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">472094</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_ComputerEquipmentMember"
      decimals="0"
      unitRef="USD">443865</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">327894</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">321033</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_us-gaap_ToolsDiesAndMoldsMember"
      decimals="0"
      unitRef="USD">260002</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_us-gaap_ToolsDiesAndMoldsMember"
      decimals="0"
      unitRef="USD">260002</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-06-30_custom_OfficeFurnitureAndEquipmentMember"
      decimals="0"
      unitRef="USD">143013</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2020-12-31_custom_OfficeFurnitureAndEquipmentMember"
      decimals="0"
      unitRef="USD">138699</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3707666</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3669469</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3454405</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3422146</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">253261</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">247323</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">17000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">9000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">32000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">18000</us-gaap:Depreciation>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zUZIrEOaPobk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
6 &#x2014; &lt;span id="xdx_827_ziVLcjfC4Ea1"&gt;ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES &lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zknWsIWftFY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued
expenses and other current liabilities consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zeLQwaM7pAPd" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210630_zNqkTzsNOZd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20201231_zi57gCz66qd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedCompensation_iI_pp0p0_maALCz4Fv_zM89Pg3c6Jc1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Board compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;50,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;15,091&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCz4Fv_zXu34xOTSRli" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCz4Fv_zUnW6pFqF934" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCz4Fv_z1a9YqTVYZ1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;744,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCz4Fv_z3BwqWil0ZF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedWarrantyCostsCurrent_iI_pp0p0_maALCz4Fv_z142s1ScbKS6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warranty costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCz4Fv_zdf0hc56hNZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,566&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AccruedPatentAndLicenseFeesCurrent_iI_pp0p0_maALCz4Fv_zVXXmR9dGz24" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Patent and license fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maALCz4Fv_z0MM8Hb8QPr5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Franchise, sales and use taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCz4Fv_zvdb97Z8BTwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCz4Fv_z6U54f6BSU4i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;317,730&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;134,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCz4Fv_zLe38PjFctJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Accrued expenses and
    other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,923,708&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;746,738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zcAuYlfE27Cg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zknWsIWftFY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accrued
expenses and other current liabilities consisted of the following at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zeLQwaM7pAPd" style="display: none"&gt;SCHEDULE
OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49D_20210630_zNqkTzsNOZd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_499_20201231_zi57gCz66qd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40A_ecustom--AccruedCompensation_iI_pp0p0_maALCz4Fv_zM89Pg3c6Jc1" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Board compensation&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;50,776&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;15,091&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCz4Fv_zXu34xOTSRli" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Vacation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;290,587&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;230,457&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCz4Fv_zUnW6pFqF934" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Royalties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,078&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;491&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCz4Fv_z1a9YqTVYZ1a" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Research and development&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;744,640&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;237,504&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCz4Fv_z3BwqWil0ZF9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Professional fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;271,377&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;58,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_ecustom--AccruedWarrantyCostsCurrent_iI_pp0p0_maALCz4Fv_z142s1ScbKS6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Warranty costs&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;47,854&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24,871&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCz4Fv_zdf0hc56hNZi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Payroll&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;176,275&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4,566&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_ecustom--AccruedPatentAndLicenseFeesCurrent_iI_pp0p0_maALCz4Fv_zVXXmR9dGz24" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Patent and license fees&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1247"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,204&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maALCz4Fv_z0MM8Hb8QPr5" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Franchise, sales and use taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;21,130&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30,353&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCz4Fv_zvdb97Z8BTwd" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Income taxes&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,261&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3,326&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCz4Fv_z6U54f6BSU4i" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;317,730&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;134,614&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCz4Fv_zLe38PjFctJg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Accrued expenses and
    other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,923,708&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;746,738&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <QLGN:AccruedCompensation contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">50776</QLGN:AccruedCompensation>
    <QLGN:AccruedCompensation contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15091</QLGN:AccruedCompensation>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">290587</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">230457</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1078</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">491</us-gaap:AccruedRoyaltiesCurrent>
    <QLGN:AccruedResearchAndDevelopmentCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">744640</QLGN:AccruedResearchAndDevelopmentCurrent>
    <QLGN:AccruedResearchAndDevelopmentCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">237504</QLGN:AccruedResearchAndDevelopmentCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">271377</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">58261</us-gaap:AccruedProfessionalFeesCurrent>
    <QLGN:AccruedWarrantyCostsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">47854</QLGN:AccruedWarrantyCostsCurrent>
    <QLGN:AccruedWarrantyCostsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24871</QLGN:AccruedWarrantyCostsCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">176275</us-gaap:AccruedPayrollTaxesCurrent>
    <us-gaap:AccruedPayrollTaxesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">4566</us-gaap:AccruedPayrollTaxesCurrent>
    <QLGN:AccruedPatentAndLicenseFeesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7204</QLGN:AccruedPatentAndLicenseFeesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">21130</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">30353</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2261</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3326</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">317730</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">134614</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1923708</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">746738</us-gaap:AccruedLiabilitiesCurrent>
    <QLGN:WarrantLiabilitiesTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80E_ecustom--WarrantLiabilitiesTextBlock_z6nQsV0augN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
7 &#x2013; &lt;span id="xdx_822_zbIvoxysRFYe"&gt;WARRANT LIABILITIES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#x201c;Series C Warrants&#x201d;). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted. The Series C Warrants were classified as liabilities, but had minimal fair value prior to the merger with Ritter.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase an aggregate of
&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_pdd"&gt;4,713,490
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;shares of the Company&#x2019;s common stock at
$&lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_pdd"&gt;0.72
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share, subject to adjustment. As of June
30, 2021, the warrants received in exchange for the Series C Warrants have remaining terms ranging from &lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MinimumMember_zYLP8QH5cbJ2"&gt;2.4
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;to &lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MaximumMember_zSZGUbFmXjU2"&gt;3.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years. The warrants were determined to be
liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged ratchet provision for
subsequent dilutive issuances.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-HVF_zIBruZ56MXte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants for the six months ended June
30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BF_zkvxIGOm7U5b" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common Stock Warrants (received in exchange for the&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series C Warrants)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;br/&gt; Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zDaxPDbnKUl5" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;3,378,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zStbWShS2lMf" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;0.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zg9vSYTLyv0l" style="text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCvou4jClwBf" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(542,737&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;0.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(36,097&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;0.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1290"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1292"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcbNS4q2OtX" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;2,799,762&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCmR7vjK49T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zkoYGshadwE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;2,799,762&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zfuT5h3k2XGa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zgPYgZcHeZB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zRdhng9g0ri5" title="Weighted Average Remaining Life (Years) Exercisable"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zyjRbB8a89y9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Of
the &lt;span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Shares issued upon the exercise of warrants"&gt;542,737&lt;/span&gt; shares issued upon the exercise of warrants (previously received in exchange for the Series C Warrants) during the six months
ended June 30, 2021, &lt;span id="xdx_90C_ecustom--NumberOfWarrantExercisedOnCashlessBasis_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUTMA63LIrG8" title="Shares issued upon net-exercise of warrants"&gt;156,861&lt;/span&gt; shares were issued upon net-exercises rather than upon exercises for cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants activity for the six months ended
June 30, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C02_gL3SOSENWORTB-HVF_zmp4GprQzn33"&gt;&lt;table cellpadding="0" cellspacing="0" id="xdx_306_133_z9cZFuv8bvj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common Stock Warrants (received in exchange for the&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series C Warrants)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013; Average Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total outstanding &#x2013; December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z55WScidoXii" style="text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1312"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzg5D37vqJx9" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left; padding-left: 10pt"&gt;Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z5F2hAAfkbyg" style="width: 12%; text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger"&gt;4,713,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzYYlcEHss7g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger"&gt;0.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1324"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1330"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCZPSOaRBzk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;4,713,490&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zrQKZTCBhAA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zNRnfOYyDl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;4,713,490&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zXoyCEVmqAse" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zQqW9Rqd8c3a" title="Weighted Average Remaining Life (Years) Exercisable"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_C07_gL3SOSENWORTB-HVF_zlWKVsXUPWPc"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_896_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zci8YKS0KK1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its warrant liabilities (all of which arise under the warrants
received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span id="xdx_8BB_zCeGJCyPl59i" style="display: none"&gt;SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; padding-bottom: 2.5pt"&gt;Balance as of December 31. 2020&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcWsKV4o9Ecg" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ikU4uxxzNa" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeOj9aLw7l81" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231_zTuVPoyBlM0c" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7Mj8rQWaWJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLbedbEb8mnf" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx8I03Rnxbyg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;4,112,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630_zIKu76ZVXgH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;4,112,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zj0RwQwpELYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were no transfers of financial assets or liabilities between category levels for the three and six months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the six months ended June 30, 2021 the Company recorded&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh2rXF5byK3b"&gt;4.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million gain
&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;in other income because the fair value of the
warrant liabilities declined to $&lt;span id="xdx_908_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbs361zMjhj6"&gt;4.1
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million from $&lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvL4sTmvT0Pj"&gt;8.3
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million at December 31, 2020, primarily due to
a reduction in the stock price and to warrant exercises. For the six months ended June 30, 2020, change in fair value of warrant liabilities
was $&lt;span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zssDGYyspVSj"&gt;16.2
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million due to the reverse recapitalization transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zlfJeT57pXwg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of June 30, 2021 and December
31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z8MEEy2aESzg" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December
    31, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zK94R0DS9ZS1" title="Fair value assumptions, measurement input, percentages"&gt;0.34&lt;/span&gt;%
    &#x2014; &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zntNlY0eUaI5" title="Fair value assumptions, measurement input, percentages"&gt;0.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zwKTxpiUH5Yl" title="Fair value assumptions, measurement input, percentages"&gt;0.17&lt;/span&gt;%
    &#x2014; &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zNCCsWNJwP7g" title="Fair value assumptions, measurement input, percentages"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    volatility (peer group)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_za9tyFt3yra7" title="Fair value assumptions, measurement input, percentages"&gt;82.00&lt;/span&gt;
    &#x2014; &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zATWqLnWH8ja" title="Fair value assumptions, measurement input, percentages"&gt;83.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOahHKARziM2" title="Fair value assumptions, measurement input, percentages"&gt;82.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Term
    of warrants (in years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zTGA01eevXn8" title="Fair value assumptions, measurement input, term"&gt;2.41&lt;/span&gt;
    &#x2014; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z7JuTZjNTKIf" title="Fair value assumptions, measurement input, term"&gt;2.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zomSgy8h899d" title="Fair value assumptions, measurement input, term"&gt;2.90&lt;/span&gt;
    &#x2014; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zb0kn7hRmcqc" title="Fair value assumptions, measurement input, term"&gt;3.49&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zwf9yBh3xzkb" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCwGmmUYzigf" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AA_ztiBgY0ZQg81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:WarrantLiabilitiesTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">4713490</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MinimumMember">P2Y4M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-06-30_custom_SeriesCWarrantsMember_srt_MaximumMember">P3Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-HVF_zIBruZ56MXte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants for the six months ended June
30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BF_zkvxIGOm7U5b" style="display: none"&gt;SCHEDULE OF WARRANTS ACTIVITY&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common Stock Warrants (received in exchange for the&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series C Warrants)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Remaining&lt;br/&gt; Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%"&gt;Total outstanding &#x2013; December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zDaxPDbnKUl5" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;3,378,596&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zStbWShS2lMf" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;0.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 10pt"&gt;Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zg9vSYTLyv0l" style="text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1276"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCvou4jClwBf" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1278"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Exercised"&gt;(542,737&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;0.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;(36,097&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;0.72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1288"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1290"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1292"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1294"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcbNS4q2OtX" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;2,799,762&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCmR7vjK49T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zkoYGshadwE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;2,799,762&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zfuT5h3k2XGa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zgPYgZcHeZB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zRdhng9g0ri5" title="Weighted Average Remaining Life (Years) Exercisable"&gt;2.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_133_z9cZFuv8bvj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common Stock Warrants (received in exchange for the&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Series C Warrants)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013; Average Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total outstanding &#x2013; December 31, 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z55WScidoXii" style="text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1312"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzg5D37vqJx9" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1314"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 36%; text-align: left; padding-left: 10pt"&gt;Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z5F2hAAfkbyg" style="width: 12%; text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger"&gt;4,713,490&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzYYlcEHss7g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger"&gt;0.72&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1320"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1322"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1324"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1326"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt"&gt;Granted&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1328"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1330"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Total outstanding &#x2013; June 30, 2020&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCZPSOaRBzk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;4,713,490&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zrQKZTCBhAA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zNRnfOYyDl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;4,713,490&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zXoyCEVmqAse" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable"&gt;0.72&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zQqW9Rqd8c3a" title="Weighted Average Remaining Life (Years) Exercisable"&gt;3.82&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">3378596</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">-542737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">-36097</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">2799762</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">2799762</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">P2Y6M</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">542737</QLGN:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised>
    <QLGN:NumberOfWarrantExercisedOnCashlessBasis
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">156861</QLGN:NumberOfWarrantExercisedOnCashlessBasis>
    <QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="0"
      unitRef="USD">4713490</QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger>
    <QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">4713490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="Shares">4713490</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.72</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember">P3Y9M25D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_896_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zci8YKS0KK1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table presents the Company&#x2019;s fair value hierarchy for its warrant liabilities (all of which arise under the warrants
received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span id="xdx_8BB_zCeGJCyPl59i" style="display: none"&gt;SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Quoted&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Market&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Prices for&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Other&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Significant&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Identical&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Observable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Unobservable&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Assets&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center"&gt;Inputs&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrant liabilities&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 1)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 2)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;(Level 3)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 36%; padding-bottom: 2.5pt"&gt;Balance as of December 31. 2020&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcWsKV4o9Ecg" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1346"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ikU4uxxzNa" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1348"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeOj9aLw7l81" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231_zTuVPoyBlM0c" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"&gt;8,310,100&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance as of June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7Mj8rQWaWJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1354"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLbedbEb8mnf" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1356"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx8I03Rnxbyg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;4,112,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630_zIKu76ZVXgH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"&gt;4,112,100&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2020-01-012020-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">8310100</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2020-01-012020-12-31"
      decimals="0"
      unitRef="USD">8310100</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2021-01-012021-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">4112100</QLGN:FairValueAdjustmentOfWarrant>
    <QLGN:FairValueAdjustmentOfWarrant
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">4112100</QLGN:FairValueAdjustmentOfWarrant>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="-5"
      unitRef="USD">4200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="-5"
      unitRef="USD">4100000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="-5"
      unitRef="USD">8300000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember"
      decimals="-5"
      unitRef="USD">16200000</us-gaap:FairValueAdjustmentOfWarrants>
    <QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_898_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zlfJeT57pXwg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of June 30, 2021 and December
31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_z8MEEy2aESzg" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;June
    30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;December
    31, 2020&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    &lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zK94R0DS9ZS1" title="Fair value assumptions, measurement input, percentages"&gt;0.34&lt;/span&gt;%
    &#x2014; &lt;span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zntNlY0eUaI5" title="Fair value assumptions, measurement input, percentages"&gt;0.46&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zwKTxpiUH5Yl" title="Fair value assumptions, measurement input, percentages"&gt;0.17&lt;/span&gt;%
    &#x2014; &lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zNCCsWNJwP7g" title="Fair value assumptions, measurement input, percentages"&gt;0.22&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    volatility (peer group)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_za9tyFt3yra7" title="Fair value assumptions, measurement input, percentages"&gt;82.00&lt;/span&gt;
    &#x2014; &lt;span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zATWqLnWH8ja" title="Fair value assumptions, measurement input, percentages"&gt;83.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOahHKARziM2" title="Fair value assumptions, measurement input, percentages"&gt;82.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Term
    of warrants (in years)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zTGA01eevXn8" title="Fair value assumptions, measurement input, term"&gt;2.41&lt;/span&gt;
    &#x2014; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z7JuTZjNTKIf" title="Fair value assumptions, measurement input, term"&gt;2.99&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zomSgy8h899d" title="Fair value assumptions, measurement input, term"&gt;2.90&lt;/span&gt;
    &#x2014; &lt;span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zb0kn7hRmcqc" title="Fair value assumptions, measurement input, term"&gt;3.49&lt;/span&gt; &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zwf9yBh3xzkb" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;%&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCwGmmUYzigf" title="Fair value assumptions, measurement input, percentages"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;%&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.34</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.46</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">0.17</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">0.22</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="Pure">82.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-06-30_us-gaap_MeasurementInputPriceVolatilityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="Pure">83.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputPriceVolatilityMember"
      decimals="INF"
      unitRef="Pure">82.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">P2Y4M28D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2021-06-30_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">P2Y11M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MinimumMember">P2Y10M24D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedTermMember_srt_MaximumMember">P3Y5M26D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2021-06-30_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="AsOf2020-12-31_us-gaap_MeasurementInputExpectedDividendRateMember"
      decimals="INF"
      unitRef="Pure">0.00</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:LeasesOfLesseeDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zPErSFj5Pmdd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
8 &#x2014; &lt;span id="xdx_825_zl6DYcI8hvDg"&gt;LEASES&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_zoVpgJ3yxoz7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases its facilities under a long-term operating lease agreement expiring in October 2022. The tables below show the operating
lease right-of-use assets and operating lease liabilities as of December 31, 2020 and June 30, 2021, including the changes during the
periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zxgSC1D22YA5" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease&lt;br/&gt;
 right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Net right-of-use assets at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zB6B7GBLTW6e" style="width: 16%; text-align: right" title="Operating lease right-of-use assets"&gt;430,795&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amortization of operating lease right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9Hs7w4GqnMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets"&gt;(109,719&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease right-of-use assets at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z8EMRGxbC3F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;321,076&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease&lt;br/&gt;
 liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;At December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zVGOAE31lqcf" style="width: 16%; text-align: right" title="Operating lease liabilities"&gt;491,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less principal payments on operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zz2UiEkr3aO1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities"&gt;(122,780&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zgVasBo025h4" style="text-align: right" title="Operating lease liabilities"&gt;368,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z5OgPJ56SJpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion"&gt;(98,145&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Current portion at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_ztDMb9pI3DEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at June 30, 2021"&gt;270,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zrdgvJmWKH7i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, the Company&#x2019;s operating leases have a weighted-average remaining lease term of &lt;span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210630_z2G09xQT506c" title="Weighted-average remaining lease term"&gt;1.3&lt;/span&gt; years and a weighted-average
discount rate of &lt;span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20210630_zd13cRMMm1c6" title="Discount rate operating lease"&gt;8.9&lt;/span&gt;%.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zdtcnbpO4Pt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, future minimum payments during the next five fiscal years and thereafter are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zJZzWsebBMSi" style="display: none"&gt;SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2021 (six months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" style="width: 20%; text-align: right" title="2021 (nine months)"&gt;145,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="2022"&gt;246,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" style="text-align: right" title="Total"&gt;392,608&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20210630_zjgjDCWWcQ73" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less present value discount"&gt;(23,823&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liabilities"&gt;368,785&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_ztPevmm4o3l9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
lease expense was approximately $&lt;span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210401__20210630_zGiPFYxUxCE1" title="Lease expense"&gt;&lt;span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20200401__20200630_zymfjyOG28S" title="Lease expense"&gt;86,000&lt;/span&gt;&lt;/span&gt; for each of the three month periods ended June 30, 2021 and 2020, and approximately $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20210101__20210630_pp0p0" title="Lease expense"&gt;172,000&lt;/span&gt;
and $&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pp0p0" title="Lease expense"&gt;171,000&lt;/span&gt;, respectively, for the six month periods ended June 30, 2021 and 2020. Lease expense was recorded in cost of product sales,
general and administrative expenses, research and development and sales and marketing expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LeasesOfLesseeDisclosureTextBlock>
    <QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_zoVpgJ3yxoz7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company leases its facilities under a long-term operating lease agreement expiring in October 2022. The tables below show the operating
lease right-of-use assets and operating lease liabilities as of December 31, 2020 and June 30, 2021, including the changes during the
periods:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zxgSC1D22YA5" style="display: none"&gt;SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease&lt;br/&gt;
 right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;Net right-of-use assets at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zB6B7GBLTW6e" style="width: 16%; text-align: right" title="Operating lease right-of-use assets"&gt;430,795&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less amortization of operating lease right-of-use assets&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9Hs7w4GqnMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets"&gt;(109,719&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease right-of-use assets at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z8EMRGxbC3F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets"&gt;321,076&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Operating lease&lt;br/&gt;
 liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%"&gt;At December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zVGOAE31lqcf" style="width: 16%; text-align: right" title="Operating lease liabilities"&gt;491,565&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less principal payments on operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zz2UiEkr3aO1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities"&gt;(122,780&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Operating lease liabilities at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zgVasBo025h4" style="text-align: right" title="Operating lease liabilities"&gt;368,785&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less non-current portion&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z5OgPJ56SJpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion"&gt;(98,145&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Current portion at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_ztDMb9pI3DEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at June 30, 2021"&gt;270,640&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">430795</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="From2021-01-012021-06-30_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">109719</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">321076</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">491565</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments
      contextRef="From2021-01-012021-06-30_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">122780</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">368785</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">98145</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="AsOf2021-06-30_custom_LongtermOperatingLeaseAgreementMember"
      decimals="0"
      unitRef="USD">270640</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="AsOf2021-06-30">P1Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="AsOf2021-06-30" decimals="INF" unitRef="Pure">0.089</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zdtcnbpO4Pt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, future minimum payments during the next five fiscal years and thereafter are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BE_zJZzWsebBMSi" style="display: none"&gt;SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Year Ending December 31,&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Amount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;2021 (six months)&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" style="width: 20%; text-align: right" title="2021 (nine months)"&gt;145,958&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="2022"&gt;246,650&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Total&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" style="text-align: right" title="Total"&gt;392,608&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Less present value discount&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20210630_zjgjDCWWcQ73" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less present value discount"&gt;(23,823&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt"&gt;Operating lease liabilities&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liabilities"&gt;368,785&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">145958</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">246650</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">392608</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">23823</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">368785</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">86000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">86000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">172000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">171000</us-gaap:OperatingLeaseExpense>
    <QLGN:ResearchAndLicenseAgreementsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_809_ecustom--ResearchAndLicenseAgreementsTextBlock_z2TONLNY0DLb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
9 &#x2014; &lt;span id="xdx_822_zYKMu8rtYvdb"&gt;RESEARCH AND LICENSE AGREEMENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;The
University of Louisville Research Foundation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville Research
Foundation (&#x201c;ULRF&#x201d;) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements,
the Company will take over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance
of the related intellectual property portfolio. In return, ULRF received a $&lt;span id="xdx_904_eus-gaap--RepaymentsOfConvertibleDebt_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Payment of convertible promissory note"&gt;&lt;span id="xdx_90C_eus-gaap--RepaymentsOfConvertibleDebt_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Payment of convertible promissory note"&gt;50,000&lt;/span&gt;&lt;/span&gt; convertible promissory note in payment of an upfront
license fee, which was subsequently converted into the Company&#x2019;s common stock, and the Company agreed to reimburse ULRF for sponsored
research expenses of up to $&lt;span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement of research expenses"&gt;&lt;span id="xdx_905_ecustom--ReimbursementOfResearchExpenses_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement of research expenses"&gt;805,000&lt;/span&gt;&lt;/span&gt; and prior patent costs of up to $&lt;span id="xdx_908_ecustom--ReimbursementPatentCost_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"&gt;&lt;span id="xdx_900_ecustom--ReimbursementPatentCost_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"&gt;200,000&lt;/span&gt;&lt;/span&gt;. &lt;span id="xdx_907_ecustom--AgreementTermPaymentDescription_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"&gt;&lt;span id="xdx_90E_ecustom--AgreementTermPaymentDescription_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"&gt;In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $&lt;span id="xdx_902_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Milestone payment"&gt;&lt;span id="xdx_90A_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Milestone payment"&gt;100,000&lt;/span&gt;&lt;/span&gt; to $&lt;span id="xdx_900_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"&gt;&lt;span id="xdx_908_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"&gt;5,000,000&lt;/span&gt;&lt;/span&gt;
upon the achievement of certain regulatory and commercial milestones.&lt;/span&gt;&lt;/span&gt; Milestone payments for the first therapeutic indication would be
$&lt;span id="xdx_90C_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"&gt;&lt;span id="xdx_907_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"&gt;100,000&lt;/span&gt;&lt;/span&gt; for first dosing in a Phase 1 clinical trial, $&lt;span id="xdx_905_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"&gt;&lt;span id="xdx_90D_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"&gt;200,000&lt;/span&gt;&lt;/span&gt; for first dosing in a Phase 2 clinical trial, $&lt;span id="xdx_902_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_pp0p0" title="Milestone payment"&gt;&lt;span id="xdx_90A_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_pp0p0" title="Milestone payment"&gt;350,000&lt;/span&gt;&lt;/span&gt; for first dosing
in a Phase 3 clinical trial, $&lt;span id="xdx_90E_ecustom--MilestonePaymentForMarketingExpenses_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Milestone payment for marketing expenses"&gt;&lt;span id="xdx_907_ecustom--MilestonePaymentForMarketingExpenses_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Milestone payment for marketing expenses"&gt;500,000&lt;/span&gt;&lt;/span&gt; for regulatory marketing approval and $5,000,000 upon achieving a cumulative $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"&gt;&lt;span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"&gt;500,000,000&lt;/span&gt;&lt;/span&gt; of Licensed
Product sales; the Company would also pay another $500,000 milestone payment for any additional regulatory marketing approval for each
additional therapeutic (or diagnostic) indication. The Company also must pay ULRF shortfall payments if the total amounts actually paid
with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $&lt;span id="xdx_908_ecustom--ShortfallPayments_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"&gt;&lt;span id="xdx_900_ecustom--ShortfallPayments_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"&gt;10,000&lt;/span&gt;&lt;/span&gt;
to $&lt;span id="xdx_90E_ecustom--ShortfallPayments_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"&gt;&lt;span id="xdx_906_ecustom--ShortfallPayments_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"&gt;50,000&lt;/span&gt;&lt;/span&gt;) for such year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zb0w5Xuo576c" title="Research and development"&gt;89,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zO7gH4LRXena" title="Research and development"&gt;2,000&lt;/span&gt;,
and for the six months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Research and development"&gt;152,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Research and development"&gt;2,000&lt;/span&gt;, respectively, and these amounts are recorded
in research and development expenses in the statements of operations. Minimum annual royalties of $&lt;span id="xdx_907_eus-gaap--RoyaltyExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z0AMNEA51QIc" title="Minimum annual royalties"&gt;&lt;span id="xdx_90E_eus-gaap--RoyaltyExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zmAyy375iv96" title="Minimum annual royalties"&gt;0&lt;/span&gt;&lt;/span&gt; for each period related to these
agreements are included in research and development expenses in the statements of operations for the three months ended June 30, 2021
and 2020, respectively, and approximately $&lt;span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Minimum annual royalties"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_eus-gaap--RoyaltyExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Minimum annual royalties"&gt;10,000&lt;/span&gt; related to these agreements are included in research and development expenses
in the statements of operations for the six months ended June 30, 2021 and 2020, respectively. License costs were approximately $&lt;span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zmIbooK5WE8e" title="License costs"&gt;17,000&lt;/span&gt;
and $&lt;span id="xdx_907_ecustom--LicenseCost_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zpAVwl58omh9" title="License costs"&gt;0&lt;/span&gt; related to these agreements for the three months ended June 30, 2021 and 2020, respectively, and approximately $&lt;span id="xdx_903_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="License costs"&gt;53,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="License costs"&gt;0&lt;/span&gt;
related to these agreements for the six months ended June 30, 2021 and 2020, respectively, and are included in research and development
expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company will reimburse ULRF
for sponsored research expenses of up to $&lt;span id="xdx_909_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zTmRwYcmoSLb" title="Reimbursement of research expenses"&gt;693,000&lt;/span&gt; for this program. In February 2021, the Company extended the term of this agreement
for an additional 18 months (expires July 2022) and increased the amount that the Company will reimburse ULRF for sponsored research
expenses from $&lt;span id="xdx_901_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zAiOMZgsBdNi" title="Reimbursement of research expenses"&gt;693,000&lt;/span&gt; to approximately $&lt;span id="xdx_901_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLhai4x4by2j" title="Reimbursement of research expenses"&gt;1.4&lt;/span&gt; million. In July 2020, the Company entered into an exclusive license agreement with ULRF
for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization
of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $&lt;span id="xdx_903_ecustom--ReimbursementPatentCost_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"&gt;112,000&lt;/span&gt; for an upfront license fee and reimbursement of prior patent costs. &lt;span id="xdx_90A_ecustom--AgreementTermPaymentDescription_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"&gt;In addition, the Company has agreed to pay
ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000)
or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not
covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first
two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and
30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated
with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging
from $&lt;span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_zMxcihhstK06" title="Milestone payment"&gt;50,000&lt;/span&gt; to $&lt;span id="xdx_90A_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"&gt;5,000,000&lt;/span&gt; upon the achievement of certain regulatory and commercial milestones.&lt;/span&gt; Milestone payments for the first therapeutic
indication would be $&lt;span id="xdx_902_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"&gt;50,000&lt;/span&gt; for first dosing in a Phase 1 clinical trial, $&lt;span id="xdx_904_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"&gt;100,000&lt;/span&gt; for first dosing in a Phase 2 clinical trial, $&lt;span id="xdx_902_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zQHNLJQd862f" title="Milestone payment"&gt;150,000&lt;/span&gt;
for first dosing in a Phase 3 clinical trial, $&lt;span id="xdx_907_ecustom--RegulatoryMarketingApprovalExpenses_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Regulatory marketing approval, expenses"&gt;300,000&lt;/span&gt; for regulatory marketing approval and $&lt;span id="xdx_90C_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember_zbHNEPKe4Etg" title="Regulatory marketing approval, expenses"&gt;5,000,000&lt;/span&gt; upon achieving a cumulative $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"&gt;500,000,000&lt;/span&gt;
of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties
and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $&lt;span id="xdx_90A_ecustom--UpfrontLicenseFee_c20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Upfront license fee"&gt;20,000&lt;/span&gt; to $&lt;span id="xdx_908_ecustom--UpfrontLicenseFee_c20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Upfront license fee"&gt;100,000&lt;/span&gt;) for such
year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zRMOPwfKB9J3" title="Research and development"&gt;99,000&lt;/span&gt; and $&lt;span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z2o9hA2osK7l"&gt;139,000&lt;/span&gt;,
respectively, and for the six months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Research and development"&gt;206,000&lt;/span&gt; and $&lt;span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Research and development"&gt;247,000&lt;/span&gt;, respectively, and are recorded
in research and development expenses in the statements of operations. License costs related to these agreements for the three months
ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zlM5wazLFpze" title="License costs"&gt;0&lt;/span&gt; and $&lt;span id="xdx_908_ecustom--LicenseCost_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zsN5aApOJoc5" title="License costs"&gt;0&lt;/span&gt;, respectively, and for the six months ended June 30, 2021 and 2020 were approximately
$&lt;span id="xdx_904_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="License costs"&gt;40,000&lt;/span&gt; and $&lt;span id="xdx_906_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="License costs"&gt;0&lt;/span&gt;, respectively, and are included in research and development expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company will take over development, regulatory approval and commercialization of the
compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF
received approximately $&lt;span id="xdx_90B_ecustom--UpfrontLicenseFee_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Upfront license fee"&gt;24,000&lt;/span&gt; for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required
to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $&lt;span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20200601__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Research and development"&gt;250,000&lt;/span&gt;. In November
2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$&lt;span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Research and development"&gt;430,000&lt;/span&gt; in research which satisfied this requirement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--UlrfLicenseAgreementDescription_c20200601__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="ULRF license agreement description"&gt;In
addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165
as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $&lt;span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_zaVxo99JS9k5" title="Milestone payment"&gt;50,000&lt;/span&gt; to $&lt;span id="xdx_902_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_zmeLZ2N0rXjb" title="Milestone payment"&gt;5,000,000&lt;/span&gt; upon the achievement of certain
regulatory and commercial milestones.&lt;/span&gt; Milestone payments would be $&lt;span id="xdx_907_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zx67h8sqwUq8" title="Milestone payment"&gt;50,000&lt;/span&gt; for first dosing in a Phase 1 clinical trial, $&lt;span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zDduFHD1wgbl" title="Milestone payment"&gt;100,000&lt;/span&gt; for
first dosing in a Phase 2 clinical trial, $&lt;span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zMeZ5djxENh3" title="Milestone payment"&gt;150,000&lt;/span&gt; for first dosing in a Phase 3 clinical trial, $&lt;span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGhk9qPoZRy4" title="Regulatory marketing approval, expenses"&gt;300,000&lt;/span&gt; for regulatory marketing approval
and $&lt;span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember_zmcRsoIJtlJc" title="Regulatory marketing approval, expenses"&gt;5,000,000&lt;/span&gt; upon achieving a cumulative $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXQhklepvuTa" title="Licensed product sales, revenue"&gt;500,000,000&lt;/span&gt; of Licensed Product sales. The Company also must pay ULRF shortfall payments
if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable
annual minimum (ranging from $&lt;span id="xdx_906_ecustom--ShortfallPayments_c20200627__20200630__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--RoyaltiesAndNonRoyaltySublicenseeIncomeMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"&gt;5,000&lt;/span&gt; to $&lt;span id="xdx_907_ecustom--ShortfallPayments_c20200626__20200630__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--RoyaltiesAndNonRoyaltySublicenseeIncomeMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"&gt;50,000&lt;/span&gt;) for such year.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zx5DlN0F2SG4" title="Sponsored research expense"&gt;25,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQ8Acwmi7Gh2"&gt;0&lt;/span&gt;, respectively,
and for the six months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_908_eus-gaap--OtherResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Sponsored research expense"&gt;94,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Sponsored research expense"&gt;0&lt;/span&gt;, respectively, and are recorded in research and
development expenses in the statements of operations. License costs related to these agreements for the three months ended June 30, 2021
and 2020 were approximately $&lt;span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zisYcJSjJYjd" title="License costs"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zepdM0Sfq5B1" title="Sponsored research expense"&gt;0&lt;/span&gt;, respectively, and for the six months ended June 30, 2021 and 2020 were approximately
$&lt;span id="xdx_906_ecustom--LicenseCost_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zHEQM2T52lqf" title="Sponsored research expense"&gt;16,000&lt;/span&gt; and $&lt;span id="xdx_900_ecustom--LicenseCost_pp0p0_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zgMqeQ8fymYd" title="Sponsored research expense"&gt;0&lt;/span&gt;, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Advanced
Cancer Therapeutics&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
December 2018, &lt;span id="xdx_906_ecustom--AgreementDescription_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember" title="Agreement description"&gt;the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#x201c;ACT&#x201d;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $&lt;span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Proceeds from convertible promissory note"&gt;25,000&lt;/span&gt; convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#x2019;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000)&lt;/span&gt;,
until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $&lt;span id="xdx_90E_ecustom--MilestoneMethodRevenueRecognized_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Milestone payment"&gt;100,000&lt;/span&gt; for the Company raising a cumulative
total of $&lt;span id="xdx_904_ecustom--CumulativeAmount_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Cumulative amount"&gt;2,000,000&lt;/span&gt; in new equity financing after the date of the ACT license agreement, $&lt;span id="xdx_907_ecustom--MilestoneMethodRevenueRecognized_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember__srt--TitleOfIndividualAxis__custom--CEMarkMember_pp0p0" title="Milestone payment"&gt;100,000&lt;/span&gt; upon any first QN-165-based licensed
product receiving the CE Mark or similar FDA status, and $&lt;span id="xdx_905_ecustom--CumulativeAmount_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember__srt--TitleOfIndividualAxis__custom--CEMarkMember_pp0p0" title="Cumulative amount"&gt;500,000&lt;/span&gt; upon cumulative worldwide QN-165-based licensed product net sales reaching
$&lt;span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Licensed product sales, revenue"&gt;3,000,000&lt;/span&gt;. For the three months ended June 30, 2021 and 2020, there were &lt;span id="xdx_902_ecustom--LicenseCost_pp0p0_do_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zg9CsN29iKeb" title="License costs"&gt;&lt;span id="xdx_90D_ecustom--LicenseCost_pp0p0_do_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zNFXdk20sTo7"&gt;no&lt;/span&gt;&lt;/span&gt; license costs and for the six months ended June 30, 2021
and 2020, there were approximately $&lt;span id="xdx_90B_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="License costs"&gt;2,000&lt;/span&gt; and $&lt;span id="xdx_905_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="License costs"&gt;0&lt;/span&gt;, respectively, in license costs related to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Prediction
Biosciences&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture
diagnostic tests for use in the stroke point-of-care market. The Company recognizes development revenue and product sales over the performance
period of the contract. For the three months ended June 30, 2021 and 2020 there was $&lt;span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_zfbLNyPJsNG5" title="Product sales"&gt;&lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_zf0cDJ875f29"&gt;0&lt;/span&gt;&lt;/span&gt; for each period, and for the six months ended
June 30, 2021 and 2020, there was $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_pp0p0" title="Product sales"&gt;0&lt;/span&gt; and $&lt;span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_pp0p0" title="Product sales"&gt;45,000&lt;/span&gt;, respectively, in collaborative research revenue related to this agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Sekisui
Diagnostics&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the year ended March 31, 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui Diagnostics, LLC (&#x201c;Sekisui&#x201d;)
until May 2022. The Company appointed Sekisui as its diagnostics commercial partner and exclusive worldwide distributor with the exception
of certain customer accounts retained by Qualigen. The agreement contains a right of first refusal for Sekisui against any potential
acquisition of the Company until May 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were product sales to Sekisui of approximately $&lt;span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zuAfQmi6xC55" title="Product sales"&gt;701,000&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20200630__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zzH2MZnlYtFg"&gt;420,000&lt;/span&gt; for the three months ended June 30, 2021 and 2020, and product sales
of approximately $&lt;span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20210330__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zbjLj90fGz7e" title="Product sales"&gt;1.7&lt;/span&gt; million and $&lt;span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20200101__20200330__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zTlELjhDgs6e" title="Product sales"&gt;1.4&lt;/span&gt; million related to this agreement, for the six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Yi
Xin&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
October 2020, the Company entered into a Technology Transfer Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#x201c;Yi Xin&#x201d;),
of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on the Company&#x2019;s
core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to manufacture and sell the Company&#x2019;s
current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Under
the Technology Transfer Agreement, the Company received net cash payments of $&lt;span id="xdx_908_eus-gaap--DeferredRevenue_c20201231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Deferred revenue"&gt;250,000&lt;/span&gt; in the final quarter of the year ended December
31, 2020, classified as deferred revenue on the December 31, 2020 balance sheet, and a cash payment of $&lt;span id="xdx_900_eus-gaap--DeferredRevenue_c20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Deferred revenue"&gt;420,000&lt;/span&gt; during the first quarter
of 2021. The Company will also receive low- to mid-single-digit royalties on any future new-generations and current-generations product
sales by Yi Xin. Of these amounts, the Company recognized approximately $&lt;span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Product sales"&gt;38,000&lt;/span&gt; in product sales and $&lt;span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zIlApYx4eqLg" title="Product sales"&gt;479,000&lt;/span&gt; in license revenue included
in the statement of operations for the six months ended June 30, 2021. On the balance sheet at June 30, 2021, the Company had
deferred revenue of approximately $&lt;span id="xdx_90C_eus-gaap--DeferredRevenue_iI_c20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember__us-gaap--TypeOfArrangementAxis__custom--TechnologyTransferAgreementMember_zGuslToQocme" title="Deferred revenue"&gt;153,000&lt;/span&gt; related to this agreement. The Company provided technology transfer and patent/know-how
license rights to facilitate Yi Xin&#x2019;s development and commercialization.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company gave Yi Xin the exclusive rights for China &#x2013; which is a market the Company has not otherwise entered &#x2013; both for Yi
Xin&#x2019;s new generations of FastPack-based products and for Yi Xin-manufactured versions of the Company&#x2019;s existing FastPack
product lines. Yi Xin will also have the right to sell its new generations of FastPack-based diagnostic test systems throughout the world
(but not to or toward current customers of the Company&#x2019;s existing generations of FastPack products); any such non-China sales would,
until Spring&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022,
need to be through Sekisui. In addition, after Spring 2022, Yi Xin will have the right to sell Yi Xin-manufactured versions of existing
FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US customers
of those products). Also, after Spring&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022,
Yi Xin will have the right to buy Company-manufactured FastPack 1.0, IP and PRO products from the Company at distributor prices for resale
in and for the United States (but not to or toward current US customers of those products); the Company did not license Yi Xin to sell
in the United States market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines, even after Spring
&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022. In the Technology Transfer Agreement, the
Company confirmed that it would not, after Spring&lt;/span&gt; &lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2022,
seek new FastPack customers outside the United States.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;STA
Pharmaceutical&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, the Company&#x2019;s lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials
in 2021. In connection with this agreement, the Company paid an upfront deposit of approximately $&lt;span id="xdx_902_eus-gaap--DepositAssets_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zkKoViqNtT7j" title="Upfront deposit"&gt;1.1&lt;/span&gt; million which was classified as
prepaid expenses on the December 31, 2020 balance sheet date, and all of which was included in research and development expenses in the
statement of operations for the six months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Research
and development expenses related to this agreement for the three months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210401__20210630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zFZog1FdfL0k" title="Research and development"&gt;1.9&lt;/span&gt; million
and $&lt;span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200401__20200630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zE2xTb2IEZL3"&gt;0&lt;/span&gt;, respectively, and for the six months ended June 30, 2021 and 2020 were approximately $&lt;span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20210630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_znYKqu7syUGd"&gt;3.1&lt;/span&gt; million and $&lt;span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200101__20200630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zLN83j6BoaRi"&gt;0&lt;/span&gt;, respectively, and are
recorded in research and development expenses in the statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</QLGN:ResearchAndLicenseAgreementsTextBlock>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">50000</us-gaap:RepaymentsOfConvertibleDebt>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">805000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">805000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementPatentCost
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">200000</QLGN:ReimbursementPatentCost>
    <QLGN:ReimbursementPatentCost
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">200000</QLGN:ReimbursementPatentCost>
    <QLGN:AgreementTermPaymentDescription contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones.</QLGN:AgreementTermPaymentDescription>
    <QLGN:AgreementTermPaymentDescription contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember">In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones.</QLGN:AgreementTermPaymentDescription>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember"
      decimals="0"
      unitRef="USD">200000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember"
      decimals="0"
      unitRef="USD">200000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      unitRef="USD">350000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      unitRef="USD">350000</QLGN:MilestonePayment>
    <QLGN:MilestonePaymentForMarketingExpenses
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000</QLGN:MilestonePaymentForMarketingExpenses>
    <QLGN:MilestonePaymentForMarketingExpenses
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000</QLGN:MilestonePaymentForMarketingExpenses>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:ShortfallPayments
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">10000</QLGN:ShortfallPayments>
    <QLGN:ShortfallPayments
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">10000</QLGN:ShortfallPayments>
    <QLGN:ShortfallPayments
      contextRef="From2018-06-012018-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000</QLGN:ShortfallPayments>
    <QLGN:ShortfallPayments
      contextRef="From2020-09-012020-09-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000</QLGN:ShortfallPayments>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">89000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">152000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">2000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">10000</us-gaap:RoyaltyExpense>
    <QLGN:LicenseCost
      contextRef="From2021-04-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">17000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-04-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">53000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-01-012020-06-30_custom_SponsoredResearchAgreementAndLicenseMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">693000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">693000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementOfResearchExpenses
      contextRef="From2019-03-012019-03-31_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="-5"
      unitRef="USD">1400000</QLGN:ReimbursementOfResearchExpenses>
    <QLGN:ReimbursementPatentCost
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">112000</QLGN:ReimbursementPatentCost>
    <QLGN:AgreementTermPaymentDescription contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember">In addition, the Company has agreed to pay
ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000)
or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not
covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first
two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and
30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated
with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging
from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.</QLGN:AgreementTermPaymentDescription>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember"
      decimals="0"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      unitRef="USD">150000</QLGN:MilestonePayment>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">300000</QLGN:RegulatoryMarketingApprovalExpenses>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_LicensedProductSalesMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:RegulatoryMarketingApprovalExpenses>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">20000</QLGN:UpfrontLicenseFee>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2019-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">100000</QLGN:UpfrontLicenseFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">99000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">139000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">206000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">247000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2021-04-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-04-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">40000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-01-012020-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:UpfrontLicenseFee
      contextRef="AsOf2020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">24000</QLGN:UpfrontLicenseFee>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-11-012020-11-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">430000</us-gaap:ResearchAndDevelopmentExpense>
    <QLGN:UlrfLicenseAgreementDescription contextRef="From2020-06-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember">In
addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165
as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain
regulatory and commercial milestones.</QLGN:UlrfLicenseAgreementDescription>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseOneClinicalTrialMember"
      decimals="0"
      unitRef="USD">50000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseTwoClinicalTrialMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestonePayment>
    <QLGN:MilestonePayment
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_PhaseThreeClinicalTrialMember"
      decimals="0"
      unitRef="USD">150000</QLGN:MilestonePayment>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">300000</QLGN:RegulatoryMarketingApprovalExpenses>
    <QLGN:RegulatoryMarketingApprovalExpenses
      contextRef="From2019-06-012019-06-30_custom_LicenseAndSponsoredResearchAgreementsMember_custom_UniversityOfLouisvilleResearchFoundationMember_custom_LicensedProductSalesMember"
      decimals="0"
      unitRef="USD">5000000</QLGN:RegulatoryMarketingApprovalExpenses>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2019-06-012019-06-30_custom_SponsoredResearchAgreementAndLicenseMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">500000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:ShortfallPayments
      contextRef="From2020-06-272020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MinimumMember"
      decimals="0"
      unitRef="USD">5000</QLGN:ShortfallPayments>
    <QLGN:ShortfallPayments
      contextRef="From2020-06-262020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MaximumMember"
      decimals="0"
      unitRef="USD">50000</QLGN:ShortfallPayments>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">94000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">16000</QLGN:LicenseCost>
    <us-gaap:OtherResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherResearchAndDevelopmentExpense>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">16000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_UniversityOfLouisvilleResearchFoundationMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:AgreementDescription contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#x201c;ACT&#x201d;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $25,000 convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#x2019;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000)</QLGN:AgreementDescription>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">25000</us-gaap:ProceedsFromConvertibleDebt>
    <QLGN:MilestoneMethodRevenueRecognized
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestoneMethodRevenueRecognized>
    <QLGN:CumulativeAmount
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">2000000</QLGN:CumulativeAmount>
    <QLGN:MilestoneMethodRevenueRecognized
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember_custom_CEMarkMember"
      decimals="0"
      unitRef="USD">100000</QLGN:MilestoneMethodRevenueRecognized>
    <QLGN:CumulativeAmount
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember_custom_CEMarkMember"
      decimals="0"
      unitRef="USD">500000</QLGN:CumulativeAmount>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="From2018-12-012018-12-31_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">3000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <QLGN:LicenseCost
      contextRef="From2021-04-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-04-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2021-01-012021-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">2000</QLGN:LicenseCost>
    <QLGN:LicenseCost
      contextRef="From2020-01-012020-06-30_custom_LicenseAgreementMember_custom_AdvancedCancerTherapeuticsLLCMember"
      decimals="0"
      unitRef="USD">0</QLGN:LicenseCost>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember"
      decimals="0"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_CollaborativeResearchRevenueMember_custom_PredictionBiosciencesSASMember"
      decimals="0"
      unitRef="USD">45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-04-012021-06-30_custom_SekisuiDiagnosticsLLCMember"
      decimals="0"
      unitRef="USD">701000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-04-012020-06-30_custom_SekisuiDiagnosticsLLCMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-30_custom_SekisuiDiagnosticsLLCMember"
      decimals="-5"
      unitRef="USD">1700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2020-01-012020-03-30_custom_SekisuiDiagnosticsLLCMember"
      decimals="-5"
      unitRef="USD">1400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2020-12-31_custom_YiXinZhenDuanJishuLtdMember"
      decimals="0"
      unitRef="USD">250000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember"
      decimals="0"
      unitRef="USD">38000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_LicenseRevenueMember"
      decimals="0"
      unitRef="USD">479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="AsOf2021-06-30_custom_YiXinZhenDuanJishuLtdMember_custom_TechnologyTransferAgreementMember"
      decimals="0"
      unitRef="USD">153000</us-gaap:DeferredRevenue>
    <us-gaap:DepositAssets
      contextRef="AsOf2020-12-31_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">1100000</us-gaap:DepositAssets>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">1900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-06-30_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">3100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30_custom_STAPharmaceuticalCoLtdMember"
      decimals="-5"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zr30Mvgz6Y4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
10 &#x2014; &lt;span id="xdx_822_z9AtyuwoVjm"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021 and December 31, 2020, the Company had two classes of capital stock: common stock and Series Alpha convertible preferred
stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Common
Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, as
of June 30, 2021 any remaining assets would be distributed ratably among the holders of the common stock and, on an as-if-converted basis,
the holders of Series Alpha convertible preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The
holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_ecustom--ScheduleOfReservedSharesTableTextBlock_zUhHeLMgL6ik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
June 30, 2021, the Company has reserved &lt;span id="xdx_903_eus-gaap--CommonStockSharesSubscribedButUnissued_c20210630_pdd" title="Shares of authorized but unissued common stock"&gt;13,917,461&lt;/span&gt; shares of authorized but unissued common stock for possible future issuance. At June
30, 2021, shares were reserved in connection with the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zhSYbgOdMeNk" style="display: none"&gt;SCHEDULE
OF RESERVED SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Exercise of outstanding stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockOptionsMember_zo3DUyEoEGa1" style="width: 20%; text-align: right" title="Total"&gt;4,133,856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise of outstanding stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockWarrantMember_zkXGif7XmMEi" style="text-align: right"&gt;9,540,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Conversion of outstanding Series Alpha preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--SerieAlphaPreferredStockMember_z5vjFpOt7Nbj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,418&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630_zNi6r5qjfPCb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,917,461&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zknFm4gi0Wpe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Series
Alpha Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
the six-month period ended June 30, 2021, no shares of Series Alpha convertible preferred stock were converted into shares of the Company&#x2019;s
common stock, and there were &lt;span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20210630_zasxxUu8l1P6" title="Preferred stock, shares outstanding"&gt;180&lt;/span&gt; shares of Series Alpha preferred stock outstanding at June 30, 2021 and December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Alpha
Securities Purchase Agreements&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 10, 2020, the Company closed a Securities Purchase Agreement (dated July 8, 2020) with a single institutional investor for the purchase
and sale for $&lt;span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200709__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_z2z2McRF0pL7" title="Sale of stock"&gt;8.0&lt;/span&gt; million for (i) &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200709__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock"&gt;1,140,570&lt;/span&gt; shares of Company common stock, (ii) &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of stock warrants"&gt;780,198&lt;/span&gt; pre-funded warrants (i.e., warrants to purchase
shares of Company common stock, for which the exercise price is almost entirely prepaid) and (iii) &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants"&gt;1,920,768&lt;/span&gt; two-year warrants to purchase
shares of Company common stock for an exercise price of $&lt;span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price"&gt;5.25&lt;/span&gt; per share. Both sets of warrants included a &lt;span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQavFKjktyXf" title="Beneficial-ownership percentage"&gt;9.99&lt;/span&gt;% beneficial-ownership
blocker provision. The &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200721__20200722__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z0qHvXa5Kh33" title="Warrants exercise"&gt;780,198&lt;/span&gt; pre-funded warrants were then exercised on July 21 and 22, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 4, 2020, the Company closed a Securities Purchase Agreement (dated August 2, 2020) with a single institutional investor for the
purchase and sale for $&lt;span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_zzGVjp4ZZj7k" title="Sale of stock"&gt;10.0&lt;/span&gt; million for (i) &lt;span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock"&gt;1,717,106&lt;/span&gt; shares of Company common stock, and (ii) &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants"&gt;1,287,829&lt;/span&gt; two-year warrants to purchase
shares of Company common stock for an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share. The warrants included a &lt;span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUiMLYXk3rqf" title="Beneficial-ownership percentage"&gt;9.99&lt;/span&gt;% beneficial-ownership blocker provision.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
December 18, 2020, the Company closed a Securities Purchase Agreement (dated December 16, 2020) with a single institutional investor
for the purchase and sale for $&lt;span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20201216__20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_pp0p0" title="Sale of stock"&gt;12,000,000&lt;/span&gt; of (i) &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201216__20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock"&gt;2,370,786&lt;/span&gt; shares of Company common stock, (ii) &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of stock warrants"&gt;1,000,000&lt;/span&gt; pre-funded warrants (i.e.,
warrants to purchase shares of Company common stock, for which the exercise price is almost entirely prepaid) (iii) &lt;span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants"&gt;1,348,314&lt;/span&gt; two-year
warrants to purchase shares of Company common stock for an exercise price of $&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price"&gt;4.07&lt;/span&gt; per share, and (iv) &lt;span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Purchase of stock warrants"&gt;842,696&lt;/span&gt; warrants (first exercisable
6 months after issuance, and with an expiration date 30 months after issuance) to purchase shares of Company common stock for an exercise
price of $&lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrant exercise price"&gt;4.07&lt;/span&gt; per share. The warrants included a &lt;span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFp8A21Vcndg" title="Beneficial-ownership percentage"&gt;9.99&lt;/span&gt;% beneficial-ownership blocker provision. The &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210203__20210204__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z1r3DXDwpAY4"&gt;1,000,000&lt;/span&gt; pre-funded warrants were
exercised on February 4, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Stock
Options and Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting
period.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#x201c;2020 Plan&#x201d;) which provides for the granting of incentive
or nonstatutory common stock options to qualified employees, officers, directors, consultants and other service providers. At June 30,
2021 and December 31, 2020 there were &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd"&gt;4,040,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zzk9s2D0LLhh"&gt;3,917,500
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;outstanding options respectively under the 2020
Plan and on those dates there were &lt;span id="xdx_904_ecustom--StockOptionsSharesFutureGrant_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd"&gt;17,157
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_90A_ecustom--StockOptionsSharesFutureGrant_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd"&gt;139,657
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;unused 2020 Plan shares available, respectively,
for future grant.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuuDS8dQT2fh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2021, and changes during the six-month period then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zsA2VITac1A7" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;
    Average &lt;br/&gt;
    Exercise &lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;
    Average Remaining &lt;br/&gt;
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 39%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGZIeRguF763" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Options Outstanding, Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,011,356&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNG1FtDfIxe7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.05&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2TfsjjRSYHg" title="Range of Exercise price, Options Outstanding"&gt;3.52&lt;/span&gt;&#x2014;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zesHnaej9rr2" title="Range of Exercise price, Options Outstanding"&gt;1,465.75&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3r0SiApwfxa" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;9.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;127,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Granted"&gt;1.80&lt;/span&gt;&#x2014;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Granted"&gt;3.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4JC7iBSZbY5" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;9.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--RangeOfExercisePriceOptionsExpired_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise price, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znlDhZ0qQq57" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Forfeited"&gt;3.52&lt;/span&gt;
    &#x2014; &lt;span id="xdx_90E_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Forfeited"&gt;4.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGD3wHgiHYKk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,133,856&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAPZM8OKVyme" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMjGUy7A2uP9" title="Range of Exercise price, Options Outstanding"&gt;1.80&lt;/span&gt;
    &#x2014; &lt;span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEz1cL2XsGXl" title="Range of Exercise price, Options Outstanding"&gt;1,465.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHSjUCZ8a2k5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable
    (vested)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSdZKQlVBMM6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Exercisable (vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,296,860&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zPjAvqCRwcjk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable (vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zo7WNz4ixrni" title="Range of Exercise price, Options Exercisable (vested)"&gt;4.97&lt;/span&gt;
    &#x2014; &lt;span id="xdx_903_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Exercisable (vested)"&gt;1,465.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjcHVACkl421" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;8.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable
    (non-vested)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zo6LEmEpSo6h" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Non-Exercisable (non-vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,836,996&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjz5DW3HszD8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Non-Exercisable (non-vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)"&gt;1.80&lt;/span&gt;
    &#x2014; &lt;span id="xdx_905_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)"&gt;5.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zfTNyjgx9T7e" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;9.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AD_zaHrrgNTB7b4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
was approximately $&lt;span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20210401__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zI534eYSIuFd"&gt;1.3&lt;/span&gt; million and $&lt;span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20200401__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zlFjcxaJwUXa"&gt;0.4&lt;/span&gt; million of compensation cost related to outstanding options for the three months ended June
30, 2021 and 2020, respectively, and approximately&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt; $&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zCeyEiqPnoae"&gt;2.5 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
and $&lt;span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zc3EyAilcMu9"&gt;0.4 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
of compensation cost related to outstanding options for the six months ended June 30, 2021 and 2020, respectively. As of June 30,
2021, there was approximately $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zd31GG43YY91"&gt;10.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million
of total unrecognized compensation cost related to unvested stock-based compensation arrangements. This cost is expected to be
recognized over a weighted average period of &lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zwTlKOzTCR61"&gt;1.98 &lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;years.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zggKq2xevmGe" title="Stock options exercised"&gt;&lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zaY3QnESTdOg" title="Stock options exercised"&gt;No&lt;/span&gt;&lt;/span&gt;
stock options were exercised during the six months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember" title="Stock options description"&gt;The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.&lt;/span&gt; The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a ten-year
period. The weighted average grant date fair value per share of options granted during the six months ended June 30, 2021 was $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_pdd" title="Stock option granted exercise price"&gt;1.68&lt;/span&gt;.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Fair
Value of Equity Awards&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company utilizes the Black-Scholes option pricing model to value awards under its Plans. Key valuation assumptions include:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
    dividend yield.&lt;/i&gt; The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#x2019;s common stock.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
    stock-price volatility.&lt;/i&gt; The Company&#x2019;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#x2019;s industry that the Company considers to be comparable to the Company&#x2019;s business
    over a period approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Risk-free
    interest rate.&lt;/i&gt; The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
    term.&lt;/i&gt; The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#x2019;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the Securities
    and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual
    life of the options.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zhMJCwb3Nvq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zypqMcSXiXa8" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For
the six months&lt;br/&gt;
ended &lt;br/&gt;
June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20210630_zgviF8xlXhVd" title="Expected dividend yield"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    stock-price volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20210630_z9MaedWULN8g" title="Expected stock-price volatility"&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20210101__20210630_zo1twREqmpi3" title="Risk-free interest rate, minimum"&gt;0.84&lt;/span&gt;%
    &#x2014; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20210101__20210630_zYGLh6nVGlX4" title="Risk-free interest rate, maximum"&gt;1.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Expected
    average term of options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zp9wn2ZilkTe" title="Average expected remaining years of life of options"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharePrice_c20210630_pdd" title="Stock price"&gt;2.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A6_zp2HEeIYtp13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_890_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zLcG6bpugaBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zMdYUrsZNdyf" style="display: none"&gt;SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the six months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7egFqhcBdBd" style="width: 20%; text-align: right" title="Total"&gt;2,201,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqhAcfvZcEHd" style="width: 20%; text-align: right" title="Total"&gt;277,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zK7inVm28ael" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;347,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqCUHEU4Ifq3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;88,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_zG9rAHPnEZF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,549,049&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630_zTaUiVSIXXF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;366,491&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zJun7vuJdv3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Equity
Classified Compensatory Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the $&lt;span id="xdx_901_ecustom--EquityCapitalRaise_iI_pn5n6_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_z6D4WpaEl8r3" title="Equity capital raise"&gt;4.0&lt;/span&gt; million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Purchase of stock warrants"&gt;811,431&lt;/span&gt; shares of the Company&#x2019;s common stock at an exercise
price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Warrant exercise price"&gt;1.11&lt;/span&gt; per share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense
on the Company&#x2019;s statements of operations.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of &lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20171231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Purchase of stock warrants"&gt;668,024&lt;/span&gt; shares
of Company common stock at a weighted average exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20171231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Warrant exercise price"&gt;2.34&lt;/span&gt; per share. These are to be differentiated from the Series C Warrants
described in Note 7.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;No
compensatory warrants were issued during the six months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89B_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_gL3SOWATTB-XCNSZ_ze9Cvv2uEijh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zz0DeCBA5H5k" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
    Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt;
    Remaining &lt;br/&gt;
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztJPt0tKB5W6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,294,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVYkjfKsgOLd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zC5KDPgMmXHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1JG4rJahtKh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1840"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Legacy
    Ritter warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRQw9aW18Ec" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvMc2kCuqEc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1844"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1846"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1848"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(38,390&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.09&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1856"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(65,179&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.07&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RYTQiEnCDj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,190,648&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zi0WH4YIOGwa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.62&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR2z8g3LZho7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,187,052&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbnSiTJp3qKh" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.62&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;1.11&lt;/span&gt;
    &#x2014; &lt;span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdYAqANed95k" title="Weighted Average Remaining Life (Years) Exercisable"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbVhuLk43Bvf" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,596&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zSFTVvAFI1a6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.54
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.54&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4JSgNsnKVm" title="Weighted Average Remaining Life (Years) Non-Exercisable"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A4_zqKyYscW9vy4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Of
the &lt;span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zxXv4Ufjrzi5" title="Stock issued upon exercise of  stock options"&gt;38,390&lt;/span&gt; shares issued upon the exercise of equity classified compensatory warrants during the six months ended June 30, 2021, &lt;span id="xdx_90D_ecustom--SharesIssuedUponNetExercises_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zZIvYPIG1rA8" title="Shares issued on net exercises"&gt;35,512&lt;/span&gt;
shares were issued upon net-exercises rather than upon exercises for cash.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C03_gL3SOWATTB-XCNSZ_zqsVpz8dwtRh"&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B3_zNtEjVZ5xzkf" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
    Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;
    Average Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life
    (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRPgZtofBdl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z66E65pFepNc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.99&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3F0agyTu3oi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;668,024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zFzKhwhNafmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Legacy
    Ritter warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zEptr09bcs83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7etL0b2V5ml" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;811,431&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMmPCwmC2Pi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zLL0Ke1UL8u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1908"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RloP4fvTyi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1910"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zZQm2lRUhPCc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,479,455&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za9epGDPPV0c" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.67&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfRQiexHvsB3" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;660,832&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMrKiLC8mghj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;2.07&lt;/span&gt;
    &#x2014; &lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmD95OhSynA2" title="Weighted Average Remaining Life (Years) Exercisable"&gt;3.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9tnexDfrbBa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;818,623&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1roXZzS8sub" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Non-Exercisable"&gt;1.11&lt;/span&gt;
    &#x2014; &lt;span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Non-Exercisable"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziEKMWF29x0k" title="Weighted Average Remaining Life (Years) Non-Exercisable"&gt;4.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_C0B_gL3SOWATTB-XCNSZ_zirtWBfn8c79"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were &lt;span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_do_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zIVFZT7Rn6ac" title="Stock based compensation expense"&gt;no&lt;/span&gt; compensation cost related to outstanding equity classified compensatory warrants for the six months ended June 30, 2021 and approximately
$&lt;span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zpsuktLGUBi4" title="Stock based compensation expense"&gt;8,000&lt;/span&gt; for the six months ended June 30, 2020. As of June 30, 2021 and 2020, there was &lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_do_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_znWMFDVOZkh4" title="Unrecognized compensation cost"&gt;&lt;span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zJxXVuX0Wen" title="Unrecognized compensation cost"&gt;no&lt;/span&gt;&lt;/span&gt; unrecognized compensation cost related to nonvested
equity classified compensatory warrants.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Noncompensatory
Equity Classified Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to an investor for the purchase of &lt;span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200531__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants"&gt;270,478&lt;/span&gt;
shares of Company common stock at an exercise price of $&lt;span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200531__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price"&gt;1.11&lt;/span&gt; per share (of which warrants for &lt;span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_c20201201__20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Shares issued upon the exercise of warrants"&gt;200,000&lt;/span&gt; shares were subsequently exercised
in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to such investor for the purchase of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200731__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants"&gt;780,198&lt;/span&gt;
shares of Company common stock at an exercise price of $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200731__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price"&gt;0.001&lt;/span&gt; per share (which were subsequently exercised in July 2020), and &lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants"&gt;1,920,678&lt;/span&gt;
shares of Company common stock at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price"&gt;5.25&lt;/span&gt; per share. In August 2020 the Company issued noncompensatory equity classified
warrants to such investor for the purchase of &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Purchase of stock warrants"&gt;1,287,829&lt;/span&gt; shares of Company common stock at an exercise price of $&lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Warrant exercise price"&gt;6.00&lt;/span&gt; per share. Lastly,
in December 2020, the Company issued noncompensatory equity classified warrants to such investor for the purchase of &lt;span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Purchase of stock warrants"&gt;1,000,000&lt;/span&gt; shares
of Company common stock at an exercise price of $&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Warrant exercise price"&gt;0.01&lt;/span&gt; per share (which were exercised in February 2021) and &lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Purchase of stock warrants"&gt;2,191,010&lt;/span&gt; shares of Company
common stock at an exercise price of $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Warrant exercise price"&gt;4.07&lt;/span&gt; per share. No noncompensatory equity classified warrants were issued during the six months
ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zhvZKGrwksr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B5_zz92liI2luSj" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
    Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt;
    Remaining &lt;br/&gt;
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zQhwqpdEym8e" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,549,777&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zxtC0XknraS7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.37&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1982"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1986"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1990"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zL1FaaiiJEb1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,549,777&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zYEbzYgcSMki" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.15&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z8ZdcQ0BJeE1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,549,777&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zXGXhpg0ZWM5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.15&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" style="font: 10pt Times New Roman, Times, Serif"&gt;1.11
    &lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd"&gt;2,325.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zGzT4vMFUq6h" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zZFK6wpzMyj8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2004"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zC4ecpj8SH0i" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2006"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zpSLrAfjVjGb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <QLGN:ScheduleOfReservedSharesTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_893_ecustom--ScheduleOfReservedSharesTableTextBlock_zUhHeLMgL6ik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
June 30, 2021, the Company has reserved &lt;span id="xdx_903_eus-gaap--CommonStockSharesSubscribedButUnissued_c20210630_pdd" title="Shares of authorized but unissued common stock"&gt;13,917,461&lt;/span&gt; shares of authorized but unissued common stock for possible future issuance. At June
30, 2021, shares were reserved in connection with the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BF_zhSYbgOdMeNk" style="display: none"&gt;SCHEDULE
OF RESERVED SHARES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%"&gt;Exercise of outstanding stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockOptionsMember_zo3DUyEoEGa1" style="width: 20%; text-align: right" title="Total"&gt;4,133,856&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Exercise of outstanding stock warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockWarrantMember_zkXGif7XmMEi" style="text-align: right"&gt;9,540,187&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Conversion of outstanding Series Alpha preferred stock&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--SerieAlphaPreferredStockMember_z5vjFpOt7Nbj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;243,418&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 2.5pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630_zNi6r5qjfPCb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;13,917,461&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</QLGN:ScheduleOfReservedSharesTableTextBlock>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="AsOf2021-06-30_custom_ExerciseOfOutstandingStockOptionsMember"
      decimals="INF"
      unitRef="Shares">4133856</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="AsOf2021-06-30_custom_ExerciseOfOutstandingStockWarrantMember"
      decimals="INF"
      unitRef="Shares">9540187</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued
      contextRef="AsOf2021-06-30_custom_SerieAlphaPreferredStockMember"
      decimals="INF"
      unitRef="Shares">243418</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:CommonStockSharesSubscribedButUnissued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">13917461</us-gaap:CommonStockSharesSubscribedButUnissued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">180</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember"
      decimals="-5"
      unitRef="USD">8000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-07-092020-07-10_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1140570</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">780198</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember"
      decimals="INF"
      unitRef="Shares">1920768</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-07-10_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2020-07-212020-07-22_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">780198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember"
      decimals="-5"
      unitRef="USD">10000000.0</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-08-032020-08-04_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1717106</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember"
      decimals="INF"
      unitRef="Shares">1287829</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-08-04_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_SingleInstitutionalInvestorMember"
      decimals="0"
      unitRef="USD">12000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-12-162020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2370786</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember"
      decimals="INF"
      unitRef="Shares">1348314</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_custom_TwoYearWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">842696</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="AsOf2020-12-18_custom_SecuritiesPurchaseAgreementMember"
      decimals="INF"
      unitRef="Pure">0.0999</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-02-032021-02-04_custom_SecuritiesPurchaseAgreementMember_custom_PrefundedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">4040000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-12-31_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">3917500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <QLGN:StockOptionsSharesFutureGrant
      contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">17157</QLGN:StockOptionsSharesFutureGrant>
    <QLGN:StockOptionsSharesFutureGrant
      contextRef="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember"
      decimals="INF"
      unitRef="Shares">139657</QLGN:StockOptionsSharesFutureGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuuDS8dQT2fh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2021, and changes during the six-month period then ended:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zsA2VITac1A7" style="display: none"&gt;SCHEDULE
OF STOCK OPTION ACTIVITY&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;
    Average &lt;br/&gt;
    Exercise &lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;
    Average Remaining &lt;br/&gt;
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 39%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGZIeRguF763" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Options Outstanding, Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,011,356&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNG1FtDfIxe7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;7.05&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2TfsjjRSYHg" title="Range of Exercise price, Options Outstanding"&gt;3.52&lt;/span&gt;&#x2014;&lt;span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zesHnaej9rr2" title="Range of Exercise price, Options Outstanding"&gt;1,465.75&lt;/span&gt;
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3r0SiApwfxa" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"&gt;9.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;127,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Granted"&gt;1.80&lt;/span&gt;&#x2014;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Granted"&gt;3.29&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4JC7iBSZbY5" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted"&gt;9.83&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1734"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1736"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_ecustom--RangeOfExercisePriceOptionsExpired_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise price, Options Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1738"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znlDhZ0qQq57" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(4,500&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3.68&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Forfeited"&gt;3.52&lt;/span&gt;
    &#x2014; &lt;span id="xdx_90E_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Forfeited"&gt;4.97&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGD3wHgiHYKk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Outstanding at Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4,133,856&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAPZM8OKVyme" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6.90&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMjGUy7A2uP9" title="Range of Exercise price, Options Outstanding"&gt;1.80&lt;/span&gt;
    &#x2014; &lt;span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEz1cL2XsGXl" title="Range of Exercise price, Options Outstanding"&gt;1,465.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHSjUCZ8a2k5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"&gt;8.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable
    (vested)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSdZKQlVBMM6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Exercisable (vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,296,860&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zPjAvqCRwcjk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable (vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;11.50&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zo7WNz4ixrni" title="Range of Exercise price, Options Exercisable (vested)"&gt;4.97&lt;/span&gt;
    &#x2014; &lt;span id="xdx_903_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Exercisable (vested)"&gt;1,465.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90D_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjcHVACkl421" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"&gt;8.36&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable
    (non-vested)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zo6LEmEpSo6h" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Non-Exercisable (non-vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2,836,996&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjz5DW3HszD8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Non-Exercisable (non-vested)"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.80&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)"&gt;1.80&lt;/span&gt;
    &#x2014; &lt;span id="xdx_905_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)"&gt;5.13&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zfTNyjgx9T7e" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"&gt;9.04&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">4011356</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">7.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">3.52</QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange>
    <QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange
      contextRef="AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1465.75</QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">P9Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">127000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">2.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOptionsGranted
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.80</QLGN:RangeOfExercisePriceOptionsGranted>
    <QLGN:RangeOfExercisePriceOptionsGranted
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">3.29</QLGN:RangeOfExercisePriceOptionsGranted>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">P9Y9M29D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">4500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">3.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOptionsForfeited
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">3.52</QLGN:RangeOfExercisePriceOptionsForfeited>
    <QLGN:RangeOfExercisePriceOptionsForfeited
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">4.97</QLGN:RangeOfExercisePriceOptionsForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">4133856</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">6.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.80</QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange>
    <QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1465.75</QLGN:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange>
    <QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y9M25D</QLGN:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">1296860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">11.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOptionsExercisableVested
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">4.97</QLGN:RangeOfExercisePriceOptionsExercisableVested>
    <QLGN:RangeOfExercisePriceOptionsExercisableVested
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">1465.75</QLGN:RangeOfExercisePriceOptionsExercisableVested>
    <QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">P8Y4M9D</QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="Shares">2836996</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember"
      decimals="INF"
      unitRef="USDPShares">4.80</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice>
    <QLGN:RangeOfExercisePriceOptionsNonexercisableNonvested
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.80</QLGN:RangeOfExercisePriceOptionsNonexercisableNonvested>
    <QLGN:RangeOfExercisePriceOptionsNonexercisableNonvested
      contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">5.13</QLGN:RangeOfExercisePriceOptionsNonexercisableNonvested>
    <QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested contextRef="From2021-01-012021-06-30_custom_EmployeesAndNonemployeeServiceProviderMember">P9Y14D</QLGN:WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-04-012021-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="-5"
      unitRef="USD">1300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-04-012020-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="-5"
      unitRef="USD">400000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2021-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="-5"
      unitRef="USD">10300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember">P1Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember_custom_TwoThousandTwentyStockIncentivePlanMember">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_StockOptionsAndWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zhMJCwb3Nvq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zypqMcSXiXa8" style="display: none"&gt;SCHEDULE
OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;For
the six months&lt;br/&gt;
ended &lt;br/&gt;
June 30, 2021&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 76%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    dividend yield&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20210630_zgviF8xlXhVd" title="Expected dividend yield"&gt;0.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expected
    stock-price volatility&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20210630_z9MaedWULN8g" title="Expected stock-price volatility"&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Risk-free
    interest rate&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20210101__20210630_zo1twREqmpi3" title="Risk-free interest rate, minimum"&gt;0.84&lt;/span&gt;%
    &#x2014; &lt;span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20210101__20210630_zYGLh6nVGlX4" title="Risk-free interest rate, maximum"&gt;1.18&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; background-color: white"&gt;Expected
    average term of options&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zp9wn2ZilkTe" title="Average expected remaining years of life of options"&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Stock
    price&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90E_eus-gaap--SharePrice_c20210630_pdd" title="Stock price"&gt;2.12&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">1.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0118</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-06-30">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">2.12</us-gaap:SharePrice>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_890_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zLcG6bpugaBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span id="xdx_8BF_zMdYUrsZNdyf" style="display: none"&gt;SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;For the six months ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7egFqhcBdBd" style="width: 20%; text-align: right" title="Total"&gt;2,201,499&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqhAcfvZcEHd" style="width: 20%; text-align: right" title="Total"&gt;277,807&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Research and development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zK7inVm28ael" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;347,550&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqCUHEU4Ifq3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total"&gt;88,684&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 10pt"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_zG9rAHPnEZF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;2,549,049&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630_zTaUiVSIXXF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total"&gt;366,491&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">2201499</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">277807</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">347550</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">88684</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">2549049</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">366491</us-gaap:ShareBasedCompensation>
    <QLGN:EquityCapitalRaise
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember"
      decimals="-5"
      unitRef="USD">4000000.0</QLGN:EquityCapitalRaise>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="Shares">811431</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="Shares">668024</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2017-12-31_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">2.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:SummaryOfWarrantActivityTableTextBlock contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember">&lt;p id="xdx_89B_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_gL3SOWATTB-XCNSZ_ze9Cvv2uEijh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B7_zz0DeCBA5H5k" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
    Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt;
    Remaining &lt;br/&gt;
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 36%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztJPt0tKB5W6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,294,217&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVYkjfKsgOLd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.66&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 2%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zC5KDPgMmXHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1838"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1JG4rJahtKh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1840"&gt;-&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Legacy
    Ritter warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRQw9aW18Ec" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1842"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvMc2kCuqEc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1844"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1846"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1848"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(38,390&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.09&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1854"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1856"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(65,179&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.07&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RYTQiEnCDj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,190,648&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zi0WH4YIOGwa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.62&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR2z8g3LZho7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,187,052&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbnSiTJp3qKh" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.62&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;1.11&lt;/span&gt;
    &#x2014; &lt;span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdYAqANed95k" title="Weighted Average Remaining Life (Years) Exercisable"&gt;3.75&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbVhuLk43Bvf" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;3,596&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zSFTVvAFI1a6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.54
    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.54&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4JSgNsnKVm" title="Weighted Average Remaining Life (Years) Non-Exercisable"&gt;5.23&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B3_zNtEjVZ5xzkf" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
    Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;
    Average Remaining&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Life
    (Years)&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2019&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRPgZtofBdl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1888"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z66E65pFepNc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.99&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3F0agyTu3oi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;668,024&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zFzKhwhNafmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Legacy
    Ritter warrants&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zEptr09bcs83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1896"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7etL0b2V5ml" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1898"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;811,431&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMmPCwmC2Pi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.11&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1904"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zLL0Ke1UL8u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1906"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1908"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RloP4fvTyi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1910"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zZQm2lRUhPCc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1,479,455&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za9epGDPPV0c" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.67&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfRQiexHvsB3" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;660,832&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMrKiLC8mghj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;2.34&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;2.07&lt;/span&gt;
    &#x2014; &lt;span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmD95OhSynA2" title="Weighted Average Remaining Life (Years) Exercisable"&gt;3.82&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9tnexDfrbBa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;818,623&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1roXZzS8sub" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;1.12&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Non-Exercisable"&gt;1.11&lt;/span&gt;
    &#x2014; &lt;span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Non-Exercisable"&gt;2.54&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziEKMWF29x0k" title="Weighted Average Remaining Life (Years) Non-Exercisable"&gt;4.91&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&#160;</QLGN:SummaryOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">1294217</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.66</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">-38390</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">2.09</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">-65179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">2.07</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">1190648</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.62</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">1187052</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.62</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.11</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">2.54</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember">P3Y9M</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">3596</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">2.54</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">2.54</QLGN:RangeOfExercisePriceNonexercisableNonvested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember">P5Y2M23D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="Shares">38390</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <QLGN:SharesIssuedUponNetExercises
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember"
      decimals="INF"
      unitRef="Shares">35512</QLGN:SharesIssuedUponNetExercises>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2019-12-31_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.99</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="0"
      unitRef="USD">668024</QLGN:NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger>
    <QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">2.34</QLGN:WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">811431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.11</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">1479455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.67</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">660832</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">2.34</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">2.07</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">2.54</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember">P3Y9M25D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber
      contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">818623</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise
      contextRef="AsOf2020-06-30_custom_CompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">1.12</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.11</QLGN:RangeOfExercisePriceNonexercisableNonvested>
    <QLGN:RangeOfExercisePriceNonexercisableNonvested
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">2.54</QLGN:RangeOfExercisePriceNonexercisableNonvested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantActivityMember">P4Y10M28D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-06-30_custom_CompensatoryWarrantsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30_custom_CompensatoryWarrantsMember"
      decimals="0"
      unitRef="USD">8000</us-gaap:ShareBasedCompensation>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="AsOf2021-06-30_custom_CompensatoryWarrantsMember"
      decimals="0"
      unitRef="USD">0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">270478</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-05-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">1.11</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised
      contextRef="From2020-12-012020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">200000</QLGN:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">780198</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-07-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="Shares">1920678</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">5.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="Shares">1287829</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-08-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">6.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="Shares">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_InvestorMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">2191010</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2020-12-31_custom_NoncompensatoryEquityClassifiedWarrantsMember_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="USDPShares">4.07</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <QLGN:SummaryOfWarrantActivityTableTextBlock contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember">&lt;p id="xdx_89E_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zhvZKGrwksr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B5_zz92liI2luSj" style="display: none"&gt;SCHEDULE
OF WARRANT ACTIVITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Common
    Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Shares&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Average&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Exercise&lt;br/&gt;
    Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Range
    of Exercise&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Price&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted&#x2013;&lt;br/&gt;
    Average&lt;br/&gt;
    Remaining &lt;br/&gt;
    Life (Years)&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 42%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; December 31, 2020&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zQhwqpdEym8e" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;6,549,777&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zxtC0XknraS7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;4.37&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 1%"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercised&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;(1,000,000&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;)&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;0.01&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Granted&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1980"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1982"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Expired&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1984"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1986"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1988"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1990"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total
    outstanding &#x2013; June 30, 2021&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zL1FaaiiJEb1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,549,777&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zYEbzYgcSMki" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.15&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z8ZdcQ0BJeE1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5,549,777&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zXGXhpg0ZWM5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;5.15&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" style="font: 10pt Times New Roman, Times, Serif"&gt;1.11
    &lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#x2014;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;
    &lt;span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd"&gt;2,325.00&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zGzT4vMFUq6h" title="Weighted Average Remaining Life (Years) Exercisable"&gt;1.33&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Non-Exercisable&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zZFK6wpzMyj8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2004"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zC4ecpj8SH0i" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2006"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl2008"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</QLGN:SummaryOfWarrantActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">6549777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">4.37</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">-1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">0.01</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">5549777</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">5.15</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber
      contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="Shares">5549777</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice
      contextRef="AsOf2021-06-30_custom_NonCompensatoryWarrantActivityMember"
      decimals="INF"
      unitRef="USDPShares">5.15</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">1.11</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:RangeOfExercisePriceExercisableVested
      contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">2325.00</QLGN:RangeOfExercisePriceExercisableVested>
    <QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 contextRef="From2021-01-012021-06-30_custom_NonCompensatoryWarrantActivityMember">P1Y3M29D</QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zSOynDE0cNL3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
11 &#x2014; &lt;span id="xdx_82C_zF4iUwfgZ5xg"&gt;RELATED PARTY TRANSACTIONS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
October 2017, Sekisui purchased all outstanding shares of the Company&#x2019;s Series D and Series D-1 preferred stock from Gen-Probe
Incorporated. As such, Sekisui became a related party as of October 2017. These Series D and Series D-1 preferred stock shares were converted
into &lt;span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20200501__20200531__us-gaap--StatementClassOfStockAxis__custom--SeriesDAndSeriesDOnePreferredStockMember_pdd" title="Conversion of preferred stock"&gt;1,980,233&lt;/span&gt; shares of the Company&#x2019;s common stock in connection with the reverse recapitalization transaction in May 2020. During
the nine-months transition period ended December 31, 2020, Sekisui ceased to be a related party as to the Company. In the attached financial
statements, information for 2020 periods and dates is presented without distinct &#x201c;related party&#x201d; treatment for items pertaining
to Sekisui.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="From2020-05-012020-05-31_custom_SeriesDAndSeriesDOnePreferredStockMember"
      decimals="INF"
      unitRef="Shares">1980233</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zEBEXoJeaHil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;NOTE
12 &#x2014; &lt;span id="xdx_827_zdZwxWRj39Ta"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Management
has evaluated subsequent events pursuant to the requirements of ASC Topic 855, &lt;i&gt;Subsequent Events&lt;/i&gt;, from the balance sheet date
through the date the financial statements were available to be issued, and has determined that there are no material subsequent events
that require disclosure in these financial statements, except that effective July 1, 2021, the Company and Sekisui amended the scheduled
termination date of the Sekisui Distribution and Development Agreement (see Note 9) to be March 31, 2022 instead of May 1, 2022, and by virtue
of a 2020 Plan amendment approved by the Company&#x2019;s stockholders on August 9, 2021, the number of shares of common stock available
for issuance under the 2020 Plan was increased by &lt;span id="xdx_90B_ecustom--CommonStockSharesAvailableForFutureIssuance_iI_c20210809__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwpThousandTwentyPlanMember_z0bf0S2psDA8"&gt;3,500,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.&lt;/span&gt;&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <QLGN:CommonStockSharesAvailableForFutureIssuance
      contextRef="AsOf2021-08-09_us-gaap_SubsequentEventMember_custom_TwpThousandTwentyPlanMember"
      decimals="INF"
      unitRef="Shares">3500000</QLGN:CommonStockSharesAvailableForFutureIssuance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204348152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 12, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Qualigen Therapeutics, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001460702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-3474527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2042 Corte Del Nogal<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Carlsbad<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">918-9165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
Stock, par value $.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">QLGN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,998,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204087720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 15,232,402<span></span>
</td>
<td class="nump">$ 23,976,570<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">766,911<span></span>
</td>
<td class="nump">615,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">1,073,335<span></span>
</td>
<td class="nump">953,458<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,033,857<span></span>
</td>
<td class="nump">2,678,894<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">19,106,505<span></span>
</td>
<td class="nump">28,224,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">321,076<span></span>
</td>
<td class="nump">430,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">253,261<span></span>
</td>
<td class="nump">247,323<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_EquipmentHeldForLeaseNet', window );">Equipment held for lease, net</a></td>
<td class="nump">5,821<span></span>
</td>
<td class="nump">17,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">183,933<span></span>
</td>
<td class="nump">187,694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">18,334<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">19,888,930<span></span>
</td>
<td class="nump">29,126,772<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">784,474<span></span>
</td>
<td class="nump">500,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,923,708<span></span>
</td>
<td class="nump">746,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable, current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">131,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">325,988<span></span>
</td>
<td class="nump">486,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability, current portion</a></td>
<td class="nump">270,640<span></span>
</td>
<td class="nump">254,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingLiabilitiesCurrent', window );">Warrant liabilities</a></td>
<td class="nump">4,112,100<span></span>
</td>
<td class="nump">8,310,100<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,416,910<span></span>
</td>
<td class="nump">10,430,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, net of current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">98,145<span></span>
</td>
<td class="nump">236,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">112,057<span></span>
</td>
<td class="nump">158,271<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">7,627,112<span></span>
</td>
<td class="nump">10,832,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Series Alpha convertible preferred stock, $0.001 par value; 7,000 shares authorized; 180 shares issued and outstanding as of June 30, 2021 and December 31, 2020</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 225,000,000 shares authorized; 28,902,188 and 27,296,061 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">28,902<span></span>
</td>
<td class="nump">27,296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">88,058,267<span></span>
</td>
<td class="nump">85,114,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(75,825,352)<span></span>
</td>
<td class="num">(66,847,492)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">12,261,818<span></span>
</td>
<td class="nump">18,294,560<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 19,888,930<span></span>
</td>
<td class="nump">$ 29,126,772<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EquipmentHeldForLeaseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equipment held for lease net.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EquipmentHeldForLeaseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=28183603&amp;loc=d3e692-112598<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840199150808">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series Alpha convertible preferred stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Series Alpha convertible preferred stock, shares authorized</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Series Alpha convertible preferred stock, shares issued</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Series Alpha convertible preferred stock, shares outstanding</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000,000<span></span>
</td>
<td class="nump">225,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">28,902,188<span></span>
</td>
<td class="nump">27,296,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">28,902,188<span></span>
</td>
<td class="nump">27,296,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204928760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,117,935<span></span>
</td>
<td class="nump">$ 904,067<span></span>
</td>
<td class="nump">$ 3,017,430<span></span>
</td>
<td class="nump">$ 2,360,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>EXPENSES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_CostOfProductSales', window );">Cost of product sales</a></td>
<td class="nump">916,624<span></span>
</td>
<td class="nump">807,922<span></span>
</td>
<td class="nump">2,119,103<span></span>
</td>
<td class="nump">1,799,574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,952,100<span></span>
</td>
<td class="nump">1,979,614<span></span>
</td>
<td class="nump">5,826,038<span></span>
</td>
<td class="nump">2,897,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,508,466<span></span>
</td>
<td class="nump">597,345<span></span>
</td>
<td class="nump">8,007,840<span></span>
</td>
<td class="nump">835,403<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Sales and marketing</a></td>
<td class="nump">135,543<span></span>
</td>
<td class="nump">88,844<span></span>
</td>
<td class="nump">272,129<span></span>
</td>
<td class="nump">181,106<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total expenses</a></td>
<td class="nump">8,512,733<span></span>
</td>
<td class="nump">3,473,725<span></span>
</td>
<td class="nump">16,225,110<span></span>
</td>
<td class="nump">5,714,076<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">LOSS FROM OPERATIONS</a></td>
<td class="num">(7,394,798)<span></span>
</td>
<td class="num">(2,569,658)<span></span>
</td>
<td class="num">(13,207,680)<span></span>
</td>
<td class="num">(3,353,253)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER (INCOME) EXPENSE, NET</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Loss (gain) on change in fair value of warrant liabilities</a></td>
<td class="num">(2,075,100)<span></span>
</td>
<td class="nump">16,201,400<span></span>
</td>
<td class="num">(4,198,000)<span></span>
</td>
<td class="nump">16,201,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest (income) expense, net</a></td>
<td class="num">(12,718)<span></span>
</td>
<td class="nump">57,364<span></span>
</td>
<td class="num">(30,061)<span></span>
</td>
<td class="nump">148,121<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income), net</a></td>
<td class="num">(2,352)<span></span>
</td>
<td class="num">(250,114)<span></span>
</td>
<td class="num">(2,894)<span></span>
</td>
<td class="num">(251,272)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (income) expense, net</a></td>
<td class="num">(2,090,170)<span></span>
</td>
<td class="nump">16,008,650<span></span>
</td>
<td class="num">(4,230,955)<span></span>
</td>
<td class="nump">16,098,249<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">LOSS BEFORE PROVISION FOR INCOME TAXES</a></td>
<td class="num">(5,304,628)<span></span>
</td>
<td class="num">(18,578,308)<span></span>
</td>
<td class="num">(8,976,725)<span></span>
</td>
<td class="num">(19,451,502)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">PROVISION (BENEFIT) FOR INCOME TAXES</a></td>
<td class="nump">605<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="num">(22)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET LOSS</a></td>
<td class="num">$ (5,305,233)<span></span>
</td>
<td class="num">$ (18,578,905)<span></span>
</td>
<td class="num">$ (8,977,860)<span></span>
</td>
<td class="num">$ (19,451,480)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per common share, basic and diluted</a></td>
<td class="num">$ (0.18)<span></span>
</td>
<td class="num">$ (2.12)<span></span>
</td>
<td class="num">$ (0.31)<span></span>
</td>
<td class="num">$ (2.71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted&#8212;average number of shares outstanding, basic and diluted</a></td>
<td class="nump">28,850,451<span></span>
</td>
<td class="nump">8,746,250<span></span>
</td>
<td class="nump">28,510,014<span></span>
</td>
<td class="nump">7,174,233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_NetProductSalesMember', window );">Net Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,117,935<span></span>
</td>
<td class="nump">$ 904,067<span></span>
</td>
<td class="nump">$ 2,538,776<span></span>
</td>
<td class="nump">$ 2,315,823<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">478,654<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember', window );">Collaborative Research Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 45,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CostOfProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cost of product sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CostOfProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_NetProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_NetProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840199820008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Series A Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series B Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series C Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series D Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series D One Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Series Alpha Convertible Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 24,129<span></span>
</td>
<td class="nump">$ 77,077<span></span>
</td>
<td class="nump">$ 33,007<span></span>
</td>
<td class="nump">$ 15,083<span></span>
</td>
<td class="nump">$ 6,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,026<span></span>
</td>
<td class="nump">$ 45,153,733<span></span>
</td>
<td class="num">$ (46,428,550)<span></span>
</td>
<td class="num">$ (1,063,060)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">2,412,887<span></span>
</td>
<td class="nump">7,707,736<span></span>
</td>
<td class="nump">3,300,715<span></span>
</td>
<td class="nump">1,508,305<span></span>
</td>
<td class="nump">643,511<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,602,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,866<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(872,576)<span></span>
</td>
<td class="num">(872,576)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 24,129<span></span>
</td>
<td class="nump">$ 77,077<span></span>
</td>
<td class="nump">$ 33,007<span></span>
</td>
<td class="nump">$ 15,083<span></span>
</td>
<td class="nump">$ 6,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,026<span></span>
</td>
<td class="nump">45,161,599<span></span>
</td>
<td class="num">(47,301,126)<span></span>
</td>
<td class="num">(1,927,770)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2020</a></td>
<td class="nump">2,412,887<span></span>
</td>
<td class="nump">7,707,736<span></span>
</td>
<td class="nump">3,300,715<span></span>
</td>
<td class="nump">1,508,305<span></span>
</td>
<td class="nump">643,511<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,602,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2019</a></td>
<td class="nump">$ 24,129<span></span>
</td>
<td class="nump">$ 77,077<span></span>
</td>
<td class="nump">$ 33,007<span></span>
</td>
<td class="nump">$ 15,083<span></span>
</td>
<td class="nump">$ 6,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,026<span></span>
</td>
<td class="nump">45,153,733<span></span>
</td>
<td class="num">(46,428,550)<span></span>
</td>
<td class="num">(1,063,060)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2019</a></td>
<td class="nump">2,412,887<span></span>
</td>
<td class="nump">7,707,736<span></span>
</td>
<td class="nump">3,300,715<span></span>
</td>
<td class="nump">1,508,305<span></span>
</td>
<td class="nump">643,511<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,602,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,451,480)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 13,588<span></span>
</td>
<td class="nump">52,713,683<span></span>
</td>
<td class="num">(65,880,031)<span></span>
</td>
<td class="num">(13,152,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">13,588,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2020</a></td>
<td class="nump">$ 24,129<span></span>
</td>
<td class="nump">$ 77,077<span></span>
</td>
<td class="nump">$ 33,007<span></span>
</td>
<td class="nump">$ 15,083<span></span>
</td>
<td class="nump">$ 6,435<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 56,026<span></span>
</td>
<td class="nump">45,161,599<span></span>
</td>
<td class="num">(47,301,126)<span></span>
</td>
<td class="num">(1,927,770)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2020</a></td>
<td class="nump">2,412,887<span></span>
</td>
<td class="nump">7,707,736<span></span>
</td>
<td class="nump">3,300,715<span></span>
</td>
<td class="nump">1,508,305<span></span>
</td>
<td class="nump">643,511<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,602,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="nump">239,953<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for professional services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of preferred stock</a></td>
<td class="num">$ (24,129)<span></span>
</td>
<td class="num">$ (77,077)<span></span>
</td>
<td class="num">$ (33,007)<span></span>
</td>
<td class="num">$ (15,083)<span></span>
</td>
<td class="num">$ (6,435)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="nump">$ 7,042<span></span>
</td>
<td class="nump">148,690<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock for conversion of preferred stock, shares</a></td>
<td class="num">(2,412,887)<span></span>
</td>
<td class="num">(7,707,736)<span></span>
</td>
<td class="num">(3,300,715)<span></span>
</td>
<td class="num">(1,508,305)<span></span>
</td>
<td class="num">(643,511)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
<td class="nump">7,042,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Issuance of common stock for conversion of notes payable and accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,775<span></span>
</td>
<td class="nump">1,582,633<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,584,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Issuance of common stock for conversion of notes payable and accrued interest, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,775,096<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of Series Alpha preferred shares upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 4,009,995<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of Series Alpha preferred shares upon closing of private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,010<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization', window );">Effect of reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (52,519)<span></span>
</td>
<td class="nump">863,405<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">810,886<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares', window );">Effect of reverse recapitalization, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,095,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable', window );">Issuance of Series Alpha preferred stock for conversion of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares', window );">Issuance of Series Alpha preferred stock for conversion of notes payable, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement', window );">Shares and warrants issued to advisor upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,217<span></span>
</td>
<td class="nump">1,103,891<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,105,108<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares', window );">Shares and warrants issued to advisor upon closing of private placement, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,217,147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket', window );">Fair value of shares issued to advisor upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(902,250)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(902,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrants issued to advisor upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(202,858)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(202,858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">358,625<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">358,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,578,905)<span></span>
</td>
<td class="num">(18,578,905)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 13,588<span></span>
</td>
<td class="nump">52,713,683<span></span>
</td>
<td class="num">(65,880,031)<span></span>
</td>
<td class="num">(13,152,756)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">13,588,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 27,296<span></span>
</td>
<td class="nump">85,114,755<span></span>
</td>
<td class="num">(66,847,492)<span></span>
</td>
<td class="nump">18,294,560<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">27,296,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValueWarrantsExercised', window );">Stock issued upon cash-exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,320<span></span>
</td>
<td class="nump">243,261<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">244,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock issued upon cash-exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,319,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis', window );">Stock issued upon net-exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 192<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis', window );">Stock issued upon net-exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">192,373<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Stock issued for professional services</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">101,725<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">101,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Stock issued for professional services, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,262,123<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,262,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(3,672,627)<span></span>
</td>
<td class="num">(3,672,627)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 28,833<span></span>
</td>
<td class="nump">86,721,672<span></span>
</td>
<td class="num">(70,520,119)<span></span>
</td>
<td class="nump">16,230,387<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">28,833,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Dec. 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 27,296<span></span>
</td>
<td class="nump">85,114,755<span></span>
</td>
<td class="num">(66,847,492)<span></span>
</td>
<td class="nump">18,294,560<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">27,296,061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,977,860)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 28,902<span></span>
</td>
<td class="nump">88,058,267<span></span>
</td>
<td class="num">(75,825,352)<span></span>
</td>
<td class="nump">12,261,818<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">28,902,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance, value at Mar. 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 28,833<span></span>
</td>
<td class="nump">86,721,672<span></span>
</td>
<td class="num">(70,520,119)<span></span>
</td>
<td class="nump">16,230,387<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">28,833,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodValueWarrantsExercised', window );">Stock issued upon cash-exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">49,669<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">49,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Stock issued upon cash-exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">69,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,286,926<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,286,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,305,233)<span></span>
</td>
<td class="num">(5,305,233)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance, value at Jun. 30, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 28,902<span></span>
</td>
<td class="nump">$ 88,058,267<span></span>
</td>
<td class="num">$ (75,825,352)<span></span>
</td>
<td class="nump">$ 12,261,818<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">28,902,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series Alpha preferred stock for conversion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Series Alpha preferred stock for conversion of notes payable, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares and warrants issued to advisor upon closing of private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares and warrants issued to advisor upon closing of private placement, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period effect of reverse recapitalization transaction, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised on a net basis, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period effect of reverse recapitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants exercised on a net basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840199265608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (8,977,860)<span></span>
</td>
<td class="num">$ (19,451,480)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">53,736<span></span>
</td>
<td class="nump">82,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_OperatingLeaseRightOfUseAssetAmortization', window );">Amortization of right-of-use assets</a></td>
<td class="nump">109,719<span></span>
</td>
<td class="nump">50,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Accounts receivable reserves and allowances</a></td>
<td class="nump">3,645<span></span>
</td>
<td class="nump">19,951<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory reserves</a></td>
<td class="nump">40,644<span></span>
</td>
<td class="num">(2,828)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,549,049<span></span>
</td>
<td class="nump">366,491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of warrant liabilities</a></td>
<td class="num">(4,198,000)<span></span>
</td>
<td class="nump">16,201,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(154,799)<span></span>
</td>
<td class="nump">798,585<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease', window );">Inventory and equipment held for lease</a></td>
<td class="num">(89,617)<span></span>
</td>
<td class="nump">20,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther', window );">Prepaid expenses and other assets</a></td>
<td class="nump">746,787<span></span>
</td>
<td class="num">(1,016,203)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">283,706<span></span>
</td>
<td class="nump">188,840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,176,970<span></span>
</td>
<td class="nump">1,072,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IncreaseDecreaseInLeaseLiabilities', window );">Lease liability</a></td>
<td class="num">(122,780)<span></span>
</td>
<td class="num">(54,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(206,257)<span></span>
</td>
<td class="num">(57,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(8,785,057)<span></span>
</td>
<td class="num">(1,782,080)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(107,798)<span></span>
</td>
<td class="num">(110,427)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments for patents and licenses</a></td>
<td class="num">(6,893)<span></span>
</td>
<td class="num">(382,732)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(114,691)<span></span>
</td>
<td class="num">(493,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from issuance of Series Alpha preferred shares upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">4,010,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Net proceeds from the issuance of notes payable</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,682,661<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from warrant exercises</a></td>
<td class="nump">294,319<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(138,739)<span></span>
</td>
<td class="num">(1,164,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">155,580<span></span>
</td>
<td class="nump">4,528,661<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="num">(8,744,168)<span></span>
</td>
<td class="nump">2,253,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS &#8211; beginning of period</a></td>
<td class="nump">23,976,570<span></span>
</td>
<td class="nump">128,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH AND CASH EQUIVALENTS &#8211; end of period</a></td>
<td class="nump">15,232,402<span></span>
</td>
<td class="nump">2,382,118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_CashPaidForAbstract', window );"><strong>Cash paid for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">1,683<span></span>
</td>
<td class="nump">25,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Taxes</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">3,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>&#160; NONCASH FINANCING AND INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IssuanceOfCommonStockForProfessionalServices', window );">Issuance of common stock for professional services</a></td>
<td class="nump">101,750<span></span>
</td>
<td class="nump">240,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionOriginalDebtAmount1', window );">Issuance of common stock for conversion of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,350,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest', window );">Issuance of common stock for conversion of accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">234,210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IssuanceOfCommonStockForConversionOfPreferredStock', window );">Issuance of common stock for conversion of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">148,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_IssuanceOfPreferredStockForConversionOfDebt', window );">Issuance of preferred stock for conversion of debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement', window );">Fair value of shares issued to advisor upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">902,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement', window );">Fair value of warrants issued to advisor upon closing of private placement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">202,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_EffectOfReverseRecapitalization', window );">Effect of reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">810,886<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets', window );">Initial measurement of operating lease right-of-use assets</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">663,110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NetTransfersToInventoryFromEquipmentHeldForLease', window );">Net transfers to inventory from equipment held for lease</a></td>
<td class="nump">$ 1,304<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CashPaidForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CashPaidForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EffectOfReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period effect of reverse recapitalization transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EffectOfReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of shares issued to advisor upon closing of private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrants issued to advisor upon closing of private placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory and equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IncreaseDecreaseInLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change during the period in carrying value of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IncreaseDecreaseInLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Measurement of Operating Lease Right of use Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of debt and accrued interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfCommonStockForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfCommonStockForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfCommonStockForProfessionalServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance common stock for professional services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfCommonStockForProfessionalServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_IssuanceOfPreferredStockForConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of Preferred Stock for Conversion of Debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_IssuanceOfPreferredStockForConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NetTransfersToInventoryFromEquipmentHeldForLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net transfers to inventory from equipment held for lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NetTransfersToInventoryFromEquipmentHeldForLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_OperatingLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right of use asset amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_OperatingLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionOriginalDebtAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionOriginalDebtAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpensesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpensesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203757208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</a></td>
<td class="text"><p id="xdx_807_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zzGqGWJYEpF2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
1 &#8212; <span id="xdx_826_zjrCLcqTrMl">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_ecustom--OrganizationPolicyTextBlock_zpwygdJ0lrG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zyZAFSLnlQQ3">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221;) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.&#8217;s capital stock were exchanged for Qualigen Therapeutics,
Inc.&#8217;s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol &#8220;RTTR,&#8221; commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol &#8220;QLGN&#8221; on May 26, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qualigen,
Inc. was determined to be the accounting acquirer in a reverse recapitalization based upon the terms of the merger and other factors.
All references to financial figures of the Company presented in the accompanying condensed consolidated financial statements and in these
Notes through May 22, 2020 are to those of Qualigen, Inc. All references to financial figures after May 22, 2020 are to those of Qualigen
Therapeutics, Inc. and Qualigen, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_845_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zmadOOwyuhVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_za6Kn8G6tyB7">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission
(&#8220;SEC&#8221;) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should
be read in conjunction with the audited financial statements and notes thereto contained in the Company&#8217;s Transition Report on
Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 31, 2021. In the opinion of management, the accompanying
condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading.
The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other
future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited
financial statements for the most recent fiscal year as reported in the Company&#8217;s Transition Report on Form 10-K have been omitted.
The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited balance sheet at December
31, 2020 contained in such Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zGTCw7etT4N1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zZUP69kkfxPb">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned
subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable
guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_841_eus-gaap--UseOfEstimates_z0lSKQfjPQt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zTLxBTpfgUJe">Accounting
Estimates </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation,
write-off of patents and licenses, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and
warranty costs. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBSstpTFtg83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_znxLp2OVmSgc">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company maintains its cash and cash equivalents in bank deposits which at times may exceed federally insured limits. The Company has
not experienced any losses in such accounts and believes it is not exposed to any significant credit risks on cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z1J1S9bzyx6d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zxVC5aoFwVPe">Inventory,
Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records specific reserves for identified items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13Usu4O9oQ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zr72LivyHt9">Long-Lived
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three months and six months periods ended June 30, 2021
and 2020, <span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210101__20210630_zRrhw7o42pv8" title="Long-lived assets impairment losses"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200101__20200630_zDkes1HZANW7" title="Long-lived assets impairment losses"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210401__20210630_zVdcw2M5jRPh" title="Long-lived assets impairment losses"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200401__20200630_zoWZyNNnND6g" title="Long-lived assets impairment losses">no</span></span></span></span> such impairment losses have been recorded. All long-lived assets of the Company are located in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zVpRYEku6J79" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zuyumM9NCDYg">Accounts
Receivable, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the creditworthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#8217;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">784,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">629,630</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,517</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,873</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Accounts receivable, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766,911</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">615,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zZdyffaZrq1i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVtfKVLGbQuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zwc5fojeouqe">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company expenses research and development costs as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_ecustom--ShippingAndHandlingCostsPolicyTextBlock_ztZhHIaeTcDh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_z2BqBwkVfmMc">Shipping
and Handling Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zJGR7OcjBcs2" title="Shipping and handling costs">28,000</span> and $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630_zRxE5bOpJ6ef">26,000</span>, respectively, for the three
months ended June 30, 2021 and 2020, and approximately $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630_pp0p0" title="Shipping and handling costs">58,000</span> and $<span id="xdx_90E_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630_pp0p0" title="Shipping and handling costs">56,000</span>, respectively, for the six months ended June 30, 2021 and
2020. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing expenses
totaled approximately $<span id="xdx_90D_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z8nO35EuYhR4" title="Shipping and handling costs">4,000</span> and $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zFhWBbNeQGHc">6,000</span> for the three months ended June 30. 2021 and 2020, respectively, and approximately $<span id="xdx_90F_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs">5,000</span> and
$<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs">6,000</span> for the six months ended June 30, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zW2BUDsO4TJh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zbSF2phBMy89">Revenue
from Contracts with Customers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 1, 2020, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i>Revenue from Contracts with Customers
</i>(&#8220;ASC 606&#8221;), using the modified retrospective approach. The adoption of ASC 606 did not have a material impact on the
measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of the adoption date of April
1, 2020. Therefore, no cumulative adjustment has been made to the opening balance of accumulated deficit at April 1, 2020. The comparative
information has not been restated and continues to be reported under the accounting standards in effect for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Product
Sales</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs which are diagnostic tests for PSA, testosterone, thyroid disorders, pregnancy, and Vitamin
D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#8220;analyzer&#8221;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#8220;FOB&#8221;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#8217;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfil the promise to transfer the disposable products and not as a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#8217;s
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License
Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During the three months ended June 30, 2021 and 2020, the Company recognized
license revenue of $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zykC2i3HoA76" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1027">0</span></span> and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zHhXBTbPYKo2" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1028">0</span></span>, respectively, and during the six months ended June 30, 2021 and 2020, the Company recognized license revenue
of $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zed2L7Ioq7Bg" title="Revenues">479,000</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_z5jehxvl04df" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1032">0</span></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Collaborative
Research Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606, the Company recognized research revenue over the term of various agreements, as negotiated contracted amounts
were earned or reimbursable costs were incurred related to those agreements. Negotiated contracted amounts were earned in relative proportion
to the performance required under the applicable contracts. Any amounts received prior to satisfying these revenue recognition criteria
were recorded as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the
entity satisfies the relevant performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Collaborative
research revenue is recognized as research services are performed over the development periods for each agreement. During the three months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zGx3zEhB6eMa" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1034">0</span></span> and $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zxrpEkq22s" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1035">0</span></span>, respectively, and during the six months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zlTtTSiS0esc" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1037">0</span></span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_pp0p0" title="Revenues">45,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Contract
Balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
timing of the Company&#8217;s revenue recognition may differ from the timing of payment by the Company&#8217;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606 effective April 1, 2020 (using the modified retrospective approach), the Company accounted for its revenue
arrangements under ASC 605, Revenue Recognition (&#8220;ASC 605&#8221;). Under ASC 605, revenue arrangements with multiple deliverables
were evaluated for proper accounting treatment. In these arrangements, the Company recorded revenue as separate units of accounting if
the delivered items have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative
to the delivered items, and if delivery or performance of the undelivered items is considered probable and substantially within the Company&#8217;s
control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
ASC 605, revenues from product sales which included both the analyzer and various immunoassay products (&#8220;reagents&#8221;) were
generally recognized upon shipment, as no significant continuing performance obligations remained post shipment. Cash payments received
in advance were classified as deferred revenue and recorded as a liability. The Company was generally not contractually obligated to
accept returns, except for defective products. Revenue was recorded net of an allowance for estimated returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Multiple
element arrangements included contracts that combined both the Company&#8217;s analyzer and a customer&#8217;s future reagent purchases
under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was
maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated returns of approximately $<span id="xdx_905_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20210401__20210630_z7NYC0kl3Xm8" title="Estimated returns net of allowances">0</span>
and $<span id="xdx_90A_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20200401__20200630_za6TsZHWm2Ha">12,000</span>, respectively. During the six months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated
returns of approximately $<span id="xdx_901_ecustom--EstimatedReturnsNetOfAllowances_c20210101__20210630_pp0p0" title="Estimated returns net of allowances">0</span> and $<span id="xdx_903_ecustom--EstimatedReturnsNetOfAllowances_c20200101__20200630_pp0p0" title="Estimated returns net of allowances">24,000</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Deferred
Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606, payments received in advance from customers pursuant to certain collaborative research and license agreements,
deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current
deferred revenue liability based on the time from the balance sheet date to the future date of revenue recognition. The adoption of ASC
606 had no material effect on deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zkwYxQRHfu7f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zhqJeuVqvP43">Operating
Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company adopted ASC Topic 842, <i>Leases</i> (&#8220;Topic 842&#8221;) in the nine-months transition period ended December 31, 2020.
In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding right-of-use-assets for all
leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for in a manner similar to the
guidance for operating leases prior to the adoption of Topic 842. Refer to Recent Accounting Pronouncements below and Note 8 for
more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPRki3wNZEde" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zj4qokND7Ib8">Property
and Equipment, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zgbdMTw9LWNb" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"><span style="font: 10pt Times New Roman, Times, Serif">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life">3</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A8_zS4L8HTdKZI9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5Rg8dVyuxn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zpmermdSsUy">Intangible
Assets, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Intangibles
consist of patent-related costs and costs for in-license agreements. Management reviews the carrying value of intangible assets that
are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment
exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends
and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected
to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MinimumMember_zfs2rfRygQn8" title="Estimated useful lives">5</span> to <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MaximumMember_zzq4DvoKUDMa" title="Estimated useful lives">17</span>
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent has been obtained.
Patent and licenses costs are charged to operations if it is determined that the patent will not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the patents of approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">168,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">169,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at June 30, 2021 and December 31, 2020, respectively,
are stated net of accumulated amortization of approximately $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">311,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">303,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2021 and 2020 was approximately $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3v0zQLmdV6">3,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each period, and for the six months ended
June 30, 2021 and 2020 was approximately $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">6,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each period. Total future estimated amortization
of patent costs for the five succeeding years is approximately $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znkm94YkiKci">8,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the remaining six months in the year
ending December 31, 2021, approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7shlPclUFP5"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">15,000</span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each of the years ending December 31, 2022
through 2023, approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAEaHE3uqRK3" title="Future estimated amortization for year ending December 31, 2024">11,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for year 2024, approximately $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjz7njIiVoy" title="Future estimated amortization for year ending December 31, 2025">11,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for year 2025 and approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2j1ZVeBMoR4" title="Future estimated amortization, Thereafter">108,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the in-licenses of approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value">16,000</span> and $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value">19,000</span> at June 30, 2021 and December 31, 2020 are stated net of accumulated
amortization of approximately $<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization">403,000</span> and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization">400,000</span>, respectively. Amortization of licenses charged to operations for the three months
ended June 30, 2021 and 2020 was approximately $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8YvYvtaC6Tj" title="Amortization expense"><span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxA8zHH8UQz7" title="Amortization expense">2,000</span></span>, and for the six months ended June 30, 2021 and 2020 was approximately $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Amortization expense">4,000</span> and
$<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdWTl5CE1vvf" title="Amortization expense">3,000</span>, respectively. Total future estimated amortization of license costs is approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zjy5zkQ7KGW" title="Future estimated amortization, remainder of fiscal year">4,000</span> for the remaining six months in the
year ending December 31, 2021, approximately $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2022">7,000</span> for the year ending December 31, 2022 and approximately $<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2023">5,000</span> for the year ending
December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_zbwmhrCnUZxl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zI47w6nORUMl">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company
uses either the Black-Scholes option-pricing model or a Monte Carlo simulation to value the derivative instruments at inception and subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is re-assessed at the end of each reporting period (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zFzmkGcDqPof" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zbv4T442pOn8">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 - Inputs that are unobservable. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztpH2j2FsKdg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zS8v1jlo1Eha">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt are carried at cost, which management believes
approximates fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zPt7xnUlRljk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zPl0T18VEjFi">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company-issued
stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation
expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zHrnRPHbJan3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_z2q0zNL63lLl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
The components of the deferred tax asset and liability are individually classified as current and noncurrent based on their characteristics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_844_ecustom--SalesAndExciseTaxesPolicyTextBlock_zjnO3gcEnz52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zOX37w6oIsXj">Sales
and Excise Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the balance sheet as cash is collected from customers and remitted to the
tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_849_ecustom--WarrantyCostsPolicyTextBlock_zaRanNxFwzwh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zzOJlFS5EOoe">Warranty
Costs </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#8217;s best estimates of analyzer failure rates
and costs to repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
warranty liabilities were approximately $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities">48,000</span> and $<span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities">25,000</span>, respectively, for the periods ended June 30, 2021 and December 31, 2020
and are included in accrued expenses and other current liabilities on the balance sheets. Warranty costs were approximately $<span id="xdx_90E_ecustom--WarrantyCosts_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLArjq1M0zFg" title="Warranty costs">20,000</span> and
$<span id="xdx_90C_ecustom--WarrantyCosts_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM9DQPsjm61b">31,000</span> for the three months ended June 30, 2021 and 2020, respectively, and approximately $<span id="xdx_906_ecustom--WarrantyCosts_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs">41,000</span> and $<span id="xdx_904_ecustom--WarrantyCosts_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs">58,000</span> for the six months ended
June 30, 2021 and 2020, respectively, and are included in cost of product sales in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/>

<p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGsIPjhAUcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is calculated by dividing
the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.
Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents
outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, employee stock
purchase plan rights, restricted stock units, and warrants, and convertible preferred stock are considered to be common stock equivalents
but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be anti-dilutive.
The Company incurred net losses for all periods presented and there were no reconciling items for potentially dilutive securities. More
specifically, at June 30, 2021 and 2020, stock options, warrants, and convertible preferred stock exercisable
or convertible for approximately <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20210101__20210630_ztVfLrEYZEGd">13.9
</span>million shares and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20200101__20200630_zCvq2P9SIIMl">16.5
</span>million shares, respectively, were excluded from the calculation of diluted net loss per share as their effect would have been
anti-dilutive. Comprehensive loss is the same as net loss for all periods presented.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLVYGecyFne3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zhmEcnMuVYBd">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when
it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses
on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition
of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued
ASU No. 2019-10, Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842),
which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard
will be effective for the Company in the first quarter of the fiscal year beginning January 1, 2023, and early adoption is permitted.
The Company has not completed its review of the impact of this standard on its consolidated financial statements. However, based on the
Company&#8217;s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard
will have a material effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair
Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221;
an amendment to the accounting guidance on fair value measurements. The guidance modifies the disclosure requirements on fair value measurements,
including the removal of disclosures of the amount of and reasons for transfers between Level 1 of the fair value hierarchy, the policy
for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain
disclosure requirements related to Level 3 fair value measurements. The guidance is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019. The Company adopted ASU No. 2018-13 on April 1, 2020 and the adoption of this guidance
did not have a material impact on its financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major
separation models required under prior U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts
to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU
2020-06 is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the
beginning of the Company&#8217;s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203570568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">LIQUIDITY</a></td>
<td class="text"><p id="xdx_806_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_zoiprZkNN32f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
2 &#8212; <span id="xdx_82A_zXlWPEpBMtD2">LIQUIDITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has incurred recurring losses from operations and has an accumulated deficit at June 30, 2021, and the Company expects to continue
to incur losses subsequent to the balance sheet date of June 30, 2021. The Company&#8217;s reverse recapitalization transaction with
Ritter closed in May 2020 together with an associated new equity capital raise of approximately $<span id="xdx_90A_ecustom--NewEquityCapitalRaise_pn5n6_c20200501__20200531_zqUoCRTS0LA" title="New equity capital raise">4.0</span> million, and approximately $<span id="xdx_904_eus-gaap--ConvertibleNotesPayable_iI_pn5n6_c20200531_zFCoqLGzMJM1" title="Convertible notes payable">1.9</span>
million in convertible notes payable were converted into shares of the Company&#8217;s capital stock. In July, August and December 2020,
the Company raised an additional $<span id="xdx_90E_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200701__20200731__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_z1vQOJCCNDjj" title="Proceeds from sale of equity"><span id="xdx_903_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20200801__20200831__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zztW8WkqmUKh" title="Proceeds from sale of equity"><span id="xdx_906_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_pn5n6_c20201201__20201231__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_zzYgTIiBjor8" title="Proceeds from sale of equity">30.0</span></span></span> million through three Securities Purchase Agreements with a single institutional investor (see
Note 10). Based on the Company&#8217;s current cash position, currently planned expenditures and level of operations, the Company
believes it has sufficient capital to fund operations for the 12-month period subsequent to the issuance of the interim financial information.
However, there is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on a continuing basis.
Also, beyond such 12-month period, planned research and development activities, capital expenditures, clinical and pre-clinical testing,
and commercialization activities of the Company&#8217;s products are expected to require significant additional financing. Additional
financing may not be available on acceptable terms or at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203444776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY, NET</a></td>
<td class="text"><p id="xdx_803_eus-gaap--InventoryDisclosureTextBlock_ziy8oKxYjJPf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
3 &#8212; <span id="xdx_82D_zb0217Ucayll">INVENTORY, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zweDtfgSxQ6a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory,
net consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zyek1WxxDOR4" style="display: none">SCHEDULE
OF INVENTORY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210630_zddzIVsz88J6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20201231_zqmjVAirAkSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINz4Kh_z5xcwEDCHx25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">779,936</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">579,765</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINz4Kh_zjdyDzKJfQQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,826</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINz4Kh_zYCMrqiKQ5a6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryNet_iTI_pp0p0_mtINz4Kh_zB9CNfzPsgB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Inventory net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,073,335</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">953,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of June 30, 2021 and December 31, 2020, total inventory is recorded
net of inventory reserves of $149,000 and $108,000, respectively.</p>

<p id="xdx_8A6_z5oJsBpY1luf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>



<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203764808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_80E_ecustom--PrepaidExpensesAndOtherCurrentAssetsTextBlock_zP6z8batpk9g" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
4 &#8212; <span id="xdx_822_zqEItuj9Liw8">PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zTrCqblKHtn5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zw9lcaI91hWf" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210630_zTj5DmXdaem2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20201231_zfWuwFIvMfxg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzTBJ_zb3uxuB9si06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,916,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,307,864</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidManufacturingExpenses_iI_pp0p0_maPEAOAzTBJ_zsIu2p5Wbkgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,181,029</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--PrepaidInvestorRelationsExpenses_iI_pp0p0_maPEAOAzTBJ_zsBsOWTQ2nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid investor relations expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzTBJ_zjRQVQOU3ym1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,726</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,001</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzTBJ_zKLqbdsBQmw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,033,857</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,678,894</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A8_zzUszgzqVto6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Expenses And Other Current Assets [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203216632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="text"><p id="xdx_803_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zXoWru4FyZyf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
5 &#8212; <span id="xdx_824_zKY5Ri9mxDb1">PROPERTY AND EQUIPMENT, NET</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8vn5kLdV2Vj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment, net consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B3_zQPlJkdETztl" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zUN0RR2satU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zte766wi6Fr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhZDykO8MJs" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,409,946</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,401,470</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_zNNg3LU1HtBc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Construction in progress&#8211;equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,400</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTJvxMrKYNJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">472,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,865</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJsUcYOnRNW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">327,894</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321,033</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zKCMD3ln1hQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Molds and tooling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_znB86KyBRn33" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzgSC_z2npNgYtg1Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,707,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,669,469</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzgSC_zEl0k06NM36j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,454,405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,422,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzgSC_zzGX836GFucc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">253,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">247,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zrTNH6DuEFlf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Depreciation
expense relating to property and equipment was approximately $<span id="xdx_90A_eus-gaap--Depreciation_c20210401__20210630_pp0p0" title="Depreciation expense">17,000</span> and $<span id="xdx_90C_eus-gaap--Depreciation_c20200401__20200630_pp0p0" title="Depreciation expense">9,000</span> for the three months ended June 30, 2021 and 2020, respectively,
and $<span id="xdx_90F_eus-gaap--Depreciation_c20210101__20210630_pp0p0" title="Depreciation expense">32,000</span> and $<span id="xdx_902_eus-gaap--Depreciation_c20200101__20200630_pp0p0" title="Depreciation expense">18,000</span> for the six months ended June 30, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840289123528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_804_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zUZIrEOaPobk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
6 &#8212; <span id="xdx_827_ziVLcjfC4Ea1">ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES </span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zknWsIWftFY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zeLQwaM7pAPd" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210630_zNqkTzsNOZd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zi57gCz66qd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedCompensation_iI_pp0p0_maALCz4Fv_zM89Pg3c6Jc1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">50,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">15,091</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCz4Fv_zXu34xOTSRli" style="vertical-align: bottom; background-color: White">
    <td>Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,457</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCz4Fv_zUnW6pFqF934" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">491</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCz4Fv_z1a9YqTVYZ1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">744,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,504</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCz4Fv_z3BwqWil0ZF9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,261</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedWarrantyCostsCurrent_iI_pp0p0_maALCz4Fv_z142s1ScbKS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warranty costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,871</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCz4Fv_zdf0hc56hNZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,566</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccruedPatentAndLicenseFeesCurrent_iI_pp0p0_maALCz4Fv_zVXXmR9dGz24" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent and license fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,204</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maALCz4Fv_z0MM8Hb8QPr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Franchise, sales and use taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,353</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCz4Fv_zvdb97Z8BTwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,326</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCz4Fv_z6U54f6BSU4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317,730</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCz4Fv_zLe38PjFctJg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Accrued expenses and
    other current liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,923,708</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">746,738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A9_zcAuYlfE27Cg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203855832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WarrantLiabilitiesTextBlock', window );">WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_80E_ecustom--WarrantLiabilitiesTextBlock_z6nQsV0augN3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
7 &#8211; <span id="xdx_822_zbIvoxysRFYe">WARRANT LIABILITIES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the &#8220;Series C Warrants&#8221;). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted. The Series C Warrants were classified as liabilities, but had minimal fair value prior to the merger with Ritter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase an aggregate of
<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_pdd">4,713,490
</span></span><span style="font: 10pt Times New Roman, Times, Serif">shares of the Company&#8217;s common stock at
$<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember_pdd">0.72
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, subject to adjustment. As of June
30, 2021, the warrants received in exchange for the Series C Warrants have remaining terms ranging from <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MinimumMember_zYLP8QH5cbJ2">2.4
</span></span><span style="font: 10pt Times New Roman, Times, Serif">to <span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--StatementEquityComponentsAxis__custom--SeriesCWarrantsMember__srt--RangeAxis__srt--MaximumMember_zSZGUbFmXjU2">3.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">years. The warrants were determined to be
liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, resulting from inclusion of a leveraged ratchet provision for
subsequent dilutive issuances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-HVF_zIBruZ56MXte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants for the six months ended June
30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BF_zkvxIGOm7U5b" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock Warrants (received in exchange for the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Series C Warrants)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining<br/> Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zDaxPDbnKUl5" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">3,378,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zStbWShS2lMf" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">0.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zg9vSYTLyv0l" style="text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCvou4jClwBf" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Exercised">(542,737</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">0.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited">(36,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">0.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1290">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1292">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcbNS4q2OtX" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">2,799,762</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCmR7vjK49T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zkoYGshadwE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">2,799,762</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zfuT5h3k2XGa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zgPYgZcHeZB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zRdhng9g0ri5" title="Weighted Average Remaining Life (Years) Exercisable">2.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zyjRbB8a89y9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Of
the <span id="xdx_90B_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Shares issued upon the exercise of warrants">542,737</span> shares issued upon the exercise of warrants (previously received in exchange for the Series C Warrants) during the six months
ended June 30, 2021, <span id="xdx_90C_ecustom--NumberOfWarrantExercisedOnCashlessBasis_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUTMA63LIrG8" title="Shares issued upon net-exercise of warrants">156,861</span> shares were issued upon net-exercises rather than upon exercises for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants activity for the six months ended
June 30, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<div id="xdx_C02_gL3SOSENWORTB-HVF_zmp4GprQzn33"><table cellpadding="0" cellspacing="0" id="xdx_306_133_z9cZFuv8bvj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock Warrants (received in exchange for the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Series C Warrants)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211; Average Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total outstanding &#8211; December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z55WScidoXii" style="text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzg5D37vqJx9" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z5F2hAAfkbyg" style="width: 12%; text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger">4,713,490</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzYYlcEHss7g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger">0.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1328">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1330">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCZPSOaRBzk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">4,713,490</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zrQKZTCBhAA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zNRnfOYyDl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">4,713,490</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zXoyCEVmqAse" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zQqW9Rqd8c3a" title="Weighted Average Remaining Life (Years) Exercisable">3.82</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C07_gL3SOSENWORTB-HVF_zlWKVsXUPWPc">&#160;</span></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_896_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zci8YKS0KK1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents the Company&#8217;s fair value hierarchy for its warrant liabilities (all of which arise under the warrants
received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span id="xdx_8BB_zCeGJCyPl59i" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 2.5pt">Balance as of December 31. 2020</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcWsKV4o9Ecg" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ikU4uxxzNa" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeOj9aLw7l81" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231_zTuVPoyBlM0c" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7Mj8rQWaWJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLbedbEb8mnf" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx8I03Rnxbyg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">4,112,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630_zIKu76ZVXgH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">4,112,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zj0RwQwpELYd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were no transfers of financial assets or liabilities between category levels for the three and six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021 the Company recorded</span> <span style="font: 10pt Times New Roman, Times, Serif">$<span id="xdx_906_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zh2rXF5byK3b">4.2
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million gain
</span><span style="font: 10pt Times New Roman, Times, Serif">in other income because the fair value of the
warrant liabilities declined to $<span id="xdx_908_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbs361zMjhj6">4.1
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million from $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstanding_iI_pn5n6_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvL4sTmvT0Pj">8.3
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million at December 31, 2020, primarily due to
a reduction in the stock price and to warrant exercises. For the six months ended June 30, 2020, change in fair value of warrant liabilities
was $<span id="xdx_908_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zssDGYyspVSj">16.2
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million due to the reverse recapitalization transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zlfJeT57pXwg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of June 30, 2021 and December
31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_z8MEEy2aESzg" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June
    30, 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December
    31, 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zK94R0DS9ZS1" title="Fair value assumptions, measurement input, percentages">0.34</span>%
    &#8212; <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zntNlY0eUaI5" title="Fair value assumptions, measurement input, percentages">0.46</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%<span style="font: 10pt Times New Roman, Times, Serif"/></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zwKTxpiUH5Yl" title="Fair value assumptions, measurement input, percentages">0.17</span>%
    &#8212; <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zNCCsWNJwP7g" title="Fair value assumptions, measurement input, percentages">0.22</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    volatility (peer group)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_za9tyFt3yra7" title="Fair value assumptions, measurement input, percentages">82.00</span>
    &#8212; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zATWqLnWH8ja" title="Fair value assumptions, measurement input, percentages">83.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOahHKARziM2" title="Fair value assumptions, measurement input, percentages">82.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Term
    of warrants (in years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zTGA01eevXn8" title="Fair value assumptions, measurement input, term">2.41</span>
    &#8212; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z7JuTZjNTKIf" title="Fair value assumptions, measurement input, term">2.99</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zomSgy8h899d" title="Fair value assumptions, measurement input, term">2.90</span>
    &#8212; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zb0kn7hRmcqc" title="Fair value assumptions, measurement input, term">3.49</span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zwf9yBh3xzkb" title="Fair value assumptions, measurement input, percentages">0.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCwGmmUYzigf" title="Fair value assumptions, measurement input, percentages">0.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p id="xdx_8AA_ztiBgY0ZQg81" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant Liabilities [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840198216136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOfLesseeDisclosureTextBlock', window );">LEASES</a></td>
<td class="text"><p id="xdx_809_eus-gaap--LeasesOfLesseeDisclosureTextBlock_zPErSFj5Pmdd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
8 &#8212; <span id="xdx_825_zl6DYcI8hvDg">LEASES</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_zoVpgJ3yxoz7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases its facilities under a long-term operating lease agreement expiring in October 2022. The tables below show the operating
lease right-of-use assets and operating lease liabilities as of December 31, 2020 and June 30, 2021, including the changes during the
periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zxgSC1D22YA5" style="display: none">SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/>
 right-of-use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net right-of-use assets at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zB6B7GBLTW6e" style="width: 16%; text-align: right" title="Operating lease right-of-use assets">430,795</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amortization of operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9Hs7w4GqnMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets">(109,719</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z8EMRGxbC3F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">321,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/>
 liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">At December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zVGOAE31lqcf" style="width: 16%; text-align: right" title="Operating lease liabilities">491,565</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less principal payments on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zz2UiEkr3aO1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities">(122,780</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zgVasBo025h4" style="text-align: right" title="Operating lease liabilities">368,785</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z5OgPJ56SJpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion">(98,145</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Current portion at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_ztDMb9pI3DEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at June 30, 2021">270,640</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zrdgvJmWKH7i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company&#8217;s operating leases have a weighted-average remaining lease term of <span id="xdx_905_eus-gaap--OperatingLeaseWeightedAverageRemainingLeaseTerm1_iI_dtY_c20210630_z2G09xQT506c" title="Weighted-average remaining lease term">1.3</span> years and a weighted-average
discount rate of <span id="xdx_90B_eus-gaap--OperatingLeaseWeightedAverageDiscountRatePercent_iI_dp_uPure_c20210630_zd13cRMMm1c6" title="Discount rate operating lease">8.9</span>%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zdtcnbpO4Pt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, future minimum payments during the next five fiscal years and thereafter are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zJZzWsebBMSi" style="display: none">SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2021 (six months)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" style="width: 20%; text-align: right" title="2021 (nine months)">145,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="2022">246,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" style="text-align: right" title="Total">392,608</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20210630_zjgjDCWWcQ73" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less present value discount">(23,823</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liabilities">368,785</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_ztPevmm4o3l9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Total
lease expense was approximately $<span id="xdx_908_eus-gaap--OperatingLeaseExpense_pp0p0_c20210401__20210630_zGiPFYxUxCE1" title="Lease expense"><span id="xdx_904_eus-gaap--OperatingLeaseExpense_pp0p0_c20200401__20200630_zymfjyOG28S" title="Lease expense">86,000</span></span> for each of the three month periods ended June 30, 2021 and 2020, and approximately $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20210101__20210630_pp0p0" title="Lease expense">172,000</span>
and $<span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pp0p0" title="Lease expense">171,000</span>, respectively, for the six month periods ended June 30, 2021 and 2020. Lease expense was recorded in cost of product sales,
general and administrative expenses, research and development and sales and marketing expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -URI http://asc.fasb.org/topic&amp;trid=2208923<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204218136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DisclosureResearchAndLicenseAgreementsAbstract', window );"><strong>Research And License Agreements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ResearchAndLicenseAgreementsTextBlock', window );">RESEARCH AND LICENSE AGREEMENTS</a></td>
<td class="text"><p id="xdx_809_ecustom--ResearchAndLicenseAgreementsTextBlock_z2TONLNY0DLb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
9 &#8212; <span id="xdx_822_zYKMu8rtYvdb">RESEARCH AND LICENSE AGREEMENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
University of Louisville Research Foundation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Between
June 2018 and September 2020, the Company entered into license and sponsored research agreements with the University of Louisville Research
Foundation (&#8220;ULRF&#8221;) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements,
the Company will take over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance
of the related intellectual property portfolio. In return, ULRF received a $<span id="xdx_904_eus-gaap--RepaymentsOfConvertibleDebt_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Payment of convertible promissory note"><span id="xdx_90C_eus-gaap--RepaymentsOfConvertibleDebt_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Payment of convertible promissory note">50,000</span></span> convertible promissory note in payment of an upfront
license fee, which was subsequently converted into the Company&#8217;s common stock, and the Company agreed to reimburse ULRF for sponsored
research expenses of up to $<span id="xdx_90A_ecustom--ReimbursementOfResearchExpenses_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement of research expenses"><span id="xdx_905_ecustom--ReimbursementOfResearchExpenses_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement of research expenses">805,000</span></span> and prior patent costs of up to $<span id="xdx_908_ecustom--ReimbursementPatentCost_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost"><span id="xdx_900_ecustom--ReimbursementPatentCost_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost">200,000</span></span>. <span id="xdx_907_ecustom--AgreementTermPaymentDescription_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description"><span id="xdx_90E_ecustom--AgreementTermPaymentDescription_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description">In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $<span id="xdx_902_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Milestone payment"><span id="xdx_90A_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Milestone payment">100,000</span></span> to $<span id="xdx_900_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment"><span id="xdx_908_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment">5,000,000</span></span>
upon the achievement of certain regulatory and commercial milestones.</span></span> Milestone payments for the first therapeutic indication would be
$<span id="xdx_90C_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment"><span id="xdx_907_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment">100,000</span></span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_905_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment"><span id="xdx_90D_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment">200,000</span></span> for first dosing in a Phase 2 clinical trial, $<span id="xdx_902_ecustom--MilestonePayment_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_pp0p0" title="Milestone payment"><span id="xdx_90A_ecustom--MilestonePayment_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_pp0p0" title="Milestone payment">350,000</span></span> for first dosing
in a Phase 3 clinical trial, $<span id="xdx_90E_ecustom--MilestonePaymentForMarketingExpenses_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Milestone payment for marketing expenses"><span id="xdx_907_ecustom--MilestonePaymentForMarketingExpenses_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Milestone payment for marketing expenses">500,000</span></span> for regulatory marketing approval and $5,000,000 upon achieving a cumulative $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue"><span id="xdx_90F_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue">500,000,000</span></span> of Licensed
Product sales; the Company would also pay another $500,000 milestone payment for any additional regulatory marketing approval for each
additional therapeutic (or diagnostic) indication. The Company also must pay ULRF shortfall payments if the total amounts actually paid
with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_908_ecustom--ShortfallPayments_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments"><span id="xdx_900_ecustom--ShortfallPayments_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments">10,000</span></span>
to $<span id="xdx_90E_ecustom--ShortfallPayments_c20180601__20180630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments"><span id="xdx_906_ecustom--ShortfallPayments_c20200901__20200930__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments">50,000</span></span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zb0w5Xuo576c" title="Research and development">89,000</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zO7gH4LRXena" title="Research and development">2,000</span>,
and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Research and development">152,000</span> and $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Research and development">2,000</span>, respectively, and these amounts are recorded
in research and development expenses in the statements of operations. Minimum annual royalties of $<span id="xdx_907_eus-gaap--RoyaltyExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_z0AMNEA51QIc" title="Minimum annual royalties"><span id="xdx_90E_eus-gaap--RoyaltyExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zmAyy375iv96" title="Minimum annual royalties">0</span></span> for each period related to these
agreements are included in research and development expenses in the statements of operations for the three months ended June 30, 2021
and 2020, respectively, and approximately $<span id="xdx_90A_eus-gaap--RoyaltyExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Minimum annual royalties">0</span> and $<span id="xdx_908_eus-gaap--RoyaltyExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="Minimum annual royalties">10,000</span> related to these agreements are included in research and development expenses
in the statements of operations for the six months ended June 30, 2021 and 2020, respectively. License costs were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zmIbooK5WE8e" title="License costs">17,000</span>
and $<span id="xdx_907_ecustom--LicenseCost_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_zpAVwl58omh9" title="License costs">0</span> related to these agreements for the three months ended June 30, 2021 and 2020, respectively, and approximately $<span id="xdx_903_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="License costs">53,000</span> and $<span id="xdx_905_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember_pp0p0" title="License costs">0</span>
related to these agreements for the six months ended June 30, 2021 and 2020, respectively, and are included in research and development
expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company will reimburse ULRF
for sponsored research expenses of up to $<span id="xdx_909_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zTmRwYcmoSLb" title="Reimbursement of research expenses">693,000</span> for this program. In February 2021, the Company extended the term of this agreement
for an additional 18 months (expires July 2022) and increased the amount that the Company will reimburse ULRF for sponsored research
expenses from $<span id="xdx_901_ecustom--ReimbursementOfResearchExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zAiOMZgsBdNi" title="Reimbursement of research expenses">693,000</span> to approximately $<span id="xdx_901_ecustom--ReimbursementOfResearchExpenses_pn5n6_c20190301__20190331__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zLhai4x4by2j" title="Reimbursement of research expenses">1.4</span> million. In July 2020, the Company entered into an exclusive license agreement with ULRF
for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization
of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $<span id="xdx_903_ecustom--ReimbursementPatentCost_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Reimbursement patent cost">112,000</span> for an upfront license fee and reimbursement of prior patent costs. <span id="xdx_90A_ecustom--AgreementTermPaymentDescription_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="Agreement term payment, description">In addition, the Company has agreed to pay
ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000)
or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not
covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first
two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and
30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated
with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging
from $<span id="xdx_90A_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_zMxcihhstK06" title="Milestone payment">50,000</span> to $<span id="xdx_90A_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Milestone payment">5,000,000</span> upon the achievement of certain regulatory and commercial milestones.</span> Milestone payments for the first therapeutic
indication would be $<span id="xdx_902_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_pp0p0" title="Milestone payment">50,000</span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_904_ecustom--MilestonePayment_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_pp0p0" title="Milestone payment">100,000</span> for first dosing in a Phase 2 clinical trial, $<span id="xdx_902_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zQHNLJQd862f" title="Milestone payment">150,000</span>
for first dosing in a Phase 3 clinical trial, $<span id="xdx_907_ecustom--RegulatoryMarketingApprovalExpenses_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Regulatory marketing approval, expenses">300,000</span> for regulatory marketing approval and $<span id="xdx_90C_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember_zbHNEPKe4Etg" title="Regulatory marketing approval, expenses">5,000,000</span> upon achieving a cumulative $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Licensed product sales, revenue">500,000,000</span>
of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties
and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $<span id="xdx_90A_ecustom--UpfrontLicenseFee_c20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Upfront license fee">20,000</span> to $<span id="xdx_908_ecustom--UpfrontLicenseFee_c20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Upfront license fee">100,000</span>) for such
year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zRMOPwfKB9J3" title="Research and development">99,000</span> and $<span id="xdx_90C_eus-gaap--ResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_z2o9hA2osK7l">139,000</span>,
respectively, and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Research and development">206,000</span> and $<span id="xdx_907_eus-gaap--ResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Research and development">247,000</span>, respectively, and are recorded
in research and development expenses in the statements of operations. License costs related to these agreements for the three months
ended June 30, 2021 and 2020 were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zlM5wazLFpze" title="License costs">0</span> and $<span id="xdx_908_ecustom--LicenseCost_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zsN5aApOJoc5" title="License costs">0</span>, respectively, and for the six months ended June 30, 2021 and 2020 were approximately
$<span id="xdx_904_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="License costs">40,000</span> and $<span id="xdx_906_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="License costs">0</span>, respectively, and are included in research and development expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company will take over development, regulatory approval and commercialization of the
compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF
received approximately $<span id="xdx_90B_ecustom--UpfrontLicenseFee_c20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Upfront license fee">24,000</span> for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required
to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $<span id="xdx_902_eus-gaap--ResearchAndDevelopmentExpense_c20200601__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Research and development">250,000</span>. In November
2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$<span id="xdx_90A_eus-gaap--ResearchAndDevelopmentExpense_c20201101__20201130__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Research and development">430,000</span> in research which satisfied this requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--UlrfLicenseAgreementDescription_c20200601__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember" title="ULRF license agreement description">In
addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165
as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MinimumMember_zaVxo99JS9k5" title="Milestone payment">50,000</span> to $<span id="xdx_902_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--RangeAxis__srt--MaximumMember_zmeLZ2N0rXjb" title="Milestone payment">5,000,000</span> upon the achievement of certain
regulatory and commercial milestones.</span> Milestone payments would be $<span id="xdx_907_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseOneClinicalTrialMember_zx67h8sqwUq8" title="Milestone payment">50,000</span> for first dosing in a Phase 1 clinical trial, $<span id="xdx_90E_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseTwoClinicalTrialMember_zDduFHD1wgbl" title="Milestone payment">100,000</span> for
first dosing in a Phase 2 clinical trial, $<span id="xdx_909_ecustom--MilestonePayment_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__us-gaap--AwardTypeAxis__custom--PhaseThreeClinicalTrialMember_zMeZ5djxENh3" title="Milestone payment">150,000</span> for first dosing in a Phase 3 clinical trial, $<span id="xdx_908_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zGhk9qPoZRy4" title="Regulatory marketing approval, expenses">300,000</span> for regulatory marketing approval
and $<span id="xdx_900_ecustom--RegulatoryMarketingApprovalExpenses_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--LicenseAndSponsoredResearchAgreementsMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--LicensedProductSalesMember_zmcRsoIJtlJc" title="Regulatory marketing approval, expenses">5,000,000</span> upon achieving a cumulative $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_pp0p0_c20190601__20190630__us-gaap--TypeOfArrangementAxis__custom--SponsoredResearchAgreementAndLicenseMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zXQhklepvuTa" title="Licensed product sales, revenue">500,000,000</span> of Licensed Product sales. The Company also must pay ULRF shortfall payments
if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable
annual minimum (ranging from $<span id="xdx_906_ecustom--ShortfallPayments_c20200627__20200630__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--RoyaltiesAndNonRoyaltySublicenseeIncomeMember__srt--RangeAxis__srt--MinimumMember_pp0p0" title="Shortfall payments">5,000</span> to $<span id="xdx_907_ecustom--ShortfallPayments_c20200626__20200630__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember__srt--ProductOrServiceAxis__custom--RoyaltiesAndNonRoyaltySublicenseeIncomeMember__srt--RangeAxis__srt--MaximumMember_pp0p0" title="Shortfall payments">50,000</span>) for such year.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sponsored
research expenses related to these agreements for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_902_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zx5DlN0F2SG4" title="Sponsored research expense">25,000</span> and $<span id="xdx_909_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zQ8Acwmi7Gh2">0</span>, respectively,
and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_908_eus-gaap--OtherResearchAndDevelopmentExpense_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Sponsored research expense">94,000</span> and $<span id="xdx_90A_eus-gaap--OtherResearchAndDevelopmentExpense_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_pp0p0" title="Sponsored research expense">0</span>, respectively, and are recorded in research and
development expenses in the statements of operations. License costs related to these agreements for the three months ended June 30, 2021
and 2020 were approximately $<span id="xdx_904_ecustom--LicenseCost_pp0p0_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zisYcJSjJYjd" title="License costs">16,000</span> and $<span id="xdx_903_eus-gaap--OtherResearchAndDevelopmentExpense_pp0p0_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zepdM0Sfq5B1" title="Sponsored research expense">0</span>, respectively, and for the six months ended June 30, 2021 and 2020 were approximately
$<span id="xdx_906_ecustom--LicenseCost_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zHEQM2T52lqf" title="Sponsored research expense">16,000</span> and $<span id="xdx_900_ecustom--LicenseCost_pp0p0_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--UniversityOfLouisvilleResearchFoundationMember_zgMqeQ8fymYd" title="Sponsored research expense">0</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Advanced
Cancer Therapeutics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
December 2018, <span id="xdx_906_ecustom--AgreementDescription_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember" title="Agreement description">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#8220;ACT&#8221;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $<span id="xdx_902_eus-gaap--ProceedsFromConvertibleDebt_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Proceeds from convertible promissory note">25,000</span> convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000)</span>,
until the 15th anniversary of the ACT license agreement and (ii) milestone payments of $<span id="xdx_90E_ecustom--MilestoneMethodRevenueRecognized_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Milestone payment">100,000</span> for the Company raising a cumulative
total of $<span id="xdx_904_ecustom--CumulativeAmount_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Cumulative amount">2,000,000</span> in new equity financing after the date of the ACT license agreement, $<span id="xdx_907_ecustom--MilestoneMethodRevenueRecognized_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember__srt--TitleOfIndividualAxis__custom--CEMarkMember_pp0p0" title="Milestone payment">100,000</span> upon any first QN-165-based licensed
product receiving the CE Mark or similar FDA status, and $<span id="xdx_905_ecustom--CumulativeAmount_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember__srt--TitleOfIndividualAxis__custom--CEMarkMember_pp0p0" title="Cumulative amount">500,000</span> upon cumulative worldwide QN-165-based licensed product net sales reaching
$<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_c20181201__20181231__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="Licensed product sales, revenue">3,000,000</span>. For the three months ended June 30, 2021 and 2020, there were <span id="xdx_902_ecustom--LicenseCost_pp0p0_do_c20210401__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zg9CsN29iKeb" title="License costs"><span id="xdx_90D_ecustom--LicenseCost_pp0p0_do_c20200401__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_zNFXdk20sTo7">no</span></span> license costs and for the six months ended June 30, 2021
and 2020, there were approximately $<span id="xdx_90B_ecustom--LicenseCost_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="License costs">2,000</span> and $<span id="xdx_905_ecustom--LicenseCost_c20200101__20200630__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--AdvancedCancerTherapeuticsLLCMember_pp0p0" title="License costs">0</span>, respectively, in license costs related to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Prediction
Biosciences</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture
diagnostic tests for use in the stroke point-of-care market. The Company recognizes development revenue and product sales over the performance
period of the contract. For the three months ended June 30, 2021 and 2020 there was $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_zfbLNyPJsNG5" title="Product sales"><span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_zf0cDJ875f29">0</span></span> for each period, and for the six months ended
June 30, 2021 and 2020, there was $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_pp0p0" title="Product sales">0</span> and $<span id="xdx_90E_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember__dei--LegalEntityAxis__custom--PredictionBiosciencesSASMember_pp0p0" title="Product sales">45,000</span>, respectively, in collaborative research revenue related to this agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Sekisui
Diagnostics</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the year ended March 31, 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui Diagnostics, LLC (&#8220;Sekisui&#8221;)
until May 2022. The Company appointed Sekisui as its diagnostics commercial partner and exclusive worldwide distributor with the exception
of certain customer accounts retained by Qualigen. The agreement contains a right of first refusal for Sekisui against any potential
acquisition of the Company until May 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were product sales to Sekisui of approximately $<span id="xdx_900_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210401__20210630__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zuAfQmi6xC55" title="Product sales">701,000</span> and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20200401__20200630__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zzH2MZnlYtFg">420,000</span> for the three months ended June 30, 2021 and 2020, and product sales
of approximately $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20210101__20210330__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zbjLj90fGz7e" title="Product sales">1.7</span> million and $<span id="xdx_903_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn5n6_c20200101__20200330__dei--LegalEntityAxis__custom--SekisuiDiagnosticsLLCMember_zTlELjhDgs6e" title="Product sales">1.4</span> million related to this agreement, for the six months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Yi
Xin</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2020, the Company entered into a Technology Transfer Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (&#8220;Yi Xin&#8221;),
of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on the Company&#8217;s
core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to manufacture and sell the Company&#8217;s
current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Technology Transfer Agreement, the Company received net cash payments of $<span id="xdx_908_eus-gaap--DeferredRevenue_c20201231__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Deferred revenue">250,000</span> in the final quarter of the year ended December
31, 2020, classified as deferred revenue on the December 31, 2020 balance sheet, and a cash payment of $<span id="xdx_900_eus-gaap--DeferredRevenue_c20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Deferred revenue">420,000</span> during the first quarter
of 2021. The Company will also receive low- to mid-single-digit royalties on any future new-generations and current-generations product
sales by Yi Xin. Of these amounts, the Company recognized approximately $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember_pp0p0" title="Product sales">38,000</span> in product sales and $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_c20210101__20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zIlApYx4eqLg" title="Product sales">479,000</span> in license revenue included
in the statement of operations for the six months ended June 30, 2021. On the balance sheet at June 30, 2021, the Company had
deferred revenue of approximately $<span id="xdx_90C_eus-gaap--DeferredRevenue_iI_c20210630__dei--LegalEntityAxis__custom--YiXinZhenDuanJishuLtdMember__us-gaap--TypeOfArrangementAxis__custom--TechnologyTransferAgreementMember_zGuslToQocme" title="Deferred revenue">153,000</span> related to this agreement. The Company provided technology transfer and patent/know-how
license rights to facilitate Yi Xin&#8217;s development and commercialization.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company gave Yi Xin the exclusive rights for China &#8211; which is a market the Company has not otherwise entered &#8211; both for Yi
Xin&#8217;s new generations of FastPack-based products and for Yi Xin-manufactured versions of the Company&#8217;s existing FastPack
product lines. Yi Xin will also have the right to sell its new generations of FastPack-based diagnostic test systems throughout the world
(but not to or toward current customers of the Company&#8217;s existing generations of FastPack products); any such non-China sales would,
until Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
need to be through Sekisui. In addition, after Spring 2022, Yi Xin will have the right to sell Yi Xin-manufactured versions of existing
FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US customers
of those products). Also, after Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
Yi Xin will have the right to buy Company-manufactured FastPack 1.0, IP and PRO products from the Company at distributor prices for resale
in and for the United States (but not to or toward current US customers of those products); the Company did not license Yi Xin to sell
in the United States market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines, even after Spring
</span><span style="font: 10pt Times New Roman, Times, Serif">2022. In the Technology Transfer Agreement, the
Company confirmed that it would not, after Spring</span> <span style="font: 10pt Times New Roman, Times, Serif">2022,
seek new FastPack customers outside the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>STA
Pharmaceutical</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production
of QN-165, the Company&#8217;s lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials
in 2021. In connection with this agreement, the Company paid an upfront deposit of approximately $<span id="xdx_902_eus-gaap--DepositAssets_iI_pn5n6_c20201231__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zkKoViqNtT7j" title="Upfront deposit">1.1</span> million which was classified as
prepaid expenses on the December 31, 2020 balance sheet date, and all of which was included in research and development expenses in the
statement of operations for the six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses related to this agreement for the three months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210401__20210630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zFZog1FdfL0k" title="Research and development">1.9</span> million
and $<span id="xdx_906_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200401__20200630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zE2xTb2IEZL3">0</span>, respectively, and for the six months ended June 30, 2021 and 2020 were approximately $<span id="xdx_90E_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20210101__20210630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_znYKqu7syUGd">3.1</span> million and $<span id="xdx_908_eus-gaap--ResearchAndDevelopmentExpense_pn5n6_c20200101__20200630__dei--LegalEntityAxis__custom--STAPharmaceuticalCoLtdMember_zLN83j6BoaRi">0</span>, respectively, and are
recorded in research and development expenses in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureResearchAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureResearchAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ResearchAndLicenseAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and license agreements [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ResearchAndLicenseAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840196790584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zr30Mvgz6Y4j" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
10 &#8212; <span id="xdx_822_z9AtyuwoVjm">STOCKHOLDERS&#8217; EQUITY</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021 and December 31, 2020, the Company had two classes of capital stock: common stock and Series Alpha convertible preferred
stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Common
Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, as
of June 30, 2021 any remaining assets would be distributed ratably among the holders of the common stock and, on an as-if-converted basis,
the holders of Series Alpha convertible preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The
holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_893_ecustom--ScheduleOfReservedSharesTableTextBlock_zUhHeLMgL6ik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2021, the Company has reserved <span id="xdx_903_eus-gaap--CommonStockSharesSubscribedButUnissued_c20210630_pdd" title="Shares of authorized but unissued common stock">13,917,461</span> shares of authorized but unissued common stock for possible future issuance. At June
30, 2021, shares were reserved in connection with the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zhSYbgOdMeNk" style="display: none">SCHEDULE
OF RESERVED SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Exercise of outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockOptionsMember_zo3DUyEoEGa1" style="width: 20%; text-align: right" title="Total">4,133,856</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise of outstanding stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockWarrantMember_zkXGif7XmMEi" style="text-align: right">9,540,187</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of outstanding Series Alpha preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--SerieAlphaPreferredStockMember_z5vjFpOt7Nbj" style="border-bottom: Black 1.5pt solid; text-align: right">243,418</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630_zNi6r5qjfPCb" style="border-bottom: Black 2.5pt double; text-align: right">13,917,461</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AE_zknFm4gi0Wpe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Series
Alpha Preferred Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the six-month period ended June 30, 2021, no shares of Series Alpha convertible preferred stock were converted into shares of the Company&#8217;s
common stock, and there were <span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_c20210630_zasxxUu8l1P6" title="Preferred stock, shares outstanding">180</span> shares of Series Alpha preferred stock outstanding at June 30, 2021 and December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Alpha
Securities Purchase Agreements</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 10, 2020, the Company closed a Securities Purchase Agreement (dated July 8, 2020) with a single institutional investor for the purchase
and sale for $<span id="xdx_90F_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200709__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_z2z2McRF0pL7" title="Sale of stock">8.0</span> million for (i) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200709__20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock">1,140,570</span> shares of Company common stock, (ii) <span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of stock warrants">780,198</span> pre-funded warrants (i.e., warrants to purchase
shares of Company common stock, for which the exercise price is almost entirely prepaid) and (iii) <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants">1,920,768</span> two-year warrants to purchase
shares of Company common stock for an exercise price of $<span id="xdx_903_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price">5.25</span> per share. Both sets of warrants included a <span id="xdx_908_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200710__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zQavFKjktyXf" title="Beneficial-ownership percentage">9.99</span>% beneficial-ownership
blocker provision. The <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20200721__20200722__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z0qHvXa5Kh33" title="Warrants exercise">780,198</span> pre-funded warrants were then exercised on July 21 and 22, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
August 4, 2020, the Company closed a Securities Purchase Agreement (dated August 2, 2020) with a single institutional investor for the
purchase and sale for $<span id="xdx_90D_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_pn5n6_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_zzGVjp4ZZj7k" title="Sale of stock">10.0</span> million for (i) <span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200803__20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock">1,717,106</span> shares of Company common stock, and (ii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants">1,287,829</span> two-year warrants to purchase
shares of Company common stock for an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price">6.00</span> per share. The warrants included a <span id="xdx_902_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20200804__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zUiMLYXk3rqf" title="Beneficial-ownership percentage">9.99</span>% beneficial-ownership blocker provision.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
December 18, 2020, the Company closed a Securities Purchase Agreement (dated December 16, 2020) with a single institutional investor
for the purchase and sale for $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20201216__20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__srt--TitleOfIndividualAxis__custom--SingleInstitutionalInvestorMember_pp0p0" title="Sale of stock">12,000,000</span> of (i) <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201216__20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Number of shares common stock">2,370,786</span> shares of Company common stock, (ii) <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_pdd" title="Purchase of stock warrants">1,000,000</span> pre-funded warrants (i.e.,
warrants to purchase shares of Company common stock, for which the exercise price is almost entirely prepaid) (iii) <span id="xdx_90F_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Purchase of stock warrants">1,348,314</span> two-year
warrants to purchase shares of Company common stock for an exercise price of $<span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--AwardTypeAxis__custom--TwoYearWarrantsMember_pdd" title="Warrant exercise price">4.07</span> per share, and (iv) <span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Purchase of stock warrants">842,696</span> warrants (first exercisable
6 months after issuance, and with an expiration date 30 months after issuance) to purchase shares of Company common stock for an exercise
price of $<span id="xdx_905_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Warrant exercise price">4.07</span> per share. The warrants included a <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_dp_uPure_c20201218__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember_zFp8A21Vcndg" title="Beneficial-ownership percentage">9.99</span>% beneficial-ownership blocker provision. The <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210203__20210204__us-gaap--TypeOfArrangementAxis__custom--SecuritiesPurchaseAgreementMember__us-gaap--StatementEquityComponentsAxis__custom--PrefundedWarrantsMember_z1r3DXDwpAY4">1,000,000</span> pre-funded warrants were
exercised on February 4, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Stock
Options and Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting
period.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the &#8220;2020 Plan&#8221;) which provides for the granting of incentive
or nonstatutory common stock options to qualified employees, officers, directors, consultants and other service providers. At June 30,
2021 and December 31, 2020 there were <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd">4,040,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20200101__20201231__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_zzk9s2D0LLhh">3,917,500
</span></span><span style="font: 10pt Times New Roman, Times, Serif">outstanding options respectively under the 2020
Plan and on those dates there were <span id="xdx_904_ecustom--StockOptionsSharesFutureGrant_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd">17,157
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_90A_ecustom--StockOptionsSharesFutureGrant_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember_pdd">139,657
</span></span><span style="font: 10pt Times New Roman, Times, Serif">unused 2020 Plan shares available, respectively,
for future grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuuDS8dQT2fh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2021, and changes during the six-month period then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zsA2VITac1A7" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average <br/>
    Exercise <br/>
    Price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average Remaining <br/>
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 39%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGZIeRguF763" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Options Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">4,011,356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNG1FtDfIxe7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">7.05</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2TfsjjRSYHg" title="Range of Exercise price, Options Outstanding">3.52</span>&#8212;<span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zesHnaej9rr2" title="Range of Exercise price, Options Outstanding">1,465.75</span>
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3r0SiApwfxa" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">9.29</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">127,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">2.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Granted">1.80</span>&#8212;<span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Granted">3.29</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4JC7iBSZbY5" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">9.83</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1734">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_ecustom--RangeOfExercisePriceOptionsExpired_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise price, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1738">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znlDhZ0qQq57" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(4,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">3.68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Forfeited">3.52</span>
    &#8212; <span id="xdx_90E_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Forfeited">4.97</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGD3wHgiHYKk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Outstanding at Ending"><span style="font: 10pt Times New Roman, Times, Serif">4,133,856</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAPZM8OKVyme" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"><span style="font: 10pt Times New Roman, Times, Serif">6.90</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMjGUy7A2uP9" title="Range of Exercise price, Options Outstanding">1.80</span>
    &#8212; <span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEz1cL2XsGXl" title="Range of Exercise price, Options Outstanding">1,465.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHSjUCZ8a2k5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.82</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable
    (vested)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSdZKQlVBMM6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Exercisable (vested)"><span style="font: 10pt Times New Roman, Times, Serif">1,296,860</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zPjAvqCRwcjk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable (vested)"><span style="font: 10pt Times New Roman, Times, Serif">11.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zo7WNz4ixrni" title="Range of Exercise price, Options Exercisable (vested)">4.97</span>
    &#8212; <span id="xdx_903_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Exercisable (vested)">1,465.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjcHVACkl421" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">8.36</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable
    (non-vested)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zo6LEmEpSo6h" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Non-Exercisable (non-vested)"><span style="font: 10pt Times New Roman, Times, Serif">2,836,996</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjz5DW3HszD8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Non-Exercisable (non-vested)"><span style="font: 10pt Times New Roman, Times, Serif">4.80</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)">1.80</span>
    &#8212; <span id="xdx_905_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)">5.13</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zfTNyjgx9T7e" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">9.04</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p id="xdx_8AD_zaHrrgNTB7b4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
was approximately $<span id="xdx_90D_eus-gaap--ShareBasedCompensation_pn5n6_c20210401__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zI534eYSIuFd">1.3</span> million and $<span id="xdx_902_eus-gaap--ShareBasedCompensation_pn5n6_c20200401__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zlFjcxaJwUXa">0.4</span> million of compensation cost related to outstanding options for the three months ended June
30, 2021 and 2020, respectively, and approximately</span><span style="font: 10pt Times New Roman, Times, Serif"> $<span id="xdx_909_eus-gaap--ShareBasedCompensation_pn5n6_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zCeyEiqPnoae">2.5 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
and $<span id="xdx_904_eus-gaap--ShareBasedCompensation_pn5n6_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zc3EyAilcMu9">0.4 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
of compensation cost related to outstanding options for the six months ended June 30, 2021 and 2020, respectively. As of June 30,
2021, there was approximately $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pn5n6_c20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zd31GG43YY91">10.3 </span></span><span style="font: 10pt Times New Roman, Times, Serif">million
of total unrecognized compensation cost related to unvested stock-based compensation arrangements. This cost is expected to be
recognized over a weighted average period of <span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zwTlKOzTCR61">1.98 </span></span><span style="font: 10pt Times New Roman, Times, Serif">years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zggKq2xevmGe" title="Stock options exercised"><span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_do_c20200101__20200630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_zaY3QnESTdOg" title="Stock options exercised">No</span></span>
stock options were exercised during the six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember__us-gaap--PlanNameAxis__custom--TwoThousandTwentyStockIncentivePlanMember" title="Stock options description">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.</span> The options awarded under the 2020 Plan will vest as determined by the Board of Directors but will not exceed a ten-year
period. The weighted average grant date fair value per share of options granted during the six months ended June 30, 2021 was $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockOptionsAndWarrantsMember_pdd" title="Stock option granted exercise price">1.68</span>.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Fair
Value of Equity Awards</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company utilizes the Black-Scholes option pricing model to value awards under its Plans. Key valuation assumptions include:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
    dividend yield.</i> The expected dividend is assumed to be zero, as the Company has never paid dividends and has no current plans
    to pay any dividends on the Company&#8217;s common stock.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
    stock-price volatility.</i> The Company&#8217;s expected volatility is derived from the average historical volatilities of publicly
    traded companies within the Company&#8217;s industry that the Company considers to be comparable to the Company&#8217;s business
    over a period approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risk-free
    interest rate.</i> The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of grant for zero coupon
    U.S. Treasury notes with maturities approximately equal to the expected term.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
    term.</i> The expected term represents the period that the stock-based awards are expected to be outstanding. The Company&#8217;s
    historical share option exercise experience does not provide a reasonable basis upon which to estimate an expected term because of
    a lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method provided by the Securities
    and Exchange Commission. The simplified method calculates the expected term as the average of the time-to-vesting and the contractual
    life of the options.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zhMJCwb3Nvq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zypqMcSXiXa8" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the six months<br/>
ended <br/>
June 30, 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20210630_zgviF8xlXhVd" title="Expected dividend yield">0.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    stock-price volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20210630_z9MaedWULN8g" title="Expected stock-price volatility">102</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20210101__20210630_zo1twREqmpi3" title="Risk-free interest rate, minimum">0.84</span>%
    &#8212; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20210101__20210630_zYGLh6nVGlX4" title="Risk-free interest rate, maximum">1.18</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Expected
    average term of options</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zp9wn2ZilkTe" title="Average expected remaining years of life of options">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharePrice_c20210630_pdd" title="Stock price">2.12</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p id="xdx_8A6_zp2HEeIYtp13" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_890_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zLcG6bpugaBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zMdYUrsZNdyf" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7egFqhcBdBd" style="width: 20%; text-align: right" title="Total">2,201,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqhAcfvZcEHd" style="width: 20%; text-align: right" title="Total">277,807</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zK7inVm28ael" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">347,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqCUHEU4Ifq3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">88,684</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_zG9rAHPnEZF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,549,049</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630_zTaUiVSIXXF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">366,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zJun7vuJdv3c" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Equity
Classified Compensatory Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the $<span id="xdx_901_ecustom--EquityCapitalRaise_iI_pn5n6_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_z6D4WpaEl8r3" title="Equity capital raise">4.0</span> million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Purchase of stock warrants">811,431</span> shares of the Company&#8217;s common stock at an exercise
price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Warrant exercise price">1.11</span> per share. The issuance cost of these warrants was charged to additional paid-in capital, and did not result in expense
on the Company&#8217;s statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to
purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of <span id="xdx_904_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20171231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Purchase of stock warrants">668,024</span> shares
of Company common stock at a weighted average exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20171231__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_pdd" title="Warrant exercise price">2.34</span> per share. These are to be differentiated from the Series C Warrants
described in Note 7.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">No
compensatory warrants were issued during the six months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89B_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_gL3SOWATTB-XCNSZ_ze9Cvv2uEijh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zz0DeCBA5H5k" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br/>
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;<br/>
    Average<br/>
    Remaining <br/>
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztJPt0tKB5W6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1,294,217</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVYkjfKsgOLd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1.66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zC5KDPgMmXHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1JG4rJahtKh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1840">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Legacy
    Ritter warrants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRQw9aW18Ec" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvMc2kCuqEc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1844">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1846">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(38,390</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">2.09</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1856">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(65,179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">2.07</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RYTQiEnCDj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1,190,648</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zi0WH4YIOGwa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR2z8g3LZho7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1,187,052</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbnSiTJp3qKh" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable">1.11</span>
    &#8212; <span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable">2.54</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdYAqANed95k" title="Weighted Average Remaining Life (Years) Exercisable">3.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbVhuLk43Bvf" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="font: 10pt Times New Roman, Times, Serif">3,596</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zSFTVvAFI1a6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2.54
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_989_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4JSgNsnKVm" title="Weighted Average Remaining Life (Years) Non-Exercisable">5.23</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p id="xdx_8A4_zqKyYscW9vy4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Of
the <span id="xdx_906_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zxXv4Ufjrzi5" title="Stock issued upon exercise of  stock options">38,390</span> shares issued upon the exercise of equity classified compensatory warrants during the six months ended June 30, 2021, <span id="xdx_90D_ecustom--SharesIssuedUponNetExercises_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zZIvYPIG1rA8" title="Shares issued on net exercises">35,512</span>
shares were issued upon net-exercises rather than upon exercises for cash.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<div id="xdx_C03_gL3SOWATTB-XCNSZ_zqsVpz8dwtRh"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zNtEjVZ5xzkf" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br/>
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life
    (Years)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRPgZtofBdl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z66E65pFepNc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1.99</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3F0agyTu3oi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"><span style="font: 10pt Times New Roman, Times, Serif">668,024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zFzKhwhNafmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"><span style="font: 10pt Times New Roman, Times, Serif">2.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Legacy
    Ritter warrants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zEptr09bcs83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1896">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7etL0b2V5ml" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif">811,431</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMmPCwmC2Pi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif">1.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1904">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zLL0Ke1UL8u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1906">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1908">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RloP4fvTyi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zZQm2lRUhPCc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1,479,455</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za9epGDPPV0c" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1.67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfRQiexHvsB3" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">660,832</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMrKiLC8mghj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable">2.07</span>
    &#8212; <span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable">2.54</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmD95OhSynA2" title="Weighted Average Remaining Life (Years) Exercisable">3.82</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9tnexDfrbBa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="font: 10pt Times New Roman, Times, Serif">818,623</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1roXZzS8sub" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Non-Exercisable">1.11</span>
    &#8212; <span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Non-Exercisable">2.54</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziEKMWF29x0k" title="Weighted Average Remaining Life (Years) Non-Exercisable">4.91</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C0B_gL3SOWATTB-XCNSZ_zirtWBfn8c79">&#160;</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">There
were <span id="xdx_90E_eus-gaap--ShareBasedCompensation_pp0p0_do_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zIVFZT7Rn6ac" title="Stock based compensation expense">no</span> compensation cost related to outstanding equity classified compensatory warrants for the six months ended June 30, 2021 and approximately
$<span id="xdx_909_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zpsuktLGUBi4" title="Stock based compensation expense">8,000</span> for the six months ended June 30, 2020. As of June 30, 2021 and 2020, there was <span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_do_c20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_znWMFDVOZkh4" title="Unrecognized compensation cost"><span id="xdx_90A_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_iI_pp0p0_c20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantsMember_zJxXVuX0Wen" title="Unrecognized compensation cost">no</span></span> unrecognized compensation cost related to nonvested
equity classified compensatory warrants.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Noncompensatory
Equity Classified Warrants</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to an investor for the purchase of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200531__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants">270,478</span>
shares of Company common stock at an exercise price of $<span id="xdx_904_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200531__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price">1.11</span> per share (of which warrants for <span id="xdx_904_ecustom--ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised_c20201201__20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Shares issued upon the exercise of warrants">200,000</span> shares were subsequently exercised
in December 2020). In July 2020 the Company issued noncompensatory equity classified warrants to such investor for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200731__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants">780,198</span>
shares of Company common stock at an exercise price of $<span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200731__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price">0.001</span> per share (which were subsequently exercised in July 2020), and <span id="xdx_901_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Purchase of stock warrants">1,920,678</span>
shares of Company common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember_pdd" title="Warrant exercise price">5.25</span> per share. In August 2020 the Company issued noncompensatory equity classified
warrants to such investor for the purchase of <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Purchase of stock warrants">1,287,829</span> shares of Company common stock at an exercise price of $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20200831__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Warrant exercise price">6.00</span> per share. Lastly,
in December 2020, the Company issued noncompensatory equity classified warrants to such investor for the purchase of <span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Purchase of stock warrants">1,000,000</span> shares
of Company common stock at an exercise price of $<span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--StatementEquityComponentsAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__srt--TitleOfIndividualAxis__us-gaap--InvestorMember_pdd" title="Warrant exercise price">0.01</span> per share (which were exercised in February 2021) and <span id="xdx_909_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Purchase of stock warrants">2,191,010</span> shares of Company
common stock at an exercise price of $<span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_c20201231__us-gaap--AwardTypeAxis__custom--NoncompensatoryEquityClassifiedWarrantsMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Warrant exercise price">4.07</span> per share. No noncompensatory equity classified warrants were issued during the six months
ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89E_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zhvZKGrwksr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B5_zz92liI2luSj" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br/>
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;<br/>
    Average<br/>
    Remaining <br/>
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zQhwqpdEym8e" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">6,549,777</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zxtC0XknraS7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">4.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(1,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">0.01</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1980">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1984">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1986">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1988">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zL1FaaiiJEb1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">5,549,777</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zYEbzYgcSMki" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">5.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z8ZdcQ0BJeE1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">5,549,777</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zXGXhpg0ZWM5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">5.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" style="font: 10pt Times New Roman, Times, Serif">1.11
    </span><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span><span style="font: 10pt Times New Roman, Times, Serif">
    <span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd">2,325.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zGzT4vMFUq6h" title="Weighted Average Remaining Life (Years) Exercisable">1.33</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zZFK6wpzMyj8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2004">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zC4ecpj8SH0i" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2006">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2008">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p id="xdx_8AE_zpSLrAfjVjGb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840197913048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zSOynDE0cNL3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
11 &#8212; <span id="xdx_82C_zF4iUwfgZ5xg">RELATED PARTY TRANSACTIONS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0.25in; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
October 2017, Sekisui purchased all outstanding shares of the Company&#8217;s Series D and Series D-1 preferred stock from Gen-Probe
Incorporated. As such, Sekisui became a related party as of October 2017. These Series D and Series D-1 preferred stock shares were converted
into <span id="xdx_906_eus-gaap--ConversionOfStockSharesConverted1_c20200501__20200531__us-gaap--StatementClassOfStockAxis__custom--SeriesDAndSeriesDOnePreferredStockMember_pdd" title="Conversion of preferred stock">1,980,233</span> shares of the Company&#8217;s common stock in connection with the reverse recapitalization transaction in May 2020. During
the nine-months transition period ended December 31, 2020, Sekisui ceased to be a related party as to the Company. In the attached financial
statements, information for 2020 periods and dates is presented without distinct &#8220;related party&#8221; treatment for items pertaining
to Sekisui.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840196756040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p id="xdx_805_eus-gaap--SubsequentEventsTextBlock_zEBEXoJeaHil" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>NOTE
12 &#8212; <span id="xdx_827_zdZwxWRj39Ta">SUBSEQUENT EVENTS</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management
has evaluated subsequent events pursuant to the requirements of ASC Topic 855, <i>Subsequent Events</i>, from the balance sheet date
through the date the financial statements were available to be issued, and has determined that there are no material subsequent events
that require disclosure in these financial statements, except that effective July 1, 2021, the Company and Sekisui amended the scheduled
termination date of the Sekisui Distribution and Development Agreement (see Note 9) to be March 31, 2022 instead of May 1, 2022, and by virtue
of a 2020 Plan amendment approved by the Company&#8217;s stockholders on August 9, 2021, the number of shares of common stock available
for issuance under the 2020 Plan was increased by <span id="xdx_90B_ecustom--CommonStockSharesAvailableForFutureIssuance_iI_c20210809__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--PlanNameAxis__custom--TwpThousandTwentyPlanMember_z0bf0S2psDA8">3,500,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204564136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_OrganizationPolicyTextBlock', window );">Organization</a></td>
<td class="text"><p id="xdx_843_ecustom--OrganizationPolicyTextBlock_zpwygdJ0lrG8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_865_zyZAFSLnlQQ3">Organization</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qualigen,
Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the &#8220;Company&#8221;) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (&#8220;Ritter&#8221;) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.&#8217;s capital stock were exchanged for Qualigen Therapeutics,
Inc.&#8217;s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol &#8220;RTTR,&#8221; commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol &#8220;QLGN&#8221; on May 26, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Qualigen,
Inc. was determined to be the accounting acquirer in a reverse recapitalization based upon the terms of the merger and other factors.
All references to financial figures of the Company presented in the accompanying condensed consolidated financial statements and in these
Notes through May 22, 2020 are to those of Qualigen, Inc. All references to financial figures after May 22, 2020 are to those of Qualigen
Therapeutics, Inc. and Qualigen, Inc.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_845_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zmadOOwyuhVe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_za6Kn8G6tyB7">Basis
of Presentation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles
generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules of the Securities and Exchange Commission
(&#8220;SEC&#8221;) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should
be read in conjunction with the audited financial statements and notes thereto contained in the Company&#8217;s Transition Report on
Form 10-K for the fiscal year ended December 31, 2020 filed with the SEC on March 31, 2021. In the opinion of management, the accompanying
condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading.
The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other
future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited
financial statements for the most recent fiscal year as reported in the Company&#8217;s Transition Report on Form 10-K have been omitted.
The accompanying condensed consolidated balance sheet at December 31, 2020 has been derived from the audited balance sheet at December
31, 2020 contained in such Form 10-K.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p id="xdx_843_eus-gaap--ConsolidationPolicyTextBlock_zGTCw7etT4N1" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zZUP69kkfxPb">Principles
of Consolidation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s unaudited interim condensed consolidated financial statements include the accounts of the Company and its wholly owned
subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable
guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Accounting Estimates</a></td>
<td class="text"><p id="xdx_841_eus-gaap--UseOfEstimates_z0lSKQfjPQt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zTLxBTpfgUJe">Accounting
Estimates </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation,
write-off of patents and licenses, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and
warranty costs. Actual results could vary from the estimates that were used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p id="xdx_843_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zBSstpTFtg83" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_znxLp2OVmSgc">Cash
and Cash Equivalents</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company maintains its cash and cash equivalents in bank deposits which at times may exceed federally insured limits. The Company has
not experienced any losses in such accounts and believes it is not exposed to any significant credit risks on cash and cash equivalents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Net</a></td>
<td class="text"><p id="xdx_840_eus-gaap--InventoryPolicyTextBlock_z1J1S9bzyx6d" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zxVC5aoFwVPe">Inventory,
Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records specific reserves for identified items.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_z13Usu4O9oQ" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_zr72LivyHt9">Long-Lived
Assets</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three months and six months periods ended June 30, 2021
and 2020, <span id="xdx_901_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210101__20210630_zRrhw7o42pv8" title="Long-lived assets impairment losses"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200101__20200630_zDkes1HZANW7" title="Long-lived assets impairment losses"><span id="xdx_902_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20210401__20210630_zVdcw2M5jRPh" title="Long-lived assets impairment losses"><span id="xdx_90F_eus-gaap--ImpairmentOfLongLivedAssetsHeldForUse_pp0p0_do_c20200401__20200630_zoWZyNNnND6g" title="Long-lived assets impairment losses">no</span></span></span></span> such impairment losses have been recorded. All long-lived assets of the Company are located in the U.S.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable, Net</a></td>
<td class="text"><p id="xdx_841_eus-gaap--TradeAndOtherAccountsReceivablePolicy_zVpRYEku6J79" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_862_zuyumM9NCDYg">Accounts
Receivable, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the creditworthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company&#8217;s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">784,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">629,630</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,517</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,873</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Accounts receivable, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766,911</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">615,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A2_zZdyffaZrq1i" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><p id="xdx_844_eus-gaap--ResearchAndDevelopmentExpensePolicy_zVtfKVLGbQuf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zwc5fojeouqe">Research
and Development</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company expenses research and development costs as incurred.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShippingAndHandlingCostsPolicyTextBlock', window );">Shipping and Handling Costs</a></td>
<td class="text"><p id="xdx_844_ecustom--ShippingAndHandlingCostsPolicyTextBlock_ztZhHIaeTcDh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_z2BqBwkVfmMc">Shipping
and Handling Costs</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630_zJGR7OcjBcs2" title="Shipping and handling costs">28,000</span> and $<span id="xdx_901_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630_zRxE5bOpJ6ef">26,000</span>, respectively, for the three
months ended June 30, 2021 and 2020, and approximately $<span id="xdx_908_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630_pp0p0" title="Shipping and handling costs">58,000</span> and $<span id="xdx_90E_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630_pp0p0" title="Shipping and handling costs">56,000</span>, respectively, for the six months ended June 30, 2021 and
2020. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing expenses
totaled approximately $<span id="xdx_90D_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_z8nO35EuYhR4" title="Shipping and handling costs">4,000</span> and $<span id="xdx_90A_eus-gaap--CostOfGoodsAndServicesSold_pp0p0_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_zFhWBbNeQGHc">6,000</span> for the three months ended June 30. 2021 and 2020, respectively, and approximately $<span id="xdx_90F_eus-gaap--CostOfGoodsAndServicesSold_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs">5,000</span> and
$<span id="xdx_909_eus-gaap--CostOfGoodsAndServicesSold_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__custom--GeneralAdministrativeResearchAndDevelopmentExpensesMember_pp0p0" title="Shipping and handling costs">6,000</span> for the six months ended June 30, 2021 and 2020, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue from Contracts with Customers</a></td>
<td class="text"><p id="xdx_844_eus-gaap--RevenueRecognitionPolicyTextBlock_zW2BUDsO4TJh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zbSF2phBMy89">Revenue
from Contracts with Customers</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Effective
April 1, 2020, the Company adopted Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, <i>Revenue from Contracts with Customers
</i>(&#8220;ASC 606&#8221;), using the modified retrospective approach. The adoption of ASC 606 did not have a material impact on the
measurement or on the recognition of revenue of contracts for which all revenue had not been recognized as of the adoption date of April
1, 2020. Therefore, no cumulative adjustment has been made to the opening balance of accumulated deficit at April 1, 2020. The comparative
information has not been restated and continues to be reported under the accounting standards in effect for the periods presented.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
core principle of ASC 606 is that a company should recognize revenue to depict the transfer of promised goods or services to customers
in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Product
Sales</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs which are diagnostic tests for PSA, testosterone, thyroid disorders, pregnancy, and Vitamin
D.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (&#8220;analyzer&#8221;) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (&#8220;FOB&#8221;) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company&#8217;s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfil the promise to transfer the disposable products and not as a separate performance obligation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company&#8217;s
contracts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">License
Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable
upfront license fees and/or sales-based royalties.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified
in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred
to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management
uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is
satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing
revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts
the measure of progress and related revenue recognition. During the three months ended June 30, 2021 and 2020, the Company recognized
license revenue of $<span id="xdx_90B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zykC2i3HoA76" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1027">0</span></span> and $<span id="xdx_904_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200401__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zHhXBTbPYKo2" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1028">0</span></span>, respectively, and during the six months ended June 30, 2021 and 2020, the Company recognized license revenue
of $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pn3p0_c20210101__20210630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_zed2L7Ioq7Bg" title="Revenues">479,000</span> and $<span id="xdx_90D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20200101__20200630__srt--ProductOrServiceAxis__custom--LicenseRevenueMember_z5jehxvl04df" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1032">0</span></span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Collaborative
Research Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606, the Company recognized research revenue over the term of various agreements, as negotiated contracted amounts
were earned or reimbursable costs were incurred related to those agreements. Negotiated contracted amounts were earned in relative proportion
to the performance required under the applicable contracts. Any amounts received prior to satisfying these revenue recognition criteria
were recorded as deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">To
determine revenue recognition for contracts with customers within the scope of ASC 606, the Company performs the following five steps:
(i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction
price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the
entity satisfies the relevant performance obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Collaborative
research revenue is recognized as research services are performed over the development periods for each agreement. During the three months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zGx3zEhB6eMa" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1034">0</span></span> and $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210401__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zxrpEkq22s" title="::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1035">0</span></span>, respectively, and during the six months
ended June 30, 2021 and 2020, the Company recognized collaborative research revenue of $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_pp0p0_dxL_c20210101__20210630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_zlTtTSiS0esc" title="Revenues::XDX::-"><span style="-sec-ix-hidden: xdx2ixbrl1037">0</span></span> and $<span id="xdx_906_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200101__20200630__srt--ProductOrServiceAxis__custom--CollaborativeResearchRevenueMember_pp0p0" title="Revenues">45,000</span>, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Contract
Balances</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
timing of the Company&#8217;s revenue recognition may differ from the timing of payment by the Company&#8217;s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606 effective April 1, 2020 (using the modified retrospective approach), the Company accounted for its revenue
arrangements under ASC 605, Revenue Recognition (&#8220;ASC 605&#8221;). Under ASC 605, revenue arrangements with multiple deliverables
were evaluated for proper accounting treatment. In these arrangements, the Company recorded revenue as separate units of accounting if
the delivered items have value to the customer on a stand-alone basis, if the arrangement includes a general right of return relative
to the delivered items, and if delivery or performance of the undelivered items is considered probable and substantially within the Company&#8217;s
control.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Under
ASC 605, revenues from product sales which included both the analyzer and various immunoassay products (&#8220;reagents&#8221;) were
generally recognized upon shipment, as no significant continuing performance obligations remained post shipment. Cash payments received
in advance were classified as deferred revenue and recorded as a liability. The Company was generally not contractually obligated to
accept returns, except for defective products. Revenue was recorded net of an allowance for estimated returns.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Multiple
element arrangements included contracts that combined both the Company&#8217;s analyzer and a customer&#8217;s future reagent purchases
under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was
maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated returns of approximately $<span id="xdx_905_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20210401__20210630_z7NYC0kl3Xm8" title="Estimated returns net of allowances">0</span>
and $<span id="xdx_90A_ecustom--EstimatedReturnsNetOfAllowances_pp0p0_c20200401__20200630_za6TsZHWm2Ha">12,000</span>, respectively. During the six months ended June 30, 2021 and 2020, product sales are stated net of an allowance for estimated
returns of approximately $<span id="xdx_901_ecustom--EstimatedReturnsNetOfAllowances_c20210101__20210630_pp0p0" title="Estimated returns net of allowances">0</span> and $<span id="xdx_903_ecustom--EstimatedReturnsNetOfAllowances_c20200101__20200630_pp0p0" title="Estimated returns net of allowances">24,000</span> respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline">Deferred
Revenue</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prior
to the adoption of ASC 606, payments received in advance from customers pursuant to certain collaborative research and license agreements,
deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current
deferred revenue liability based on the time from the balance sheet date to the future date of revenue recognition. The adoption of ASC
606 had no material effect on deferred revenue.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Operating Leases</a></td>
<td class="text"><p id="xdx_840_eus-gaap--LesseeLeasesPolicyTextBlock_zkwYxQRHfu7f" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zhqJeuVqvP43">Operating
Leases</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company adopted ASC Topic 842, <i>Leases</i> (&#8220;Topic 842&#8221;) in the nine-months transition period ended December 31, 2020.
In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding right-of-use-assets for all
leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for in a manner similar to the
guidance for operating leases prior to the adoption of Topic 842. Refer to Recent Accounting Pronouncements below and Note 8 for
more information.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zPRki3wNZEde" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zj4qokND7Ib8">Property
and Equipment, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zgbdMTw9LWNb" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"><span style="font: 10pt Times New Roman, Times, Serif">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life">3</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  </table>
<p id="xdx_8A8_zS4L8HTdKZI9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets, Net</a></td>
<td class="text"><p id="xdx_840_eus-gaap--IntangibleAssetsFiniteLivedPolicy_z5Rg8dVyuxn3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zpmermdSsUy">Intangible
Assets, Net</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Intangibles
consist of patent-related costs and costs for in-license agreements. Management reviews the carrying value of intangible assets that
are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment
exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends
and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected
to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally <span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MinimumMember_zfs2rfRygQn8" title="Estimated useful lives">5</span> to <span id="xdx_90D_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_dtY_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndLicensesMember__srt--RangeAxis__srt--MaximumMember_zzq4DvoKUDMa" title="Estimated useful lives">17</span>
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent has been obtained.
Patent and licenses costs are charged to operations if it is determined that the patent will not be obtained.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the patents of approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">168,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">169,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">at June 30, 2021 and December 31, 2020, respectively,
are stated net of accumulated amortization of approximately $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">311,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">303,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2021 and 2020 was approximately $<span id="xdx_90E_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zU3v0zQLmdV6">3,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each period, and for the six months ended
June 30, 2021 and 2020 was approximately $<span id="xdx_909_eus-gaap--AmortizationOfIntangibleAssets_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">6,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each period. Total future estimated amortization
of patent costs for the five succeeding years is approximately $<span id="xdx_908_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_znkm94YkiKci">8,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for the remaining six months in the year
ending December 31, 2021, approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z7shlPclUFP5"><span id="xdx_900_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_pp0p0">15,000</span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for each of the years ending December 31, 2022
through 2023, approximately $<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zAEaHE3uqRK3" title="Future estimated amortization for year ending December 31, 2024">11,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for year 2024, approximately $<span id="xdx_902_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_zjz7njIiVoy" title="Future estimated amortization for year ending December 31, 2025">11,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">for year 2025 and approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--PatentsMember_z2j1ZVeBMoR4" title="Future estimated amortization, Thereafter">108,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">thereafter.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
carrying value of the in-licenses of approximately $<span id="xdx_90A_eus-gaap--FiniteLivedIntangibleAssetsNet_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value">16,000</span> and $<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetsNet_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Carrying value">19,000</span> at June 30, 2021 and December 31, 2020 are stated net of accumulated
amortization of approximately $<span id="xdx_90C_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization">403,000</span> and $<span id="xdx_901_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_c20201231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Accumulated amortization">400,000</span>, respectively. Amortization of licenses charged to operations for the three months
ended June 30, 2021 and 2020 was approximately $<span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20210401__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_z8YvYvtaC6Tj" title="Amortization expense"><span id="xdx_906_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200401__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zxA8zHH8UQz7" title="Amortization expense">2,000</span></span>, and for the six months ended June 30, 2021 and 2020 was approximately $<span id="xdx_901_eus-gaap--AmortizationOfIntangibleAssets_c20210101__20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Amortization expense">4,000</span> and
$<span id="xdx_905_eus-gaap--AmortizationOfIntangibleAssets_pp0p0_c20200101__20200630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zdWTl5CE1vvf" title="Amortization expense">3,000</span>, respectively. Total future estimated amortization of license costs is approximately $<span id="xdx_904_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_iI_pp0p0_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_zjy5zkQ7KGW" title="Future estimated amortization, remainder of fiscal year">4,000</span> for the remaining six months in the
year ending December 31, 2021, approximately $<span id="xdx_905_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2022">7,000</span> for the year ending December 31, 2022 and approximately $<span id="xdx_906_eus-gaap--FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c20210630__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicenseMember_pp0p0" title="Future estimated amortization for year ending December 31, 2023">5,000</span> for the year ending
December 31, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock', window );">Derivative Financial Instruments and Warrant Liabilities</a></td>
<td class="text"><p id="xdx_849_ecustom--DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock_zbwmhrCnUZxl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86F_zI47w6nORUMl">Derivative
Financial Instruments and Warrant Liabilities</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company
uses either the Black-Scholes option-pricing model or a Monte Carlo simulation to value the derivative instruments at inception and subsequent
valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or
as equity, is re-assessed at the end of each reporting period (see Note 7).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p id="xdx_844_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_zFzmkGcDqPof" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86C_zbv4T442pOn8">Fair
Value Measurements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability
    to access at the measurement date;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs
    in markets that are not considered to be active; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 - Inputs that are unobservable. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p id="xdx_846_eus-gaap--FairValueOfFinancialInstrumentsPolicy_ztpH2j2FsKdg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86B_zS8v1jlo1Eha">Fair
Value of Financial Instruments</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Cash
and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and debt are carried at cost, which management believes
approximates fair value due to the short-term nature of these instruments.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p id="xdx_84D_eus-gaap--CompensationRelatedCostsPolicyTextBlock_zPt7xnUlRljk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86E_zPl0T18VEjFi">Stock-Based
Compensation</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company-issued
stock options could change significantly. Higher volatility and longer expected lives would result in an increase to stock-based compensation
expense to employees and non-employees determined at the date of grant.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_847_eus-gaap--IncomeTaxPolicyTextBlock_zHrnRPHbJan3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_864_z2q0zNL63lLl">Income
Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
The components of the deferred tax asset and liability are individually classified as current and noncurrent based on their characteristics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SalesAndExciseTaxesPolicyTextBlock', window );">Sales and Excise Taxes</a></td>
<td class="text"><p id="xdx_844_ecustom--SalesAndExciseTaxesPolicyTextBlock_zjnO3gcEnz52" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_866_zOX37w6oIsXj">Sales
and Excise Taxes</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the balance sheet as cash is collected from customers and remitted to the
tax authority.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WarrantyCostsPolicyTextBlock', window );">Warranty Costs</a></td>
<td class="text"><p id="xdx_849_ecustom--WarrantyCostsPolicyTextBlock_zaRanNxFwzwh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_868_zzOJlFS5EOoe">Warranty
Costs </span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company&#8217;s best estimates of analyzer failure rates
and costs to repair.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
warranty liabilities were approximately $<span id="xdx_906_eus-gaap--AccruedLiabilitiesCurrent_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities">48,000</span> and $<span id="xdx_903_eus-gaap--AccruedLiabilitiesCurrent_c20201231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Accrued liabilities">25,000</span>, respectively, for the periods ended June 30, 2021 and December 31, 2020
and are included in accrued expenses and other current liabilities on the balance sheets. Warranty costs were approximately $<span id="xdx_90E_ecustom--WarrantyCosts_pp0p0_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zLArjq1M0zFg" title="Warranty costs">20,000</span> and
$<span id="xdx_90C_ecustom--WarrantyCosts_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zM9DQPsjm61b">31,000</span> for the three months ended June 30, 2021 and 2020, respectively, and approximately $<span id="xdx_906_ecustom--WarrantyCosts_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs">41,000</span> and $<span id="xdx_904_ecustom--WarrantyCosts_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pp0p0" title="Warranty costs">58,000</span> for the six months ended
June 30, 2021 and 2020, respectively, and are included in cost of product sales in the statements of operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"/>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><p id="xdx_844_eus-gaap--EarningsPerSharePolicyTextBlock_zCGsIPjhAUcc" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>Net Loss Per Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Basic net loss per share is calculated by dividing
the net loss by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents.
Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common stock equivalents
outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, employee stock
purchase plan rights, restricted stock units, and warrants, and convertible preferred stock are considered to be common stock equivalents
but are not included in the calculations of diluted net loss per share for the periods presented as their effect would be anti-dilutive.
The Company incurred net losses for all periods presented and there were no reconciling items for potentially dilutive securities. More
specifically, at June 30, 2021 and 2020, stock options, warrants, and convertible preferred stock exercisable
or convertible for approximately <span id="xdx_904_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20210101__20210630_ztVfLrEYZEGd">13.9
</span>million shares and <span id="xdx_907_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pn5n6_c20200101__20200630_zCvq2P9SIIMl">16.5
</span>million shares, respectively, were excluded from the calculation of diluted net loss per share as their effect would have been
anti-dilutive. Comprehensive loss is the same as net loss for all periods presented.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_840_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zLVYGecyFne3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i><span id="xdx_86A_zhmEcnMuVYBd">Recent
Accounting Pronouncements</span></i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
June 2016, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2016-13,
Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when
it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses
on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition
of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued
ASU No. 2019-10, Financial Instruments &#8211; Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842),
which extends the effective date of Topic 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard
will be effective for the Company in the first quarter of the fiscal year beginning January 1, 2023, and early adoption is permitted.
The Company has not completed its review of the impact of this standard on its consolidated financial statements. However, based on the
Company&#8217;s history of immaterial credit losses from trade receivables, management does not expect that the adoption of this standard
will have a material effect on the Company&#8217;s consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"/></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2018, the FASB issued ASU No. 2018-13, &#8220;Fair
Value Measurement (Topic 820): Disclosure Framework &#8212; Changes to the Disclosure Requirements for Fair Value Measurement,&#8221;
an amendment to the accounting guidance on fair value measurements. The guidance modifies the disclosure requirements on fair value measurements,
including the removal of disclosures of the amount of and reasons for transfers between Level 1 of the fair value hierarchy, the policy
for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. The guidance also adds certain
disclosure requirements related to Level 3 fair value measurements. The guidance is effective for fiscal years, and interim periods within
those fiscal years, beginning after December 15, 2019. The Company adopted ASU No. 2018-13 on April 1, 2020 and the adoption of this guidance
did not have a material impact on its financial statements.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2020, the FASB issued ASU No. 2020-06, &#8220;Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives
and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an
Entity&#8217;s Own Equity&#8221; (&#8220;ASU 2020-06&#8221;), which simplifies accounting for convertible instruments by removing major
separation models required under prior U.S. GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts
to qualify for the derivative scope exception and it also simplifies the diluted earnings per share calculation in certain areas. ASU
2020-06 is effective for the Company for fiscal years beginning after December 15, 2023, including interim periods within those fiscal
years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020 and adoption must be as of the
beginning of the Company&#8217;s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated
financial statements and related disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company&#8217;s
condensed consolidated financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Derivative Financial Instruments and Warrant Liabilities [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_OrganizationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_OrganizationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SalesAndExciseTaxesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales and excise taxes [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SalesAndExciseTaxesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShippingAndHandlingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shipping and handling costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShippingAndHandlingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantyCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warranty costs [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantyCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155638-234783<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 920<br> -SubTopic 350<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120155617&amp;loc=SL120155628-234783<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e4975-111524<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5212-111524<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953423-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5093-111524<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204400392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">SCHEDULE OF ACCOUNTS RECEIVABLE</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_zJ3g9XlXDho" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accounts
receivable is comprised of the following at:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zg6HNKE9ZTUb" style="display: none">SCHEDULE
OF ACCOUNTS RECEIVABLE</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_497_20210630" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_494_20201231" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccountsReceivableGrossCurrent_iI_pp0p0_maARNCz0uk_z7noFEurQ6fc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Accounts Receivable</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">784,429</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">629,630</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iNI_pp0p0_di_msARNCz0uk_zJcfWyUWrTLi" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(17,517</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(13,873</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--AccountsReceivableNetCurrent_iTI_pp0p0_mtARNCz0uk_zbgdqrB1DK4a" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Accounts receivable, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">766,911</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">615,757</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock', window );">SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_89D_ecustom--ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock_z8nx1D3dJa76" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zgbdMTw9LWNb" style="display: none">SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 80%"><span style="font: 10pt Times New Roman, Times, Serif">Machinery
    and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zuI6JAcQIxTl" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Computer
    equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zfoPctOqt7jg" title="Property and equipment, useful life">3</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Molds
    and tooling</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zQ81DiNazzJ6" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Office
    furniture and equipment</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210101__20210630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_zXprvBSCodNh" title="Property and equipment, useful life">5</span>
    years</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Useful Lives of Property and Equipment [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840198043400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORY, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">SCHEDULE OF INVENTORY</a></td>
<td class="text"><p id="xdx_89A_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zweDtfgSxQ6a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Inventory,
net consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_zyek1WxxDOR4" style="display: none">SCHEDULE
OF INVENTORY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20210630_zddzIVsz88J6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_491_20201231_zqmjVAirAkSe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINz4Kh_z5xcwEDCHx25" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Raw materials</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">779,936</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">579,765</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINz4Kh_zjdyDzKJfQQ9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Work in process</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">241,677</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">309,826</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINz4Kh_zYCMrqiKQ5a6" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Finished goods</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">51,722</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">63,867</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InventoryNet_iTI_pp0p0_mtINz4Kh_zB9CNfzPsgB7" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Inventory net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,073,335</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">953,458</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify">As of June 30, 2021 and December 31, 2020, total inventory is recorded
net of inventory reserves of $149,000 and $108,000, respectively.</p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840197907720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</a></td>
<td class="text"><p id="xdx_894_ecustom--ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_zTrCqblKHtn5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other current assets consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zw9lcaI91hWf" style="display: none">SCHEDULE
OF PREPAID EXPENSES AND OTHER CURRENT ASSETS</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20210630_zTj5DmXdaem2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_492_20201231_zfWuwFIvMfxg" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAzTBJ_zb3uxuB9si06" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Prepaid insurance</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,916,387</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,307,864</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--PrepaidManufacturingExpenses_iI_pp0p0_maPEAOAzTBJ_zsIu2p5Wbkgb" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Prepaid manufacturing expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,617</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,181,029</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--PrepaidInvestorRelationsExpenses_iI_pp0p0_maPEAOAzTBJ_zsBsOWTQ2nNi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Prepaid investor relations expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">49,127</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">150,000</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAzTBJ_zjRQVQOU3ym1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">18,726</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">40,001</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAzTBJ_zKLqbdsBQmw5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Prepaid expenses and other current assets</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,033,857</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">2,678,894</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840197913048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">SCHEDULE OF PROPERTY AND EQUIPMENT</a></td>
<td class="text"><p id="xdx_898_eus-gaap--PropertyPlantAndEquipmentTextBlock_z8vn5kLdV2Vj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Property
and equipment, net consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B3_zQPlJkdETztl" style="display: none">SCHEDULE
OF PROPERTY AND EQUIPMENT</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zUN0RR2satU9" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zte766wi6Fr1" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhZDykO8MJs" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Machinery and equipment</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,409,946</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">2,401,470</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ConstructionInProgressEquipmentMember_zNNg3LU1HtBc" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Construction in progress&#8211;equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">94,717</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">104,400</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ComputerEquipmentMember_zTJvxMrKYNJ1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computer equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">472,094</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">443,865</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJsUcYOnRNW8" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Leasehold improvements</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">327,894</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">321,033</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--ToolsDiesAndMoldsMember_zKCMD3ln1hQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Molds and tooling</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">260,002</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeFurnitureAndEquipmentMember_znB86KyBRn33" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Office furniture and equipment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">143,013</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">138,699</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_maPPAENzgSC_z2npNgYtg1Y7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, gross</span></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,707,666</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,669,469</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_msPPAENzgSC_zEl0k06NM36j" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less Accumulated depreciation</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,454,405</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,422,146</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentNet_iTI_pp0p0_mtPPAENzgSC_zzGX836GFucc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt"><span style="display: none; font-family: Times New Roman, Times, Serif">Property and equipment, net</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">253,261</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">247,323</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840197825160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zknWsIWftFY9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Accrued
expenses and other current liabilities consisted of the following at June 30, 2021 and December 31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zeLQwaM7pAPd" style="display: none">SCHEDULE
OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_49D_20210630_zNqkTzsNOZd8" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" id="xdx_499_20201231_zi57gCz66qd2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--AccruedCompensation_iI_pp0p0_maALCz4Fv_zM89Pg3c6Jc1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">Board compensation</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">50,776</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">15,091</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--AccruedVacationCurrent_iI_pp0p0_maALCz4Fv_zXu34xOTSRli" style="vertical-align: bottom; background-color: White">
    <td>Vacation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">290,587</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">230,457</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedRoyaltiesCurrent_iI_pp0p0_maALCz4Fv_zUnW6pFqF934" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Royalties</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,078</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">491</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maALCz4Fv_z1a9YqTVYZ1a" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Research and development</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">744,640</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">237,504</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maALCz4Fv_z3BwqWil0ZF9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Professional fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">271,377</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">58,261</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_ecustom--AccruedWarrantyCostsCurrent_iI_pp0p0_maALCz4Fv_z142s1ScbKS6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Warranty costs</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">47,854</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24,871</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--AccruedPayrollTaxesCurrent_iI_pp0p0_maALCz4Fv_zdf0hc56hNZi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Payroll</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">176,275</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,566</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_ecustom--AccruedPatentAndLicenseFeesCurrent_iI_pp0p0_maALCz4Fv_zVXXmR9dGz24" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Patent and license fees</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1247">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,204</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--SalesAndExciseTaxPayableCurrent_iI_pp0p0_maALCz4Fv_z0MM8Hb8QPr5" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Franchise, sales and use taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21,130</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30,353</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedIncomeTaxesCurrent_iI_pp0p0_maALCz4Fv_zvdb97Z8BTwd" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Income taxes</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,326</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maALCz4Fv_z6U54f6BSU4i" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt">Other</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">317,730</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">134,614</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCz4Fv_zLe38PjFctJg" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Accrued expenses and
    other current liabilities</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,923,708</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">746,738</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203526616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DisclosureWarrantLiabilitiesAbstract', window );"><strong>Warrant Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">SCHEDULE OF WARRANTS ACTIVITY</a></td>
<td class="text"><p id="xdx_899_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SOSENWORTB-HVF_zIBruZ56MXte" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the warrants received in exchange for the Series C Warrants for the six months ended June
30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BF_zkvxIGOm7U5b" style="display: none">SCHEDULE OF WARRANTS ACTIVITY</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock Warrants (received in exchange for the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Series C Warrants)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Remaining<br/> Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%">Total outstanding &#8211; December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zDaxPDbnKUl5" style="width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning">3,378,596</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zStbWShS2lMf" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning">0.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="display: none; vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zg9vSYTLyv0l" style="text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger"><span style="-sec-ix-hidden: xdx2ixbrl1276">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCvou4jClwBf" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger"><span style="-sec-ix-hidden: xdx2ixbrl1278">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Exercised">(542,737</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised">0.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited">(36,097</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited">0.72</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1288">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1290">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1292">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1294">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zcbNS4q2OtX" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">2,799,762</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCmR7vjK49T" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zkoYGshadwE9" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">2,799,762</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zfuT5h3k2XGa" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zgPYgZcHeZB7" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_908_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zRdhng9g0ri5" title="Weighted Average Remaining Life (Years) Exercisable">2.5</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<table cellpadding="0" cellspacing="0" id="xdx_306_133_z9cZFuv8bvj9" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common Stock Warrants (received in exchange for the</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Series C Warrants)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range of Exercise</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211; Average Remaining</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life (Years)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total outstanding &#8211; December 31, 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z55WScidoXii" style="text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1312">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzg5D37vqJx9" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="-sec-ix-hidden: xdx2ixbrl1314">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 36%; text-align: left; padding-left: 10pt">Common stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_z5F2hAAfkbyg" style="width: 12%; text-align: right" title="Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger">4,713,490</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zzYYlcEHss7g" style="width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger">0.72</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1320">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1322">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Number of Shares, Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1324">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="-sec-ix-hidden: xdx2ixbrl1326">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt">Granted</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1328">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1330">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Total outstanding &#8211; June 30, 2020</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zCZPSOaRBzk5" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Outstanding Ending">4,713,490</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zrQKZTCBhAA6" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt; text-align: right">&#160;</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Exercisable</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zNRnfOYyDl3" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of Shares, Warrants Exercisable">4,713,490</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zXoyCEVmqAse" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Range of Exercise Price, Exercisable">0.72</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><span id="xdx_90E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantsMember__us-gaap--StatementClassOfStockAxis__custom--SeriesCWarrantsMember_zQqW9Rqd8c3a" title="Weighted Average Remaining Life (Years) Exercisable">3.82</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_896_ecustom--ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock_zci8YKS0KK1a" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table presents the Company&#8217;s fair value hierarchy for its warrant liabilities (all of which arise under the warrants
received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span id="xdx_8BB_zCeGJCyPl59i" style="display: none">SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Quoted</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Market</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Prices for</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Other</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Significant</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Identical</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Observable</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Unobservable</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Assets</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Inputs</td><td style="font-weight: bold">&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrant liabilities</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 1)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 2)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(Level 3)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 36%; padding-bottom: 2.5pt">Balance as of December 31. 2020</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zcWsKV4o9Ecg" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1346">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z4ikU4uxxzNa" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1348">&#8212;</span></td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zeOj9aLw7l81" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="width: 2%; padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_988_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20200101__20201231_zTuVPoyBlM0c" style="border-bottom: Black 2.5pt double; width: 12%; text-align: right" title="Fair value for warrant liabilities">8,310,100</td><td style="width: 1%; padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance as of June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z7Mj8rQWaWJj" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1354">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_989_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zLbedbEb8mnf" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities"><span style="-sec-ix-hidden: xdx2ixbrl1356">&#8212;</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zx8I03Rnxbyg" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">4,112,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_983_ecustom--FairValueAdjustmentOfWarrant_pp0p0_c20210101__20210630_zIKu76ZVXgH1" style="border-bottom: Black 2.5pt double; text-align: right" title="Fair value for warrant liabilities">4,112,100</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES</a></td>
<td class="text"><p id="xdx_898_ecustom--ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock_zlfJeT57pXwg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of June 30, 2021 and December
31, 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_z8MEEy2aESzg" style="display: none">SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 90%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>June
    30, 2021</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>December
    31, 2020</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    </b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 52%; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zK94R0DS9ZS1" title="Fair value assumptions, measurement input, percentages">0.34</span>%
    &#8212; <span id="xdx_90D_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zntNlY0eUaI5" title="Fair value assumptions, measurement input, percentages">0.46</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%<span style="font: 10pt Times New Roman, Times, Serif"/></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MinimumMember_zwKTxpiUH5Yl" title="Fair value assumptions, measurement input, percentages">0.17</span>%
    &#8212; <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember__srt--RangeAxis__srt--MaximumMember_zNCCsWNJwP7g" title="Fair value assumptions, measurement input, percentages">0.22</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    volatility (peer group)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MinimumMember_za9tyFt3yra7" title="Fair value assumptions, measurement input, percentages">82.00</span>
    &#8212; <span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember__srt--RangeAxis__srt--MaximumMember_zATWqLnWH8ja" title="Fair value assumptions, measurement input, percentages">83.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zOahHKARziM2" title="Fair value assumptions, measurement input, percentages">82.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Term
    of warrants (in years)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zTGA01eevXn8" title="Fair value assumptions, measurement input, term">2.41</span>
    &#8212; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_z7JuTZjNTKIf" title="Fair value assumptions, measurement input, term">2.99</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MinimumMember_zomSgy8h899d" title="Fair value assumptions, measurement input, term">2.90</span>
    &#8212; <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingTerm_iI_dtY_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember__srt--RangeAxis__srt--MaximumMember_zb0kn7hRmcqc" title="Fair value assumptions, measurement input, term">3.49</span> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: white">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20210630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zwf9yBh3xzkb" title="Fair value assumptions, measurement input, percentages">0.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;%</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20201231__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zCwGmmUYzigf" title="Fair value assumptions, measurement input, percentages">0.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">%<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosureWarrantLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosureWarrantLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Assumptions of Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Fair Value Hierarchy for Warrant Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203423432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock', window );">SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_899_ecustom--ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock_zoVpgJ3yxoz7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company leases its facilities under a long-term operating lease agreement expiring in October 2022. The tables below show the operating
lease right-of-use assets and operating lease liabilities as of December 31, 2020 and June 30, 2021, including the changes during the
periods:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zxgSC1D22YA5" style="display: none">SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/>
 right-of-use assets</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">Net right-of-use assets at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--OperatingLeaseRightOfUseAsset_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zB6B7GBLTW6e" style="width: 16%; text-align: right" title="Operating lease right-of-use assets">430,795</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less amortization of operating lease right-of-use assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--OperatingLeaseRightOfUseAssetAmortizationExpense_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z9Hs7w4GqnMb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less amortization of operating lease right-of-use assets">(109,719</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease right-of-use assets at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--OperatingLeaseRightOfUseAsset_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z8EMRGxbC3F9" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease right-of-use assets">321,076</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Operating lease<br/>
 liabilities</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%">At December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_980_eus-gaap--OperatingLeaseLiability_iS_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zVGOAE31lqcf" style="width: 16%; text-align: right" title="Operating lease liabilities">491,565</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less principal payments on operating lease liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--OperatingLeasePayments_iN_pp0p0_di_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zz2UiEkr3aO1" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less principal payments on operating lease liabilities">(122,780</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating lease liabilities at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iE_pp0p0_c20210101__20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_zgVasBo025h4" style="text-align: right" title="Operating lease liabilities">368,785</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_iNI_pp0p0_di_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_z5OgPJ56SJpg" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less non-current portion">(98,145</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Current portion at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_c20210630__us-gaap--TypeOfArrangementAxis__custom--LongtermOperatingLeaseAgreementMember_ztDMb9pI3DEf" style="border-bottom: Black 2.5pt double; text-align: right" title="Current portion at June 30, 2021">270,640</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zdtcnbpO4Pt4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, future minimum payments during the next five fiscal years and thereafter are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BE_zJZzWsebBMSi" style="display: none">SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Year Ending December 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">2021 (six months)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_c20210630_pp0p0" style="width: 20%; text-align: right" title="2021 (nine months)">145,958</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: justify; padding-bottom: 1.5pt">2022</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="2022">246,650</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Total</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_c20210630_pp0p0" style="text-align: right" title="Total">392,608</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Less present value discount</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_c20210630_zjgjDCWWcQ73" style="border-bottom: Black 1.5pt solid; text-align: right" title="Less present value discount">(23,823</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liabilities</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--OperatingLeaseLiability_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Operating lease liabilities">368,785</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Operating Lease Right of Use Assets and Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203603192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ScheduleOfReservedSharesTableTextBlock', window );">SCHEDULE OF RESERVED SHARES</a></td>
<td class="text"><p id="xdx_893_ecustom--ScheduleOfReservedSharesTableTextBlock_zUhHeLMgL6ik" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2021, the Company has reserved <span id="xdx_903_eus-gaap--CommonStockSharesSubscribedButUnissued_c20210630_pdd" title="Shares of authorized but unissued common stock">13,917,461</span> shares of authorized but unissued common stock for possible future issuance. At June
30, 2021, shares were reserved in connection with the following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BF_zhSYbgOdMeNk" style="display: none">SCHEDULE
OF RESERVED SHARES</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%">Exercise of outstanding stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockOptionsMember_zo3DUyEoEGa1" style="width: 20%; text-align: right" title="Total">4,133,856</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Exercise of outstanding stock warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--ExerciseOfOutstandingStockWarrantMember_zkXGif7XmMEi" style="text-align: right">9,540,187</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Conversion of outstanding Series Alpha preferred stock</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98C_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630__us-gaap--StatementClassOfStockAxis__custom--SerieAlphaPreferredStockMember_z5vjFpOt7Nbj" style="border-bottom: Black 1.5pt solid; text-align: right">243,418</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--CommonStockSharesSubscribedButUnissued_iI_c20210630_zNi6r5qjfPCb" style="border-bottom: Black 2.5pt double; text-align: right">13,917,461</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">SCHEDULE OF STOCK OPTION ACTIVITY</a></td>
<td class="text"><p id="xdx_893_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zuuDS8dQT2fh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2021, and changes during the six-month period then ended:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8B0_zsA2VITac1A7" style="display: none">SCHEDULE
OF STOCK OPTION ACTIVITY</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average <br/>
    Exercise <br/>
    Price</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average Remaining <br/>
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 39%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGZIeRguF763" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Options Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">4,011,356</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zNG1FtDfIxe7" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Weighted Average Exercise Price, Outstanding, Beginning"><span style="font: 10pt Times New Roman, Times, Serif">7.05</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_z2TfsjjRSYHg" title="Range of Exercise price, Options Outstanding">3.52</span>&#8212;<span id="xdx_90A_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iS_c20201231__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zesHnaej9rr2" title="Range of Exercise price, Options Outstanding">1,465.75</span>
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z3r0SiApwfxa" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning">9.29</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">127,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Granted"><span style="font: 10pt Times New Roman, Times, Serif">2.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Granted">1.80</span>&#8212;<span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsGranted_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Granted">3.29</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_z4JC7iBSZbY5" title="Weighted- Average Remaining Contractual Life (in Years), Options Granted">9.83</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1734">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1736">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_ecustom--RangeOfExercisePriceOptionsExpired_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise price, Options Expired"><span style="-sec-ix-hidden: xdx2ixbrl1738">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_znlDhZ0qQq57" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(4,500</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">3.68</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_900_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Forfeited">3.52</span>
    &#8212; <span id="xdx_90E_ecustom--RangeOfExercisePriceOptionsForfeited_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Forfeited">4.97</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zGD3wHgiHYKk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Outstanding at Ending"><span style="font: 10pt Times New Roman, Times, Serif">4,133,856</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zAPZM8OKVyme" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Outstanding at Ending"><span style="font: 10pt Times New Roman, Times, Serif">6.90</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zMjGUy7A2uP9" title="Range of Exercise price, Options Outstanding">1.80</span>
    &#8212; <span id="xdx_901_ecustom--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange_iE_c20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_zEz1cL2XsGXl" title="Range of Exercise price, Options Outstanding">1,465.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zHSjUCZ8a2k5" title="Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending">8.82</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable
    (vested)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zSdZKQlVBMM6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Exercisable (vested)"><span style="font: 10pt Times New Roman, Times, Serif">1,296,860</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zPjAvqCRwcjk" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Exercisable (vested)"><span style="font: 10pt Times New Roman, Times, Serif">11.50</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_zo7WNz4ixrni" title="Range of Exercise price, Options Exercisable (vested)">4.97</span>
    &#8212; <span id="xdx_903_ecustom--RangeOfExercisePriceOptionsExercisableVested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Exercisable (vested)">1,465.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90D_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjcHVACkl421" title="Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)">8.36</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable
    (non-vested)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zo6LEmEpSo6h" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Options Non-Exercisable (non-vested)"><span style="font: 10pt Times New Roman, Times, Serif">2,836,996</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice_iE_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zjz5DW3HszD8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price, Options Non-Exercisable (non-vested)"><span style="font: 10pt Times New Roman, Times, Serif">4.80</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)">1.80</span>
    &#8212; <span id="xdx_905_ecustom--RangeOfExercisePriceOptionsNonexercisableNonvested_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise price, Options Non-Exercisable (non-vested)">5.13</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested_dtY_c20210101__20210630__srt--TitleOfIndividualAxis__custom--EmployeesAndNonemployeeServiceProviderMember_zfTNyjgx9T7e" title="Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)">9.04</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zhMJCwb3Nvq6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zypqMcSXiXa8" style="display: none">SCHEDULE
OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 80%; border-collapse: collapse; margin-right: auto">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the six months<br/>
ended <br/>
June 30, 2021</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 76%"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    dividend yield</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_uPure_c20210101__20210630_zgviF8xlXhVd" title="Expected dividend yield">0.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Expected
    stock-price volatility</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_uPure_c20210101__20210630_z9MaedWULN8g" title="Expected stock-price volatility">102</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Risk-free
    interest rate</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20210101__20210630_zo1twREqmpi3" title="Risk-free interest rate, minimum">0.84</span>%
    &#8212; <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20210101__20210630_zYGLh6nVGlX4" title="Risk-free interest rate, maximum">1.18</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">%</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif; background-color: white">Expected
    average term of options</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zp9wn2ZilkTe" title="Average expected remaining years of life of options">6.0</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Stock
    price</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_eus-gaap--SharePrice_c20210630_pdd" title="Stock price">2.12</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE</a></td>
<td class="text"><p id="xdx_890_eus-gaap--ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_zLcG6bpugaBl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span id="xdx_8BF_zMdYUrsZNdyf" style="display: none">SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE</span><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left">General and administrative</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_z7egFqhcBdBd" style="width: 20%; text-align: right" title="Total">2,201,499</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zqhAcfvZcEHd" style="width: 20%; text-align: right" title="Total">277,807</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Research and development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zK7inVm28ael" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">347,550</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zqCUHEU4Ifq3" style="border-bottom: Black 1.5pt solid; text-align: right" title="Total">88,684</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 10pt">Total</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--ShareBasedCompensation_pp0p0_c20210101__20210630_zG9rAHPnEZF8" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">2,549,049</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensation_pp0p0_c20200101__20200630_zTaUiVSIXXF6" style="border-bottom: Black 2.5pt double; text-align: right" title="Total">366,491</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SummaryOfWarrantActivityTableTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_89B_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_gL3SOWATTB-XCNSZ_ze9Cvv2uEijh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the activity in the common stock equity classified compensatory warrants received in exchange for the Series
C convertible preferred stock equity classified compensatory warrants for the six months ended June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B7_zz0DeCBA5H5k" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br/>
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;<br/>
    Average<br/>
    Remaining <br/>
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ztJPt0tKB5W6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1,294,217</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zVYkjfKsgOLd" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1.66</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zC5KDPgMmXHe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1838">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1JG4rJahtKh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1840">-</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Legacy
    Ritter warrants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRQw9aW18Ec" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1842">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zUvMc2kCuqEc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1844">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1846">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1848">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(38,390</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">2.09</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1854">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1856">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">(65,179</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif">2.07</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RYTQiEnCDj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1,190,648</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zi0WH4YIOGwa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zR2z8g3LZho7" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1,187,052</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbnSiTJp3qKh" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1.62</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable">1.11</span>
    &#8212; <span id="xdx_90D_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable">2.54</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zdYAqANed95k" title="Weighted Average Remaining Life (Years) Exercisable">3.75</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zbVhuLk43Bvf" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="font: 10pt Times New Roman, Times, Serif">3,596</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zSFTVvAFI1a6" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2.54
    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_989_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2.54</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z4JSgNsnKVm" title="Weighted Average Remaining Life (Years) Non-Exercisable">5.23</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B3_zNtEjVZ5xzkf" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br/>
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;
    Average Remaining</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Life
    (Years)</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2019</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zqRPgZtofBdl" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1888">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z66E65pFepNc" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">1.99</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Common
    stock warrants received in exchange for Series C preferred stock warrants upon reverse recapitalization</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z3F0agyTu3oi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"><span style="font: 10pt Times New Roman, Times, Serif">668,024</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zFzKhwhNafmh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"><span style="font: 10pt Times New Roman, Times, Serif">2.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Legacy
    Ritter warrants</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--NumberOfSharesWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zEptr09bcs83" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1896">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7etL0b2V5ml" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1898">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif">811,431</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zxMmPCwmC2Pi" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="font: 10pt Times New Roman, Times, Serif">1.11</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1904">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zLL0Ke1UL8u5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1906">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1908">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z7RloP4fvTyi" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1910">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zZQm2lRUhPCc" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1,479,455</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_za9epGDPPV0c" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">1.67</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zfRQiexHvsB3" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">660,832</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zMrKiLC8mghj" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">2.34</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Exercisable">2.07</span>
    &#8212; <span id="xdx_90F_ecustom--RangeOfExercisePriceExercisableVested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Exercisable">2.54</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_zmD95OhSynA2" title="Weighted Average Remaining Life (Years) Exercisable">3.82</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z9tnexDfrbBa" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="font: 10pt Times New Roman, Times, Serif">818,623</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_z1roXZzS8sub" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">1.12</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" title="Range of Exercise Price, Non-Exercisable">1.11</span>
    &#8212; <span id="xdx_905_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd" title="Range of Exercise Price, Non-Exercisable">2.54</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_901_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1_dtY_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CompensatoryWarrantActivityMember_ziEKMWF29x0k" title="Weighted Average Remaining Life (Years) Non-Exercisable">4.91</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SummaryOfWarrantActivityTableTextBlock', window );">SCHEDULE OF WARRANT ACTIVITY</a></td>
<td class="text"><p id="xdx_89E_ecustom--SummaryOfWarrantActivityTableTextBlock_hus-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zhvZKGrwksr8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B5_zz92liI2luSj" style="display: none">SCHEDULE
OF WARRANT ACTIVITY</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="14" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Common
    Stock</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Shares</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Average</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exercise<br/>
    Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Range
    of Exercise</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Price</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Weighted&#8211;<br/>
    Average<br/>
    Remaining <br/>
    Life (Years)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 42%"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; December 31, 2020</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zQhwqpdEym8e" style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right" title="Number of Shares, Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">6,549,777</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zxtC0XknraS7" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"><span style="font: 10pt Times New Roman, Times, Serif">4.37</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercised</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">(1,000,000</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Exercised"><span style="font: 10pt Times New Roman, Times, Serif">0.01</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Granted</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1980">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Granted"><span style="-sec-ix-hidden: xdx2ixbrl1982">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Expired</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1984">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Expired"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1986">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Forfeited</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1988">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Forfeited"><span style="font: 10pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl1990">&#8212;</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    outstanding &#8211; June 30, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zL1FaaiiJEb1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">5,549,777</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_98E_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zYEbzYgcSMki" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Warrants Outstanding Ending"><span style="font: 10pt Times New Roman, Times, Serif">5.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_z8ZdcQ0BJeE1" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of Shares, Warrants Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">5,549,777</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zXGXhpg0ZWM5" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Exercisable"><span style="font: 10pt Times New Roman, Times, Serif">5.15</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_900_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MinimumMember_pdd" style="font: 10pt Times New Roman, Times, Serif">1.11
    </span><span style="font: 10pt Times New Roman, Times, Serif">&#8212;</span><span style="font: 10pt Times New Roman, Times, Serif">
    <span id="xdx_906_ecustom--RangeOfExercisePriceExercisableVested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember__srt--RangeAxis__srt--MaximumMember_pdd">2,325.00</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zGzT4vMFUq6h" title="Weighted Average Remaining Life (Years) Exercisable">1.33</span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Non-Exercisable</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zZFK6wpzMyj8" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Number of shares, warrants non-exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2004">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td>
    <td id="xdx_987_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_zC4ecpj8SH0i" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Weighted Average Exercise Price Per Share Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2006">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td id="xdx_988_ecustom--RangeOfExercisePriceNonexercisableNonvested_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__custom--NonCompensatoryWarrantActivityMember_pdd" style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Range of Exercise Price, Non-Exercisable"><span style="-sec-ix-hidden: xdx2ixbrl2008">&#8212;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">&#8212;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ScheduleOfReservedSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Reserved Shares [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ScheduleOfReservedSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SummaryOfWarrantActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Warrant Activity [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SummaryOfWarrantActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840196489704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCOUNTS RECEIVABLE (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts Receivable</a></td>
<td class="nump">$ 784,429<span></span>
</td>
<td class="nump">$ 629,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less Allowance</a></td>
<td class="num">(17,517)<span></span>
</td>
<td class="num">(13,873)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">$ 766,911<span></span>
</td>
<td class="nump">$ 615,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203558232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tools, Dies and Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_OfficeFurnitureAndEquipmentMember', window );">Office Furniture And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840202690744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived assets impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Shipping and handling costs</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">58,000<span></span>
</td>
<td class="nump">56,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,117,935<span></span>
</td>
<td class="nump">904,067<span></span>
</td>
<td class="nump">3,017,430<span></span>
</td>
<td class="nump">2,360,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_EstimatedReturnsNetOfAllowances', window );">Estimated returns net of allowances</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">1,923,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,923,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 746,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WarrantyCosts', window );">Warranty costs</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">31,000<span></span>
</td>
<td class="nump">$ 41,000<span></span>
</td>
<td class="nump">$ 58,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember', window );">Patents and Licenses [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember', window );">Patents and Licenses [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember', window );">Patents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying value</a></td>
<td class="nump">168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Future estimated amortization, remainder of fiscal year</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future estimated amortization for year ending December 31, 2022</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future estimated amortization for year ending December 31, 2023</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future estimated amortization for year ending December 31, 2024</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future estimated amortization for year ending December 31, 2025</a></td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Future estimated amortization, Thereafter</a></td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying value</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Future estimated amortization, remainder of fiscal year</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future estimated amortization for year ending December 31, 2022</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future estimated amortization for year ending December 31, 2023</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">478,654<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember', window );">Collaborative Research Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember', window );">General, Administrative, Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Shipping and handling costs</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EstimatedReturnsNetOfAllowances">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated Returns Net of allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EstimatedReturnsNetOfAllowances</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WarrantyCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warranty costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WarrantyCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203803624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LIQUIDITY (Details Narrative) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NewEquityCapitalRaise', window );">New equity capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertibleNotesPayable', window );">Convertible notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of equity</a></td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NewEquityCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>New equity capital raise,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NewEquityCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e603758-122996<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840196818296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF INVENTORY (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 779,936<span></span>
</td>
<td class="nump">$ 579,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">241,677<span></span>
</td>
<td class="nump">309,826<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">51,722<span></span>
</td>
<td class="nump">63,867<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory net</a></td>
<td class="nump">$ 1,073,335<span></span>
</td>
<td class="nump">$ 953,458<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203376152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,916,387<span></span>
</td>
<td class="nump">$ 1,307,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_PrepaidManufacturingExpenses', window );">Prepaid manufacturing expenses</a></td>
<td class="nump">49,617<span></span>
</td>
<td class="nump">1,181,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_PrepaidInvestorRelationsExpenses', window );">Prepaid investor relations expenses</a></td>
<td class="nump">49,127<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">18,726<span></span>
</td>
<td class="nump">40,001<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,033,857<span></span>
</td>
<td class="nump">$ 2,678,894<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrepaidInvestorRelationsExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid investor relations expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrepaidInvestorRelationsExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_PrepaidManufacturingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid manufacturing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_PrepaidManufacturingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840282046104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,707,666<span></span>
</td>
<td class="nump">$ 3,669,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less Accumulated depreciation</a></td>
<td class="num">(3,454,405)<span></span>
</td>
<td class="num">(3,422,146)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">253,261<span></span>
</td>
<td class="nump">247,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,409,946<span></span>
</td>
<td class="nump">2,401,470<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_ConstructionInProgressEquipmentMember', window );">Construction In Progress Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">94,717<span></span>
</td>
<td class="nump">104,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">472,094<span></span>
</td>
<td class="nump">443,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">327,894<span></span>
</td>
<td class="nump">321,033<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember', window );">Tools, Dies and Molds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">260,002<span></span>
</td>
<td class="nump">260,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_OfficeFurnitureAndEquipmentMember', window );">Office Furniture And Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 143,013<span></span>
</td>
<td class="nump">$ 138,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_ConstructionInProgressEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_ConstructionInProgressEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ToolsDiesAndMoldsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=QLGN_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203758648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="nump">$ 9,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840282292680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AccruedCompensation', window );">Board compensation</a></td>
<td class="nump">$ 50,776<span></span>
</td>
<td class="nump">$ 15,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedVacationCurrent', window );">Vacation</a></td>
<td class="nump">290,587<span></span>
</td>
<td class="nump">230,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties</a></td>
<td class="nump">1,078<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AccruedResearchAndDevelopmentCurrent', window );">Research and development</a></td>
<td class="nump">744,640<span></span>
</td>
<td class="nump">237,504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">271,377<span></span>
</td>
<td class="nump">58,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AccruedWarrantyCostsCurrent', window );">Warranty costs</a></td>
<td class="nump">47,854<span></span>
</td>
<td class="nump">24,871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Payroll</a></td>
<td class="nump">176,275<span></span>
</td>
<td class="nump">4,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AccruedPatentAndLicenseFeesCurrent', window );">Patent and license fees</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Franchise, sales and use taxes</a></td>
<td class="nump">21,130<span></span>
</td>
<td class="nump">30,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">2,261<span></span>
</td>
<td class="nump">3,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">317,730<span></span>
</td>
<td class="nump">134,614<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">$ 1,923,708<span></span>
</td>
<td class="nump">$ 746,738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Board compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedPatentAndLicenseFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Patent and license fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedPatentAndLicenseFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedResearchAndDevelopmentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedResearchAndDevelopmentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AccruedWarrantyCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warranty costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AccruedWarrantyCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedVacationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6409733&amp;loc=d3e19396-108361<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedVacationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840204070344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANTS ACTIVITY (Details) - Common Stock Warrants [Member] - Series C Warrants [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">3,378,596<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger', window );">Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 4,713,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger', window );">Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="num">(542,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Exercised</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="num">(36,097)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Forfeited</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Warrants Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">2,799,762<span></span>
</td>
<td class="nump">4,713,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">2,799,762<span></span>
</td>
<td class="nump">4,713,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) Exercisable</a></td>
<td class="text">2 years 6 months<span></span>
</td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sttock warrant exchanged for common stock warrant upon reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants series c preferred stock warrant exchanged for common stock warrant upon reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203459736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">$ 4,112,100<span></span>
</td>
<td class="nump">$ 8,310,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_FairValueAdjustmentOfWarrant', window );">Fair value for warrant liabilities</a></td>
<td class="nump">$ 4,112,100<span></span>
</td>
<td class="nump">$ 8,310,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_FairValueAdjustmentOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_FairValueAdjustmentOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840202733544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">0.34<span></span>
</td>
<td class="nump">0.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Measurement Input, Risk Free Interest Rate [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">0.46<span></span>
</td>
<td class="nump">0.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82.00<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">82.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Measurement Input, Price Volatility [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">83.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">2 years 4 months 28 days<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Measurement Input, Expected Term [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Fair value assumptions, measurement input, term</a></td>
<td class="text">2 years 11 months 26 days<span></span>
</td>
<td class="text">3 years 5 months 26 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Fair value assumptions, measurement input, percentages</a></td>
<td class="nump">0.00<span></span>
</td>
<td class="nump">0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840282167928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>WARRANT LIABILITIES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="num">$ (2,075,100)<span></span>
</td>
<td class="nump">$ 16,201,400<span></span>
</td>
<td class="num">$ (4,198,000)<span></span>
</td>
<td class="nump">$ 16,201,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
<td class="nump">4,713,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember', window );">Series C Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised', window );">Shares issued upon the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NumberOfWarrantExercisedOnCashlessBasis', window );">Shares issued upon net-exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">156,861<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair Value Adjustment of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="nump">$ 16,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NumberOfWarrantExercisedOnCashlessBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant exercised on cashless basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NumberOfWarrantExercisedOnCashlessBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840282049848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 430,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">321,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">368,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less non-current portion</a></td>
<td class="num">(98,145)<span></span>
</td>
<td class="num">$ (236,826)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at June 30, 2021</a></td>
<td class="nump">270,640<span></span>
</td>
<td class="nump">$ 254,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember', window );">Longterm Operating Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">430,795<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Less amortization of operating lease right-of-use assets</a></td>
<td class="num">(109,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">321,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">491,565<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Less principal payments on operating lease liabilities</a></td>
<td class="num">(122,780)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">368,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Less non-current portion</a></td>
<td class="num">(98,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion at June 30, 2021</a></td>
<td class="nump">$ 270,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840196545144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (nine months)</a></td>
<td class="nump">$ 145,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">246,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">392,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less present value discount</a></td>
<td class="num">(23,823)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 368,785<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840197880088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Discount rate operating lease</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Lease expense</a></td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 86,000<span></span>
</td>
<td class="nump">$ 172,000<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840186720440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,508,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 597,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,007,840<span></span>
</td>
<td class="nump">$ 835,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,117,935<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">904,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,017,430<span></span>
</td>
<td class="nump">2,360,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember', window );">Collaborative Research Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember', window );">License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478,654<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember', window );">University Of Louisville Research Foundation [Member] | Minimum [Member] | Royalties And Non Royalty Sublicensee Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember', window );">University Of Louisville Research Foundation [Member] | Maximum [Member] | Royalties And Non Royalty Sublicensee Income [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_PredictionBiosciencesSASMember', window );">Prediction Biosciences S A S [Member] | Collaborative Research Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_SekisuiDiagnosticsLLCMember', window );">Sekisui Diagnostics L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">701,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember', window );">Yi Xin Zhen Duan Jishu Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember', window );">Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Product sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember', window );">S T A Pharmaceutical Co Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Upfront deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Payment of convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ReimbursementOfResearchExpenses', window );">Reimbursement of research expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">805,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ReimbursementPatentCost', window );">Reimbursement patent cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AgreementTermPaymentDescription', window );">Agreement term payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the Company agreed to pay ULRF (i) royalties,
on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales
up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the
licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePaymentForMarketingExpenses', window );">Milestone payment for marketing expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensed product sales, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,000<span></span>
</td>
<td class="nump">247,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Licensed Product Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpenses', window );">Regulatory marketing approval, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Phase One Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Phase Two Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Phase Three Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember', window );">License And Sponsored Research Agreements [Member] | University Of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShortfallPayments', window );">Shortfall payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research Agreement And License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Minimum annual royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research Agreement And License [Member] | University Of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ReimbursementOfResearchExpenses', window );">Reimbursement of research expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ReimbursementPatentCost', window );">Reimbursement patent cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AgreementTermPaymentDescription', window );">Agreement term payment, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In addition, the Company has agreed to pay
ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000)
or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not
covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first
two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and
30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated
with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging
from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensed product sales, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RegulatoryMarketingApprovalExpenses', window );">Regulatory marketing approval, expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research Agreement And License [Member] | University Of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember', window );">Sponsored Research Agreement And License [Member] | University Of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestonePayment', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University Of Louisville Research Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_UlrfLicenseAgreementDescription', window );">ULRF license agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In
addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165
as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000),
until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any
non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses
granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license
agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance
of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain
regulatory and commercial milestones.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Sponsored research expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University Of Louisville Research Foundation [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | University Of Louisville Research Foundation [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | Advanced Cancer Therapeutics L L C [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Licensed product sales, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_LicenseCost', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_AgreementDescription', window );">Agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (&#8220;ACT&#8221;), granting the
Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. In return, ACT received a $25,000 convertible
promissory note in payment of an upfront license fee, which was subsequently converted into the Company&#8217;s common stock. In addition,
the Company agreed to pay ACT (i) royalties, on net sales associated with the commercialization of QN-165, of 2% (only if patent-covered
and only on net sales above a cumulative $3,000,000) or 1% (if not patent-covered, but only on net sales above a cumulative $3,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from convertible promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_CumulativeAmount', window );">Cumulative amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember', window );">License Agreement [Member] | Advanced Cancer Therapeutics L L C [Member] | C E Mark [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_MilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_CumulativeAmount', window );">Cumulative amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_TechnologyTransferAgreementMember', window );">Technology Transfer Agreement [Member] | Yi Xin Zhen Duan Jishu Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 153,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_AgreementTermPaymentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement term payment, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_AgreementTermPaymentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_LicenseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_LicenseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone method revenue recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_MilestonePaymentForMarketingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment for marketing expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_MilestonePaymentForMarketingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RegulatoryMarketingApprovalExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory marketing approval, expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RegulatoryMarketingApprovalExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementOfResearchExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement of research expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementOfResearchExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ReimbursementPatentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reimbursement patent cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ReimbursementPatentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShortfallPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shortfall payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShortfallPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_UlrfLicenseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ULRF license agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_UlrfLicenseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8,17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_CollaborativeResearchRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicenseRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_PredictionBiosciencesSASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_PredictionBiosciencesSASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_SekisuiDiagnosticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_SekisuiDiagnosticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_STAPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LicenseAndSponsoredResearchAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SponsoredResearchAgreementAndLicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=QLGN_AdvancedCancerTherapeuticsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=QLGN_AdvancedCancerTherapeuticsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_CEMarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_CEMarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_TechnologyTransferAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_TechnologyTransferAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840292096328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SCHEDULE OF RESERVED SHARES (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Total</a></td>
<td class="nump">13,917,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_ExerciseOfOutstandingStockOptionsMember', window );">Exercise Of Outstanding Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Total</a></td>
<td class="nump">4,133,856<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_ExerciseOfOutstandingStockWarrantMember', window );">Exercise Of Outstanding Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Total</a></td>
<td class="nump">9,540,187<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SerieAlphaPreferredStockMember', window );">Serie Alpha Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesSubscribedButUnissued', window );">Total</a></td>
<td class="nump">243,418<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesSubscribedButUnissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesSubscribedButUnissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_ExerciseOfOutstandingStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_ExerciseOfOutstandingStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_ExerciseOfOutstandingStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_ExerciseOfOutstandingStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SerieAlphaPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SerieAlphaPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840282301336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF STOCK OPTION ACTIVITY (Details) - Employees And Nonemployee Service Provider [Member]<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding, Beginning | shares</a></td>
<td class="nump">4,011,356<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning</a></td>
<td class="nump">$ 7.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning</a></td>
<td class="text">9 years 3 months 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares, Options Granted | shares</a></td>
<td class="nump">127,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Granted</a></td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Life (in Years), Options Granted</a></td>
<td class="text">9 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares, Options Expired | shares</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsExpired', window );">Range of Exercise price, Options Expired</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Shares, Options Forfeited | shares</a></td>
<td class="num">(4,500)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Forfeited</a></td>
<td class="nump">$ 3.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Options Outstanding at Ending | shares</a></td>
<td class="nump">4,133,856<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding at Ending</a></td>
<td class="nump">$ 6.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo', window );">Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending</a></td>
<td class="text">8 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Shares, Options Exercisable (vested) | shares</a></td>
<td class="nump">1,296,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Exercisable (vested)</a></td>
<td class="nump">$ 11.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested', window );">Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)</a></td>
<td class="text">8 years 4 months 9 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Number of Shares, Options Non-Exercisable (non-vested) | shares</a></td>
<td class="nump">2,836,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Options Non-Exercisable (non-vested)</a></td>
<td class="nump">$ 4.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested', window );">Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)</a></td>
<td class="text">9 years 14 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsGranted', window );">Range of Exercise price, Options Granted</a></td>
<td class="nump">1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsForfeited', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="nump">3.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">1.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsExercisableVested', window );">Range of Exercise price, Options Exercisable (vested)</a></td>
<td class="nump">4.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested', window );">Range of Exercise price, Options Non-Exercisable (non-vested)</a></td>
<td class="nump">1.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems', window );"><strong>Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">1,465.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsGranted', window );">Range of Exercise price, Options Granted</a></td>
<td class="nump">3.29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsForfeited', window );">Range of Exercise price, Options Forfeited</a></td>
<td class="nump">4.97<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange', window );">Range of Exercise price, Options Outstanding</a></td>
<td class="nump">1,465.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsExercisableVested', window );">Range of Exercise price, Options Exercisable (vested)</a></td>
<td class="nump">1,465.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested', window );">Range of Exercise price, Options Non-Exercisable (non-vested)</a></td>
<td class="nump">$ 5.13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOptionsExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, options exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOptionsExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOptionsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, options expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOptionsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOptionsForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOptionsForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOptionsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, options granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOptionsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- Average Remaining Contractual Life (in Years), Options Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- average remaining contractual life (in years), options exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840198125192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock-price volatility</a></td>
<td class="nump">102.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.84%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.18%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Average expected remaining years of life of options</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Stock price</a></td>
<td class="nump">$ 2.12<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840203582824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 2,549,049<span></span>
</td>
<td class="nump">$ 366,491<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">2,201,499<span></span>
</td>
<td class="nump">277,807<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Total</a></td>
<td class="nump">$ 347,550<span></span>
</td>
<td class="nump">$ 88,684<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840282374248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE OF WARRANT ACTIVITY (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">1,294,217<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger', window );">Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 668,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger', window );">Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NumberOfSharesWarrantsLegacyRitterWarrant', window );">Number of Shares, Warrants Legacy Ritter warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant', window );">Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Warrants Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">811,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="num">(38,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Exercised</a></td>
<td class="nump">$ 2.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="num">(65,179)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Forfeited</a></td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">1,190,648<span></span>
</td>
<td class="nump">1,479,455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">1,187,052<span></span>
</td>
<td class="nump">660,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) Exercisable</a></td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber', window );">Number of shares, warrants non-exercisable</a></td>
<td class="nump">3,596<span></span>
</td>
<td class="nump">818,623<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise', window );">Weighted Average Exercise Price Per Share Non-Exercisable</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) Non-Exercisable</a></td>
<td class="text">5 years 2 months 23 days<span></span>
</td>
<td class="text">4 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">2.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="nump">6,549,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="nump">$ 4.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Warrants Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Number of Shares, Warrants Exercised</a></td>
<td class="num">(1,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Exercised</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Expired</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Forfeited</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="nump">5,549,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="nump">5,549,777<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="nump">$ 5.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) Exercisable</a></td>
<td class="text">1 year 3 months 29 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber', window );">Number of shares, warrants non-exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise', window );">Weighted Average Exercise Price Per Share Non-Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember', window );">Non Compensatory Warrant Activity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="nump">$ 2,325.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NumberOfSharesWarrantsLegacyRitterWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares, Warrants Legacy Ritter warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NumberOfSharesWarrantsLegacyRitterWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sttock warrant exchanged for common stock warrant upon reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares, warrants non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants series c preferred stock warrant exchanged for common stock warrant upon reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840188117208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS&#8217; EQUITY (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 04, 2021</div></th>
<th class="th"><div>Dec. 18, 2020</div></th>
<th class="th"><div>Aug. 04, 2020</div></th>
<th class="th"><div>Jul. 22, 2020</div></th>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jul. 31, 2020</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,549,049<span></span>
</td>
<td class="nump">$ 366,491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_StockOptionsAndWarrantsMember', window );">Stock Options And Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 11 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Stock option granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=QLGN_StockOptionsAndWarrantsMember', window );">Stock Options And Warrants [Member] | Two Thousand Twenty Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,040,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,917,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_StockOptionsSharesFutureGrant', window );">[custom:StockOptionsSharesFutureGrant]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,157<span></span>
</td>
<td class="nump">139,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription', window );">Stock options description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Noncompensatory Equity Classified Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,191,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,191,010<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised', window );">Shares issued upon the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantsMember', window );">Compensatory Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">811,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">668,024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock issued upon exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_EquityCapitalRaise', window );">Equity capital raise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_SharesIssuedUponNetExercises', window );">Shares issued on net exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294,217<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger', window );">Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 668,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger', window );">Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_NumberOfSharesWarrantsLegacyRitterWarrant', window );">Number of Shares, Warrants Legacy Ritter warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant', window );">Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of Shares, Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">811,431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Number of Shares, Warrants Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Number of Shares, Warrants Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(65,179)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of Shares, Warrants Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,294,217<span></span>
</td>
<td class="nump">1,190,648<span></span>
</td>
<td class="nump">1,479,455<span></span>
</td>
<td class="nump">1,190,648<span></span>
</td>
<td class="nump">1,479,455<span></span>
</td>
<td class="nump">1,294,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price Per Share Warrants Outstanding Ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">$ 1.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber', window );">Number of Shares, Warrants Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187,052<span></span>
</td>
<td class="nump">660,832<span></span>
</td>
<td class="nump">1,187,052<span></span>
</td>
<td class="nump">660,832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice', window );">Weighted Average Exercise Price Per Share Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="nump">$ 1.62<span></span>
</td>
<td class="nump">$ 2.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months<span></span>
</td>
<td class="text">3 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber', window );">Number of shares, warrants non-exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,596<span></span>
</td>
<td class="nump">818,623<span></span>
</td>
<td class="nump">3,596<span></span>
</td>
<td class="nump">818,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise', window );">Weighted Average Exercise Price Per Share Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Life (Years) Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 2 months 23 days<span></span>
</td>
<td class="text">4 years 10 months 28 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="nump">$ 2.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember', window );">Compensatory Warrant Activity [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceExercisableVested', window );">Range of Exercise Price, Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="nump">2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_RangeOfExercisePriceNonexercisableNonvested', window );">Range of Exercise Price, Non-Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember', window );">Noncompensatory Equity Classified Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920,678<span></span>
</td>
<td class="nump">780,198<span></span>
</td>
<td class="nump">270,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised', window );">Shares issued upon the exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember', window );">Investor [Member] | Noncompensatory Equity Classified Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,287,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Beneficial-ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Two Year Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,314<span></span>
</td>
<td class="nump">1,287,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,920,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="nump">$ 6.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,370,786<span></span>
</td>
<td class="nump">1,717,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,140,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Prefunded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Warrants exercise</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">780,198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Purchase of stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">842,696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Single Institutional Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_EquityCapitalRaise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity capital raise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_EquityCapitalRaise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NumberOfSharesWarrantsLegacyRitterWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Shares, Warrants Legacy Ritter warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NumberOfSharesWarrantsLegacyRitterWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sttock warrant exchanged for common stock warrant upon reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceExercisableVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceExercisableVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_RangeOfExercisePriceNonexercisableNonvested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Range of exercise price, non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_RangeOfExercisePriceNonexercisableNonvested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares, warrants non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share non-exercisable (non-vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share exercisable (vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_SharesIssuedUponNetExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares issued upon net exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_SharesIssuedUponNetExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_StockOptionsSharesFutureGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock options shares future grant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_StockOptionsSharesFutureGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price per share warrants series c preferred stock warrant exchanged for common stock warrant upon reverse merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_StockOptionsAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_StockOptionsAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=us-gaap_InvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=us-gaap_InvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=QLGN_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=QLGN_TwoYearWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=QLGN_TwoYearWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=QLGN_SingleInstitutionalInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=QLGN_SingleInstitutionalInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840196500808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesDAndSeriesDOnePreferredStockMember', window );">Series D And Series D One Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_AffiliateCollateralizedSecurityLineItems', window );"><strong>Affiliate, Collateralized Security [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Conversion of preferred stock</a></td>
<td class="nump">1,980,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_AffiliateCollateralizedSecurityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_AffiliateCollateralizedSecurityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=QLGN_SeriesDAndSeriesDOnePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=QLGN_SeriesDAndSeriesDOnePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139840198216136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details Narrative)<br></strong></div></th>
<th class="th">
<div>Aug. 09, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Twp Thousand Twenty Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_QLGN_CommonStockSharesAvailableForFutureIssuance', window );">[custom:CommonStockSharesAvailableForFutureIssuance-0]</a></td>
<td class="nump">3,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_QLGN_CommonStockSharesAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock shares available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">QLGN_CommonStockSharesAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>QLGN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=QLGN_TwpThousandTwentyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=QLGN_TwpThousandTwentyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>67
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #Z@1!3;4HH33(%  !C%0  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;)6877/B-A2&KW=_A8;I13L3P)8)'SL),X0DNVFS+ EI.]M.+X0ML&=MR97E
M$/Y]CX2Q"6..Z0WXZ[Q^=&2]1]+51JH?6<BY)F])+++K5JAU^JG;S?R0)RSK
MR)0+N+.2*F$:3M6ZFZ6*L\ &)7&7.DZ_F[!(M,97]MI<C:]DKN-(\+DB69XD
M3&UO>"PWURVWM;_P'*U#;2YTQU<I6_,%U[^G<P5GW5(EB!(NLD@*HOCJNC5Q
M/TT]:@+L$W]$?),='!/3E*64/\S)0W#=<@P1C[FOC02#OU<^Y7%LE(#CWT*T
M5;[3!!X>[]7O;>.A,4N6\:F,_XP"'5ZWABT2\!7+8_TL-U]XT:!+H^?+.+._
M9+-[MM=K$3_/M$R*8"!((K'[9V]%(@X#G!,!M B@1P'NJ3=X18!G&[HCL\VZ
M99J-KY3<$&6>!C5S8'-CHZ$UD3#=N- *[D80I\=3^<H5:9,L9(IG5UT-FN9.
MUR_B;W;Q]$1\GWR50H<9N1,!#]['=X&E!*)[H!N*"OZ:BP[QG M"'>K6\$SQ
M\$F^[A"7UH6_P_'*_'A6ST/S\_=DF6D%G]P_B&2OE.Q9R=X)R5OIYS 0-'G9
MIKPNXWBXZ[2?$(K+DN(2E9D 0F Q[F.VKL/ XU<LSCC"T2\Y^N=EXREG2G,5
M;\DS3Z72=4BXE%8Y1C0HB09G]H]B8%?6;4XCX5I-61J63,/SF.9<13(PHXW
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MI! *:OXF+%!*(LR(0_5$)>+'TD> $E=%?;=?W\>I\WB<? M_8AP%QEI@PQF
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MR6CV)_'[&R5W_6'VK51*5OWE5G (0!O ]QL)+<UPH\_'Q]]#UO\!4$L#!!0
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M?J=T@ZS0Y>Y;YMEL-=6HD(E;P3H,WU:&^#[U# %MF,!!2*DAH VCA(0$,T-
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M.)UF"W7XNAG?H50Y2^XZX&[ZT(!8"6GC>,!\LP"YPC%XP".F!C:.>()0TJ)
MXU4([U1@I.<JW]!OI\T=&< X-5F[8!P3J\DZ@2+T3-K.>* W;>'=&"O2[:SJ
MTIOML/_^XMN&!_9!".;2V@<.:^1C+'QN[0-'3(\R'')NBN&,&0KJA2UJ-(:+
M=#NNJB!?1)>C<81NQZ-/5Q,HR0@N45VAT-W[+Z:A74MBVZ CSK#G4VM'.)!$
M\$ P;-5H!Q2\E6]UL\@9-/0XX;@M11HC1KJ=6"/$P45T$UU>W1WN)XGMCWQL
M/LHX0.#)3!UL$"'F4U'D0!W1-O:-&R/==@PZ$2K3PLDPM)Z<RD7GU+8E#F2U
MZ*&IR- %A44/A&\U!%?0<M$]T=(1:&/):+<ENU'0#<OFN83" %5A =VSF,L<
MBL*#+.)I;<OC9*6=9Q87Z_!B^][PL=4>7#!Z3,P',7<T9G8'=[2@I3G0QJ?1
M;I_VN3IC4[/??A'@BG^7S_!8!C8B72T>0!WP#Y4R!<I6NM @#%CV?66RK145
M@F-81%,I&RD"*"]6(76&+"V*V7PB!S(@@;>=O;N"-;:.TN]FS^WZ6;U^GOGK
M6I5B_=UU/M6X.OKF0QG:>!_ZUF,9NN^YC /H/)AQX,!+BR#PS15R'<T0WGHT
M0QN_0[O]SL=X6K9X-*YY[[4^C:F@_IO7I^G)M+LG[[$^G0'*]PLGQ5).U5EO
M";M4Y<^J=XZ<!YL_*="0VNW8@P+.K1WX]@EW56V:.NUNZH,L2>1#5A\GH<UA
MRX^D0]-":?C6=&!-8V+[G!5TI4-W@!](AY\5:/BS D7K0-OUP./8>O[K;[T$
M6:C\J7K[5$ ;7Z6Z/OK>_+IYP_6^>J]C_'Y!3@;$\?N0G$3U^ZLF?/TZ[5KF
M3W%:H$0]PE3X.( ]D-=OJ.H+G2VK5S /F=;9HOHZ5W*F\A( _W_,,OUZ44ZP
M>4]X_A]02P,$%     @ ^H$04Y+3IYG;#0  ,WT  !@   !X;"]W;W)K<VAE
M971S+W-H965T-2YX;6RUG6UOXS82Q[^*$!QP+5 WXI,>BMT 7>O!MJYWB^[U
M[L7A7FAM92/4MEQ)2=K[]$?96LLB1[3D3 ML$\?#'REJ1AS^24GO7HORU^HI
MRVKK]]UV7[V_>ZKKPP_W]]7Z*=NEU??%(=O+;QZ+<I?6\F/YY;XZE%FZ.1;:
M;>^I;3OWNS3?WSV\._[M8_GPKGBNM_D^^UA:U?-NEY9_?,BVQ>O[.W+W]0\_
MYU^>ZN8/]P_O#NF7[%-6_W+X6,I/]V?*)M]E^RHO]E:9/;Z_^Y'\D B_*7"T
M^%>>O587OUO-H7PNBE^;#\O-^SN[:5&VS=9U@TCECY=LGFVW#4FVX[<6>G>N
MLREX^?M7>G0\>'DPG],JFQ?;?^>;^NG]G7=G;;+']'E;_UR\+K+V@$3#6Q?;
MZOA_Z[6UM>^L]7-5%[NVL&S!+M^??J:_MQUQ48 [ P5H6X".+<#: FQL =X6
MX&,+B+: 4 J(H8-VV@+.V )N6\!5"E Z4,!K"WA* 39T#'Y;P%=K<(=.G/WU
MS-E*$<*&BIQ/]LGI3EYR=+$@K=.'=V7Q:I6-O>0UOQS]]%A>>E:^;T+J4UW*
M;W-9KGZ8%_N-#)!L8\G?JF*;;]):?OA4RQ\R<NK**AZM^5.Z_Y)55KZ77Q3K
M7Y^*[28KJ[]:X6_/>?V']<TO^_1YD\N"WUHSZY=/@?7-7[Y]=U_+]C6UW*_;
MMGPXM84.M.535N:REA^;IKQD99U_WF;61QEB65D>VR2KMO[S4[;[G)7_!?#S
M4?@/M^*#4?CYK?AP%#ZX%1^-Q/]CG]U:13SN]&X/3^FM52S,5<R+W:[87\<L
MS9@?-]*9Y04_W5H?TWPSDWX_3P]Y+3\;H"LS].>LEB.</,@P+??Y_DME8B5F
MUC\+V99^L7L9^.?HI^?HIT<.'^!\R+[D^Z8Q<EC:IOMU]IWUDFZ?,RNMK2!;
M?V\Q\IU%;>)#P7Q".T=T,W*_/%!.J#1]N8Q)W<IU;=?M6P6Z%6.VK5B%NA41
MML?Z5I%NY7 F^D:QL5^:/.:'ZI"NL_=W,E&ILO(ENWNP('_4*Q..39U^;4O=
MB@LBF,N4MJ]TPQEW./6$L/N6"6!);(?93F?8<PEV=@DVU26JIU1VPBB?.+&%
MXA.>IYS)N6YW] JF=%R@VQW]@BBG,]3MCIYA*W:1;M?X!B&*=QB[:()WZ-4U
MWD$)A\\1/Y\C;CQ'Q^O;K,DD-]:ZV,GTNDJ;ZQ5T1HRD\8<R1^($2)P0B1,A
M<6(DS@*)L^1ZA'F.$EXKI,J2*Y7UG%R<G5P8G?SO<C[YMZ*J(*<VEIS@U$B<
M (D3(G$B)$Z,Q%D@<99(G)70_'7FN52X2GPDU^UZKNV<7=LQNG:XW\ YUT]I
M^75\I3;D^,ZHG$NW@G(NW0K*N70K*.?2K8"<R]@I$[Q)KPS*N1SMW,F<RR'"
M5WIKI1O.N,ML0E1D E@2G[JR<V%_<,_^X$[RAR[ANNH0[LB$2[>#$R[=#DZX
M=#LXX=+MP(3+V#\37$.OSIAP>><3Y/UY\R1O5,SJ5E#,ZE90S.I64,SJ5D#,
M&OMEPHG1*X-BUH-B%IHGZ89#\R3 TCA/\L\NX?^)\R1_9-CJ=G#8ZG9PV.IV
M<-CJ=F#8&KMH@G?HU1G#EMB=NFG?FD0F;5'E<BX=CGL#OD$N5%5RVPB_>MY+
MS["'+^AF\(3<%@L48(%"+%"$!8I;4$^8Z;OX C A3'B><N5JS7HN3%W"'/6R
MNP(L9XX$VC93PBN!3 DC$BP&,E#2*7_$+/T-YQS7711)/)MC@0(L4(@%BK!
M<0OJC8D.M54OU:V.7DJ%-^ HG1Y()@N"X^<K+?M:\@.80=D/8 :E/X 9E/\
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MX1H%&9QO=_H@->N#2"%@'.AUU:SI5,('9'+:J6;4K)I%:5ZVB\NR4>V$ BN
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MH<4\WLFUW"S7OOFFM=A<P92.UZ4Z*@9W)O%.IN-FF6[2XPJQA#DL4( %"K%
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MJ,8"!5B@$ L488'B%F2*:L"$>KZMZI)"U\<\SVYNCU-2M15@.7.EH6!"C6K
ME%#J$(\,K$B+3G83TQYA"6]=  =- 8@E6D@#1L=N(]Y0TSM-1=S^6I.K.:F9
M/26\L/;(88%"+%"$!8H%\$H7U4^ ]\P .:G0Q:N!G!2P',I) 5-S3BHZ44R\
MX3TK5]-2 :@6>H0!;V,QIJ6BTS:$6=MXXV*ZF3XEQK#D#RQ0B 6*L$ Q%FC1
M@GH/S%3OAA? 1BK?4<U66&U*P/I<-C2$7+Q\9,*3$F]?2#?7,J7O]=FQXU\^
M\JU_G-W46(QX9MY(;=Z,FA*U2*  "Q1B@2(L4(P%6F"!E@*00JCG^.K39E=8
M-28C:NR[?2>K"+.L8GRY$)9J@@4*L$ A%BC" L58H 46:(D%6@E G!$R^:)J
M[IJ,L>P[>J?-"+,V\P:9 6D/V!P+%&"!0BQ0A 6*!?#*%C6;!]XC \D,NMF0
MS*!;#LH,0//,,D,GOPFS_/86F0%X:J$^"0)>M0++#/<7;U%N7B<N)V%RBE99
MV^Q1%K6_=R6C/+VA^_2A+@['%RM_+NJZV!U_?<K2358V!O+[QZ*HOWYHWM5\
M?D_ZP_\!4$L#!!0    ( /J!$%/<-+WYEP@  *,D   8    >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&ULK5II<^,V$OTK*"652JK6(^+@Y=BNTOC8:&M&XQUY
M)I]A$K*X0Y$*2/G87Y\&10L2<=C:VB\623> UXWN?MT@SYYJ^:-9"M&BYU59
M->>C9=NN3\?C)EN*%6\^U&M1P7\6M5SQ%F[EP[A92\'S;M"J'),@B,8K7E2C
MB[/NV:V\.*LW;5E4XE:B9K-:<?GR493UT_D(CUX??"T>EJUZ,+XX6_,',1?M
MM_6MA+OQ;I:\6(FJ*>H*2;$X'TWPZ26+U8!.XGLAGIJ]:Z14N:_K'^IFFI^/
M H5(E")KU10<?A[%I2A+-1/@^*N?=+1;4PW<OWZ=_:93'I2YYXVXK,L_B[Q=
MGH^2$<K%@F_*]FO]](?H%0K5?%E=-MU?]-3+!B.4;9JV7O6# <&JJ+:__+DW
MQ-X F,<^@/0#R'  <PR@_0#:*;I%UJEUQ5M^<2;K)R25-,RF+CK;=*-!FZ)2
MVSAO)?RW@''MQ65=Y; I(D=PU=1ED?,6;N8M_,!NM0VJ%^B2-TMT SO>H%^_
M57R3%R#S&SI!W^97Z->??SL;MP!%33C.^F4_;I<ECF4C]+FNVF6#KF'Y_'#\
M&%38Z4%>]?A(O!/^:U-]0#3X!R(!P18\E^\?'GC@T)U9:3<?=9EU,O\#W7SZ
M\N<<W7S]\AE]N;W^.KF;SOZ))I=WT^_3N^GU_-2S#MNMP[IUF&.=&01Z63>-
M;0>V(Z-NI(KFQXN3)(WC) (%'_=-8Q'$*0LQ2[3D ;IPAR[T6F&2_P<\>.M&
M;0U1G]555I0"53UL]51=9\K!-LH+BPI!BI*\+:J';8P7;2$:GZVB'9K(:ZLK
M 8DN*_@V?50YXJM:ML5_NP<V VZG"_?L$M*81@/KF5()22BU6R[>88V]6"=[
MT%0$2I6-3NK%"1@)\:81K77+8P,+#M(8IP/(IE@84)S8(2<[R(D?<I;5&[73
M8&11//)[V&<I&B$?1;,U=PD9A%>9L$)/#$PT8N$ N"F$TS3$=N#I#GCJ!3ZM
M'L%#:_FR@VO#EQI+LR!B; #0E#HAX YV@#C023KP0IRW=?;C1-%5CK)Z!1S>
M.+VVGVH? PE9&K"A%U@$:12QU&%.O$<IV(OV<LFK!Z%"><$+B1YYN1'*B9^X
ME+R"R"_X?5%V<6U5 )M&9#A-@F"8N"R2."(!9H$C<6&B=2#^!-[IT SR41=X
MG3/OZ>#+35@3!J;'AH_5.-0T#@Y9G!J[:PK&:1(FH<,RFG&PGW)TN"@[B+\V
MQ5IE>+0498Z@KD2E #^U8F<F]B2-<#R$;LH!+>\EWD/DFHUPZ$5^*\6:%X#Y
M6050GY7J=BFD)Z7V<Q[8D45Q8H VY4YPH-S10058\Q;V$]?.-=;\Q>D7)@T!
M"\7!D*TL<CA)$N8*&$U8^ W&RC*Y$5;C9ALIQ3OBWL)>.([2V A[&\W%A!"7
M$IK"L)_#/BG7W>%\L:(T.>@$$Q(G!DJ+( 1J[ I 35?8SU=78B' H#ED"HC$
MC=T=;$041"0TW-8B&,91Y* LHBF+^"EK]IZRS@:=F+1TDL1)&!C8;9(X3DC@
MJEN)IC""CZK?I[/OU_,CZG>BB880?U+:R&S)5<  0ZZELE([2*U6*Q%;NHDA
MQ0^-9!/$ 2.QPT::L8B?L6[YR[:T5TE_#?UBM>/&K$L!5MP6_HJ2E Y16\1H
M0F)*'*@U?9&W.Z8#ORR SYKW^*6%O3!FT5Z]U&.W"+*4XC!U8-<$1OS]U- K
M;Z:SR>SR"*_4E$/\E',KZTR('/96UBM4-,U&%>[*1>="@H'0I%PO.?CK:RYJ
MEARJ9[190[^206NG[-DY-)0RK4#KDF?"Z<M>+.H@Z[19P_CST;JOT$<7R-KC
MF^3& AP$KG*0:'8C?G937K,^L DPVX%=JKH57H;VKW",EA;ZBQ(218["G6CZ
M(W[Z.]SUUW)=/ N9%:YX-EF.I(P:+:=_Y7=I?ZB4IDOBI\M;6519L>:EVIS^
M2*MZQW99B!'3)*:&9C9!'#&GUU'-H?2=' JN]UCD$&;W+VA15.!S;^<K:K(C
M#L/0J%,L<BPDB=.=J"91ZN\#._B[7K!31-%#=Z'(#1I#M1U6\)8>,(D9P]&0
MWRR2A(24$0=34,W,U,_,7;:=S*Y0=W'][V_3[Y-/U[.[.?KEIX1@_#NZ%P]%
M5;VF.DB,=6Y5QJ1@0M,X"HW*UB*)82M21^M#]XXC_5S]MBY"E>M>+4Q*QB&A
MA 5DJ(4I2:A:Q5%44DW>E/D)L L&U<-!S>%C.JHYE?J;PFG5"L@X5F*B9D\'
M#CBL52Q2)&2)H[ZBFH.IGX/O^+,CLBV]'C$.1RQ2-,#,@4HS(8U]6V#/U+_\
MA*/@=S3[,MN6*+HN 9<[MG:FFJ^HGZ^F>_R;U:L5Y/5&G91M*U)9+T2C7C=!
MZE<X"\?)([6<*@8X#@V#6JB.N8L+JAF*OG$ Z5,CJZ$^E4U_#IR+>[NG>E<X
MHKB@)IMA&@8X=<0NTV3&_&1VA):\/TLH/+'I7^T(C9GEO!3H SNVE6GZ8W[Z
M.T+AO3I:25CU]2YVC+Z60U,&'./25_,E\_/EOKX#A8[P9/\BQ^AI<BDXLC-<
MF>92YN?2FX-#[;[Q4:T :-O6B.>/10/J_D^MD'_I8[0W.3@-H#!R:;_WPM'?
M/]_8CO3_?_I[%S]&?^L9<A*ZTIBN%YB_7KA>+$36=N_DA')G]9(KX^NBY:7G
M5:)_TF/T,HN-! =)XJ@0F:XVF+_:F%;020!3K@1O-K+;(*6D/K7KCO7?^R+2
MO]@Q^II53!11[,S.NHYA;W?T+?AN WFJ>P]=[-YK=-WO,2\V^J6B ](,AN\&
M_8".:(''>Y][K(1\Z+Z":5#WDF#[Q<3NZ>Y+FTGW?<G@^4=\>KG]7D9/L_U\
MYS.7T-HTH/("I@P^Q+ !<OM%S/:FK=?=1R7W==O6J^YR*7@NI!* _R]J:+#[
M&[7 [KNDB[\!4$L#!!0    ( /J!$%-X<]8G/"8  )-S   8    >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&ULQ5U;;]M(EGZO7U'(# 8)("N6[=PZW0TXCM/M
MV<3QQ$XO9A?[0)$EB1V*5+-(.^I?O^=6-XIRG)D%%@VD;8FL.G7J7+YSJ?*/
M=TW[Q:Z,Z?37=57;GQZMNF[SP].G-E^9=6:GS<;4\,VB:==9![^VRZ=VTYJL
MH)?6U=.CP\/G3]=963_Z^4?Z[*K]^<>F[ZJR-E>MMOUZG;7;-Z9J[GYZ-'OD
M/OA4+E<=?O#TYQ\WV=)<F^[SYJJ%WY[Z48IR;6I;-K5NS>*G1Z>S']Z<X//T
MP&^EN;/1SQI7,F^:+_C+1?'3HT,DR%0F[W"$#/YW:\Y,5>% 0,8?,N8C/R6^
M&/_L1G]':X>US#-KSIKJ/\NB6_WTZ.4C79A%UE?=I^;N5R/K>8;CY4UEZ5]]
M)\\>/M)Y;[MF+2\#!>NRYO]G7X4/#WGA2%XX(KIY(J+R;=9E/__8-G>ZQ:=A
M-/R!EDIO W%EC9MRW;7P;0GO=3]__/3+Z>7%?YW>7'R\U*>7;_7UYP\?3C_]
M4W]\IZ\O?KF\>'=Q=GIYHT_/SCY^OKRYN/Q%7WU\?W%V<7Y-CY]?WUQ\.+TY
MO_[Q:0?DX*!/<YGZ#4]]M&?JY_I#4W<KJ\_KPA3I^T]A&7XM1VXM;X[N'?#O
M?3W5QX<3?71X-+MGO&//FV,:[W@?;]IE5I=_9B@^$WW6U+:IRB)C::H+?=4:
M:^J./V@6^EU99W5>9I6^A@\-B&YG]7^?SFW7@O#]SST4G7B*3HBBD_^/W;IW
M:C0./]A-EIN?'FUPW>VM>?3SY<>;<S73?_O+RZ/9T6O]?T:>CEFO_]%G5;DT
M]41=U/ETHFM@6@9F9&[+H@1+@KQWS^B;E6FSC>F[,K<3S2_<95:7==ZTFZ:%
MC2G@%_VAK&MCFR[#7V:O7CW770/J;,LE['5A;L%<;2:@:76_@,WK6T-;#N:D
M4INFK+N#9G&09_#Q'WU6=R5*P:W1Y7K=UTUF;;;50-NR;BP0HC=M4_0Y2 -8
M4=U;@W-N5EM;@K2@Z"S*W%B:H.F ?IW.8$W7E?72HH&K"K /9H+/*EQ6:X8+
M>VNJ[ Y?XW6]FM['&_T8YJ/].SI\?=:L-UF]I=]FKY]HL/PX*O).-[71\]Z"
M4%@+!"U1N*<PA/H *P5] ZWSV\0CYS!:99"H#*B\-2TLNS5YM@%>56YK03-J
MF[&!OBN[E?Y4=ATPX&J5@<G-B=2L\L0*H?R0IQ-Y(>\Q2^IL#=/>M^S3JM(6
MYH#%1<+#7Y(TOWAMM="JP0CG7_2= 9Z:K_DJJY<P.N[D^ SJGD& D\CPM6F7
MIIW*:I^.CH,,7 -;Z$60X569KVA]H'ZW9=/;:HOL ].I&Q[U,K-%]H<^XQEA
M9]HOX-5[L*XM?0^C?H$?[78]!S_C>'ES\VDBK*0I39W#D#@RR-SXT)J'GN"W
M&0BK[0YDAP^(V@.[J<I.9\7OX,!,H<!MEL#YB!(9/27E'^]_N724P,@D6<_)
MFA].!T: &%& =+7@$Y'<1L\-#9WE>=/7J"_PXQ]]V<*497V?#*)3+W2_D:7B
MF"058:,BS41CT+1VJE"" $" 4-2HNT# PIO_1;GL1;1P$-$KO6%_P6KJ:*6O
MD-J\ ?;42$KN/0W*F1_5!J>"]/ 8UJC+!G6T6[5-OUPQUXZ8:QK- %#6K1I8
M^(Z@ZX>L(5N@7CUH5#6B:$CI8-8W* T*WDO\)[RK$G[T==879<?\>#!G!BQ?
M96"4YP94"YB_ <*);SA/6\#+AHU.)#.;%NQI"8;+*J 8EE.!FL'W9A/MV^>:
MZ"(O3U.>@IR H?(&ZO/T>JI_.3V]BFT4O=KV51",:Y/W;=F58OO/Q;@@]>O2
M(NY5;L3K\[,PU@;4*\_F%6T#> J8? T;"4Z .<!<Q&$7946:8-%AKF$QL)?\
M((L<<6F*S(>M'&6H735]!2J,BI,1!V 3?N_KR&:3*,M>[1776J04A V(AC&Z
MC#176!KY'C*;-^@82IKC$]$+%D$A#M>SPX/_(.N+KRU*"_Y!;TW6:H,P$MQ?
M;M9S6.;Q3,05> "?>TJ!DVQ=6K"G\M ,71E]VVS*6N <^'X(2W %DQUM57MD
MTFW&*!M LJJ^@(% [=@V\N<UD R( 8 ,.MJ6C&0#TW\QLL:1L8"=$ [8RI A
MG:+JP099B$5( MAUPT(8<CBRX-.R*2QI,([@9BXKG+L H2(4(^+IQF/C:KYN
M()(2ST=T]95POD$+N64+J18]H26>:JK/3(L[[?:_V;^D;I5U '% V@C;=0BK
M2/V*GN2]8W84L.558\DX[8B1B*$:G< 1O@:'A6X /DP$B+ #RMKWB:4.8AG,
M3;-&UU[PQCS$SL^SB@P2A^+ B5U!7@&!-#A("&P3[$3;K!/MVSN(\H,D++,]
MZ( G?PH6V5L_D($TXD$#/61'L-%.PK['5CM]B-SVC@$G3P<?WZT:%(7F#BA7
M ?JS#Z/)A<6.!VQU(GQIH]TQ50FXP2'F/%XGC B#>*_HW6P0X&!^U;(OV8V4
M%J """Q^3^_B#]X+D('U2[K%S (M*M)2))8-#G_EL;9@;WD4,9,#WZ?>:ZES
MB#+6Y(P^>*.E(,ZPVOAO< 8(3/KUAF<LG4_$07'*[]NZ'2>:K!:1@9]:#:?.
M%@LP)6)C1.&RM=]_>-2(UZC*; XN#%WD9*#][.AH_:C(^U[RCE<F4H@#ZUX8
M@D8-EFQYA\@P8 180D"&NQFXUT)4U1EGO]SGP)VL;/5M5O5$#\1=+;Z74,"0
MF%$F"BE,R"D%=0?.WT"8M\!W-S!>[5>0$UD39 OXZC]#TJ$PL&NP'9R4*&M8
M# !2E%B*R?&5JFKN6 70XA5-/^_ 5@<5PV' "_=M;5T@261O@3S;692L#B";
MM_\YV>1;=%#>X@3.L-G&X @$#@U^9E>TX_B#/@<(#NRAE446A$0, MG6DC=<
ME<L5:'=5PM,%+<KYQDT/;II8QTBMAF]+] N@+1V")XK^7QWJ(MM:=$05*@UI
M$ZC-%IZB(&@!L8=S9#D2: )=TX0P3&2B@60UQ&=I-/HA>@DU8)[57W _&LL6
M"@,TX 4P!MBR!L0,T:)!&3&% $D8MD<,BN9')HZ@JE7HDU$DVY*C,/P<I-UR
M#$[6.MG%.1@R$&>D%4V0O-Y8CHCP[5B:<Y@:'FQ+^\6BW]J[.$1#(E<3=0GL
M\[^J$E4!%1^I8Q4&:0-[1]H(Z@-;4!MTKQ1@(48E[0"YP&_+)&I#&[<40-!"
M$%F"1/-/30_PQD"$4:1,PM 7K*?"=U"78(_%:)2T)TX;.# E"%+FFN)/4@;<
M$4MRTLS!Q $IX:6)* :N#G OH!UDG%<L!E)@(3OX&!T'V$+@U/NF7AZ\1W>L
M3MD$Q=*$5HFV;].@=J/<EO!-V0KD:8CN"L>HR*6+&;M;F9K!,K(,%EV0,R)=
M0_O5T1HX7"#9R,LV[]<(FG+Z@+"<4?2"C(D2B1)"4#YO(!K&[4%_%]%$XB8H
M3!X$ ?H3]4](POR]\](!$S+H RT#^XSR:42J%B =%J6&]!+(X3%RL#B$AMCL
MN_&84M[R\,V .K!Z"Y3M"9@$L!TA3)MCO)ZQAF56W,7".?*YZ>[ ]Y/HH(1B
MI2!8[C"[\QA@U\?,/%#WMF^=W$+4;=!O4!Z;$H3E5_>K ]L<E_R]!R_NDM-D
M'SEK5C?.D5OU"= :Z"#LRD2CVL62M$0+;9T.8ZZR61M.+KI$(G FAW"/@F]R
M%:7MVG+>4\(B42,@#>LY: 66#8%2'M;@$@61B$YQ#0(,-=$<F-T:2JZ@T0%-
MK- [PA>@YNYYV./:FV^=2QC@,Z$N7Y$Y@('"L 1NTCZ3W*:!O"4/H#!?VG?H
M.T"D,IN$L9]]@LF/Q*AA\*1;)P>DLO@[<+0KQEPB#V[I,/"&"DB8!4 %4_*
M+$;/M\GSXW.V!FT^N/DMK[!)<2ZHJ7;*@YN%!BLP!OTSPSJT!\@(8()"[>PQ
MIY4.ECHT(!+-!XIG@ ;?1@;H#\!:[0 >B/QAM[&FAK;=H[8VV (98#H:,41X
M%.P%@R+@+2P7I!1SO=H-[U"QHX= I#B L$-MBSQ!9-KSOF%&-"RH]1HU#6H6
M/D1FXOZ 2T0Z>-!%@UPBMG<_Z.NS7\_??GY_KCZ^<W6+:_WI_.S\XK?3-_!Q
MHM>[09MRL^J@W/JO^L7+D\G)T2OXZ?G1J\GSXT/U'@7OU._/X]F+R;/9"_T$
M?CJ>O'QQK)^$H=K(3J I@_&>/Y^\FLUPO-FSR8MG+V Z:S#%06K[ENL9)#^Q
M;#CX2TZ.$B(,,</3A @UUT^0V>"/KU?E9H-1!S[[*_Q#*:8S>C >7,([3"'Q
M"S3XRKVP,/ 5H.2*P8JW,^C-<%$6L(@-LZ4O.[)L@U#8H<.RG@.#"L*TH!_\
MRZ*ERBS)6VR^!,10_&?)S]",@N.ZILN0,@CVVN8KB2R\]5=]]')R>'B(>6G\
MWS/^[1G_=D+_RC?1SY\XXE $GB&HIG(@:W%D+L\I* (0H$Y!'BLM C1)S431
M4"(RQ'Z8A:R+#"'+&8"=!>5P0*-<XO#T.B0.;YH-^(OGA\\GCB9]+TV8O%#
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M;[.V)"%.M"5&WT-W1VB=9 00*%$(JSSFO GK[KX=!G!$_MJE?MS^Z1U) D'
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M<O7]!NPD50!X9HIR9%"*+Z00T#;;K,+)I_IB0;OMWDAC>2^(Z* H,$;?",3
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M4:5"D@R!<TR!/DXIX)LKO) $.;("["I\RUND4>&+DE/J;W]Y]?S%J]?:+?<
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M36VH+;;)YQ1MN8YS-ZV37\Q5%IRF#' I; XFUB=.@O=<',<7LZ!I@G5\,60
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M3@2V64'-@4P5QGYFB)=($ O>VFB] =_/C:'UP0?H_@<FOP%02P,$%     @
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M90&O!:\>2%8:D=DPJ23+F'OU1B#7#FI]RY@\#G2 ]M49_P)02P,$%     @
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M&@64;X30YXUQT+^3HW\ 4$L#!!0    ( /J!$%-)JZB^] @  "P8   9
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M^FR7]E!$+!=I-LF EPT%J\I89J3+7+$%\DD7 6.=5>9K$=\M=KA=HIG*+"+
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M%I>7]<IH&WC2V=VXZIZQ^52"Q^B"F.?MM8F#FF5%?#FG.S1%]!;[[_&3CZC
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MIS933G.I^Y/I1,Q!9 QHIG,QR:T$O&![#J@>S12N>V@DG9YUC3"1Z-AX1JS
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MZU$PZ5Q->\[?.SQ*W-N3.;A,5EH_.>-+.@HB%Q#FF) C"/[L<(9Y[D <QO;
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M(OCHVRCK/YAMFNF?'VT1]>9./XI )O_LTK)8Z6JBKJML.DDJ0"\%X5V8(B]
M?G&7]IGDXUHWZ59W;9&92<(OW*<F*:JL;K9U R3(X9?D;5%5VM1MBK_,SL_/
MDK8&&3+%"JB:ZSM0$ML)L'?5+8%,7:.)N"##I=K61=4>U<NC+(6/_^S2JBV0
MWG<Z*3:;KJI38])= KBMJMH (LFVJ?,N [J#[DHZHW'-[7IG@$E3/*1ED6E#
M"]0MX)_$*QC=MD6U,JA5RAR$4D_P687;:G1_8Z]TF=[C:[RO\^D8;9+'L%[R
M]_]X,9\?_WA9;[9IM:/?9C\^24#?(E2D75)7.EET!L[.&$!HA6PT!1#J+>P4
M.!OXVQT30\X 6JD1J12PO-,-;+O16;H%6I7V:($'*Y.R5KPOVG7RH6A;(,#-
M.@4]EQ&J:>F0%43Y(8<GTD+>8Y)4Z0:6'=OV15DF!M: S07,PW]$N+/G/YI$
M<$U \V6?DWL---5?LG5:K0 ZGN3P"FH$"% 2";[1S4HW4]GMTT$X2, -D(5>
M!!Y>%]F:]@=2<E?4G2EW2#Y04DG-4-^E)D__3"YY13B9YC/8T@[T6$-_!ZB?
MX4>SVRQ N5M:?OSX82*DI"5UE0%(A P\-PPZ8= 3_&L*S&K:(SGA(\+VR&S+
MHDW2_ ^P&CI78*L*H'R B4"/4?GGFU_?64P ,G'6&>G-XVE/"1 A<N"N!@P1
MHELG"TV@TRRKNPKE!7[\LRL:6+*HQG@0+6F>=%O9*L(DKO '%4@F*H.Z,5.%
M' 16&YBB0MD%!)9.T2Z+52>LA4!$KI(M:V864XLK_0FQS6H@3X6H9$ZG(Y\Y
MJ,:K;\2'81BMWM4HH^VZJ;O5FJDV9ZHEJ 8 LW9=P\;W&#UYR![2)<K5@Z"J
M 4%#3'NKCEB<4V=Q3D<MSDMD*%PZ-'9#IF<4S+#I(=BJ!QLE4T7'U55IEQ<M
M']>##Z['$>L4;,9"@^3#^EN@*QTKKM/D\+)FG1BP]+8!=5^ 7C4*" K4+D$+
MP-_U-F"K3Q7A1>:>EKP -@8]ZO3GI^GM-/GUXN(F5*'T:M.5GF]O==8U15N(
M:;H2W8?8;PJ#SK"R$&^O+CVL+4A_EBY*XA(P9+#X!O@,;!13@*F(8)=%28)J
MT)YO8#/ :OP@2P11:8K$!TX;)*A9UUT)&@;E.B4*P"'\T56!22%)D[,Z*$V5
M"!'( B -,-J4%(N0-#"-I-4_HMTJ:(T/A"\H+(6^>3([/OI/,@[XVK(P8+Z2
MG4Z;1*,_"=8YTYL%;/-D)M($-(#/':9 259^#:A[>6B&EI;^6F^+2OPZ<$T@
M5L$=3/:4B3K D_8P!LD G%5V.0 "K<"JFS^O &5P:,#/0C^@(1U>P_*?M>QQ
M !:0$T($4VK2\U/4#'! !N(3X@#V+& C[!%9M.#3HLX-*1B$8%<N2EP[!Z8B
M)TO8T\)CW:^_;"&Z$L-,>'6E4+Y&!;YC!:Z6'3ESO-0TN=0-GK0]__KPEMIU
MVH('!MQ&KF>+7A^)7]X1O[=,CAR.O*P-Z<X]-A(V5(,+6,0W8$_12L&'$0.1
M:X.\]FULF7BV].JFWJ#GD?/!/,0,+=*2%!+'YT")?49> X($'#@$C@E.HJDW
MD?0=!*(<D(ADI@,9<.B/6HXS9SG.1BW'C5.@R$91]#1D/T:!#=L/OX+JKT!6
MI']FWI!8,?@6@V*%-G!]]JP,>0OP\?VZ1GZM[X&\RH=/[ ?0XL(']J!8-08^
MN@E82)<%^%XVZLC"?0)$ .(\"^>J>"GS-D*MNH)M'5CTC0:IPK_3N_B#,U5D
M!=R6[C E0IL*5 DBRUJ1_^3B%8E?Y%'T.VT ,\)1SQU'/1_EJ MOG:\@V-N@
MT1UBI5$HPZSD02L'&BR#U?L*(DF3:/<7W#^$GMUFR_0HK%N!N"%!OHVQ]OR0
MZ"S0]W-+J_[2Z7()VEC4M.BL=..X$Q[58GC+(EV %X!>QJ2G0-E7H/VC+CST
MDO-=9"&%GG[5"4'0+L"6#?,/Z5:,\0L(N9'7//4:B)M;;4V _1RHDQ9-<I>6
M'>$#D76#[T48<-##<02*$"S(Z1EU#_Z3AD!^B>]N 5[E=I 16A,D"[@[?_D$
M3J[AU. X.,%35+ 9"#E0GH@M\)6RK.]90-%HY'6W:,'<>06 8,"1Z9K*V%0!
MH;T#]$P+M+C(6G#*G0G-R*S=H8UW2MM3ABT?AK_ </FHT+QP0O-B5&@N4[,F
M+.F'*XC3@,)(G"')&04U+#D(5@W!#U4P24$!ULJ0S[,N5FM0CV4!3^=$=^L!
M;3MPQNATV1^OX*\%6G]0-RVZR)2".C].\G1GT-TH4>N0.@*]LX.G*!)?0@!L
MW94,$=0>KVF$&.:PT0RR'LLLL>B'X"44TD5:?4:6J0VK>,P2P''!V<');2!L
MTU\RC6RL<PD7 &R'D0;J;UDX"$B,0L\+I:8I.!6 GX- &DX$D4V.&&T!E@ D
M#G%%'2ZOUX;#<GP[%+@,EH8'F\)\-NB='-S<*)^=.SX['^6S:RL]D^2=;H>8
M:_3]8>;R0!4 3=ROJD M@CH3J<;:#P05#!DI,M \P!J51N>.L@\8(9%B 3<4
M_UI$*0TT7BMQ1QO3'A6@#/BGN@/G6D/XG<>'AWDA,(L*WT$U!+PG^K8@7K&*
MA+,VY  764+)&=(CR"F&^+=>@'4 5/Q+$]$IN#N(NL#7Q@-U.HG=># N+7R,
M'@&8D?$3G!W[LL#QZ!F^J:O5T1OR*"_(! PF]4=A#)^C!ZP8<"2#:&Z(Z;<U
MJFV4]@+^4C02#M1$U1)AE(2<V*?[M:XXD,0#A2/)R0<B)8J&J24*<RA-$I45
M3=9M,*#(Z .*<[2B%P0FRC'*%86Y67T'D@S,@VY6@!,)J40H\B"(W5^HM00E
M+'A9Y]#'2QP0@6X"PXM2K446E\"[!GF:M!F@PS R,"44*; ]M_ 84V9(_Y<>
M=F#.EJ@1)J!(0>/Z%,8"4VTIZZ74B!^PM/[C0K?WX'(28Z/\8&7-FV2_NG4%
MP& /V6_ [E776*EJUXU&AX"*/93;+[[87VT@RC'[/SIP'FT%AZP*)[RK>I3!
M@[K7["$>I(&8+=.@_N!H#ZJK<5"C;J11/?@1NZ_0/S!6/6,MI-YH+E[80@4<
M7P8+4G*/')7"M$VQZ"@A&FDBH!]6:5'!KVJ**AFLQG,0;UW4$A<6P08383U'
M-)J2MVA/0)F5Z)O!'T!3VN>!$2MGF9-,XGA7:;'YT-2ZM\BQ*SAR8D82KC@3
M9\BX*ZS'="VZ!<#WJ8GR4)]< MM!8I^U]Z3=)V>49//WX.:M.1X1IK5;!\!;
MJ@IC&@^U@)('9#/)8A<]/[QFH]&<@Y.YXQW6<0P(NB2Q$HZ'A3K?$P:]0PXJ
M4&DA(8 ("E5(ASGS&%CLJP"2J.-0AKQC^G6_%$T]J-0]=[NK\+2Q4([FT<4,
MC5=8 F Z&$T'T1 H-7;)@;:P7>!2K"4E%KR-&"T^%,*(#?4GU#1($XR+.CXW
MK+CX#35.HM"G%C'S'R(Q\7S VT$\&.BR1BH1V=L?DMO+WZY>?7ISI=Z_MI7M
MV^3#U>75]>\7+^'C2/GL9UW4@/)(_I8\?_%L\FQ^#C^=S<\G9R?'Z@TRWH4[
MG\>SYY/3V?/D"?QT,GGQ_"1YXD$U@9Y ?0OPSLXFY[,9PIN=3IZ?/A_5?'.O
M^>:CFN\#J"A*="+Q7W'1%9EP4/.-@AK6?!:^ZL&/&-A&B.3,.&SRX&D*FA(N
M(B-'C,= ,U_)GYV,;O]V76RWQ BPX&_P#V7#T1<<]G%&H0U3P"ZA]I>(B"!Y
M)$RH!SBM[0M+#7^"@+=DI]XI;?1?D$,,^.P@D;>#+UORF1JC6AM%%=4"N"VG
M\!24#?^R;*AWA80WM 7B5%.BR9!G02M*O-/6;8J8I5M01E](_N&MOR7S%Y/C
MXV,L(N+_3OFW4_[M&?TK?PE^'CM8WQ Q&^^(^, 9" ZF+\&GP%8+UJO>@ T>
M\7?T2LAB:G2QY(HR,N"HJ@M01V4B^F,26XF\ID)2D-.Z!8N4I^CT7T*XL*0<
M/"A46_BYN/6%GX_U%MR%L^.S2?(@ F#R6<'):E_6HFK5[24"0=W)/K S<5SL
M\9YM(ID>;MV Q5M;7:[,DL,N8(@-*=]5C0X=V!&D6B'E3N]\8+JKLHXK+=OH
M)=H),>&2*9"NA=HRGD1:5HUDOAR!/2$ELZQM&I ,/V;.]K"9)C=L[-4M,7;D
MFI$@<(XJ("OVHN )O4Y->Y-FGY/;G8&P"_:1EKN_8%,3<BE [!I;P@,'  )S
MLA'.4>I<7@-WTP,V5:\&7K%)9XAC*3,''/G9Y1X:'7:^ -92VKBYO9C0K_ '
MW4!LBJRW:^J"T**Z$F ,;+U"KT0"SM^+-H5P6+TZX',,;8BR?N \LN[NTS\Z
M2=M646>@UR5T2QU78)V'?*K4^YF$I[(IQ^_ 1_Q.<B"EZP"XGR,_^@N$W#7\
M/DU^M?IO$NA;AXA?205'R<GM;8KLTD/:EO+)W7+H6#FV3..$V55S9&^Y==6\
MU_J1L.5$6*XQ"&YVUG4--DP^5L@HC99.""K[ LJEMA$#^2;UHBQ6/A\J/A3W
M$A'!R#_9[OG%C%&(B4[A<+'2 >@P,^0%;(93GQZE'D:.?L,X+7268@\7YYS#
MC5&SENA+#+PG^ GETZBZPAEF+O$#T]RG.Y^\=CR'4<T"3GX)X1*).>TAPE;<
M<U_4M+Q&!,!.-:J?AFDW95U_$+%&+U"93)SGBPD?;FZII?7E+FT*8N)(6L+@
MJV^@*5@C'H$ A#"$79YP1I1E]] )@V],'H;-.]OS2_8X"1@!\^J&,DRN7^?P
M\T,,JP8E%,\-71> ^QJS @#Z90V'Z,3C]?N73C*<AT1=>E,L4 [*/1NO$/3[
ME^YE;B*<Q&>_EM1'F"_E1"D+T3W98:R?WP/E$137$O0*(RFT-W;/O5S4('X0
M0-YI-51&=CM<IEE0F^E,C&Z]X!PUUFB:NA0DV4))*E024*G85-HT*;IBHV.5
MCGNG!FF=2^R+)4<,V-"PYH55)6$S#';Y[A+75HW99OZKJZ4/>[/8;X*^$/>V
MM+6"('4)/I'$W.@P$"&M'W&(@M(X(OTKXVIC.%S-8M?(ZWDO6U1Q32L?_^9=
MXYI[L:QI>QPP3><4"G@OZ%CU4QQ"876(PG TUOT" N#>I!R'FIX;[TEH%ZA_
M"@H5L59!IS&X;<.U8/ 8&DHO4 !NR$U2S#\!#5!8? +=6 ]G8JG!#)"#0X"9
M)VX&D>@MC,Z 0DX0P&5LVHAD PRO' K3Y T7YI3U8*-($;4XK@/ @0!'4L3S
MV2![C)1&;8 ?A,%L-(D;>$I.R 9.&4NNZ,52VL;[5K&_4M45G"7$1F3JNRWH
M22H_\LH4EPE0BHBD"MG4N[3$Q:?)]9).V[X1IW(<(Z*!HKP(VD9 !DZSW?4J
M$NS98M8/*-UZC2TV:/C\@ZJ LETP/ML4AQ].8_0\W8@&B:4![[TLZXRLJFS,
M[M.I/OL!AA,BT U*0&P<'F"( V"L]&T-UVOZ!>#HNKE&R3()^K>XCO]'EZ^L
MV>+: ZU8I:V4PB786-!9'+"FQ&IR8$@"0N$A+Q9&>=N*!092T=0ZU5*/;Z"X
MD5:4R7?/20<:AM_@S*(2Y/H4]:E17I^;%VL0%,/A #BG6",D<V;/'>WB P\^
MSC?'^5:I)$CXQTN*%V5;"SG![S;B6MPFTOG&1;0A0&SDV)&SN K^K.8/E1@&
M:@F)KR4,BD&N+//:E0"3OR7'\-^SY^>4KCB&M\H2]#&K0^4R:E9_W<!&&\OM
M%-^+'A0]?VAIGPUS:]_9[FW@+^LEUN 4>/4W035<Z57=<J+'ZE7?_:&XC3YM
MD!=K[/8L-@N(O<3;1,M 3SA=;FGM&H[]:M/DW=A22;A443$D-!G(I<@'=67I
M$@J%\V5]NWK0T1I8"K1K=BG.F*)X(;D169:FG;!"<(0!LR09MH> P#!50M.7
M:]93]C7@]UIYT1X")M'ML#\A'CF9Q RT^T$.<*6;.%6]1,)!X+XU/ZC'Q1.K
MU7<V.T*K/C9/I$/"K?QC\KCH/W[04E01-'H5WO6[=LD=[D93%#CC8W=/G"'H
M/\31=3)PT*-+HV0^!K#[N28R+(]1,<)NX25%J9Z="TV,!(8E*"6,V ZY1;'<
M[DE;SX$.LM,N@94V;D-.:5- Y#/7MI!)Y7U4@4YZ#BHJ]3V*BDMT=C<#NL/J
M+=!<G&VU24'UTO8:HJ?58D_AZH";-LCU&[IIA:5B;Z4]%%L-DTS!GOMMY2,R
M)\JV.:1!)83/??ATG-#;Y9P3C@^"'X%%K2HGA#'U0"EN_S@V8 *+5T0[3/?@
M4LK"PF8PG0M;43+&!)ZL58^6*?8/"#?2UR8)1E#EJ$10X&H]@NE7S4BB;7XY
MB?++R6/?Q[*A!#)7\)H:>TCH>7(;@#>?]'+1F>U&H-Z2UAV_"OQ'(UJ:L3CU
MB></ 8L$N6I\R ;RMI[KWK7$B>"3/MMTX$QC>EJ2#<@0UI2)Z\%HLN<<!JEM
MH]/6WI834Q N,'1@P4%1%"2!95<5TC[IP1?LW0M>MO.&@T;ND.@[NM3]0UFJ
MH[2D:WU\.ZM8]IUS7Q1*703&O$L^&R:/G%&UK-%#A.-1 .VS-#V7F%?%4XQW
M0%D_3CZ1A-4+DD)JU(C:[P/+-AC6U:4<M.H?M&&-8:OL845)=IXGB]K>()$$
M*6%@/9_PNJ>+X"R[2<[.N,01\HN*JUJB0"B9A;D*CHE2TTO?21ML-Q)G2R2.
MM*(>5P$VY0Y(42;>4:&"1W['S;W(QUD)VV#Q'' _@NXO?B!U';"[V!7'BWE^
MCYA!L$:UHT\$9?+H%+<\^%95[$#;<O8&,<BLNT:$G3KAYEN>@@R6'U$F^MT'
MOJ7 -0R\%3%68)Q93X>2[L[<.U$4V+G0R?%"WXQ$O.%]'_=W:;%R25S)RQO%
MRLLEP>W"I"H,@!">= CU7#6;F7<5'PS6L%]FG38K'16XX)"B_*#%&$BI;+<I
M;G$7ZV )BL/'A9S^8:=9]EM.*!];N<X'5Y#8\T+4-X9+L<Q*WKW]%FZ@IWKU
MXN-D-I>H:L[UX5<B!^KAX=2>J"6!J)'"B:HYII,K#[:#Z8 G%32-AP&7<JV_
MZ0J3L:UEMHA"$V_!!EF?&^5;IKGTBA=Z/R&7NHX8SDP=R:]J3U\X[>![<,0S
MT]Y/B^\#Y4'[O6R"/B)C,Q!H?]P_ 86>R#K%K"RV9F-H58IG@ACL!U5CU7Y_
M&74V?AOUO;M7\D:C6 \6]K_C)JJ#JQANW)YJ2_7 =UQX?_%L/A$,1O?EKTK-
MOG972M* =/O3EE4.MR9^UV4I7D+M+Y%$?POJB5[84V[-8;5+/&\O6%LUD&4=
M<#X]'%ZK +43_(:^AM.EJ"S$16I2=':.<"/L)"D78P7]:D9CBQLZ+Z;OE-NN
M5".!M(G;O3[=7KW^]"9Y<_W[U2T..;GY\/[FZL/'?_,TDW]^NKYY>_7NHWH+
MOC&@T/0)<4J\T &7*__AB7I;ESDW4[9U3>6.4_6>)DRH)2B^PLVR"" QVZSA
M355LD!16+S3:WD]A&1XDBP\]*=O.C1>MM"C:=!$]$#7FAI2+?8@ZRU)#L5*Y
M4SR30ZX:= 5LCN]]W6/L)Y3AUSE]Q&L;TH!_:#*:D4]G&SJXC0A]S+;I,E=M
MYJQM7C2H,Z1SJ>4V5\K 6W<Z>(_*O(F;*L"J,@+,C:F40)PF[^H@C&-7)^;%
M#;88UM5!$!R]J2C-8%FMT>'@#=C/MDPSN4W)(>)P(4IJ:055*VQ,(\QL*SS,
MX]83I#"(53S0D?K@Z:0%$R1G2QS0DC6N*JPL"+\T'.*ZH-B$XLM>E^V##UK(
MQ]6UOZ\W&[^P=PW.3K6B]E)N^S^LT;[CSIZ'K@+HB?^8PA*@0NNOA!U9A2'\
M5MF?^'+T0)UI&EP#M/<^F"]M=[YKCR_\=N5HD+Z*RA5:^O@# =\_*E-#E-C\
M7^\U8)[&G2F?L#M8I;\4IG\5R5_.<DSNKB4P9S?U$B1.># H3TY$U'%SP3T
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M'9OI8#\B  @"T_KXUSXGP+][?,49>K<KX41&Y "8N;(7;N"7DP&8,X<M]:O
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MR'=FL.E[JZBLN[_=;6?GM!X9O]WKP7M/^$Z5$W+<*JA[W>]:P.MA5B\D*\T
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M&=3.@,XW2MF#X@+T_ZWY?U!+ P04    " #Z@1!3\$7V\VT#   *!P  &0
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MBO7/1+("H5>3-MTQKAII,H['.BD3)6B6DYSJ/PS&X\'7*=R,!A>CF]%T-)S
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MO)DEBAY+IAO0ZQ2%7D#S\X1H(Q_H#<KW;O\?4$L#!!0    ( /J!$%-5*>H
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M%97F ,I3(?1V80S4U[3Q?U!+ P04    " #Z@1!3](L.)/@'  "8&   &0
M 'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6S=6=MRXS82?>=7H+39K7$5)?%^
MF;%=)<O*V!O;<B1[9E.I?8!)R$*9)!2"DNQ\?;K!BR79XBC93;9J7TR*0%_0
M.-U] !^O1?XDYXP5Y#E-,GG2F1?%XF._+Z,Y2ZGLB07+8&0F\I06\#-_[,M%
MSFBLA-*D;QF&UT\ISSJGQ^K;;7YZ+)9%PC-VFQ.Y3%.:OYRQ1*Q/.F:G_C#A
MC_,"/_1/CQ?TD4U9<;^XS>%7O]$2\Y1EDHN,Y&QVTAF8'\],&P74C"^<K>7&
M.\&E/ CQA#\NXY..@1ZQA$4%JJ#P6+$A2Q+4!'[\4BGM-#91</.]UOZ]6CPL
MYH%*-A3)5QX7\Y-.T"$QF]%E4DS$^H)5"W)17R02J?Z2=3G7@\G14A8BK83!
M@Y1GY9,^5X'8$ B,/0)6)6 IOTM#RLMS6M#3XURL28ZS01N^J*4J:7".9[@K
MTR*'40YRQ>GT;CS\X6)\=3Z:3/_QM\ R_4]D]./]Y=U/Y,,=?4B8/#KN%V (
MI_>C2NE9J=3:H]0CUR(KYI*,LIC%V_)]<+#QTJJ]/+-:%?YSF?6(;>C$,BRS
M19_=K-I6^NP]^@91M$R7"2U83,;%G.5D*%) ]1SAMF+D,HM$RLB'*R'E$?GY
M"L3)9<%2^>\6XTYCW%'&G7TA'UZ,SN^O1F3\/9F,IJ/)E]$YF5X,X/V]4+<J
MPZ3]*!<T8B<=\%^R?,4ZIX-"@XBQ)F(Z@36J)=+LA<RI)-74F)BV'IJ^[G@F
MJ?W2WOJEC9Y9'G')B)@1R&U9T"SFV2,!?$9/1"PPPR1Q=-.V]<#UOC%_3?.<
M9H4DH>XZAFX&OC84V8KE*M=W1*8LYTR20;*84P)KG+$\!\=+399CZXX9:'>B
MH,GF8EKVR6WVR3UXGU2:D/'MW>7XA@R&=Y=?($/>VZU6E>_OUMV<:3.10'W$
MY>9,C6!T:%TK,22X@W6<'S%Z$(,/2\BO7 W!-AOD-J%0Y[*8",3T&N)_1 I!
M6+I(Q N#(.)8)K)N_86@"SQB$%>QXJ!+:L6<%H3F;&L/X-,.H%!3-*?9(VB-
MESE.0C<D?^ZFF/MD =LF8OR8$89EX.,6P-X-J#:=@V5)OJI:RF)5D,Q/V@"@
M 2V"3-">!L%HX'6;H_=[YS/L2^!;B0]M<TG57'+.(I8^0!1M4R^CZ.B&:>JV
MZY'OB-\S7'C8/=<B)@#+[?DN"7M6J'VN]L"T?-TP#&+U3)C2"PR8;(4P)[ A
M"Q8<L:IL69_V/37H+S/&U8XZN@O*CD")%Y1FG5[H-S/WKV-K?UXS$9SW>J$!
M#^5;LX:@%UAUEF*9USZLF 0/CF"*%7IZX"D9L^?B4_FP(6M[V@W :$L><57K
ML/3 ]O0P])1LT)AW>Z8-H3&<MOSTFOST#L[/P71Z?ZW -"7W4ZA;ES?D[&HP
M_*$+L\97HVD%M>[MY')X>?.97(_N+L;G[V5PJ]']&0P$ 1 /16@&1$/DDG#H
M(?E"Y*K)\$REQUE"HZ?N-)H+:*PD%3%+< BBQD&^3J(9Y3E9T63)]B4^L#'U
MO4PR2:J2P6)MS2!UH<"7!45N)]T?C!+B4ZNRFZCLE@AMX%5@,.98.* :O'"6
MQ,3H 7S__CJLRG1WH=)T):#C\H07+\0T+)@UX?*I.\L9TS@X#VLH"(8+E 0.
M ,8,-C71*JEA8JIZ1!43KV=H4[2BE5:^*U.Q!6!^ S#_\ : ?;![-L"H#<?7
MMZ.;Z4#5KM&_\'WT'I):M>]'4MVG<P8 BK'5857L(O>$F@N#0%*HHK3L&=]9
M68P3*B6?<01;4>,M$E!YLU(NDR+AL4(C% \@,ZK'J$!"8,M8[@/.MU:/""';
M""F+?E.6-%66L+YJGUD&!A/E-8V!TW)9H ,KM7>Z94"A"4-\]WT],'QM M&A
M>317$C%;P5%B@=X3V_%U%PI4$.A>X%0D '6X3J@;#NJP/0^TM?*!H(%#T J'
M81UZ 1WY:TEAR !/%8CHGZ]5&VDCB&%C*/SKV:EIO)X(C(-A_W4PF0QN[EHI
M3[NZ0SA/@1VD(CO\5ZB,""5:1[;!<@K(JG@?^V6)0QN@CS9WIR&8D$.,K\H"
MS)Y+PM)4SY)9:D-,#B@N!4<O=AGFH99FW\H U9BWTVHWNICZ(%N5L_?)$*G)
M3<.!#F5%OX<#(0EP=#@-JL[M>;5G._Q];W@KTCY\$\Y&=+E0QWHD_0SUT 4'
M]_BO967KDJYVQ1YI] )-HH"2_RJX2YYJ(K;[O8X&D"H[T.T06975,\)]K&R3
MA7FN;OIA*> ?3+I,W0P-W7.",FA;_ H' V"*0.C*0?4PH23V7 >(GN_N,BIB
MZZXB4#A#*Q] H"Q;:X,0^5,A](98DRL^ ^[W$]1G>70XPLRPB3Z&(0S_:GQY
M7J ;E@-!M9W?"[0 3@>.;:KM.P!,NR.'H4E1=3_4'=<M >-OH<GS#*#8ED*'
M[:B'X==8 F:_BZ7 A!9IV27HMK$'W+ZU/9H;5TEF:^, H^0_;I*F]6K.^A^T
MR=<K)-/^[[;)5G5_N$W"L6NK(;WM5Q6@7QOJ_U>K\A3;\WU?G35M?[/PFW@T
M5\?S(SR9F"W-XL])8Y.X&^[!\=?=2N/=P2HQM=J(I=N6BR<JLV?;;Y+ZM83N
MNV!X#^C]C<OBE.6/ZDI< JM99D5Y;]Q\;:[=!^5E\^OT\L[^FN:/'(X-"9N!
MJ %-K$/R\AJ\_%&(A;IZ?A!%(5+U.F<T9CE.@/&9$$7] PTT_XPX_0U02P,$
M%     @ ^H$04]S#^JY\ @  W@4  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&ULC51=;]HP%/TK5K2'5FK)%TE*%2+10-5.W8I@= _3'DQR :N.S6P#
MW7[];"=$M(6J+\2^ON?<<RZ^3G=</,L5@$(O%66R[ZR46E^[KBQ64&'9X6M@
M^F3!1865WHJE*]<"<&E!%74#SXO="A/F9*F-C466\HVBA,%8(+FI*BS^W@#E
MN[[C._O A"Q7R@3<+%WC)4Q!S=9CH7=NRU*2"I@DG"$!B[XS\*_SR.3;A"<"
M.WFP1L;)G/-GL[DO^XYG! &%0AD&K#];R(%20Z1E_&DXG;:D 1ZN]^RWUKOV
M,L<2<DY_DE*M^LZ5@TI8X U5$[Z[@\:/%5AP*NTOVC6YGH.*C52\:L!:0458
M_<4O31\. '[W!"!H ,%G 6$#"*W16IFU-<0*9ZG@.R1,MF8S"]L;B]9N"#/_
MXE0)?4HT3F73_&XTG#V,T.,M&N3YX^S[CRF:C/+1_=/@1H?/AJ PH?(<7:+9
M=(C.OIRGKM*%#=PMFB(W=9'@1)&O&]9!H7>! B_PC\#SC^%#*#3<MW#O-=S5
M=EO/0>LYL'SA";Y'L<2,_,/F'EV@G#/)*2EQ?:U8B<8")#!5!_@"W1*&64$P
M15,=!'V'E42_!G.IA+Z%OS]0%+:*0JNH>T+1H"CXQK!.H "RQ7,*Q[I<D\26
MQ(SG-DNNNMV@E[K;PVZ^3XN#7AQZ;=HKC=U68_=#C0\@)1I0/?:Z&4?EU?CH
MH.ZEGT1^\D;>L;3P*@F/RXM:>='G6BC:%EX@!NJ8T.A]'^.XY_MOA+Y/B_TH
MB9(W0MV#Z3,OWS<LEH1)1&&A@5XGT3RB?DWJC>)K.Y!SKO1XV^5*/\ @3((^
M7W"N]ALSX^V3GOT'4$L#!!0    ( /J!$%,"4H#"Q (  $()   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(Y+GAM;+56VV[B,!#]%2M/NQ)J+EQZ$2!Q"2HK
M:%DH7:VJ?3#)A%AU[*SM+.W?K^U 8*4VW3[P0CS.S#EG)F;&W1T7SS(%4.@E
MHTSVG%2I_,9U991"AN4%SX'I-PD7&5;:%%M7Y@)P;(,RZ@:>UW$S3)C3[]J]
MA>AW>:$H8; 02!99AL7K$"C?]1S?.6PLR3959L/M=W.\A16H=;X0VG(KE)AD
MP"3A# E(>L[ OQGZ+1-@/1X)[.3)&IE4-IP_&V,:]QS/* (*D3(06#_^P @H
M-4A:Q^\]J%-QFL#3]0%]8I/7R6RPA!&G/TBLTIYSY: 8$EQ0M>2[6]@GU#9X
M$:?2_J)=Z=O1C%$A%<_VP=K.""N?^&5?B), C?-V0+ /"*SNDLBJ'&.%^UW!
M=T@8;XUF%C95&ZW%$6:^RDH)_9;H.-5?C6[#\7H6HOL)6J_"R7J&9M/'<&7L
MQ?)^$2X??J+!W1B%W]?3Q3R\>T!?QJ PH?)KUU5:@<%QHSW;L&0+WF'KH#EG
M*I4H9#'$_\:[6GDE/SC('P:U@-\*=H&:7@,%7N#7X#6K<C0M7NL=O#F.4KTE
M7A%F,0I_%R371U"AISED&Q"_:BA:%47+4C3?H9B!E%PTT ST86J@,<A(D-P>
MT:>9]D53!9FL8VI73.W:9!9"_WF%*G.!0RX-5$A("HHH2>"M3U@/VD:O@(6L
MD=>IY'5JD48\RPL%XG-EOJS0+\]<YJN*Z>H<9:X';7Y8YNM*WG4MT@/7+4(7
M@("T"N><QO)_*NU[QQ[BG;G6_DF_\L]1[0]0/S[5?G!4&-1BW2<)B0!-"L&(
M*@2@P6=;B7]L5W[SW)4_]BV_=9;*UZ/65-X]&6L9B*T=WA)%O&"JG'#5;G5!
M&)1C\>A>WB[F6&P)DXA"HD.]BTO=Y$0YL$M#\=P.R0U7>N3:9:HO.2",@WZ?
M<*X.AB&HKDW]OU!+ P04    " #Z@1!3AD^2_#X'  !3)@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,"YX;6S-6EMOXC@4_BL6VH<9J5L2.R10M4B40)=5
M2ZO2[FAWM ]N,!!-+JSC]++:'[_.!4RP<5*U(_'2DO"=X_/9)^<[#CY_B>F/
M9$4( Z]A$"47K15CZ[-V._%6),3):;PF$?]F$=,0,WY)E^UD30F>YT9AT(:&
M8;=#[$>M_GE^[X[VS^.4!7Y$[BA(TC#$].V2!/'+1<ML;6[<^\L5RVZT^^=K
MO"0SPA[7=Y1?M;=>YGY(HL2/(T#)XJ(U,,_&EI,9Y(@_?/*2['P&&96G./Z1
M74SF%RTCBX@$Q&.9"\S_/9,A"8+,$X_CG])I:SMF9KC[>>-]G)/G9)YP0H9Q
M\,V?L]5%J]L"<[+ :<#NXY??2$FHD_GSXB#)_X*7$FNT@)<F+ Y+8QY!Z$?%
M?_Q:3L2. ?>C-H"E =PWL X8H-( -1W!*@VLIB-T2H-.4P.[-+#SN2\F*Y]I
M%S/</Z?Q"Z 9FGO+/N3+E5OS"?:C++-FC/)O?6['^K?W5X/IY*_!P^1V"@93
M%\P>;VX&]W^"VS&83:ZFD_%D.)@^@,%P>/LX?9A,K\#=[?5D.!G-<OAH]C"Y
M&3SPJR\N8=@/$C#%E.(L7[Z"7\'CS 5??OD*DA6F) %^!&[\(. YE9RW&8\_
MBZ+ME;%>%K'" [$B<!-';)6 430G<X6]J[>W-?9M/F_;R8.;R;N$6H>_I]$I
M0,8)@ 8T%?$,FYL;*CH?&WWTL=''>G.7>-S<5)E7YA)M$Q'E_M !?[PT!/@I
M+C('#'@*14O"2Q@#.)I7KF_9BE# 5C@"5:/OU]PGF# 2)G]K(K*V$5EY1-:!
MB*[C:/EKP!W/ 4X2PGCVAFOLTSR((.:WE#E<.+5SIUE=?^[SZ7G>S8I:A%N+
M&.D0%;:=+=N.ENULY:_7?K3,IYO/[3S(+KPX84J6A;/.SOBP:QC[3!4H6T*Y
M,JHC^QHI4!5?%=;VEK6M97U/GDF4JA?2E@8T3=/IH<X>21G7,RS#=O98RC!D
MF(Z%]GG*.(ALHPN1FJFS9>IHF8X2YG,AYLE,"4MIE("(]RWQ N" =Q<X\M23
MX$C1[*^QC#"AO,:U?D:.E-'0.KB^W2WKKI;UP/-HRCD'/G[R Y_Y:I9=F4,/
M(L?H[K'H2C$J<6,9YUBV@[IJ,KTMF9Z>3,3\N1^D>;&;$2^E.2$P>O6"E"L:
M6- XY#4Q7*<,YWT;7]X1IA%_DA-PQXOF+%/A$S (XS1B*L4I NCM$D2GO;V5
M4H#LTXZ:FVF(1L30LON6M0V\LGZ_(>$3H;H*;NYT-^:1J(H)14SP,W*R]+*;
ME)9<%MT29NMA8X4WV#GX>)E"M4W49-7>#BM%Z: RLB%+A0*&3 5=)-.582,%
MK*HI5;JB)3#U/<$=KZ 1[P2R[+GV/;[#XL_?)F/!?[RYC?PP#1LEL5!FLW,L
M22QTT]0+IY"3-"&+- !9HZ1:?[?&40>\$4P375!"XDR]QM6N#GYMO#I"8<SN
ML:R.$ I3KQ3O6!V](].I71XH*CS45_C-\C28?B@J/#R6"@]%A8?Z"C_D1?$M
M:Y^?<9 255&$<CDV;45UAW)U5^'&2G^]@P4/BOH.]?6=BU4:ID&>2SB,*?/_
MS5L+)2E5"5?4\(:XL0IGH,.D1!6'^BH^V"$"R.LZ*Q3*[;NE"$#2&@7J\,8$
MBJH/]1NR<<K;= +(]E'>G?X3WL5G[PWG/*-YD[?P$P\'^:.J7!AY[Z3*M1I4
ME8=0"J@O\%H>8!'3/&Q HGGVQ+C$RXO#YM4"5/)1;,TZ"D)UL"HC(3-0+S,?
M8X24C!2[*!6C.EB5D= PJ-\F?8R1I62DV%.I:D$=K,I(*"#4"]?'&'64C'K-
M&-7!JJ_'A'HBO7K6U(,'+FX$+QA15H#2=R4H0U$#ZG'5Z(5,(U/_,JUHQYIH
M/Q(ZB^"1:#_:>8VI%\QZ[4>RK)F*MV+-8&,5[+#P(Z&1J$8CWR'\2%9 RY"5
MTFV(&R/Y[6;V*N@@*:&I2*^I#87_$BE>7,I;UD8H5X&RY"9"@3K<Z2 AON@#
MXON^)@+):BKS<.M051Y"<M'/E%QE$X%D+744?&I053Y"<-'/%%QE"X%D)55T
M$'6H*A\AMT@OMYOR7KY/;U+F+:%\EG$D9=X2>F;I]4SWPX'>-#LK<):LL4<N
M6FM*$D*?2:L/5/N/SW+DEHXJ3Z73M3O6_J]*'Q^P.I]"RJV:+7-EN>ZY<TR]
MU;OR24BT=30_->[\UJB76VT^:4W?DT^?Y,C]+$<C2]$1'*Y'EA!Z2R_T5R0B
M% <G8# /_<A/6+%N)R*SLJ5V^:0'\3I?ZE'1#33*-"&_EGTLF2:DU-)+Z3M_
MZ+7DW^5DV1\J4(J65H&2)6I4YZO@W=XY\Q(2NLQ/)R6<1QJQXM3!]N[V!-0@
M/_>S=__2/!N:BONN>38JSC<)]\5QJQM,EWZ4@( L^%#&J<-SD18GF(H+%J_S
M$S=/,6-QF']<$<S;K S OU_$,=M<9 -LSY'U_P=02P,$%     @ ^H$04SS#
MX8'P @  3 @  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULS5;;;MLP
M#/T5PMA#"VRU<VU6) %RZ; ,39<UZX:AZ(-B,[%067(EN6F!??PHV_72+O'V
MN)=8E'0.CTB)3'^K])V)$2T\)D*:@1=;FY[YO@EC3)@Y42E*6EDKG3!+IM[X
M)M7(HAR4"+\9!%T_85QZPWX^M]##OLJLX!(7&DR6)$P_C5&H[<!K>,\35WP3
M6S?A#_LIV^ 2[76ZT&3Y%4O$$Y2&*PD:UP-OU#@[[[G]^89O'+=F9PSN)"NE
M[IPQBP9>X 2AP- Z!D:?!YR@$(Z(9-R7G%[ET@%WQ\_L'_*STUE6S.!$B>\\
MLO' ZWD0X9IEPEZI[4<LS]-Q?*$2)O^%;;DW\"#,C%5)"28%"9?%ESV6<=@!
M$,]^0+,$-%\#V@< K1+0^E= NP2T7P-:!P"=$I ?W2_.G@=NRBP;]K7:@G:[
MB<T-\NCG:(H7E^Z>+*VF54XX.[R8?;F>36=??\#1%"WCPL ETYJY]!W#.[A>
M3N'HS3&\ 2YASH6@[)J^;\FU(_##TLVX<-,\X*8!<R5M;.!<1AB]Q/LDN=+=
M?-8];M823C$\@5;C+32#9K!'SZ0>/LHVM?!I/?Q3)FKAY_7P.7LZ@'X1BU:5
MPU9.USI 1X]$L)4JD@8CRI[<(+UE"TQ&+^S/-D8--F827H)N+H@39A83<UNC
MJ%TI:N>*V@<475*!P/N,VR<(6<HM$Z 9-[@O5 53-V=R5>UAV.[[#WN<=RKG
MG5KG$R4?4%N^$@A26320LB=&UC[O!54CV''?.'F_7T"W$M"M%;#$,-/<<O*\
MR'084QV#T49CD8.;.28KU+?P$V8DE%ZXKN9J0G]:.3_]3RY#KU+4JPW'0JL0
M,3*PUBH!PR@M:EU>CWV5I/?'A6@%54**Q_WW+=/:+<4Y_)VRF:#>Y/W*0*@R
M:8M*5,U6+7&4=X)7\V-JE45G^TU3]-DYTQLN#0A<$V5P<DKW31>]JS"L2O/B
MO%*62GT^C*G=HW8;:'VMZ :7AG-0_8$8_@)02P,$%     @ ^H$04X6M\<=Z
M @  ,@8  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&ULC55=3]LP%/TK
M5K0'D#;RG;0HC00M"*8-4#M T[0'-[EM+1([L]T&_OUL)V2E3:N]-+[V/>>>
MXX_;I&;\1:P )'HM"RI&UDK*ZMRV1;:"$HLS5@%5*PO&2RQ5R)>VJ#C@W(#*
MPO8<)[)+3*B5)F;N@:<)6\N"4'C@2*S+$O.W2RA8/;)<ZWUB2I8KJ2?L-*GP
M$F8@'ZL'KB*[8\E)"5001A&'Q<BZ<,_'D<XW"4\$:K$U1MK)G+$7'=SF(\O1
M@J" 3&H&K#X;&$-1:"(EXT_+:74E-7![_,Y^;;PK+W,L8,R*9Y++U<@:6"B'
M!5X7<LKJ&VC]A)HO8X4POZAN<@//0ME:2%:V8*6@)+3YXM=V'[8 ;G  X+4
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M/T8_SXM7Q=P102<L^AZNY'9D# RPHFN21?**[;[2LB!'QPM8)/)?L"ML'<<
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MRS/C\7CZ)RY^R1V 0F\IR^3 VBFUO[5M&>\@I?*&[R'37[9<I%3II7BUY5X
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MGN,'I!DL*,&"3K %/U.F$I!-9$'-)79(5.&J"_EMV0I+J+ ;"B10$>_RBMG
M43?&O6YSJHDQK+DGOA_Z3H6R+N9Z)'#\9E!2@I).T+G@6Y"F_5*&MM"<15)W
M3;!'JOM;%PLB-VS)9%0"1IV /ZD0-%-G?3:D:J2+ZMM'HL"OP-6E7#\B+7"]
M$J[7G3UZ%IRQ)JI>O?)(Z)*@@E47\X,P;*;"SD?[=OZ#2^EBRXN/);'N*-"Z
MM]V6S+QP*_<TAH&E!P()X@C6$#6V9*=>QVY;>>*KFPAWAG*O=S_>)1*^(4G?
M>_!!!Z3H6TM$N+[5&'O5\]0@YCE>X+4 ?]P5V.T$GF6ZBW?AN76\ZU-2T-6E
M/,]M*XR/6P9W7S//:@>BD<JK^\.$U+-6E\.>'^*V??ZX7G#W_9)?J[!!\&9N
MP&*?N<'5 X\0IIQ90M<)2]IZ?>'@T[W7TSW2J?;[!D'BA\2+*C'85P.4F5[_
MH.(UR21BL-6*S@W161"7@?"R4'R?SU1KKO2$EC_N]! -P@CH[UO.U?O"C&GE
M6#[\%U!+ P04    " #Z@1!3$LI/KHX$  #W%   &0   'AL+W=O<FMS:&5E
M=',O<VAE970S-RYX;6RM6%MOXCP0_2M6]#VT4K>Y 8$*D(#2W:[:W0K:K5:K
M?3#) %&3F,\VI?WW:SLAX1),H;R0"Y[Q.<?V<)CF@M 7-@7@Z"V.$M8RIIS/
MKDR3^5.(,;LD,TC$-V-"8\S%(YV8;$8!!RHHCDS'LFIFC,/$:#?5NP?:;I(Y
MC\($'BAB\SC&]+T+$5FT#-M8OAB$DRF7+\QV<X8G, 3^-'N@XLG,LP1A# D+
M28(HC%M&Q[[J.2I C?@5PH*MW"-)943(BWRX#5J&)1%!!#Z7*;"XO$(/HDAF
M$CC^SY(:^9PR</5^F?U&D1=D1IA!CT3/8<"G+:-NH #&>![Q 5E\@XQ05>;S
M2<34)UID8RT#^7/&29P%"P1QF*17_)8)L1)@>SL"G"S V0APJCL"W"S 5413
M9(K6->:XW:1D@:@<+;+)&Z6-BA9LPD0NXY!3\6THXGA[V/O6OWZZZZ.?-^BY
M,QAT?CP.4:?W>/OK]O$W.KL&CL.(G:,OJ$?B6.@^Y,1_0<^84IQPAO[<0SP"
M^E<,& (-@:%>Z9=/PVMT]M]YT^0"M)S:]#. W12@LP-@#=V3A$\9ZB<!!.OQ
MIB";,W:6C+N.-N'W>7*)7.L".99CE^#I?3S<TL!Q\P5P53YW1[X?8J=W?)_,
M$QXF$_1 22+N?1!'12A(*.I-<3(!%";KP\+$#V<1H#]W(B&ZY1"SOQHXE1Q.
M1<&I[((SERN&R!@-IY@"NRA6\^><,XZ30,[?A4F8).*N;$'3&:IJ!EE&7MNN
MZ]6KC5K3?%T56HM$UJ\K-L,^M Q1H!C05S#:2$.QFE.L:BD^JZ,- >J\ A6E
M"O7?@/HA ZFJ+SX%?T7^".KIS/45ZM:EYVSPUL([G'<MYUT[=FGSHRMF' .E
M0ARFSOEB.0+>?+4/ R1^.I"?UH*-,?.9*NU"5:%E#'0"M$PC+<H/T4]E3//4
M5K2N>+9;:5BYW&LR>;E,WJFW1R[?0R[?1IGLY_+=R"-=6DJ?I'R#3+[[G?)I
MT1\@GZ??JFO:U7/MZL=NL:6*01FG^E;%^%*M.)[KE<-IY' :IUY*+<S& 9+9
M5O$+;!TKFM@L8PAY.9HL[9IJ;LUJ>!OE1C_]X?7&7O$6]JGUUS.V/U)>]:".
MX.L4?)WCM_\LI#M8:9,><*)/D&B=>.%A;/?T!VVW(-K)#A'D\XG6!2E<E'VT
MC?HJ+SN(?]X19<1/;*WLPEO9)S=7.D$^;Y4R04[LN>S"=-E'NZY55]E7EU(-
M:EMEWO$:#:^V5?>V!VH-D5TX(OODENB#W/:8D(S8(5;%+KR*_5FS@D<1E,+>
M]BL[EF1[H'Y)"F=CG\K:[..RQ]1D1 ZQ/DYA?1R]]1FHO[9B!=;17^P#G:7=
M WK?J'70A:MQ#G0U Y#],KG3[\(QH+/?@"D[W\M!/XN#WF4:5$.QZG^4=BKT
M*=PL12-+@9PJ"O [*ZMKYDH+2?UUDYTUAE3#(>VMY&_S[EU']:PVWG?MJU[:
M@RO2I"W!>TS%/V>&(AB+E&(EQ+&@:9<M?>!DIAI5(\(YB=7M%'  5 X0WX\)
MX<L'.4'>ZVS_ U!+ P04    " #Z@1!3!M_8"0H#  #T"@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S."YX;6S%5MMNVD 0_961U8=$2N,; 1(!$E?%%301
MA$15U(?%#+"*[26[:TC_OKMK,*0E;IHVRHN]ESEGSLS(XZFM&7\0"T0)3W&4
MB+JUD')Y8=LB7&!,Q"E;8J)N9HS'1*HMG]MBR9%,#2B.;,]QRG9,:&(U:N;L
MFC=J+)413?":@TCCF/ ?+8S8NFZYUO9@2.<+J0_L1FU)YCA".5Y><[6S<Y8I
MC3$1E"7 <5:WFNY%V_4UP%C<4ER+O37H4":,/>A-,*U;CE:$$8924Q#U6F$;
MHT@S*1V/&U(K]ZF!^^LM>\\$KX*9$(%M%MW1J5S4K:H%4YR1-))#MK[$34!G
MFB]DD3!/6&>VE8H%82HDBS=@I2"F2?8F3YM$[ $4SV& MP%XOP+*+P#\#<!D
MSLZ4F; Z1))&C;,U<&VMV/3"Y,:@530TT64<2:YNJ<+)QJA]V>V,^UVXZD&O
M&0SAMMD?=^$RZ Z;P_;E-^A=#>&N.1PVO]Y /VBV@GYP$W1'<-1!26@DCN$S
MC$<=./IT7+.E4J1Y[7#CO95Y]U[P7H8!2^1"0#>9XO0 OEV,=[T" ENE(L^'
MM\U'RRMD_)(FI^ [)^ YGGM(4#&\@Z&"NP;N%,CQ\_+XAL]_@:]'*(=;$J4(
M R0BY:@^(0E!LDRE )),S24Q7\0-AHN$/J8HX+ZO>""0&(OO!2I*N8J245$J
M4K$R*E3C@#7AG"@5$243&E%)41PJ?<99-IRZFZP:)=?U7$?E9;6?T=_MJK[K
M[-L]$WV6BS[[LVB3NI--ODZ@CRN,P(7[ <83Y$6Y*>=NRA]8H4JNHO(.%2KD
MU#^0"[$D(=8M]8<0R%=H->#0-_'O/,^"KN9!5]]88>\U%3[/W9Q_8(5=9]>I
MG7>H<3'I7Q3Y/Q ]#WSO%^6^L<[^:^KL>CM'WD=6>M?T7?\]*NV_LN$>,#S<
M<>V]N2)&/C?CEH"0I8G,1HS\-!_IFF:0L7?FV3PX('Q.$P$1SA34.:VHYLVS
M$2O;2+8T4\J$237SF.5"C:7(M8&ZGS$FMQOM(!]T&S\!4$L#!!0    ( /J!
M$%-+Y8[GK@,  . 1   9    >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;,58
M76_B.!3]*U:>=J6JB1V^.@(D"JV&59E!T'8>1OO@DDNQFL09VX%6VA^_MI,F
M829DZ*I;7B!V?.Z'S_6QG?Z.BR>Y 5#H.0IC.7 V2B6?7%>N-A!1><X3B/6;
M-1<15;HI'EV9"*"!!46A2SROXT:4Q<ZP;_OF8MCGJ0I9#'.!9!I%5+Q<0LAW
M P<[KQT+]KA1IL,=]A/Z"$M0=\E<Z)9;6 E8!+%D/$8"U@-GA#^-2=L [(A[
M!CM9>48FE0?.GTQC&@P<ST0$(:R4,4'UWQ;&$(;&DH[C1V[4*7P:8/7YU?JU
M35XG\T EC'GXC05J,W!Z#@I@3=-0+?CN,^0)V0!7/)3V%^VRL5WM<95*Q:,<
MK-L1B[-_^IQ/1 5 .@< ) >08P%^#O!MHEED-JT)5738%WR'A!FMK9D'.S<6
MK;-AL:%QJ81^RS1.#9?CSU>3NYLK]/4:C9;+N]G\=OKUR](TOXT6B]&76W0S
M'5U.;Z:WTZLE^F,"BK)0_MEWE?9N;+BKW--EYHD<\/17&I\CWSM#Q".X!CYN
MAD]@I>'8PKU]N*MS+A(G1>+$VFL=L#<#*E,!NB(5FL9)JL[0@LDG="T =(<"
M 5*A!56 OL\@>@#Q-_H'S5C,HC0JNAH"\8M ?!N(?R"0:\H$NJ=A"NB7F"2B
M<6!?4EOTM[#:Q.Q'"A)]O]%VT%1!))NB:!51M!JGPT:QM5%0J==T8OS),Q15
M0F+9-"4@5KJI%[FLJX+,#\X*SJC(=NB=^ZV^NZV273L*=XM1>TFTBR3:_P>G
M]/E83CM%()T3<MHMHNA^$*?=.K9:G9\XK1U%2#VGO2*)WELYG0NV G3/0SV!
M(5,OQS!W4;B[."%SV"MEV?L8[L:YHW:%E=X!3G!EU\#OQLK;9!.7 H[)*:DJ
M]1O['[3,<D='454*.VY6]K=2=;P:XE*7<?N45)6RC#L?157G5ZK\ U25>HV;
M!;N&JJOG1!]X(=#3(J+_NJ1*K<6]4_)4BC"^>"^>]*8>U1+4[(&@%Z!"HA:*
M>*PV$I$>"NA+O8(>9PI[A:U6C:W]4VJY$9#FC>!--7'\VB6EU!-\PIH@E?-Z
M\X']'6KB-QX*(G%!9.=@4?S&EI_;:C>:VI^*<L<AS3M.4TU,V)8%H%G9.^8V
MN2UW$M(Z9264NPEI/N:_GXKGCJHJ[OUTJ&T<DB7@5J[?YMO'C(I'%DL4PEIC
MO/.N!HOL<T+64#RQ-_('KO3]WCYN@ 8@S #]?LVY>FV82W[Q46?X+U!+ P04
M    " #Z@1!34V\A#30$  !L$0  &0   'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6S-6%M/XS@4_BM'U3[,2$#B)+V 2J72%&U7P"+*# ^C?3#):>.=7+JV
M0T':'[]VDB9I23-5V0=>6MLYWW>N\;$S7"?\IP@0);Q&82PN.X&4JPO#$%Z
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M;"]W;W)K<VAE971S+W-H965T-#,N>&ULK59M;]HP$/XK5K1)K;22-TA9!9&
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M.9=?</G_4QW4\]I[7A> ORX [-<5@.<:^7??6 +GSXN0UY2 /;A>41R)!9W
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M@JD7S,$%G7M!(-X5Q<E& XDUR/3R-(3(-A'LG_6>LN>GM43FM=-HY;CTO"/
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M*._C6#IBZT19PCJFI1>"+S29RPZK6FL(GJB7  C!G,F:I0"98.(]I8H@AH8
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M!/"TU<!3]^3J:*A>R2Z/'E).3Y;^5XNR2E'06,LB?<?8$8C5Z1V6T+BP!_^
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M^QHAN0![7BIE#H83Z-ZW] ]02P,$%     @ ^H$04WVZ;>LC @  :00  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3(N>&ULC51;;]HP%/XK5IXV:<,A0+>A
M$ DHU9#6BC70/51]<)(#L? EM1W22OOQLQV(F#30\N#XV.>['/LD<2/57I<
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M;W!S+V%P<"YX;6Q02P$"% ,4    " #Z@1!3QT/ON.\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #Z@1!3
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( /J!$%-M2BA-,@4  &,5   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #Z@1!3
MNJ%3.5@&   ;&0  &               @(%V#0  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ ^H$04^!N_H3J @  P0D  !@
M     ("!!!0  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M /J!$%-&XJ!_YP8  #,<   8              " @207  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " #Z@1!3DM.GF=L-   S?0  &
M            @(%!'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ ^H$04]PTO?F7"   HR0  !@              ("!4BP  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( /J!$%-X<]8G/"8  )-S
M   8              " @1\U  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " #Z@1!3E<TM!NX"   3!@  &               @(&16P
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ^H$04W<AC5W;
M @   P8  !@              ("!M5X  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( /J!$%.AY>THWP(  ($&   9              "
M@<9A  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ^H$0
M4T2H!M9U P  10<  !D              ("!W&0  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " #Z@1!3<UU?3FL#   S!P  &0
M        @(&(:   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( /J!$%-)JZB^] @  "P8   9              " @2IL  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ^H$04TUPRV,Y!   : D
M !D              ("!574  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " #Z@1!3'^%YV,P+  ##)@  &0              @('%>0
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( /J!$%,_&=T4
M0 T  "PF   9              " @<B%  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ ^H$04_M^:[VO @  OP4  !D
M ("!/Y,  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " #Z
M@1!3.\EN"CP"  #8!   &0              @($EE@  >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( /J!$%/'?-UO("@  !N!   9
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M970R,RYX;6Q02P$"% ,4    " #Z@1!3\$7V\VT#   *!P  &0
M    @(%NS@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M /J!$%-OAPX+5 4  /L.   9              " @1+2  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ ^H$04U4IZ@#V P  L@D  !D
M             ("!G=<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " #Z@1!3](L.)/@'  "8&   &0              @('*VP  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( /J!$%/<P_JN? (
M -X%   9              " @?GC  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ ^H$04P)2@,+$ @  0@D  !D              ("!
MK.8  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #Z@1!3
MAD^2_#X'  !3)@  &0              @(&GZ0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( /J!$%,\P^&!\ (  $P(   9
M      " @1SQ  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ ^H$04X6M\<=Z @  ,@8  !D              ("!0_0  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " #Z@1!3Z-M*D, "  !)!P
M&0              @('T]@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( /J!$%/7UT3DO ,   0/   9              " @>OY  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ^H$04UNH5MA\
M @  FP8  !D              ("!WOT  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " #Z@1!3$Y)R*;X#  "B"P  &0
M@(&1  $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( /J!
M$%,2RD^NC@0  /<4   9              " @88$ 0!X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ ^H$04P;?V D* P  ] H  !D
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M=#0R+GAM;%!+ 0(4 Q0    ( /J!$%/*TJ8IK (  #,(   9
M  " @6H; 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M^H$04_3CH'^W#@  @UT  !D              ("!31X! 'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " #Z@1!3&/L2!80"  !Q!P  &0
M            @($[+0$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( /J!$%._2!V$?@4  )D;   9              " @?8O 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ^H$04X+)54C2 @
M=@<  !D              ("!JS4! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " #Z@1!3UNO?)IT"  "N!@  &0              @(&T
M. $ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( /J!$%.H
MR70?8P<  'LN   9              " @8@[ 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ ^H$04YR3J4))#0  L$\  !D
M     ("!(D,! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M" #Z@1!3EWF/9TT"  #K!   &0              @(&B4 $ >&PO=V]R:W-H
M965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( /J!$%-]NFWK(P(  &D$   9
M              " @293 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L!
M A0#%     @ ^H$04X4W)XXJ P  #!,   T              ( !@%4! 'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " #Z@1!3EXJ[',     3 @  "P
M        @ '56 $ 7W)E;',O+G)E;'-02P$"% ,4    " #Z@1!3M, $3YT$
M  #%(@  #P              @ &^60$ >&PO=V]R:V)O;VLN>&UL4$L! A0#
M%     @ ^H$04XHQ=E_/ 0  ,Q\  !H              ( !B%X! 'AL+U]R
M96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ ^H$04S+A@>'' 0
M$A\  !,              ( !CV ! %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&
2     #P / !;$   AV(!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>323</ContextCount>
  <ElementCount>398</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - LIQUIDITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/Liquidity</Role>
      <ShortName>LIQUIDITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - INVENTORY, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/InventoryNet</Role>
      <ShortName>INVENTORY, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - WARRANT LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/WarrantLiabilities</Role>
      <ShortName>WARRANT LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/Leases</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - RESEARCH AND LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ResearchAndLicenseAgreements</Role>
      <ShortName>RESEARCH AND LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/SubsequentEvents</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - INVENTORY, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/InventoryNetTables</Role>
      <ShortName>INVENTORY, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/InventoryNet</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - WARRANT LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/WarrantLiabilitiesTables</Role>
      <ShortName>WARRANT LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/WarrantLiabilities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/LeasesTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/Leases</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - STOCKHOLDERS??? EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails</Role>
      <ShortName>SCHEDULE OF ACCOUNTS RECEIVABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative</Role>
      <ShortName>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - LIQUIDITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>LIQUIDITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/Liquidity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfInventoryDetails</Role>
      <ShortName>SCHEDULE OF INVENTORY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails</Role>
      <ShortName>SCHEDULE OF PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative</Role>
      <ShortName>PROPERTY AND EQUIPMENT, NET (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/PropertyAndEquipmentNetTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANTS ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - WARRANT LIABILITIES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative</Role>
      <ShortName>WARRANT LIABILITIES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/WarrantLiabilitiesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - LEASES (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/LeasesDetailsNarrative</Role>
      <ShortName>LEASES (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/LeasesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative</Role>
      <ShortName>RESEARCH AND LICENSE AGREEMENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/ResearchAndLicenseAgreements</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfReservedSharesDetails</Role>
      <ShortName>SCHEDULE OF RESERVED SHARES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>SCHEDULE OF STOCK OPTION ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails</Role>
      <ShortName>SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails</Role>
      <ShortName>SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails</Role>
      <ShortName>SCHEDULE OF WARRANT ACTIVITY (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>STOCKHOLDERS??? EQUITY (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/StockholdersEquityTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/RelatedPartyTransactions</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://qualigeninc.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>SUBSEQUENT EVENTS (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://qualigeninc.com/role/SubsequentEvents</ParentRole>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex10-1.htm</File>
    <File>ex10-2.htm</File>
    <File>ex3-8.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>qlgn-20210630.xsd</File>
    <File>qlgn-20210630_cal.xml</File>
    <File>qlgn-20210630_def.xml</File>
    <File>qlgn-20210630_lab.xml</File>
    <File>qlgn-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>72
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 15,
   "contextCount": 323,
   "dts": {
    "calculationLink": {
     "local": [
      "qlgn-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "qlgn-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "qlgn-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "qlgn-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "qlgn-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 514,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 175,
    "http://qualigeninc.com/20210630": 86,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 266
   },
   "keyCustom": 96,
   "keyStandard": 302,
   "memberCustom": 48,
   "memberStandard": 23,
   "nsprefix": "QLGN",
   "nsuri": "http://qualigeninc.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://qualigeninc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "role": "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - PROPERTY AND EQUIPMENT, NET",
     "role": "http://qualigeninc.com/role/PropertyAndEquipmentNet",
     "shortName": "PROPERTY AND EQUIPMENT, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "role": "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:WarrantLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - WARRANT LIABILITIES",
     "role": "http://qualigeninc.com/role/WarrantLiabilities",
     "shortName": "WARRANT LIABILITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:WarrantLiabilitiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - LEASES",
     "role": "http://qualigeninc.com/role/Leases",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasesOfLesseeDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ResearchAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - RESEARCH AND LICENSE AGREEMENTS",
     "role": "http://qualigeninc.com/role/ResearchAndLicenseAgreements",
     "shortName": "RESEARCH AND LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ResearchAndLicenseAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - STOCKHOLDERS\u2019 EQUITY",
     "role": "http://qualigeninc.com/role/StockholdersEquity",
     "shortName": "STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - RELATED PARTY TRANSACTIONS",
     "role": "http://qualigeninc.com/role/RelatedPartyTransactions",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://qualigeninc.com/role/SubsequentEvents",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:OrganizationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://qualigeninc.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - INVENTORY, NET (Tables)",
     "role": "http://qualigeninc.com/role/InventoryNetTables",
     "shortName": "INVENTORY, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "role": "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - PROPERTY AND EQUIPMENT, NET (Tables)",
     "role": "http://qualigeninc.com/role/PropertyAndEquipmentNetTables",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "role": "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables",
     "shortName": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - WARRANT LIABILITIES (Tables)",
     "role": "http://qualigeninc.com/role/WarrantLiabilitiesTables",
     "shortName": "WARRANT LIABILITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - LEASES (Tables)",
     "role": "http://qualigeninc.com/role/LeasesTables",
     "shortName": "LEASES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfReservedSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Tables)",
     "role": "http://qualigeninc.com/role/StockholdersEquityTables",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "QLGN:ScheduleOfReservedSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - SCHEDULE OF ACCOUNTS RECEIVABLE (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails",
     "shortName": "SCHEDULE OF ACCOUNTS RECEIVABLE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "us-gaap:TradeAndOtherAccountsReceivablePolicy",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccountsReceivableGrossCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_MachineryAndEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails",
     "shortName": "SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_MachineryAndEquipmentMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://qualigeninc.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-05-012020-05-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "QLGN:NewEquityCapitalRaise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - LIQUIDITY (Details Narrative)",
     "role": "http://qualigeninc.com/role/LiquidityDetailsNarrative",
     "shortName": "LIQUIDITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-05-012020-05-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "QLGN:NewEquityCapitalRaise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - SCHEDULE OF INVENTORY (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfInventoryDetails",
     "shortName": "SCHEDULE OF INVENTORY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "QLGN:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
     "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "role": "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative",
     "shortName": "PROPERTY AND EQUIPMENT, NET (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:AccruedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails",
     "shortName": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:AccruedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
     "shortName": "SCHEDULE OF WARRANTS ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_custom_CommonStockWarrantsMember_custom_SeriesCWarrantsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:FairValueAdjustmentOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails",
     "shortName": "SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "QLGN:FairValueAdjustmentOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
     "shortName": "SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30_us-gaap_MeasurementInputRiskFreeInterestRateMember_srt_MinimumMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://qualigeninc.com/role/StatementsOfOperations",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "QLGN:CostOfProductSales",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueAdjustmentOfWarrants",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - WARRANT LIABILITIES (Details Narrative)",
     "role": "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative",
     "shortName": "WARRANT LIABILITIES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:WarrantLiabilitiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_WarrantMember",
      "decimals": "INF",
      "lang": null,
      "name": "QLGN:NumberOfWarrantExercisedOnCashlessBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
     "shortName": "SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_custom_LongtermOperatingLeaseAgreementMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - LEASES (Details Narrative)",
     "role": "http://qualigeninc.com/role/LeasesDetailsNarrative",
     "shortName": "LEASES (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:LeasesOfLesseeDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - RESEARCH AND LICENSE AGREEMENTS (Details Narrative)",
     "role": "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
     "shortName": "RESEARCH AND LICENSE AGREEMENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "QLGN:ResearchAndLicenseAgreementsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-06-272020-06-30_custom_UniversityOfLouisvilleResearchFoundationMember_custom_RoyaltiesAndNonRoyaltySublicenseeIncomeMember_srt_MinimumMember",
      "decimals": "0",
      "lang": null,
      "name": "QLGN:ShortfallPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfReservedSharesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesSubscribedButUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - SCHEDULE OF RESERVED SHARES (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
     "shortName": "SCHEDULE OF RESERVED SHARES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "QLGN:ScheduleOfReservedSharesTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesSubscribedButUnissued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "SCHEDULE OF STOCK OPTION ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_custom_EmployeesAndNonemployeeServiceProviderMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000047 - Disclosure - SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails",
     "shortName": "SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000048 - Disclosure - SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
     "shortName": "SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:SummaryOfWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_custom_CompensatoryWarrantActivityMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000049 - Disclosure - SCHEDULE OF WARRANT ACTIVITY (Details)",
     "role": "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
     "shortName": "SCHEDULE OF WARRANT ACTIVITY (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "QLGN:SummaryOfWarrantActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_custom_CompensatoryWarrantActivityMember",
      "decimals": "INF",
      "lang": null,
      "name": "QLGN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-12-31_custom_SeriesAConvertiblePreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-01-012020-03-31_us-gaap_AdditionalPaidInCapitalMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "us-gaap:PreferredStockSharesIssued",
       "us-gaap:PreferredStockSharesIssued",
       "span",
       "span",
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000050 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "role": "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30_custom_StockOptionsAndWarrantsMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-05-012020-05-31_custom_SeriesDAndSeriesDOnePreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000051 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)",
     "role": "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
     "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-05-012020-05-31_custom_SeriesDAndSeriesDOnePreferredStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConversionOfStockSharesConverted1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-08-09_us-gaap_SubsequentEventMember_custom_TwpThousandTwentyPlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "QLGN:CommonStockSharesAvailableForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000052 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)",
     "role": "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative",
     "shortName": "SUBSEQUENT EVENTS (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-08-09_us-gaap_SubsequentEventMember_custom_TwpThousandTwentyPlanMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "QLGN:CommonStockSharesAvailableForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://qualigeninc.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
     "role": "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates",
     "shortName": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - LIQUIDITY",
     "role": "http://qualigeninc.com/role/Liquidity",
     "shortName": "LIQUIDITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - INVENTORY, NET",
     "role": "http://qualigeninc.com/role/InventoryNet",
     "shortName": "INVENTORY, NET",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "QLGN_AccruedCompensation": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board compensation.",
        "label": "Board compensation"
       }
      }
     },
     "localname": "AccruedCompensation",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedPatentAndLicenseFeesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent and license fees.",
        "label": "Patent and license fees"
       }
      }
     },
     "localname": "AccruedPatentAndLicenseFeesCurrent",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedResearchAndDevelopmentCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development.",
        "label": "AccruedResearchAndDevelopmentCurrent",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentCurrent",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AccruedWarrantyCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty costs.",
        "label": "AccruedWarrantyCostsCurrent",
        "verboseLabel": "Warranty costs"
       }
      }
     },
     "localname": "AccruedWarrantyCostsCurrent",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_AdvancedCancerTherapeuticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advanced Cancer Therapeutics, LLC [Member]",
        "label": "Advanced Cancer Therapeutics L L C [Member]"
       }
      }
     },
     "localname": "AdvancedCancerTherapeuticsLLCMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement description.",
        "label": "Agreement description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_AgreementTermPaymentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement term payment, description.",
        "label": "Agreement term payment, description"
       }
      }
     },
     "localname": "AgreementTermPaymentDescription",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_CEMarkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CE Mark [Member]",
        "label": "C E Mark [Member]"
       }
      }
     },
     "localname": "CEMarkMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CashPaidForAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For [Abstract]",
        "label": "Cash paid for:"
       }
      }
     },
     "localname": "CashPaidForAbstract",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrant exercised.",
        "label": "Shares issued upon the exercise of warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercised",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_CollaborativeResearchRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Research Revenue [Member]",
        "label": "Collaborative Research Revenue [Member]"
       }
      }
     },
     "localname": "CollaborativeResearchRevenueMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CommonStockSharesAvailableForFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock shares available for future issuance.",
        "label": "[custom:CommonStockSharesAvailableForFutureIssuance-0]"
       }
      }
     },
     "localname": "CommonStockSharesAvailableForFutureIssuance",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants [Member]",
        "label": "Common Stock Warrants [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CompensatoryWarrantActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensatory Warrant Activity [Member]",
        "label": "Compensatory Warrant Activity [Member]"
       }
      }
     },
     "localname": "CompensatoryWarrantActivityMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CompensatoryWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Compensatory Warrants [Member]",
        "label": "Compensatory Warrants [Member]"
       }
      }
     },
     "localname": "CompensatoryWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_ConstructionInProgressEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Construction In Progress Equipment [Member]",
        "label": "Construction In Progress Equipment [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressEquipmentMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_CostOfProductSales": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of product sales.",
        "label": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfProductSales",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_CumulativeAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative amount.",
        "label": "Cumulative amount"
       }
      }
     },
     "localname": "CumulativeAmount",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Financial Instruments and Warrant Liabilities [Policy Text Block]",
        "label": "Derivative Financial Instruments and Warrant Liabilities"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsAndWarrantLiabilitiesTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expenses And Other Current Assets",
        "verboseLabel": "Schedule Of Prepaid Expenses And Other Current Assets"
       }
      }
     },
     "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract",
     "nsuri": "http://qualigeninc.com/20210630",
     "xbrltype": "stringItemType"
    },
    "QLGN_DisclosureResearchAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research And License Agreements"
       }
      }
     },
     "localname": "DisclosureResearchAndLicenseAgreementsAbstract",
     "nsuri": "http://qualigeninc.com/20210630",
     "xbrltype": "stringItemType"
    },
    "QLGN_DisclosureWarrantLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant Liabilities"
       }
      }
     },
     "localname": "DisclosureWarrantLiabilitiesAbstract",
     "nsuri": "http://qualigeninc.com/20210630",
     "xbrltype": "stringItemType"
    },
    "QLGN_EffectOfReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period effect of reverse recapitalization transaction.",
        "label": "EffectOfReverseRecapitalization",
        "verboseLabel": "Effect of reverse recapitalization"
       }
      }
     },
     "localname": "EffectOfReverseRecapitalization",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_EmployeesAndNonemployeeServiceProviderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and Non-employee Service Provider [Member]",
        "label": "Employees And Nonemployee Service Provider [Member]"
       }
      }
     },
     "localname": "EmployeesAndNonemployeeServiceProviderMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_EquipmentHeldForLeaseNet": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment held for lease net.",
        "label": "Equipment held for lease, net"
       }
      }
     },
     "localname": "EquipmentHeldForLeaseNet",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_EquityCapitalRaise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity capital raise.",
        "label": "Equity capital raise"
       }
      }
     },
     "localname": "EquityCapitalRaise",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_EstimatedReturnsNetOfAllowances": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Returns Net of allowances.",
        "label": "Estimated returns net of allowances"
       }
      }
     },
     "localname": "EstimatedReturnsNetOfAllowances",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ExerciseOfOutstandingStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Outstanding Stock Options [Member]",
        "label": "Exercise Of Outstanding Stock Options [Member]"
       }
      }
     },
     "localname": "ExerciseOfOutstandingStockOptionsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_ExerciseOfOutstandingStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of Outstanding Stock Warrant Member]",
        "label": "Exercise Of Outstanding Stock Warrant [Member]"
       }
      }
     },
     "localname": "ExerciseOfOutstandingStockWarrantMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_FairValueAdjustmentOfWarrant": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair value for warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrant",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of shares issued to advisor upon closing of private placement.",
        "label": "Fair value of shares issued to advisor upon closing of private placement"
       }
      }
     },
     "localname": "FairValueOfSharesIssuedToAdvisorUponClosingOfPrivatePlacement",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of warrants issued to advisor upon closing of private placement.",
        "label": "Fair value of warrants issued to advisor upon closing of private placement"
       }
      }
     },
     "localname": "FairValueOfWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_GeneralAdministrativeResearchAndDevelopmentExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General, Administrative, Research and Development Expense [Member]",
        "label": "General, Administrative, Research and Development Expense [Member]"
       }
      }
     },
     "localname": "GeneralAdministrativeResearchAndDevelopmentExpensesMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_IncreaseDecreaseInInventoryAndEquipmentHeldForLease": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory and equipment held for lease.",
        "label": "Inventory and equipment held for lease"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventoryAndEquipmentHeldForLease",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IncreaseDecreaseInLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value of lease liabilities.",
        "label": "Lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilities",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_InitialMeasurementOfOperatingLeaseRightofuseAssets": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Measurement of Operating Lease Right of use Assets.",
        "label": "Initial measurement of operating lease right-of-use assets"
       }
      }
     },
     "localname": "InitialMeasurementOfOperatingLeaseRightofuseAssets",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfCommonStockForConversionOfAccruedInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for conversion of debt and accrued interest.",
        "label": "Issuance of common stock for conversion of accrued interest"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForConversionOfAccruedInterest",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfCommonStockForConversionOfPreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of common stock for conversion of preferred stock.",
        "label": "IssuanceOfCommonStockForConversionOfPreferredStock",
        "verboseLabel": "Issuance of common stock for conversion of preferred stock"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForConversionOfPreferredStock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfCommonStockForProfessionalServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance common stock for professional services.",
        "label": "Issuance of common stock for professional services"
       }
      }
     },
     "localname": "IssuanceOfCommonStockForProfessionalServices",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfPreferredStockForConversionOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Preferred Stock for Conversion of Debt.",
        "label": "Issuance of preferred stock for conversion of debt"
       }
      }
     },
     "localname": "IssuanceOfPreferredStockForConversionOfDebt",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series Alpha preferred stock for conversion of notes payable.",
        "label": "Issuance of Series Alpha preferred stock for conversion of notes payable"
       }
      }
     },
     "localname": "IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayable",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of Series Alpha preferred stock for conversion of notes payable, shares.",
        "label": "Issuance of Series Alpha preferred stock for conversion of notes payable, shares"
       }
      }
     },
     "localname": "IssuanceOfSeriesAlphaPreferredStockForConversionOfNotesPayableShares",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicenseAndSponsoredResearchAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and Sponsored Research Agreements [Member]",
        "label": "License And Sponsored Research Agreements [Member]"
       }
      }
     },
     "localname": "LicenseAndSponsoredResearchAgreementsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicenseCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License costs.",
        "label": "License costs"
       }
      }
     },
     "localname": "LicenseCost",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_LicenseRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Revenue [Member]",
        "label": "License Revenue [Member]"
       }
      }
     },
     "localname": "LicenseRevenueMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LicensedProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed Product Sales [Member]",
        "label": "Licensed Product Sales [Member]"
       }
      }
     },
     "localname": "LicensedProductSalesMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_LongtermOperatingLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of Outstanding Series Alpha Preferred Stock [Member]",
        "label": "Longterm Operating Lease Agreement [Member]"
       }
      }
     },
     "localname": "LongtermOperatingLeaseAgreementMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_MilestoneMethodRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone method revenue recognized.",
        "label": "MilestoneMethodRevenueRecognized",
        "verboseLabel": "Milestone payment"
       }
      }
     },
     "localname": "MilestoneMethodRevenueRecognized",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_MilestonePayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment.",
        "label": "Milestone payment"
       }
      }
     },
     "localname": "MilestonePayment",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_MilestonePaymentForMarketingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payment for marketing expenses.",
        "label": "Milestone payment for marketing expenses"
       }
      }
     },
     "localname": "MilestonePaymentForMarketingExpenses",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_NetProductSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Product Sales [Member]",
        "label": "Net Product Sales [Member]"
       }
      }
     },
     "localname": "NetProductSalesMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NetTransfersToInventoryFromEquipmentHeldForLease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net transfers to inventory from equipment held for lease.",
        "label": "Net transfers to inventory from equipment held for lease"
       }
      }
     },
     "localname": "NetTransfersToInventoryFromEquipmentHeldForLease",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_NewEquityCapitalRaise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "New equity capital raise,",
        "label": "New equity capital raise"
       }
      }
     },
     "localname": "NewEquityCapitalRaise",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_NonCompensatoryWarrantActivityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non Compensatory Warrant Activity [Member]",
        "label": "Non Compensatory Warrant Activity [Member]"
       }
      }
     },
     "localname": "NonCompensatoryWarrantActivityMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NoncompensatoryEquityClassifiedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncompensatory Equity Classified Warrants [Member]",
        "label": "Noncompensatory Equity Classified Warrants [Member]"
       }
      }
     },
     "localname": "NoncompensatoryEquityClassifiedWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_NumberOfSharesWarrantsLegacyRitterWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Shares, Warrants Legacy Ritter warrant.",
        "label": "Number of Shares, Warrants Legacy Ritter warrants"
       }
      }
     },
     "localname": "NumberOfSharesWarrantsLegacyRitterWarrant",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sttock warrant exchanged for common stock warrant upon reverse merger.",
        "label": "Number of Shares, Warrants Series C preferred stock warrants exchanged for common stock warrants upon reverse merger",
        "verboseLabel": "Number of Shares, Warrants Series C preferred stock compensatory warrants exchanged for common stock warrants upon reverse recapitalization"
       }
      }
     },
     "localname": "NumberOfSharesWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_NumberOfWarrantExercisedOnCashlessBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrant exercised on cashless basis.",
        "label": "Shares issued upon net-exercise of warrants"
       }
      }
     },
     "localname": "NumberOfWarrantExercisedOnCashlessBasis",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_OfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Office Furniture and Equipment [Member]",
        "label": "Office Furniture And Equipment [Member]"
       }
      }
     },
     "localname": "OfficeFurnitureAndEquipmentMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_OperatingLeaseRightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right of use asset amortization.",
        "label": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortization",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_OrganizationPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization [Policy Text Block]",
        "label": "Organization"
       }
      }
     },
     "localname": "OrganizationPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_PatentsAndLicensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents and Licenses [Member]",
        "label": "Patents and Licenses [Member]"
       }
      }
     },
     "localname": "PatentsAndLicensesMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PhaseOneClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 1 Clinical Trial [Member]",
        "label": "Phase One Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseOneClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PhaseThreeClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 3 Clinical Trial [Member]",
        "label": "Phase Three Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseThreeClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PhaseTwoClinicalTrialMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Phase 2 Clinical Trial [Member]",
        "label": "Phase Two Clinical Trial [Member]"
       }
      }
     },
     "localname": "PhaseTwoClinicalTrialMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PredictionBiosciencesSASMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prediction Biosciences SAS [Member]",
        "label": "Prediction Biosciences S A S [Member]"
       }
      }
     },
     "localname": "PredictionBiosciencesSASMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PrefundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-funded Warrants [Member]",
        "label": "Prefunded Warrants [Member]"
       }
      }
     },
     "localname": "PrefundedWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Expenses And Other Current Assets [Text Block]",
        "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_PrepaidInvestorRelationsExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid investor relations expenses.",
        "label": "Prepaid investor relations expenses"
       }
      }
     },
     "localname": "PrepaidInvestorRelationsExpenses",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_PrepaidManufacturingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid manufacturing expenses.",
        "label": "Prepaid manufacturing expenses"
       }
      }
     },
     "localname": "PrepaidManufacturingExpenses",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_RangeOfExercisePriceExercisableVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, exercisable (vested).",
        "label": "Range of Exercise Price, Exercisable"
       }
      }
     },
     "localname": "RangeOfExercisePriceExercisableVested",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceNonexercisableNonvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, non-exercisable (non-vested).",
        "label": "Range of Exercise Price, Non-Exercisable"
       }
      }
     },
     "localname": "RangeOfExercisePriceNonexercisableNonvested",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceOptionsExercisableVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, options exercisable (vested).",
        "label": "Range of Exercise price, Options Exercisable (vested)"
       }
      }
     },
     "localname": "RangeOfExercisePriceOptionsExercisableVested",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceOptionsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, options expired.",
        "label": "Range of Exercise price, Options Expired"
       }
      }
     },
     "localname": "RangeOfExercisePriceOptionsExpired",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceOptionsForfeited": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, options forfeited.",
        "label": "Range of Exercise price, Options Forfeited"
       }
      }
     },
     "localname": "RangeOfExercisePriceOptionsForfeited",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceOptionsGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, options granted.",
        "label": "Range of Exercise price, Options Granted"
       }
      }
     },
     "localname": "RangeOfExercisePriceOptionsGranted",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RangeOfExercisePriceOptionsNonexercisableNonvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, options non-exercisable (non-vested).",
        "label": "Range of Exercise price, Options Non-Exercisable (non-vested)"
       }
      }
     },
     "localname": "RangeOfExercisePriceOptionsNonexercisableNonvested",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_RegulatoryMarketingApprovalExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory marketing approval, expenses.",
        "label": "Regulatory marketing approval, expenses"
       }
      }
     },
     "localname": "RegulatoryMarketingApprovalExpenses",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ReimbursementOfResearchExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement of research expenses.",
        "label": "Reimbursement of research expenses"
       }
      }
     },
     "localname": "ReimbursementOfResearchExpenses",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ReimbursementPatentCost": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reimbursement patent cost.",
        "label": "Reimbursement patent cost"
       }
      }
     },
     "localname": "ReimbursementPatentCost",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_ResearchAndLicenseAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and license agreements [Text Block]",
        "label": "RESEARCH AND LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "ResearchAndLicenseAgreementsTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_RoyaltiesAndNonRoyaltySublicenseeIncomeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and Non-royalty Sublicensee Income [Member]",
        "label": "Royalties And Non Royalty Sublicensee Income [Member]"
       }
      }
     },
     "localname": "RoyaltiesAndNonRoyaltySublicenseeIncomeMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_STAPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "STA Pharmaceutical Co Ltd [Member]",
        "label": "S T A Pharmaceutical Co Ltd [Member]"
       }
      }
     },
     "localname": "STAPharmaceuticalCoLtdMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SalesAndExciseTaxesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales and excise taxes [Policy Text Block]",
        "label": "Sales and Excise Taxes"
       }
      }
     },
     "localname": "SalesAndExciseTaxesPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Assumptions of Warrant Liabilities [Table Text Block]",
        "label": "SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Fair Value Hierarchy for Warrant Liabilities [Table Text Block]",
        "label": "SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Operating Lease Right of Use Assets and Liabilities [Table Text Block]",
        "label": "SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Prepaid Expenses and Other Current Assets [Table Text Block]",
        "label": "SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS"
       }
      }
     },
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfReservedSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Reserved Shares [Table Text Block]",
        "label": "SCHEDULE OF RESERVED SHARES"
       }
      }
     },
     "localname": "ScheduleOfReservedSharesTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Useful Lives of Property and Equipment [Table Text Block]",
        "label": "SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_SecuritiesPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement [Member]",
        "label": "Securities Purchase Agreement [Member]"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SekisuiDiagnosticsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sekisui Diagnostics, LLC [Member]",
        "label": "Sekisui Diagnostics L L C [Member]"
       }
      }
     },
     "localname": "SekisuiDiagnosticsLLCMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SerieAlphaPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Alpha Preferred Stock [Member]",
        "label": "Serie Alpha Preferred Stock [Member]"
       }
      }
     },
     "localname": "SerieAlphaPreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesAlphaConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series Alpha Convertible Preferred Stock [Member]",
        "label": "Series Alpha Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAlphaConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Convertible Preferred Stock [Member]",
        "label": "Series C Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesCWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Warrants [Member]",
        "label": "Series C Warrants [Member]"
       }
      }
     },
     "localname": "SeriesCWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesDAndSeriesDOnePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D and Series D-1 Preferred Stock [Member]",
        "label": "Series D And Series D One Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesDAndSeriesDOnePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock [Member]",
        "label": "Series D Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SeriesDOneConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D One Convertible Preferred Stock [Member]",
        "label": "Series D One Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesDOneConvertiblePreferredStockMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares, warrants non-exercisable (non-vested).",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber",
        "periodEndLabel": "Number of shares, warrants non-exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
        "periodEndLabel": "Number of Shares, Warrants Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share non-exercisable (non-vested).",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise",
        "periodEndLabel": "Weighted Average Exercise Price Per Share Non-Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share exercisable (vested).",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Per Share Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share warrants exercised.",
        "label": "Weighted Average Exercise Price Per Share Warrants Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.",
        "label": "Weighted Average Exercise Price Per Share Warrants Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share warrants forfeited.",
        "label": "Weighted Average Exercise Price Per Share Warrants Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of non-option equity.",
        "label": "Weighted Average Exercise Price Per Share Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life (Years) Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted Average Remaining Life (Years) Non-Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price Per Share Warrants Outstanding Ending",
        "periodStartLabel": "Weighted Average Exercise Price Per Share Warrants Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price, options non-exercisable (non-vested).",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice",
        "periodEndLabel": "Weighted Average Exercise Price, Options Non-Exercisable (non-vested)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Range of exercise price, options outstanding.",
        "label": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange",
        "periodEndLabel": "Range of Exercise price, Options Outstanding",
        "periodStartLabel": "Range of Exercise price, Options Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRange",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- Average Remaining Contractual Life (in Years), Options Granted.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares and warrants issued to advisor upon closing of private placement.",
        "label": "Shares and warrants issued to advisor upon closing of private placement"
       }
      }
     },
     "localname": "SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacement",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares and warrants issued to advisor upon closing of private placement, shares.",
        "label": "Shares and warrants issued to advisor upon closing of private placement, shares"
       }
      }
     },
     "localname": "SharesAndWarrantsIssuedToAdvisorUponClosingOfPrivatePlacementShares",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_SharesIssuedUponNetExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares issued upon net exercises.",
        "label": "Shares issued on net exercises"
       }
      }
     },
     "localname": "SharesIssuedUponNetExercises",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_ShippingAndHandlingCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping and handling costs [Policy Text Block]",
        "label": "Shipping and Handling Costs"
       }
      }
     },
     "localname": "ShippingAndHandlingCostsPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_ShortfallPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shortfall payments.",
        "label": "Shortfall payments"
       }
      }
     },
     "localname": "ShortfallPayments",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_SingleInstitutionalInvestorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single Institutional Investor [Member]",
        "label": "Single Institutional Investor [Member]"
       }
      }
     },
     "localname": "SingleInstitutionalInvestorMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_SponsoredResearchAgreementAndLicenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sponsored Research and License Agreement [Member]",
        "label": "Sponsored Research Agreement And License [Member]"
       }
      }
     },
     "localname": "SponsoredResearchAgreementAndLicenseMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period effect of reverse recapitalization transaction, shares.",
        "label": "Effect of reverse recapitalization, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodEffectOfReverseRecapitalizationShares",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised, shares.",
        "label": "Stock issued upon cash-exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised on a net basis, shares.",
        "label": "Stock issued upon net-exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercisedOnNetBasis",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_StockIssuedDuringPeriodValueEffectOfReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period effect of reverse recapitalization transaction.",
        "label": "Effect of reverse recapitalization"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEffectOfReverseRecapitalization",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised.",
        "label": "Stock issued upon cash-exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants exercised on a net basis.",
        "label": "Stock issued upon net-exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercisedOnNetBasis",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_StockOptionsAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Options and Warrants [Member]",
        "label": "Stock Options And Warrants [Member]"
       }
      }
     },
     "localname": "StockOptionsAndWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_StockOptionsSharesFutureGrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock options shares future grant.",
        "label": "[custom:StockOptionsSharesFutureGrant]"
       }
      }
     },
     "localname": "StockOptionsSharesFutureGrant",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "QLGN_SummaryOfWarrantActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Warrant Activity [Table Text Block]",
        "label": "SCHEDULE OF WARRANT ACTIVITY"
       }
      }
     },
     "localname": "SummaryOfWarrantActivityTableTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_TechnologyTransferAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology Transfer Agreement [Member]",
        "label": "Technology Transfer Agreement [Member]"
       }
      }
     },
     "localname": "TechnologyTransferAgreementMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_TwoThousandTwentyStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Stock Incentive Plan [Member]",
        "label": "Two Thousand Twenty Stock Incentive Plan [Member]"
       }
      }
     },
     "localname": "TwoThousandTwentyStockIncentivePlanMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_TwoYearWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-year Warrants [Member]",
        "label": "Two Year Warrants [Member]"
       }
      }
     },
     "localname": "TwoYearWarrantsMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_TwpThousandTwentyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twp Thousand Twenty Plan [Member]"
       }
      }
     },
     "localname": "TwpThousandTwentyPlanMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_UlrfLicenseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ULRF license agreement description.",
        "label": "ULRF license agreement description"
       }
      }
     },
     "localname": "UlrfLicenseAgreementDescription",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "QLGN_UniversityOfLouisvilleResearchFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Louisville Research Foundation [Member]",
        "label": "University Of Louisville Research Foundation [Member]"
       }
      }
     },
     "localname": "UniversityOfLouisvilleResearchFoundationMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "QLGN_UpfrontLicenseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront license fee.",
        "label": "Upfront license fee"
       }
      }
     },
     "localname": "UpfrontLicenseFee",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_WarrantLiabilitiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Liabilities [Text Block]",
        "label": "WARRANT LIABILITIES"
       }
      }
     },
     "localname": "WarrantLiabilitiesTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_WarrantyCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty costs.",
        "label": "Warranty costs"
       }
      }
     },
     "localname": "WarrantyCosts",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "QLGN_WarrantyCostsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warranty costs [Policy Text Block]",
        "label": "Warranty Costs"
       }
      }
     },
     "localname": "WarrantyCostsPolicyTextBlock",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "QLGN_WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrant.",
        "label": "Weighted Average Exercise Price Per Share Warrants Legacy Ritter warrants"
       }
      }
     },
     "localname": "WeightedAverageExercisePricePerShareWarrantsLegacyRitterWarrant",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price per share warrants series c preferred stock warrant exchanged for common stock warrant upon reverse merger.",
        "label": "Weighted Average Exercise Price Per Share Warrants Series C Preferred Stock Warrants Exchanged For Common Stock Warrants Upon Reverse Merger",
        "verboseLabel": "Weighted Average Exercise Price Per Share compensatory Warrants Series C Preferred Stock Warrant Exchanged For Common Stock Warrant Upon Reverse Recapitalization"
       }
      }
     },
     "localname": "WeightedAverageExercisePricePerShareWarrantsSeriesCPreferredStockWarrantExchangedForCommonStockWarrantUponReverseMerger",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- average remaining contractual life (in years), options exercisable (vested).",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsOptionsExercisableVested",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted- average remaining contractual life (in years), options non-exercisable (non-vested).",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested)"
       }
      }
     },
     "localname": "WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "QLGN_YiXinZhenDuanJishuLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yi Xin Zhen Duan Jishu Ltd [Member]",
        "label": "Yi Xin Zhen Duan Jishu Ltd [Member]"
       }
      }
     },
     "localname": "YiXinZhenDuanJishuLtdMember",
     "nsuri": "http://qualigeninc.com/20210630",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r418",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r422"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Series [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://qualigeninc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_AffiliateCollateralizedSecurityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Affiliate, Collateralized Security [Line Items]"
       }
      }
     },
     "localname": "AffiliateCollateralizedSecurityLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r210",
      "r221",
      "r264",
      "r265",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r394",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r210",
      "r221",
      "r264",
      "r265",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r394",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r151",
      "r246",
      "r247",
      "r371",
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r151",
      "r246",
      "r247",
      "r371",
      "r393",
      "r395"
     ],
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r210",
      "r221",
      "r251",
      "r264",
      "r265",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r394",
      "r396",
      "r406",
      "r407"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r210",
      "r221",
      "r251",
      "r264",
      "r265",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r394",
      "r396",
      "r406",
      "r407"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r154",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r155",
      "r156"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r6",
      "r24",
      "r155",
      "r156"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net",
        "totalLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r19",
      "r376",
      "r385"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Accrued expenses and other current liabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedPayrollTaxesCurrent": {
     "auth_ref": [
      "r13",
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Payroll"
       }
      }
     },
     "localname": "AccruedPayrollTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Royalties"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedVacationCurrent": {
     "auth_ref": [
      "r12",
      "r45",
      "r249"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Vacation"
       }
      }
     },
     "localname": "AccruedVacationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r190"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r25",
      "r293",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r290",
      "r291",
      "r292",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalMarkToMarket": {
     "auth_ref": [
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid in capital (APIC) resulting from changes in fair value of common and preferred stock issued to employee benefit trust but unearned.",
        "label": "Adjustments to Additional Paid in Capital, Fair Value",
        "negatedLabel": "Fair value of shares issued to advisor upon closing of private placement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalMarkToMarket",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) to additional paid-in capital (APIC) for recognition and exercise of award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r209",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "negatedLabel": "Fair value of warrants issued to advisor upon closing of private placement"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r30",
      "r161",
      "r168"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "negatedLabel": "Less Allowance"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r83",
      "r177",
      "r183"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r99",
      "r140",
      "r143",
      "r149",
      "r166",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r309",
      "r312",
      "r322",
      "r349",
      "r351",
      "r375",
      "r384"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r58",
      "r99",
      "r166",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r309",
      "r312",
      "r322",
      "r349",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r267",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r101",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r37",
      "r85"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r79",
      "r85",
      "r91"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "CASH AND CASH EQUIVALENTS \u2013 end of period",
        "periodStartLabel": "CASH AND CASH EQUIVALENTS \u2013 beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r323"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCASH FINANCING AND INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r97",
      "r99",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r125",
      "r126",
      "r127",
      "r166",
      "r198",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r219",
      "r220",
      "r224",
      "r228",
      "r322",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Warrant exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right",
        "verboseLabel": "Purchase of stock warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r102",
      "r103",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesSubscribedButUnissued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of common stock allocated to investors to buy shares of a new issue of common stock before they are offered to the public. When stock is sold on a subscription basis, the issuer does not initially receive the total proceeds. In general, the issuer does not issue the shares to the investor until it receives the entire proceeds.",
        "label": "Common Stock, Shares Subscribed but Unissued",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "CommonStockSharesSubscribedButUnissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value; 225,000,000 shares authorized; 28,902,188 and 27,296,061 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationRelatedCostsPolicyTextBlock": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.",
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "CompensationRelatedCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r92",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Issuance of common stock for conversion of notes payable and accrued interest"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r88",
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Issuance of common stock for conversion of notes payable and accrued interest, shares",
        "verboseLabel": "Conversion of preferred stock"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertibleNotesPayable": {
     "auth_ref": [
      "r20",
      "r377",
      "r386",
      "r402"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.",
        "label": "Convertible notes payable"
       }
      }
     },
     "localname": "ConvertibleNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r69",
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Shipping and handling costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionOriginalDebtAmount1": {
     "auth_ref": [
      "r88",
      "r90"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the original debt being converted in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Issuance of common stock for conversion of debt"
       }
      }
     },
     "localname": "DebtConversionOriginalDebtAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]"
       }
      }
     },
     "localname": "DeferredCompensationArrangementWithIndividualPostretirementBenefitsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeCurrent": {
     "auth_ref": [
      "r197"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred revenue, current portion"
       }
      }
     },
     "localname": "DeferredIncomeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositAssets": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.",
        "label": "Upfront deposit"
       }
      }
     },
     "localname": "DepositAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r83",
      "r188"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r83",
      "r138"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per common share, basic and diluted"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r121",
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r288"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r62",
      "r63",
      "r64",
      "r102",
      "r103",
      "r104",
      "r106",
      "r111",
      "r113",
      "r124",
      "r167",
      "r235",
      "r242",
      "r290",
      "r291",
      "r292",
      "r303",
      "r304",
      "r315",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r397",
      "r398",
      "r399",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Beneficial-ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r83",
      "r215"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Loss (gain) on change in fair value of warrant liabilities",
        "terseLabel": "Fair Value Adjustment of Warrants",
        "verboseLabel": "Change in fair value of warrant liabilities"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfOperations",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r263",
      "r317",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r211",
      "r252",
      "r253",
      "r258",
      "r263",
      "r317",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r252",
      "r253",
      "r258",
      "r263",
      "r317",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r263",
      "r317",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r211",
      "r213",
      "r214",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r263",
      "r355",
      "r356",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Estimated useful lives"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization, Thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization for year ending December 31, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Future estimated amortization, remainder of fiscal year"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization for year ending December 31, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization for year ending December 31, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r184"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Future estimated amortization for year ending December 31, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r182",
      "r185",
      "r372",
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r178",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r182",
      "r372"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Carrying value"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.",
        "label": "Warrant liabilities"
       }
      }
     },
     "localname": "HedgingLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "auth_ref": [
      "r83",
      "r187",
      "r192"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).",
        "label": "Long-lived assets impairment losses"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r186",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r65",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r374",
      "r379",
      "r382",
      "r391"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "LOSS BEFORE PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r193",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r100",
      "r112",
      "r113",
      "r139",
      "r298",
      "r305",
      "r306",
      "r392"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "PROVISION (BENEFIT) FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r61",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r82",
      "r365"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpensesOther": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods.",
        "label": "Increase (Decrease) in Prepaid Expenses, Other",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpensesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsFiniteLivedPolicy": {
     "auth_ref": [
      "r93",
      "r181",
      "r368",
      "r369",
      "r370",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.",
        "label": "Intangible Assets, Net"
       }
      }
     },
     "localname": "IntangibleAssetsFiniteLivedPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r176",
      "r180"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "negatedLabel": "Interest (income) expense, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r78",
      "r80",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "INVENTORY, NET"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/InventoryNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r55",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, net",
        "totalLabel": "Inventory net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r15",
      "r56",
      "r94",
      "r123",
      "r170",
      "r172",
      "r173",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Net"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r171"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory reserves"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestorMember": {
     "auth_ref": [
      "r344",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business entity or individual that puts money, by purchase or expenditure, in something offering potential profitable returns, such as interest income or appreciation in value.",
        "label": "Investor [Member]"
       }
      }
     },
     "localname": "InvestorMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeasesOfLesseeDisclosureTextBlock": {
     "auth_ref": [
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.",
        "label": "LEASES"
       }
      }
     },
     "localname": "LeasesOfLesseeDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Operating Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Total"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "2021 (nine months)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r340"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LessorLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessor, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LessorLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r99",
      "r144",
      "r166",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r310",
      "r312",
      "r313",
      "r322",
      "r349",
      "r350"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r99",
      "r166",
      "r322",
      "r351",
      "r378",
      "r388"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r99",
      "r166",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r310",
      "r312",
      "r313",
      "r322",
      "r349",
      "r350",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermNotesPayable": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.",
        "label": "Notes payable, net of current portion"
       }
      }
     },
     "localname": "LongTermNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.",
        "label": "Sales and marketing"
       }
      }
     },
     "localname": "MarketingAndAdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r81",
      "r84"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r59",
      "r60",
      "r64",
      "r66",
      "r84",
      "r99",
      "r105",
      "r107",
      "r108",
      "r109",
      "r110",
      "r112",
      "r113",
      "r117",
      "r140",
      "r142",
      "r145",
      "r148",
      "r150",
      "r166",
      "r198",
      "r199",
      "r200",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r316",
      "r322",
      "r380",
      "r390"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Loss",
        "totalLabel": "NET LOSS",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedTotalLabel": "Total other (income) expense, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER (INCOME) EXPENSE, NET"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes payable, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EXPENSES"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r140",
      "r142",
      "r145",
      "r148",
      "r150"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "LOSS FROM OPERATIONS"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r334"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r333"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liabilities",
        "periodEndLabel": "Operating lease liabilities",
        "periodStartLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liability, current portion",
        "verboseLabel": "Current portion at June 30, 2021"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r333"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liability, net of current portion",
        "negatedLabel": "Less non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r335",
      "r337"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "negatedLabel": "Less principal payments on operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right-of-use assets",
        "periodEndLabel": "Operating lease right-of-use assets",
        "periodStartLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r83"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "negatedLabel": "Less amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r339",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Discount rate operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r338",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r101",
      "r135",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimates"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r45"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r10",
      "r175"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other prepaid expenses"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r295"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other research and development expense.",
        "label": "Sponsored research expense"
       }
      }
     },
     "localname": "OtherResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PatentsMember": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law.",
        "label": "Patents [Member]"
       }
      }
     },
     "localname": "PatentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedLabel": "Payments for patents and licenses"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r267",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Series Alpha convertible preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Series Alpha convertible preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r22",
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Series Alpha convertible preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Series Alpha convertible preferred stock, shares outstanding",
        "verboseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheetsParenthetical",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r22",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Series Alpha convertible preferred stock, $0.001 par value; 7,000 shares authorized; 180 shares issued and outstanding as of June 30, 2021 and December 31, 2020"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r8",
      "r10",
      "r174",
      "r175"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from convertible promissory note"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.",
        "label": "Proceeds from issuance of Series Alpha preferred shares upon closing of private placement"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "Proceeds from sale of equity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation.",
        "label": "Net proceeds from the issuance of notes payable"
       }
      }
     },
     "localname": "ProceedsFromNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from warrant exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r40",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r195",
      "r403",
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "PROPERTY AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r189"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r191",
      "r351",
      "r383",
      "r389"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r191",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "SCHEDULE OF PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/PropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property and equipment, useful life"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r68",
      "r169"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts receivable reserves and allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r342",
      "r343",
      "r345",
      "r347",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "RELATED PARTY TRANSACTIONS"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Payment of convertible promissory note"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation.",
        "label": "Repayments of Notes Payable",
        "negatedLabel": "Principal payments on notes payable"
       }
      }
     },
     "localname": "RepaymentsOfNotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r295",
      "r367",
      "r408"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r26",
      "r242",
      "r293",
      "r351",
      "r387",
      "r400",
      "r401"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r102",
      "r103",
      "r104",
      "r106",
      "r111",
      "r113",
      "r167",
      "r290",
      "r291",
      "r292",
      "r303",
      "r304",
      "r315",
      "r397",
      "r399"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153",
      "r245",
      "r246",
      "r371"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Total revenues",
        "terseLabel": "Product sales",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r136",
      "r137",
      "r141",
      "r146",
      "r147",
      "r151",
      "r152",
      "r153",
      "r245",
      "r246",
      "r371"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Licensed product sales, revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue from Contracts with Customers"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r70"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Minimum annual royalties"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r13",
      "r42"
     ],
     "calculation": {
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Franchise, sales and use taxes"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r51"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "SCHEDULE OF ACCOUNTS RECEIVABLE"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/AccruedExpensesAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": {
     "auth_ref": [
      "r248",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]"
       }
      }
     },
     "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfFairValueHierarchyForWarrantLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r15",
      "r32",
      "r33",
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "SCHEDULE OF INVENTORY"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/InventoryNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r271",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "SCHEDULE OF STOCK OPTION ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r48",
      "r97",
      "r125",
      "r126",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r228",
      "r233",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r243",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "SCHEDULE OF WARRANTS ACTIVITY"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://qualigeninc.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock based compensation expense",
        "terseLabel": "Total",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/StatementsOfCashFlows",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription": {
     "auth_ref": [
      "r266",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.",
        "label": "Stock options description"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected stock-price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Number of Shares, Warrants Exercised",
        "verboseLabel": "Warrants exercise"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Number of Shares, Warrants Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Number of Shares, Warrants Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Number of Shares, Warrants Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r272",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Warrants Outstanding Ending",
        "periodStartLabel": "Number of Shares, Warrants Outstanding Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Number of Shares, Options Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r277"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Number of Shares, Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of Shares, Options Granted",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r273",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares, Options Outstanding at Ending",
        "periodStartLabel": "Number of Shares, Options Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Outstanding at Ending",
        "periodStartLabel": "Weighted Average Exercise Price, Outstanding, Beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Number of Shares, Options Exercisable (vested)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Options Exercisable (vested)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r266",
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted Average Exercise Price, Options Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted Average Exercise Price, Options Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted Average Exercise Price, Options Granted",
        "verboseLabel": "Stock option granted exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Stock price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r284",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Average expected remaining years of life of options"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsUsedInBlack-scholesOption-pricingMethodDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Number of Shares, Options Non-Exercisable (non-vested)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r21",
      "r22",
      "r23",
      "r97",
      "r99",
      "r114",
      "r115",
      "r116",
      "r118",
      "r120",
      "r125",
      "r126",
      "r127",
      "r166",
      "r198",
      "r202",
      "r203",
      "r204",
      "r207",
      "r208",
      "r219",
      "r220",
      "r224",
      "r228",
      "r235",
      "r322",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfReservedSharesDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r50",
      "r62",
      "r63",
      "r64",
      "r102",
      "r103",
      "r104",
      "r106",
      "r111",
      "r113",
      "r124",
      "r167",
      "r235",
      "r242",
      "r290",
      "r291",
      "r292",
      "r303",
      "r304",
      "r315",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r397",
      "r398",
      "r399",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfWarrantActivityDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityTables",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r124",
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/RelatedPartyTransactionsDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfShare-basedCompensationExpenseDetails",
      "http://qualigeninc.com/role/ScheduleOfWarrantsActivityDetails",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StatementsOfOperations",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r49",
      "r212",
      "r235",
      "r236",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of common stock for conversion of preferred stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock issued for professional services, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r235",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Issuance of Series Alpha preferred shares upon closing of private placement, shares",
        "verboseLabel": "Number of shares common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r22",
      "r23",
      "r235",
      "r242",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock issued upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r50",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Issuance of common stock for conversion of preferred stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock issued for professional services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r235",
      "r242"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Issuance of Series Alpha preferred shares upon closing of private placement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r99",
      "r163",
      "r166",
      "r322",
      "r351"
     ],
     "calculation": {
      "http://qualigeninc.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance, value",
        "periodStartLabel": "Beginning balance, value",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets",
      "http://qualigeninc.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r98",
      "r220",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r234",
      "r242",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r330",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEventsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.",
        "label": "LIQUIDITY"
       }
      }
     },
     "localname": "SubstantialDoubtAboutGoingConcernTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/Liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ToolsDiesAndMoldsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used to cut, shape, and form metal and other materials into goods for sale.",
        "label": "Tools, Dies and Molds [Member]"
       }
      }
     },
     "localname": "ToolsDiesAndMoldsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfPropertyAndEquipmentDetails",
      "http://qualigeninc.com/role/ScheduleOfUsefulLivesOfPropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r160",
      "r162",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounts receivable.",
        "label": "Accounts Receivable, Net"
       }
      }
     },
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/LiquidityDetailsNarrative",
      "http://qualigeninc.com/role/ResearchAndLicenseAgreementsDetailsNarrative",
      "http://qualigeninc.com/role/ScheduleOfOperatingLeaseRightOfUseAssetsAndOperatingLeaseLiabilitiesDetails",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Accounting Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesAndEstimatesDetailsNarrative",
      "http://qualigeninc.com/role/StockholdersEquityDetailsNarrative",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Fair value assumptions, measurement input, percentages"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Fair value assumptions, measurement input, term",
        "verboseLabel": "Warrants and Rights Outstanding, Term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/ScheduleOfAssumptionsOfWarrantLiabilitiesDetails",
      "http://qualigeninc.com/role/WarrantLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted\u2014average number of shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://qualigeninc.com/role/StatementsOfOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=28183603&loc=d3e692-112598"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "40",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=51888271"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19524-108361"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409733&loc=d3e19396-108361"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "http://asc.fasb.org/extlink&oid=6409875&loc=d3e20015-108363"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f(1))",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "840",
   "URI": "http://asc.fasb.org/topic&trid=2208923"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(b)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155628-234783"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "350",
   "Subparagraph": "(a)",
   "Topic": "920",
   "URI": "http://asc.fasb.org/extlink&oid=120155617&loc=SL120155638-234783"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r411": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r412": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r413": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r414": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r415": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r418": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r419": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r421": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r422": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r423": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r424": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r425": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r426": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r427": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r428": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8,17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>73
<FILENAME>0001493152-21-020170-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-020170-xbrl.zip
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M&"K,E 2:/\#<W)HBB85,G!%.V:'BQY5P<J!$)#,9Z7S4H@D :2]D'-,@8&Y
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M8G;O:<A9D%JE=[4A%^%E.#LD$ G4L KD,/R,@RK_^3YNDEHU&2QZ%C,L.(_
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M$,0<WJ=B":_SW90# T*F4A'8,[Z25.!P*YQ596;AL3C6Z/-,1QY:%G[6G5G
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M8!<<W@6'=\'AG0G")LC?MM3?HCD'8?EO8L=2#[83$WFCTR18[I%D'/I''-<
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M[Q1J?XUM7;Z]]RTN>-67YV3@\;5W:.'DJ__1F%WX/%<< R7)9DU+O3B;3YH
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MSKN_G 3<$?L?)_8MI7VS#CV(O9&[_]"_AI[O#K,()TQ:)-G.9H4%(RZ^ TS
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M\?63E\_^^1C_\??37Y\__O]02P,$%     @ ^X$04XT+2G3E!P  ES(   H
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M%UZQRUO]*/?A"$?&XQL+1P'%]*QN7IX%HSSZZ/V=H@BS%ZTSV:./^;PDXP#
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MCAC^'4IM4&H+SDX6.,MN0U(,SL),"F927/)SDC9DJI&4(V*&3!EX:6#ED:/
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MF@Z9Q@7POG0976+,:,7I"Z>&]3#SOH=#UB+X7 H,+<<_G,-R\9]=2X@P?\H
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M2J?4F6?9)V!9\E)GGF4-8%GR4F>>92? LN2ESC[+\A+P+'FI-_*,PJ21ZEK
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M>R)Q3($C3:UIB;IH6P;J[;&:$5ML>4EL6[_MTY.[*DLR(\%3BC<PF@B_>8K
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MU)<U8-\&9/  .H .H /H #IO"@#H #J SJO, #J #J ?$NBI+\1 !0N  ^
M.  .@ /@V"YOA+@-V;N" [_4^PM<M;%FD8/\'G_!N]MY_MPI;^%"& TM4U -
MR\&H^@=3Z?>*BP0,B.I=ZPE+&Y"] ^@ .H .H /HO"@ H /H #JO,@/H #J
M?DB@I[X( ]4K  Z  ^  .  .@$M\:</?O[&PM@';-RBO;,#F#4CB 70 '4 '
MT %TWA0 T %T )U7F0%T !U /R304U^+@2(6  ?  7  '  'P+%=X3CM(G7D
MN-9@\]Z-9J^'5+?5NT;DU"5TC51EJ+OX7<^*JULF[.CPB.:C-%WUL'VP\/\N
MH@7+&)"I ^@ .H .H /HO"@ H /H #JO,@/H #J ?DB@I[[@ I4J  Z  ^
M.  .@$MZ&6/+"H:_C0-V;X1?Q8!-&9"P ^@ .H .H /HO"D H /H #JO,@/H
M #J ?DB@I[[N @4K  Z  ^  .  .@&.[FM&8K69,CE)J]<CSD.,=H70U.4')
M6^LXM>SY6\4OR5W85_Y5V+ OPXYT'E68Z\5AO0-2>@ =0 ?0 70 G1<% '0
M'4#G568 '4 'T \)]-179J"D!< !<  <  ?  7!LUSM.:*UWP"X.-FL>L-<#
MTGL '4 'T %T )TW!0!T !U YU5F !U !] /"?345VF@O 7  7  '  'P %P
M;-<^JG,G5WDU]KJI_51L6S%=QS_%JF/5M7O=L>SO0\ML^-=DMWI7_B795Y,[
MLF&KAT<U'T-?#L74A(<QE(+N82FXEJ#X:&Z_=AQ6.R"A!] !=  =0 ?0>5$
M0 ?0 71>90;0 70 _9! 3WU=!@I: !P !\ !<  < ,=VM:-&:;4#-GHP6?&
M?1Z0W /H #J #J #Z+PI * #Z  ZKS(#Z  Z@'Y(H*>^1@/%+0 .@ /@ #@
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MMRE!B &[ +O8(<2P;E\%4P)32K<I08@!NP"[V"'$L&[7!5,"4TJW*4&( ;L
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MO"VXLFE%2 ^RP-(TL#1L6T"!^CE7J1T,('8:B WN%UC*/TM#NU_J9[*E=C"
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MUSZX]+/YDEC(Y!.7?MQDM\U\S1F^X(_MTM\9P6Z)%+?F^"_Z'/\-9%_JLC%
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MP.N]'#<5/WIXC87+P<;"(*1N3.-%Q>AY-KK'(NU2;PZ1*=GXA1795E]4&\+
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MD-1JXP](V]+3 P!7Z+WCH_R?DQ/A7,6\[;-P(SUBTFMA]H]T&7T6"E\$XB'
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M)-L.,;&Q*H\-BN.CH8%M;0@ER&!Z/SM8'J@@0UZ0H X&CFY(EB6-!+RY1]W
MAY>A=E1Q9#:6' (0^*7#_LC"DD."#,H>E-^1-QC8:C>%X!LL9(.DL817P]04
M;$<@$;Y[? 0',]'DT6I(DU[A.7JR\ND\Z A_P20UX/.9U)<J=2V0W])?_F8Q
M%$CLPIO4D=!U+!5#S<([>@3Q>(J7.#ZZQF<%5[?HOH<M#9X*#<&NI)D!6NJ7
M90[*5]7N"W>JC34<X:8OF0-))GN5-'>W;*?T2^Y&"338@Q0HP""5N0>O:!K/
M6_,A$/TCD7O%+Y; -LLR7U\1ABIB[;*IGSC\#1159ZR"@0DPQ^S_$9FG[+S_
MA"X42-+'B-Q7Y3XYX!##4S4<2QL! &$BB4%7;4B6(CT+5?I&N!SS"=F"HV.+
MEWP!+_N$?[1&@ZZA\8N_:[?O1 9-\DZPTQ6R-$FP"5M;H$N+\%<)8ZQEG[!+
M/B';/;&&FFH+D@(, .'[Z4J6BH'OVPI;/K@7$&I\*WAI@ET%D6#87KBE$LX\
M@S,3Q%0PO9L#S"5(NE87D8N67&T9_TA&W)M !7.X L85O +)\B*8@M>TF$^3
M$8Z/6P*'-DSK]/@(:)KD&@/^DDB/Y]WLJ8\.(W98A?$ZH"0P 2CKY)MU/:Q+
M^$S)AN@:%CH^(G.?\"^FX3SV*19G*!83ARW>FMTW+#3->X0HAY!ZP.HBK8K-
M]VGF!WL-OO80$#*<M/X)*-S_;L#:/6-RL8:_9*I#9ER> ;\CR>^NC3E+,\_[
M[-7E%^N,!Y+2;+Z.G/X#.AR-_:PSE@K?]=+7@CTZ*W[ZEX#@^ BCMA\*B>Z^
MQR>9#EFM%(Z:Y-E]":O:7825)<R]AY))F3>\QU1(U1)1)'U29TCG1VH(XP_F
M>)@=:EASPE] 0Q_GO]?)QHCWA[RS0EB$Y&J=]Z>M4^%KI7+C5SS)HZ:C>:*E
MA<ULDS2B(G_G\U5@^P.5]-PX/N)+MNI5;[$AUIAD$LD@.0J8Q:L#+ JP;D]A
M0.$(Z_94C4A3"RRA 3X-E@;TBU1J$3B=@BZ)A4$H2*V^X6B@E8'TE0@,\#W\
M<72?*D[$(;NNF2)/9X(.RRN\:V"G$A'_#*@^FX+HPB3M0"7ON",;%@ <YX8Y
MP!AU\ITHU?!<3X7V(<((228T=,<+UI",!EU\T&R:B3P,!?RYNU4,2ZHQFEA+
M9E]*@XU"_FH,59W5JV%,E1[)$<0ID7]\- ,Q^7V$ D(E3;7Q2EAV4XV7?J[C
M/6-C$!NI8$*91/,U\/N?$#MDR%H8H +&$PT1[?B4R&]\1Y:C42PPW-[<!%A\
M7[3=/0T'PQ+\U:H&+U<P8A$+E>$H7X\J:>AMB&2;F31D8X[&8&^ IC6BFM;Q
M4<\AMC!]UZE012;<-L<!8_:A[+YD8_L5HQRQW&VPF0D1*@Y!>IL"1'']K=8T
M*C%4Q+L(>P/?^@!;(J!00CJ/'XF(60@(MQQN"AYJ>FS'&(#1IK"[B:(Q=B6-
M<":KC[ YAF$QC<U]O$.R.L82?%.*-^B<T^#,18Z/W%4"4+,<3 GN 1(=;PT=
M+Q Z6.AG]1H7SGFL,_[:KKX6D=W.-=*'H[>==\:_[V\*Y:>GWMM-UQW>3(0O
MYCX!B"3:VQZ?A&AODSS24^"XX%E&D>-RTN<5F-+NB!V-/W[M&R @C%<=>+[G
M[Z46,GD[X[N<,5*%Q.=1M'P\&VGJ &^)L7_9CX5X1;R(:W.[5KPGUSS5#"N0
MCDJU3-6"I',L9O 7R,/P@ZLC$NW+/=2+BEXM<BR?^(;=4EV$_LGUKS)_JY?#
MSAVNAX!6N^+@]Q9J]NIX[P/0[R=X=MK'LX-?[(Q36NO[;>_/S:V=.QPN7>B,
MVU=O9^UA[_'^&_KTKQ?1/CYRSRXD_'F/3W+MFC''1XZ%OXG<>P/.(EF6,QA2
M3J-R4QF8";":Y9CVE&T=X'+@<'1?C>W]B7=+M$J/6AU, 9<&+NNGM3ADQYHJ
M=;%A"Y:S.&$.4/.7X"<H]K,><NUQ]J+C(W QZPX#"=@Y^- 6Y<W$4K"\I X?
M_$RD$9.$6C3\<PR?L +EX!9H\(,ZL$$^X1<2=B\>'[V:6'">&+T>*5G&"^KN
M&62R+Q$ @VUXY@6'/RD(7QR^$;*$KW !7&#F"WE$TXQ7*O[ !H*,<AO;;YY\
MA66P<>Z8NN4&#LG&1WB#EHVA49%M1])<HU F=MJ+Q.LC_##@IAR$PC#2*8E(
M6L>HH+.Z)N?U1K<NHCS?&9^U+'O8/K<?2]G#$6!GG;'^=C7,-!\&K4>9#NNA
MS(>,[:G[IVDG0FQO3^(W,H@L4A4HT@)'6E]][&,#0%/Q52J$]7&WVM QY3[A
ML-33"]4/K I4LL'W2I)"RBE!D4:60,JY+*9N8[UZ! >"J'C/T17N I,)^OAF
ML!\P8WN/)PG@R4!2B9>+FDUP=>1RR0^^*P3-I2OI3R!$#8O:E)!!@>673=XV
MD$:0SX% LB.%A07PL@Z$%,!>M*V@&8>1[O@(O*N@29@J39. /V MQ:*),L3G
M%I"]76QZ8BT$-@LV(WO<L%A+$_RT7PF1\;OQ%TW5>K+ _SCS=(>+H#1)$E\,
M^ K^G5>Q4TPJ=F*MV,DG%3MQ5^P0-9+C\OLMW]F\,NQ6(<_7?U.!T6'ACW3&
MZ6_I5KD['KT5E,-1>7.=\=M#-2\9YZ\/-PA:7[#C8]NR@>Q$S]WCD[AW=7RD
M@G\!_"F@.U#'"+;@D4E]')8-"JN.((A)$N* 3Q*7PRE60RRB0OBR[!S2 HW&
M74W+/E'QF^E/AF,+ V3W(5#KUV$@=12]8CT&'@(/!5:)F2]&)3H3=S'0Q$X2
MZL4D3M(WB8<!-":+J-5&%PM1O!?O(9%Y&^!XEF -D0QZC>NMH!%K!7\7?PR>
M>!L-#EB1V0;7Q)>JFJ15B<DG>C=[5X;^> 5!9-JE9#Y'K?DYZ@K+86Z;O;><
M7+-LW!X4LS6+&7SJT85=_O0O@."$P.#XJ,+:!R7L=F]/$C 7P5M,S+.A 3Y7
M\!.H+I[3AC#X'PUN6".9%\R]_-I'.LUL J:+V:9"M&'B  6WLDV8(,WN(K:?
MK)JR,X#L%IE\0+)N$'!:R?59@\T))B!)O)(-K)8"AX<0I&]3Q)YD^3+LB]A"
M'(/#@^T)VYD#'CGUTG=H>HZC@^,<#%#$S,8>%C 6D3S$$X+W0Q>1)=,D:2O4
M(<\7I%NE8L/[R\3V1$'M@?4J8AU<TP0OKZZ+>#,N@"1SY/=X<+6+[%<$:<GP
M.8BYKF$\>3YU[_7<F:^:H0YXO+V:8W+A9_=-!!Y]W>[3!RWUC?_*,Z-H&MDW
M1T="-D6SPZC#D%:O!!E .94.9XN3S)"UR;FW$)UKUU&,C@QKI_#_=3KDIT(V
MU1G?F?W7HI'+#%]*GP1;M0&AKZ9P;@+()% YL;'S]3:6<C>6HANK/2$K??&[
MTOA17&]CF74AE@M"[$&17S/7^3]W-_T=0RP7A)CQX_>HT= ;M<+CDAN;/]PU
MRM96:L4$[8.@'=,KJ&5(CSBH;5.[G=\?;;_VBC>:HWM]%W#-Q0U7W0AIR[7"
M!TRE"/F'>DRGB,67NL.M)9KY,RVG)Q.(3#"H9,F?VGW:2JR,-:R,-A095G2E
M"=H02Q6Q[I",U!?07JA!,">E)M+SF.$/[W[5GYS"MV+Y< R)3&?LC)S!=;E1
MK?UZ=#-ML#KF 4 4$O_-?I\D8% \TK[T+%0#E>/& -%*;U[5C9^4-54G)7<D
MCT.U;%/M.J12,>"/P>HI<&D(]CP:)(6<+HM S669@LPW0]LW()-EV7@JMXE(
M624$EZAOW(8_G I5_@#6]'4W;"K(+&_?K4OG=8H2SP "D^ 1J]2$(1/S)5B
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MOF:JNSE?-#7Q]4CCZ.?#.>CEJEC-WBJMYF>YMHJEG)C+E!>VG9\+CG!".PA
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M+<Q0L^EW<ENIDW3F!.]V8[<5/M(PKMNR0_I/3-5>372;IUZ)B6X4OD1T:4*
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M%0#_[_^6,NGB%XN7S8ZP60D([)N'2[PO"G-P&3IK:P"V'R@TP%^D1PE"VL2
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MFJ>!FJ >3+MMX;^[]7B2VSN3KT&R,WU%#J?'1S55<_@ D) S8-;N3)Q 6.L
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M&RY6D^MRBF/?_)I.A^>)H_GUZN6Y-U>OKO]P#6^ X&]O?A6J]5%[7JN]<"F
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MI)96LI962FIIC5JQY M5$XI= Z^E>'8PAA0&Q"ZUL<(;;C]EM/-3/'+'/6@
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MACAS;IUBJ+""ZJTG!@@PJ+GTXQ='0J%M?:&%BS/SP1_VJHV:TE#^\.XQ=_S
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M57@6LRQB. ^O^B$9EZ,XT4SVWL CK#^JQE]5.K/<9_S)0X25."^*!AGE-F3
MW9@<5SUBJL$J$]DPF*..J&/ ]L)EN] P;_*>U2_/+J@R9W<>N?@N>6TL<\02
MA>U=OQFS])!] W$>=H0Q0[GIHXY(P:?#0/.?[.OICZ=G;?9[:+'$,2_Q0P'0
M)@]E<U&P>6-54;P1>WN)\,,R1VY8[X>,X_2!MA^^-H^:@=W-_U!]'X(<%/I0
ML\HK=D$Q00@-&_2.V>P8T-) '_'(\8$7.<[O>&9_Y(84GF/)OI(E4M1$B O.
MC*+C>(8I=)S)((S9T%EGF$Q:<//2R[?7WVSUQ[A<]JHAU=)#D6Y!BJ0,=B88
MVOJ)R:V9AY,\&C1$F,3&LTAPV,1L F=V/?F0RYU F*REC]!3J,KZ<3+C2<PJ
MD;*#@FEE4>&1LI-$(F4-9($]&C]5LA@IFY_]>II6_OQYJC]O,5+6."R5K9\J
MF8R4T:4U0F7-54-EZ?'/[H3*5F6>M$)E=;I>I$M^E=?Q0F5&7&&1BTY3""ND
MQE:[%%9822FE$59@&O5B@PG&,]I46*&>4%@A>]R7@;#"EKG-&5:H'85,G'"$
M%<!_C!--8!**)B3,-_,[X?+BX?=S67G)3C1A*3;85C2!6@PF[(*_LEN>EU6:
M1S?6=[[LA]66\;\."MY2A0C_ZWAE_\O ::5KQ')&/S4RZ'FY)[%MW.6BF4.Z
M9OW4V)K+%3*#BV9@X%'HT"-$,3]WJ[&BNY4BT^R,N[4RXZ3C;C'%<KU4K#=6
M=[=\7:UF\J[6UE@JWY4)JZFG-$+6=*0Z"JY-."CX>621O+ER;8)_74(* 83T
MN'J' @BK\7 : 81RI5$LTY7( ,)*_+KY $(&N6_[ 81M<YLS@% Y*OFU^'L"
M"&;,\W519;7RI++BVG9N_(>=TEVFE9<<5$2CPA1KS6#[SKYIR7!Q0_"@]^6@
M4#-1P\FL)!/>B3 <\5M!7TT%XD'AH1)4N>3_K4]KZ$*8<Q&D#"/+8+>M#-?G
MZ]QIQ>3X>'EU&#^>VDDFGIHTY\Q/IXT60_\:2-PH*_'4Y<X_0_%4W^*LQB:+
MLVA$O[(Q_(#94AHZLCB+5LHGOT_>IJV'2N9*L.C#$D.2U.2GY=,[V?%GH0CK
MH. JP#KE^XH.0\8J^U%(&=R)@<$!5LE!P8"8P_:/R4O[UM(L[L0U!AJ&<XPD
M80YS;$41+$VBMV0D==AF, <P$VVE G;VP*'<S,$=E/S*&Q-U>.45#%("ZU&T
MIT;;(-SP,;AH\0!4\KF]:&=J)X#2TD*FM.B3UF,Y>8K'FZ%_P[.1L :@SB6P
MDP"Q_$9$K_P(?P9\%:;T!7\*_A7_3G_Y9# %MD4XWIZ$-P*U 4@@R)L1S.<=
M%-!?T2T"(V%TS)@N?\@ *@47ZD5'V\?S__C)5)1G/.Q('B);"!E! -!MH)D7
MX2Y5=5'#%X\]3-)B7;(N@#UOV9 D!X5@3)(PM)AV$B:5H5[/L%X]ETABY4R1
M5=5_C%14O*GK@ 5M25ZCQ_XZG!I@92Q$JWIC65<1+7IO:(DSDODQ3PR^Y/#5
MTK*:@FFRY "K4%K88:QX6UX37K54\3>=[$G1:PV,!NX-S8BGQ*".P5IDTFE6
M&'0^?VZJS$GIXF(\S@JG.F=[N<>M9H=3"3A?-3U.=0)#F3K>.6&, O]!L6ZA
M@P*^=K REXSI[!P>ZAZBFBL.1'X':<D>3S%R.SZSW.I8,JP@;&NY5950#%U=
M#'JEJ"=;RW#+PB3!W>66X%&$&>*6<K-82X]==$D'+\DR=,T@/OO*"B)D##S3
M$4G5FC$; EN].^P I3#(T!J?XG\ENQ@/:"YHLZC1++8)M/;#'^>Z?M)M<#][
MS'"\19Q8/UCE-P*KO$[LP!I!@GAZ"O-*L!=%J?ID L$Z V+3O+,Q=R/9^.B^
MKRG[NH8+^DU021K,\MSPWQ#?')K_LNB> 9(HJ^$11V$PDB0I-QB#E:92'*Y,
MHWPQ2$D/*,0ELSA=Q1Z04GJ<JRWFUWF/'="M>JP!*7@T)75]TSN_OJ):[=[Y
M+\=4RB2EW88W=,(9>N$.ER:F"^TP$!5Q87I*_!?X(Y/[ )#'?^0B4F52FM4/
MI7R)P.W*\5YS&8Z8KFLIZ!S@G__?!R8(F;R_"$2Z%8*BS1#;('@S&:)KAI:2
MJR.^YR%WSW,8Z)G^0G;10J(.$*7_]17J7V-GUM@8YS_B2H!<'$J&EI(J?V"S
M;?,7\?J,> O&!R$2LH],;EM(CF$BYG.'B\(RS3"79F@INZ-0;ZT1KDXM>B$,
M>>HCU("JGS)\('[3:M:U'E<<#K6T55QN_K.Z2P=#<@S-Y'"BC ->3'4E<GS6
MRIG5%YZ@26R[%^DLQQ[^TTPPU^*8\$#J<1^%KG^D.DYG8<=TO%L2U".97G>7
M.-TWAL]M9DW._ISSMR/]M%XK^_2.$<NZ2)E%(8Z5%JEC'MU"$AY+L;H7&#!I
M<46=D&K69^&8@@L)[4S/,J>Q;L:1IHMEWX&..9"LO=[Y7Y3*Z:2C<DQ+P+C\
M7=73&U1$5V?TJ78R/'_G;41V<VF686)Y=WAUQ;T^BG&&F=!2SAKW^E$I$(IT
M^V*X5U(K**F55U)-5MX6NQ^LK*Q_"@BS9,L:!G\'J0U'7@AR&ZI+FK#_;ZI%
MHP0F<65(GHA?19Z"?[]$+ME$GU@C+'I#]>GIMOOPS6ZAP%]Q!B9(&XVO 1>>
M/$Z27$EK("#'HXL::^ND\E&5"=))V(-BOGB9J[5;S,6^.YF+5[])+/_45!3F
MKV0N)S769BZZ6*E5C^J!EYZA1[.BX_<WX,:7D[#9&=)+CWFR'VUT]I<V.JV@
M81LM%#@<J:D>KTR81TY[V)07459*7:$U?1N^LPM>Q*%/?-.Q5B.^*4@4"7$&
M>A=?8Q?"+-;=K6QH'ZK\X#.G*X"]L%!%L_DSA=9%&V;2FK+L+L'*H*QN*C@<
M-/0\_KL6QZ.O3(8S4KFSW7A]%@H?XH5VM]+GD;@J] <#\P9T#=98(6*2ERC)
MVETE&XO@TDP]K-DV@S*S7X-7=Y27T1WJ4JP;&J?=O$Z)CLWNCHI)[J RIGJ<
M7BIS1 >&0#(H<_LU)%#,FJR?>6)'Q'!HYGKHAN)Q"(L%')*VRHH32G6JM<@@
MEZG.P@)<T;M/3P^D$!RECQJ!5DE </0X/ZS@"GSN("LD&LHL'P4/E]@9';E?
M0_IWA3=[LD;XRI"C+(8C*]_;=>&X^Z?_4$T@'!F@=K8>A[23.IL[10A -LII
M!B!S&'5,M"0UP0!D!_ S]P'(N$&$) N].A9TJ>6?9BH :;!&"M$!T%2'POOA
M6. X'GT&T981WON*2-?+E0^6X9I9?MBOP2L7K22#:SZ"D=<(VW9DJ+:7H=RL
MP98A)I9C;G#4%I@^TNG>#K,W]LR^JVOP90SKL#.RN[^R;N%45H:\D(?*A40;
MH]-4_TE"!!K'HR-[WG(MA*M'3MA4=$423\9_2B\_7ZKU&)Z&Q4VI=^>N%RG[
MF&X]A,^I92PI:7>T^:$2;E<7?-JKH@0MT>2\.1^NSJLWEQ<]E7)-Q9(GFC$=
MYLZ9U1H94V,Y,>$SKLNR+9Z>A%LIEN-O*9^\EF?8VG/%K+Q#_>:H1".L?XTP
MK.'1^DV(R@]?K%ZKD1^^2+1>HW+4#)PGEGGUGX4U[*^@OS@:EF ^/2U8)Q=
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M>0C(M!XX-H!^435*X446XF2:[,*PD8TK"RV,TL8\^G^%YZD)VO%8I7B)0]\
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M4&QH:+52CTC.%0[S!0<"_,,NLA]$<P>P/O%Q(, 0X#:GFU*@\<;-7;U+X%=
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M8FNPZ#:L/"QJ:)<Y2)O2T9S^\3Z(QOT1\OLSDOL^RV9ZEF%83R1]T-Q0''<
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MCDB^  +2I#A"=!R!%\6Q<73P.'1N@SFSP9X(5XR@UJ>),S)'XZU1*4QH1^-
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M#__Q7OLN00@/5XD/_BDZ!P3!TT\"Q@?/][L)C\)'\SV"H7I[H'5(PFJ&PXF
M!U"NN*EA8%T2J$QV:56Y+!9YAWBN2\480',7PSYXR!L>G=;AX155>=0UNB^Z
M6BH,&L<YTOA1^$#[%Z/;7@T'@1!XF4YR^-D,'\]OL<22B6B9G#@Y.SC$P.P
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MFQ[I.BYQ(Q\.A<\"\T/-$63BGVA*(,[Z_O-JMFGGF*8;KC0/SPO9 V$&\_(
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MTY=HN,=@V#F^UZ1$:VN.#B3023$Q.?QKZ-\I*3(2=/19.1!N!!IM75:$B5W
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MSG/4CZ(QGFR&1\LX4)[29AW-=1@ODPF!LU*L<A*@5<$^Z_@.+X,<N\$5\V^
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M=R=M=A/$)AU0,1YS1_;FB!Z6Z2C\S,O"HLHAK^CA3@^))8=L%#_=2(0Y0N)
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MD?Z8$2'K0?-RTDEMNTVDZ&.)/88>0X_A'^61[E.T?2RQQ]!CZ#%\=QA>A4]
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M5<+1%R3O?(LLF=%]P4&_*IY[TH![$/-G8YA4O_PN@!>,R'B?$7W[ <+[#<B
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M2@8*'P24NH7$!8$H6KJ:RANCF#;N6*^E9I0T8*,ARIFTEB_D_I0'XXC6I")
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M<O<DBVZ]#N[K[KLF;TI0A?W5BNJUV*/6]>O6S?6K9V)M.6W"Q%8-S9B(ZNW
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M78]FB;V!Z>"(CL[!9D%"&Q_-AB[[IB'8,+8C)>S=BK0FLI]D:5,Y4%O'-IF
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MK>GX\;W;9P?YU'>QOL7^H14FS$FY<:M0O""(EJO8F;"5[U'J)C1>A0:UZ!K
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MHZ<0>3:R-Y33 04B,4,GI.W34-K+U@6-NXVHN4K^F;:LD);\:,L=FJX((=L
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M9W:\RW?[1(\G@\[?/P]Z-\9H_.<_?;BZ?/_7>"I6O$Z/D$LW]:%)%H\)T=C
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M2',G'ATEN%X/7=,3U\(:R3D99:U;9N#!0;)YM+G*VK/4^,PCKLY-50%!#B'
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M$1'VPC5?6L&#FO>][C_NNS=Q)>ES6L!S6L!S6L!S6L Z$DJ3+PQF&8;8(>I
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MIS1C6VY9YU375&Q4T")D<8HB521E6_WI+P ^Q >>% 6D3N\^NH[MS.0/P ]
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MR5!U(A]3F2&WE451*NAS 9H[@XC2=_&+)!!$RE:+VXM5H09]"%<AEG5."$V
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M^"?L)6H^" 3MK?EE0 _K?)X4#";(H'76\Z\QHL+6:%!WY$>1QO"@4+ WO^@
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M@NCYCBP^D\#CE8HG9(L08H E&[H2(*@@A-6)\%0)HE+2,@D>$DQ)B$E#L$>
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M1D5JLDE+%1#/3/ *&'@P@6HV+FHSELO-/'IIG$9SBY>_/JX]4H&S79;2&90
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M/ #,__?N]^_>O2<N?8)>J,&_H'^]>/?N'4KSP##>+EO'2?!W[/\%O?]C]>N
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MLPS7->"<VL>@EE)Z%2?T6=L*IVD>NC\ME&'3N!ZRIS>/A48 $%E10 TF"RQ
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MJ$PJ^Y#$*YRF+%G-(TY>@J4JX;".OH/$POK%XB005BL[)VI?Q+*$P$MFI)8
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MD68KT7>W#/2MWM,S+5;CFIZN,A@*FB+NQ(]=S,;_^</L]GHR?V0QCO_U+^S
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M&8#LQ.NL:U$J)85>.:>=ZGE(X\,/Q 6+LG&<<@,-"47=$*8+ED^4@QQ @G3
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MO,()\8.+<@IJH2-ETZ400*P3K24"9;R7P^M<^2^DACIE&XPAVS@-LCP%E;"
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M]\\0@_/YU''!>[M_@XT0Y@Y@]6E#UZ2F!\$)[!1#QPVLE)P3UQ2IL2NHQ3#
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MB4^C.%:"3GI. 9B__U&\8Q(U@U0)9+OH()8&P? /6BZ;J[&44[023Q9DXTB
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M_:+ICZ\L<>/$#R(W.:PS^I[R:D11QF2&?#"$JS"[QLG$(3*-.7JI.^C*2Y*
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MW(9*I;)UHY(TDLH>[Y<)%@E)7%.DFB]R:7[] 22EHD0"2%"$$E35QNQ,N0H
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MEI,9LY'=G)/?$CIB?\LW"$LA)K.'FQG=QYCWK_^YM@G88"!%D0=(/@]>#^R
MD")5P/@/3A?DB20#I2*"0\B[&=/E['#5_>^JYUDIVJ.QL-7.[_9?_H_7J# M
M46&<XV"1I!2"G>P0*.QQC4%<4J:Y*P"&"M\DD>N3*+HED1VZFYSY&RMRH_3%
MY$$&@.6[SEC@4KEM4H$SY&&4<AP)1#[=]\]"A+W -4U:"#A$7H9 ^Q"1\:+T
M[*0,YFD[<*[!%L)7+1-# ,MS(IYFLP5/2EAW< J %L*K)$%#4#^$L(*!YO<
M8JOMN:!.;&5R,@7.]<9RP_31:KC/73I># -_.72WQ,G"(^%0UQH-J ;:TG-I
M58,SY&N(BLQ#RR'[()U]-,^4V(0N6(\>R8CGZP2P.U )M&7MTJD$2A(T!/7"
M+>(MV1(O2,,S\[!'&>:@SD#$M27TTHFX@O0T)0&8K=S-)GOZ_LGR'2]]JQ5!
MUG+6'=P;"**VC%W:'":*\C-FUE*K(V'Y2((E2TNA<$@&= 6[1EJ%-IQ_HZ#.
MHJ.R6"DPR,).4'A;Z?H"B,L08+EO(\ HPT> 0MY*YY>J( W!_[00,67<C4EZ
M7)#978"N4,1;Z2\#BTZ3T75+TI1M]'L'V@<^I3C)B/<=]5CW\X:$HMTN]]GY
M<C%JPA_2 A92B&7J"E[Q%8: JD0KO6[*HC1-!0I,%]19MNX#NT.A;Z6G34F$
MAL#>"];,(Y#RG(>X 0_IA_L]X !0Z%OI7U,4HR'@'^JR*-RD\'I X6VE,TTF
M*%T>-"M[Y]I_8D6DL_HY,.<9H",4L!8ZSL!BTX1;;OCM%-R=XB[@ )'68041
ME2&K9=\*?==?LFJY:0YU\*(I[0B%MY5N+Z#8# %Y1+X7PGO#P*<_9KG/(\4#
MD?I(4#5HI2NLKF"O)"I\GN:L.#!5C E_7\I7UF!,>/;=UXAPL_.$VBOB)!Y)
M2RVE5_/LG5\T#"P_*B8.?[ZPASP<.6?0:PQ";T(N>LW] V4/$5DD'O,:IU'1
MY1QL<YD2I'9P_?&N,@3]3)F8M!\5T\J*MI922K[CY+)&[ _7E67V6<$.).XS
M2"DOW+(16I=]5E4X9DPV4/Y.P20L9=P#YZ,];WZ^E,2TSUH%1@J^==89THSL
M+>>FK6U"K*9,X,HLMJ(Y6\J7)\AE:\0N^@*3VIX3AV3 ;(5+OW(OA8O%C$D(
M3ELKFI:E#']JR6O-F*E7E<6V?)S>IUG-*3W*M*IN ]<9%7M&*V>H;4*(9LSR
MBI@GP70NI2&LR$JKV08V*3UMXU.R.H'8OO+K.$S+0H*RT-0?T@QC&)X-]WR.
M+^0D/(0;?7))R)[Z[.Z"D#/_X.>=FJ.B.0S/27K<D"RU(TU/6,DZS941'>HV
MUT=8<32TY!3-(%M+=F;LI=E3$='^6<I&FB6\-L+,O6CF:^D4JBB'G%X!Y&X0
M7\E(/=:P<X8V.AEV<VP:%>*1O<,Z9F=/^^[>BI.0_B_TH%)K,.S;-6 .]-IB
M,F/Y+-MMHJ6TE(:6G]C9B.6UC1F>Z5$V62=I='3F^PG6%/,5\2-W2[(8VV$0
M9:L'GR.U461SK:2Q6F8<*-VS&F/%I\XM )5.:#*(R5J05TM])#/ K:/6]: O
ML%X,^<7-VIZ'760JS@@/_#0*X\D58"WI=C7 2O@L[/2HH<W'Q-T&:\OU97M*
MJ;D9H($4\C1&N9JA9^N[R4/)X:U0$.[R VG7CMTM,ZO(^I&$%8)G'0']L!-)
M"O6H>*P RT"3;V7$PLKJP0#KBIT3$HR$BB2T.[I8TJ)P2YSTH8#J.5S<&?FD
M7==*JCZ+0^1DR&F[X$=GQ-[04Z13?"V9GM+&F8-NKW7JMX3UQ\8^BY^K& V*
MPGB]F5B[-##BNQ4Z18:8YSX#[-G9>XX.G?,=["U8HSZ=+W[C=*LX1=@3Q+L@
M+//+=L1E'EKNI72ED>?5$RU]R'B31N6HJ^!%R<$V41K75 0P=5E$^_=E)^88
MS"("=L;.:]V(2:0D*$/\TJ5@G^>G1K<DMER/XZ(NUVCJ?>K?/@S[[%U@_A9P
MUIGV>_W!Y^X-_?7O\N%>G_\9_?ROK 8?0ZKX>62DT%\J['?%C_A@(C/$W&#[
MS'?*(*$;TFV0/,:+Q"LS((=;;1CL@XU6^.M(M* -5!8+0O_H##,I<SC^-5NP
M?;)DFU3:UK258D3B&NM$L1?V@>6RRT197NIJ\2%3BSB(+>]$*5#-">F+5J%U
M4:I,5[0N'F;]NX=A9SCXW)^Q?U>_AGDU.-IA<!1?=O$>D8COX.$CF'$I=)F$
M C)9F')EST)[@C"-Z"G482L=M*JCG80=S4!;5;\K(I^$7)IR]\[E[F8WIQ\7
MW\"#.E\%GB!.#;F)YS-(/RV[EP=U-@-2!=4%OWLL,'GFS7U#8-Y;5 @^"8^,
M,.[E<MY+V G[4*>@GB>P 61AR'&=^2&3F(1@Q+@=L(]6]=&2R, 0I.9!X$6W
M6::U^\!S(AE2W [8=R'UD9+(0-,%Q7BQ<&UREX2^&[.T+Y#U+2T"+>^'?2U1
M PH@9T;-'2Z;>R_"0G#\ W5&?]L".N1 K8NR6,RX33H[,V7NLAFQ"S16S*+2
M._1!9X[*G(+.@817]U%+W$>]P*,<!AEJ1U?KOC,*?)OSYSG]*:)L' )%8+$1
M37W+C!/095Q2S4G-%.=5 QP!/%W-?L4,C=,W;TNGAR:%9XJW+0M).<S!81X[
M)/:R"3N],+40RL(0_QN'1IGG3=+-#* !"@Q#3._[F(_$)Z'E=9VUZ[MLFV/J
M)BQGS#_WLP'/& ]XA-%6J RDC<53Z-FRTW,ZC<*X, 7IOTZG'_T5.Y$ZB1V/
MPQD)M_0LS5E8:=/JEF9,,OVK*5< !7<B$G:,M9RDB+MD/M-?U1P91:YP>1A4
M\:!G71S23] )FU>)%BYYU4W1*J6+I55>Q42<:G)H'DW6_8()$36D(U[%6U7)
MP\5@B!NS4%_WM/3NS>[>^I\@['E6)'F,KC3(2]EFZLBF<$UBJ%(\4SRRUM(+
M=>6!S%".&I,"CGHUXWJVO DU?/T\N90MM_3YS='KSM94R>+:+!.&(2MR3J;L
M*O:D&7KYT#,!JN;**&!RK9$!<](,O2A=,\!4,H]XV)VR?9A_PBW\V8PMY2+'
MV@+7A5M^%&BXLV1/)G1^Z#^OEE3I5*)[4K4$Q8%$>D_G\#I9BX1ZT@1OPSZ5
M6DFFE<P@+B7WUI-4N,=-\$JQRX5;Q8PA&^@UISJ[V'D2EA#ME]>$:,U!:TQ"
MM(; R=_ZRPS9DV900U;;"0.4DJN:=J.6P<%Z8[DA4ZCQ8ACXR]0TSPSR3\1S
M[H+P(1)$] "[(T</ZH@R.;U<59&C(=BSA"CCQ<<@<(K^Y%GP+,FJ4!I^'^SW
M#!> 62XR0[#-W?QW5$:]P$_#R[ZX\:J71'&P)F'_R?82Q_673$7I?YRY]<0'
MO=9@V.\E+J -9PBY]D/U+0D?@XB<D[^ XY_=!Q$[4Q(GH1^-"%7U0W*&*IN8
M=9/VPGZ-H5,/0 (P:EW@.^ @3P5@O;$??5Q@YJN(T7CDF<K6NC9+^V&'5:&B
M712=^3@7DK1UUT$8YP'KM;#GC@74!VV7<[CZ(!&Q(3I2)(V5;S_F@:\/LGY
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MV19/-@)FS3&'&86?+3O+& /,KU=JCVZJPH&1<&(B/--@9WDJ^0_+'=!MQ;H
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M,XNM,#8@/JQ!^7PA[G(5$Z>[):&U)/N[ITE(+;>+:+68 .Q+U'8I.P1,["G
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M?U!+ 0(4 Q0    ( /N!$%.SFQ9K1!L  #3    *              "  0
M  !E>#$P+3$N:'1M4$L! A0#%     @ ^X$04WI"ARW6!   1B@   H
M         ( !;!L  &5X,3 M,BYH=&U02P$"% ,4    " #[@1!3H@R4#U))
M   KU0$ "0              @ %J(   97@S+3@N:'1M4$L! A0#%     @
M^X$04XT+2G3E!P  ES(   H              ( !XVD  &5X,S$M,2YH=&U0
M2P$"% ,4    " #[@1!3)^VOP.0'  "K,@  "@              @ 'P<0
M97@S,2TR+FAT;5!+ 0(4 Q0    ( /N!$%-D0U!2Q 4  *8F   *
M      "  ?QY  !E>#,R+3$N:'1M4$L! A0#%     @ ^X$04UY.[B8YS@$
MZ(89  P              ( !Z'\  &9O<FTQ,"UQ+FAT;5!+ 0(4 Q0    (
M /N!$%-*/+W9 14  )/P   1              "  4M. @!Q;&=N+3(P,C$P
M-C,P+GAS9%!+ 0(4 Q0    ( /N!$%/_6]L)21,  )GM   5
M  "  7MC @!Q;&=N+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4    " #[@1!3
MV1'01)0Y  !JT , %0              @ 'W=@( <6QG;BTR,#(Q,#8S,%]D
M968N>&UL4$L! A0#%     @ ^X$04P'"90/0>0  P>\& !4
M ( !OK " '%L9VXM,C R,3 V,S!?;&%B+GAM;%!+ 0(4 Q0    ( /N!$%,F
MF!V4)%$  ,Q^!0 5              "  <$J P!Q;&=N+3(P,C$P-C,P7W!R
;92YX;6Q02P4&      P # #4 @  &'P#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
